U.S. patent application number 16/254333 was filed with the patent office on 2019-09-19 for toll like receptor modulator compounds.
The applicant listed for this patent is GILEAD SCIENCES, INC.. Invention is credited to Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-Jung Pyun, Jeff Zablocki.
Application Number | 20190282576 16/254333 |
Document ID | / |
Family ID | 55590135 |
Filed Date | 2019-09-19 |
![](/patent/app/20190282576/US20190282576A1-20190919-C00001.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00002.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00003.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00004.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00005.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00006.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00007.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00008.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00009.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00010.png)
![](/patent/app/20190282576/US20190282576A1-20190919-C00011.png)
View All Diagrams
United States Patent
Application |
20190282576 |
Kind Code |
A1 |
Aktoudianakis; Evangelos ;
et al. |
September 19, 2019 |
TOLL LIKE RECEPTOR MODULATOR COMPOUNDS
Abstract
The present disclosure relates generally to toll like receptor
modulator compounds, such as diamino pyrido[3,2 D] pyrimidine
compounds and pharmaceutical compositions which, among other
things, modulate toll-like receptors (e.g. TLR-8), and methods of
making and using them.
Inventors: |
Aktoudianakis; Evangelos;
(Redwood City, CA) ; Chin; Gregory; (San
Francisco, CA) ; Mackman; Richard L.; (Millbrae,
CA) ; Metobo; Samuel E.; (Newark, CA) ; Mish;
Michael R.; (Foster City, CA) ; Pyun; Hyung-Jung;
(Fremont, CA) ; Zablocki; Jeff; (Los Altos,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GILEAD SCIENCES, INC. |
Foster City |
CA |
US |
|
|
Family ID: |
55590135 |
Appl. No.: |
16/254333 |
Filed: |
January 22, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15496283 |
Apr 25, 2017 |
10285990 |
|
|
16254333 |
|
|
|
|
15059070 |
Mar 2, 2016 |
9670205 |
|
|
15496283 |
|
|
|
|
62250403 |
Nov 3, 2015 |
|
|
|
62128397 |
Mar 4, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
A61K 31/517 20130101; A61P 31/18 20180101; C07D 239/84 20130101;
C07D 471/04 20130101; A61P 31/20 20180101; C07D 401/04
20130101 |
International
Class: |
A61K 31/517 20060101
A61K031/517; C07D 471/04 20060101 C07D471/04; C07D 239/84 20060101
C07D239/84; C07D 401/04 20060101 C07D401/04 |
Claims
1.-102. (canceled)
103. A compound of Formula (IVd), ##STR00270## or a
pharmaceutically acceptable salt thereof, wherein: R.sup.1 is
selected from the group consisting of hydrogen, halogen, C.sub.1-6
alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl is optionally
substituted with 1 to 5 R.sup.20 groups; R.sup.2 is selected from
the group consisting of hydrogen, halogen, C.sub.1-6 alkyl, CN, and
OR.sup.a, wherein C.sub.1-6 alkyl is optionally substituted with 1
to 5 R.sup.20 groups; R.sup.3 is selected from the group consisting
of hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein
C.sub.1-6 alkyl is optionally substituted with 1 to 5 R.sup.20
groups; R.sup.11 is selected from the group consisting of hydrogen,
and C.sub.1-2 alkyl; R.sup.12a is selected from the group
consisting of hydrogen, C.sub.1-2 alkyl and C.sub.1-3 haloalkyl;
R.sup.13 is C.sub.3-6 alkyl; each R.sup.20 is independently
selected from the group consisting of halogen, CN,
--NR.sup.aR.sup.b, and OR.sup.a; and each R.sup.a and R.sup.b is
independently selected from the group consisting of hydrogen and
C.sub.1-3 alkyl, wherein each C.sub.1-3 alkyl is optionally
substituted with 1 to 3 substituents independently selected from
halogen, hydroxyl, amino, and C.sub.1-6 haloalkyl.
104. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein: R.sup.1 is selected from the group
consisting of hydrogen, halogen, and C.sub.1-3 alkyl, wherein
C.sub.1-3 alkyl is optionally substituted with 1 to 5 halogen
groups; R.sup.2 is selected from the group consisting of hydrogen,
halogen, C.sub.1-3 alkyl, CN and OR.sup.a, wherein C.sub.1-3 alkyl
is optionally substituted with 1 to 5 halogen groups; and R.sup.3
is selected from the group consisting of hydrogen, halogen, and
C.sub.1-3 alkyl.
105. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein: R.sup.1 is selected from the group
consisting of hydrogen, methyl, fluoro, chloro, and CF.sub.3;
R.sup.2 is selected from the group consisting of hydrogen, methyl,
ethyl, fluoro, chloro, bromo, CF.sub.3, CN, OH, OMe, and OEt; and
R.sup.3 is selected from the group consisting of hydrogen, methyl,
fluoro, and chloro.
106. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein: R.sup.1 is hydrogen; R.sup.2 is selected
from the group consisting of hydrogen and fluoro; and R.sup.3 is
selected from the group consisting of hydrogen and methyl.
107. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.11 is methyl.
108. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.11 is hydrogen.
109. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein each R.sup.a and R.sup.b is independently
selected from the group consisting of hydrogen and C.sub.1-3 alkyl,
wherein each C.sub.1-3 alkyl is optionally substituted with 1 to 3
substituents independently selected from hydroxyl and amino.
110. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.13 is propyl, butyl or pentyl.
111. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.13 is propyl or butyl.
112. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein: R.sup.11 is methyl; and R.sup.13 is selected
from the group consisting of propyl, butyl and pentyl.
113. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.2 is hydrogen or fluoro; and R.sup.13
is selected from the group consisting of propyl and butyl.
114. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.1 is selected from the group consisting
of hydrogen, halogen, and C.sub.1-3 alkyl; R.sup.2 is selected from
the group consisting of hydrogen, halogen, and C.sub.1-3 alkyl;
R.sup.3 is selected from the group consisting of hydrogen, halogen,
and C.sub.1-3 alkyl; R.sup.11 is C.sub.1-2 alkyl; R.sup.12a is
selected from the group consisting of hydrogen, C.sub.1-2 alkyl and
C.sub.1-3 haloalkyl; R.sup.13 is C.sub.3-6 alkyl; and each R.sup.a
and R.sup.b is independently selected from the group consisting of
hydrogen and C.sub.1-3 alkyl, wherein each C.sub.1-3 alkyl is
optionally substituted with 1 to 3 substituents independently
selected from hydroxyl and amino.
115. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein the compound of Formula (IVd) has the
structure: ##STR00271## wherein R.sup.2 is selected from the group
consisting of hydrogen, methyl, fluoro, and chloro; R.sup.3 is
selected from the group consisting of hydrogen and methyl;
R.sup.12a is selected from the group consisting of hydrogen,
C.sub.1-2 alkyl and C.sub.1-3 haloalkyl; R.sup.13 is C.sub.3-6
alkyl; and R.sup.b is methyl or ethyl, each optionally substituted
with hydroxyl or amino.
116. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein the compound of Formula (IVd) has the
structure: ##STR00272## wherein R.sup.13 is C.sub.3-6 alkyl.
117. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein the compound of Formula (IVd) has the
structure: ##STR00273## wherein R.sup.2 is selected from the group
consisting of hydrogen, Cl, and F; and R.sup.13 is C.sub.3-6
alkyl.
118. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein the compound of Formula (IVd) has the
structure: ##STR00274## wherein R.sup.3 is selected from the group
consisting of hydrogen and methyl; and R.sup.13 is C.sub.3-6
alkyl.
119. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, having the structure: ##STR00275## wherein R.sup.1 is
selected from the group consisting of hydrogen, halogen, and
C.sub.1-3 alkyl; R.sup.2 is selected from the group consisting of
hydrogen, halogen, and C.sub.1-3 alkyl; R.sup.3 is selected from
the group consisting of hydrogen, halogen, and C.sub.1-3 alkyl;
R.sup.12a is selected from the group consisting of hydrogen,
C.sub.1-2 alkyl and C.sub.1-3 haloalkyl; R.sup.13 is C.sub.3-6
alkyl; and each R.sup.a and R.sup.b is independently selected from
the group consisting of hydrogen and C.sub.1-3 alkyl, wherein each
C.sub.1-3 alkyl is optionally substituted with 1 to 3 substituents
independently selected from halogen, hydroxyl, amino, and C.sub.1-6
haloalkyl.
120. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.1 is hydrogen, halogen, or C.sub.1-6
alkyl optionally substituted with 1 to 5 R.sup.20 groups.
121. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.1 is hydrogen, halogen, or C.sub.1-3
alkyl optionally substituted with 1 to 5 halogens.
122. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.1 is hydrogen, Cl, CH.sub.3, or
CF.sub.3.
123. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.2 is hydrogen, halogen, --OH, CN, or
C.sub.1-6 alkyl optionally substituted with 1 to 5 R.sup.20
groups.
124. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.2 is hydrogen, halogen, --OH, CN or
C.sub.1-3 alkyl optionally substituted with 1 to 5 halogens.
125. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.2 is hydrogen, CH.sub.3, --OH,
--CF.sub.3, --CH.sub.2CH.sub.3, F, Br, Cl, or CN.
126. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.3 is hydrogen, halogen, or C.sub.1-6
alkyl optionally substituted with 1 to 5 R.sup.20 groups.
127. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.3 is hydrogen, halogen, or C.sub.1-3
alkyl optionally substituted with 1 to 5 R.sup.20 groups.
128. The compound of claim 103, or a pharmaceutically acceptable
salt thereof, wherein R.sup.3 is hydrogen, Cl, or CH.sub.3.
129. The compound of claim 103, selected from ##STR00276## or a
pharmaceutically acceptable salt thereof.
130. A pharmaceutical composition for treating or preventing a
disease or condition responsive to the modulation of TLR-8
comprising a compound of claim 103, or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable
excipient.
131. The pharmaceutical composition of claim 130, further
comprising one or more additional therapeutic agents selected from
the group consisting of HBV DNA polymerase inhibitors, toll-like
receptor 7 modulators, toll-like receptor 8 modulators, toll-like
receptor 7 and 8 modulators, toll-like receptor 3 modulators,
interferon alpha ligands, HBsAg inhibitors, compounds targeting
HbcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV
prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors,
antisense oligonucleotide targeting viral mRNA, short interfering
RNAs (siRNA), hepatitis B virus E antigen inhibitors, HBx
inhibitors, cccDNA inhibitors, HBV antibodies including HBV
antibodies targeting the surface antigens of the hepatitis B virus,
thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or
capsid protein inhibitors), stimulators of retinoic acid-inducible
gene 1, stimulators of NOD2, recombinant thymosin alpha-1 and
hepatitis B virus replication inhibitors, hepatitis B surface
antigen (HBsAg) secretion or assembly inhibitors, IDO inhibitors,
HIV protease inhibitors, HIV non-nucleoside or non-nucleotide
inhibitors of reverse transcriptase, HIV nucleoside or nucleotide
inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV
non-catalytic site (or allosteric) integrase inhibitors,
pharmacokinetic enhancers, selected from the group consisting of
adefovir (Hepsera.RTM.), tenofovir disoproxil
fumarate+emtricitabine (Truvada.RTM.), tenofovir disoproxil
fumarate (Viread.RTM.), entecavir (Baraclude.RTM.), lamivudine
(Epivir-HBV.RTM.), tenofovir alafenamide, tenofovir, tenofovir
disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide
hemifumarate, telbivudine (Tyzeka.RTM.), Clevudine.RTM.,
emtricitabine (Emtriva.RTM.), peginterferon alfa-2b
(PEG-Intron.RTM.), Multiferon.RTM., interferon alpha 1b
(Hapgen.RTM.), interferon alpha-2b (Intron A.RTM.), pegylated
interferon alpha-2a (Pegasys.RTM.), interferon alfa-n1
(Humoferon.RTM.), ribavirin, interferon beta-la (Avonex.RTM.),
Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A,
Oligotide, Zutectra, Shaferon, interferon alfa-2b (Axxo),
Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron,
interferon-alpha 2 (CJ), Bevac, Laferonum, Vipeg, Blauferon-B,
Blauferon-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon,
PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma),
alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep,
interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon,
interferon alfa-2b (Amega), interferon alfa-2b (Virchow),
peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon,
Urifron, interferon alfa-2b (Changchun Institute of Biological
Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2),
recombinant human interleukin-2, Layfferon, Ka Shu Ning, Shang
Sheng Lei Tai, Intefen, Sinogen, Fukangtai, Alloferon, and
celmoleukin, and combinations thereof.
132. A method of treating a hepatitis B viral infection, comprising
administering to an individual in need thereof a therapeutically
effective amount of a compound of claim 103, or a pharmaceutically
acceptable salt thereof.
133. The method of claim 132, further comprising administering one
or more additional therapeutic agents selected from the group
consisting of HBV DNA polymerase inhibitors, toll-like receptor 7
modulators, toll-like receptor 8 modulators, Toll-like receptor 7
and 8 modulators, Toll-like receptor 3 modulators, interferon alpha
ligands, HBsAg inhibitors, compounds targeting HbcAg, cyclophilin
inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines,
HBV viral entry inhibitors, NTCP inhibitors, antisense
oligonucleotide targeting viral mRNA, short interfering RNAs
(siRNA), hepatitis B virus E antigen inhibitors, HBx inhibitors,
cccDNA inhibitors, HBV antibodies including HBV antibodies
targeting the surface antigens of the hepatitis B virus, thymosin
agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid
protein inhibitors), stimulators of retinoic acid-inducible gene 1,
stimulators of NOD2, recombinant thymosin alpha-1 and hepatitis B
virus replication inhibitors, hepatitis B surface antigen (HBsAg)
secretion or assembly inhibitors, IDO inhibitors, and combinations
thereof, selected from the group consisting of adefovir
(Hepsera.RTM.), tenofovir disoproxil fumarate+emtricitabine
(Truvada.RTM.), tenofovir disoproxil fumarate (Viread.RTM.),
entecavir (Baraclude.RTM.), lamivudine (Epivir-HBV.RTM.), tenofovir
alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide
fumarate, tenofovir alafenamide hemifumarate, telbivudine
(Tyzeka.RTM.), Clevudine.RTM., emtricitabine (Emtriva.RTM.),
peginterferon alfa-2b (PEG-Intron.RTM.), Multiferon.RTM.,
interferon alpha 1b (Hapgen.RTM.), interferon alpha-2b (Intron
A.RTM.), pegylated interferon alpha-2a (Pegasys.RTM.), interferon
alfa-n1 (Humoferon.RTM.), ribavirin, interferon beta-1a
(Avonex.RTM.), Bioferon, Ingaron, Inmutag (Inferon), Algeron,
Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b
(Axxo), Alfaferone, interferon alfa-2b, Feron, interferon-alpha 2
(CJ), Bevac, Laferonum, Vipeg, Blauferon-B, Blauferon-A, Intermax
Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, alfainterferona
2b, Kalferon, Pegnano, Feronsure, PegiHep, Optipeg A, Realfa 2B,
Reliferon, peginterferon alfa-2b, Reaferon-EC, Proquiferon,
Uniferon, Urifron, interferon alfa-2b, Anterferon, Shanferon,
MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2
(Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai,
Intefen, Sinogen, Fukangtai, Alloferon and celmoleukin.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Continuation of U.S. application Ser.
No. 15/496,283, filed on Apr. 25, 2017, which is a Continuation of
U.S. application Ser. No. 15/059,070, filed on Mar. 2, 2016, now
U.S. Pat. No. 9,670,205, issued on Jun. 6, 2017, which claims
priority to U.S. Provisional Application Nos. 62/128,397, filed
Mar. 4, 2015, and 62/250,403, filed Nov. 3, 2015, all of which are
incorporated herein in their entireties for all purposes.
FIELD
[0002] This application relates generally to toll like receptor
modulator compounds, including diamino pyrido[3,2 D] pyrimidine
compounds, and pharmaceutical compositions which, among other
things, modulate toll-like receptors (e.g. TLR-8), and methods of
making and using them.
BACKGROUND
[0003] The toll-like receptor (TLR) family plays a fundamental role
in pathogen recognition and activation of innate immunity.
Toll-like receptor 8 (TLR-8) is predominantly expressed by myeloid
immune cells and activation of this receptor stimulates a broad
immunological response. Agonists of TLR-8 activate myeloid
dendritic cells, monocytes, monocyte-derived dendridic cells and
Kupffer cells leading to the production of proinflammatory
cytokines and chemokines, such as interleukin-18 (IL-18),
interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF-.alpha.),
and interferon-gamma (IFN-.gamma.). Such agonists also promote the
increased expression of co-stimulatory molecules such as CD8.sup.+
cells, major histocompatibility complex molecules (MAIT, NK cells),
and chemokine receptors.
[0004] Collectively, activation of these innate and adaptive immune
responses induces an immune response and provides a therapeutic
benefit in various conditions involving autoimmunity, inflammation,
allergy, asthma, graft rejection, graft versus host disease (GvHD),
infection, cancer, and immunodeficiency. For example, with respect
to hepatitis B, activation of TLR8 on professional antigen
presenting cells (pAPCs) and other intrahepatic immune cells is
associated with induction of IL-12 and proinflammatory cytokines,
which is expected to augment HBV-specific T cell responses,
activate intrahepatic NK cells and drive reconstitution of
antiviral immunity. See e.g. Wille-Reece, U. et al. J Exp Med 203,
1249-1258 (2006); Peng, G. et al., Science 309, 1380-1384 (2005);
Jo, J. et al., PLoS Pathogens 10, e1004210 (2014) and Watashi, K.
et al., J Biol Chem 288, 31715-31727 (2013).
[0005] Given the potential to treat a wide array of diseases, there
remains a need for novel modulators of toll like receptors, for
example TLR-8. Potent and selective modulators of TLR-8 that have
reduced potential for off target liabilities are particularly
desireable.
SUMMARY
[0006] The present disclosure provides a compound of Formula
(J):
##STR00001##
[0007] or a pharmaceutically acceptable salt thereof, wherein:
[0008] X is N or CR.sup.10; [0009] R.sup.1 is selected from the
group consisting of hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0010] R.sup.2 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b,
--S(O).sub.1-2R.sup.a and OR.sup.a, wherein C.sub.1-6alkyl is
optionally substituted with 1 to 5 R.sup.20 groups; [0011] R.sup.3
is selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups; [0012] R.sup.4 is C.sub.1-12 alkyl which is
optionally substituted with 1 to 5 substituents independently
selected from halogen, --OR.sup.a, --NR.sup.aR.sup.b, CN,
--C(O)R.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b,
--OC(O)NR.sup.aR.sup.b, --NR.sup.aC(O)R.sup.b,
--NR.sup.aC(O)NR.sup.b, --NR.sup.aC(O)OR.sup.b, --SR.sup.a,
--S(O).sub.1-2R.sup.a, --S(O).sub.2NR.sup.aR.sup.b,
--NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6haloalkyl,
C.sub.3-6cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to
6 membered heterocyclyl has 1 to 3 heteroatoms selected from
oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5 to 10 membered
heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3
heteroatoms selected from oxygen, nitrogen, and sulfur; [0013]
wherein each C.sub.3-6cycloalkyl, 3 to 6 membered heterocyclyl,
C.sub.6-10 aryl, and 5 to 10 membered heteroaryl is optionally
substituted with 1 to 5 R.sup.21 groups; [0014] R.sup.10 is
selected from hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups [0015] each R.sup.20 is independently selected from the
group consisting of halogen, C.sub.1-6haloalkyl, CN,
--NR.sup.aR.sup.b, S(O).sub.1-2R.sup.a, and OR.sup.a; [0016] each
R.sup.21 is independently selected from the group consisting of
halogen, C.sub.1-6alkyl, C.sub.1-6haloalkyl, CN, --NR.sup.aR.sup.b,
S(O).sub.1-2R.sup.a, and OR.sup.a; and [0017] each R.sup.a and
R.sup.b are independently selected from the group consisting of
hydrogen and C.sub.1-6alkyl; wherein each C.sub.1-6alkyl is
optionally substituted with 1 to 5 substituents independently
selected from halogen, hydroxyl, amino, 5 to 10 membered heteroaryl
wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, and C.sub.1-6haloalkyl;
[0018] provided that when X is N, R.sup.1 is Cl, R.sup.2 is H and
R.sup.3 is H then R.sup.4 is not CH.sub.2CH.sub.2OMe or
CH.sub.2CH.sub.2SO.sub.2Me.
[0019] The present disclosure provides a compound of Formula
(I):
##STR00002##
[0020] or a pharmaceutically acceptable salt thereof, wherein:
[0021] R.sup.1 is selected from the group consisting of hydrogen,
halogen, C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b,
--S(O).sub.1-2R.sup.a, and OR.sup.a, wherein C.sub.1-6alkyl is
optionally substituted with 1 to 5 R.sup.20 groups; [0022] R.sup.2
is selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups; [0023] R.sup.3 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0024] R.sup.4 is C.sub.1-12 alkyl which is optionally
substituted with 1 to 5 substituents independently selected from
halogen, --OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a,
--C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b,
C.sub.1-6haloalkyl, C.sub.3-6cycloalkyl, 3 to 6 membered
heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3
heteroatoms selected from oxygen, nitrogen, and sulfur, C.sub.6-10
aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered
heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen,
and sulfur; [0025] wherein each C.sub.3-6cycloalkyl, 3 to 6
membered heterocyclyl, C.sub.6-10 aryl, and 5 to 10 membered
heteroaryl is optionally substituted with 1 to 5 R.sup.21 groups;
[0026] each R.sup.20 is independently selected from the group
consisting of halogen, C.sub.1-6haloalkyl, CN, --NR.sup.aR.sup.b,
S(O).sub.1-2R.sup.a, and OR.sup.a; [0027] each R.sup.21 is
independently selected from the group consisting of halogen,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, CN, --NR.sup.aR.sup.b,
S(O).sub.1-2R.sup.a, and OR.sup.a; and [0028] each R.sup.a and
R.sup.b are independently selected from the group consisting of
hydrogen and C.sub.1-6alkyl; wherein each C.sub.1-6alkyl is
optionally substituted with 1 to 5 substituents independently
selected from halogen, hydroxyl, amino, 5 to 10 membered heteroaryl
wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, and C.sub.1-6haloalkyl;
[0029] provided that when R.sup.1 is Cl, R.sup.2 is H and R.sup.3
is H then R.sup.4 is not CH.sub.2CH.sub.2OMe or
CH.sub.2CH.sub.2SO.sub.2Me.
[0030] The present disclosure provides a compound of Formula
(IV):
##STR00003##
wherein: [0031] R.sup.1 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein
C.sub.1-6 alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0032] R.sup.2 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein
C.sub.1-6 alkyl optionally substituted with 1 to 5 R.sup.20 groups;
[0033] R.sup.3 is selected from the group consisting of hydrogen,
halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl
is optionally substituted with 1 to 5 R.sup.20 groups; [0034]
R.sup.11 is selected from the group consisting of C.sub.1-2 alkyl,
C.sub.3-6 cycloalkyl, and C.sub.1-3 haloalkyl; [0035] R.sup.12 is
selected from C.sub.1-3 alkyl, halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-3 alkyl group is optionally substituted with 1
or 2 substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0036] R.sup.13 is selected from C.sub.1-6 alkyl, halogen,
--OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-6 alkyl is optionally substituted with 1 to 2
substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0037] each R.sup.20 is independently selected from the group
consisting of halogen, CN, --NR.sup.aR.sup.b, and OR.sup.a; and
[0038] each R.sup.a and R.sup.b is independently selected from the
group consisting of hydrogen and C.sub.1-3 alkyl, wherein each
C.sub.1-3 alkyl is optionally substituted with 1 to 3 substituents
independently selected from halogen, --OH, and NH.sub.2.
[0039] In certain embodiments, the present disclosure provides a
pharmaceutical composition comprising a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable excipient. In certain embodiments, the
pharmaceutical composition comprises one or more additional
therapeutic agents.
[0040] In certain embodiments, a method of modulating TLR-8 is
provided, comprising administering a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, to an
individual (e.g. a human).
[0041] In certain embodiments, a method of treating or preventing a
disease or condition responsive to the modulation of TLR-8 is
provided, comprising administering to an individual (e.g. a human)
in need thereof a therapeutically effective amount of a compound of
the present disclosure, or a pharmaceutically acceptable salt
thereof. In certain embodiments, the method of treating or
preventing a disease or condition responsive to the modulation of
TLR-8, comprises administering one or more additional therapeutic
agents.
[0042] In certain embodiments, a method of treating or preventing a
viral infection is provided, comprising administering to an
individual (e.g. a human) in need thereof a therapeutically
effective amount a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof.
[0043] In certain embodiments, a method of treating or preventing a
hepatitis B viral infection is provided, comprising administering
to an individual (e.g. a human) in need thereof a therapeutically
effective amount of a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof. In certain embodiments,
the method of treating or preventing a hepatitis B viral infection
comprises administering one or more additional therapeutic agents.
In certain embodiments, the individual is a human infected with
hepatitis B.
[0044] In certain embodiments, a method of treating or preventing a
HIV infection is provided, comprising administering to an
individual (e.g. a human) in thereof a therapeutically effective
amount a compound of the present disclosure, or a pharmaceutically
acceptable salt thereof. In certain embodiments, the method of
treating or preventing a HIV infection comprises administering one
or more additional therapeutic agents. In certain embodiments, the
individual is a human infected with HIV (e.g. HIV-1).
[0045] In certain embodiments, a method of treating a
hyperproliferative disease (e.g. cancer) is provided, comprising
administering to an individual (e.g. a human) in thereof a
therapeutically effective amount a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof. In
certain embodiments, the method of treating a hyperproliferative
disease (e.g. cancer) comprises administering one or more
additional therapeutic agents. In certain embodiments, the
individual is a human.
[0046] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, for use
in medical therapy is provided.
[0047] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, for use
in treating or preventing a disease or condition responsive to the
modulation of TLR-8, is provided. In certain embodiments, the
disease or condition is a viral infection.
[0048] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, for use
in treating or preventing hepatitis B, is provided.
[0049] In certain embodiments, the use of a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, for the
manufacture of a medicament for treating or preventing a disease or
condition responsive to the modulation of TLR-8, is provided.
[0050] In certain embodiments, the use of a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, for the
manufacture of a medicament for treating or preventing hepatitis B,
is provided.
[0051] Kits comprising the compounds, or pharmaceutically
acceptable salts thereof, or pharmaceutical compositions of the
foregoing are also provided. Articles of manufacture comprising a
unit dose of the compounds, or pharmaceutically acceptable salts
thereof, of the foregoing are also provided. Methods of preparing
compounds of the present disclosure are also provided.
DETAILED DESCRIPTION
[0052] The description below is made with the understanding that
the present disclosure is to be considered as an exemplification of
the claimed subject matter, and is not intended to limit the
appended claims to the specific embodiments illustrated. The
headings used throughout this disclosure are provided for
convenience and are not to be construed to limit the claims in any
way. Embodiments illustrated under any heading may be combined with
embodiments illustrated under any other heading.
I. DEFINITIONS
[0053] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art. A dash at the front or end of a chemical
group is a matter of convenience to indicate the point of
attachment to a parent moiety; chemical groups may be depicted with
or without one or more dashes without losing their ordinary
meaning. A prefix such as "C.sub.u-v" or (C.sub.u-C.sub.v)
indicates that the following group has from u to v carbon atoms,
where u and v are integers. For example, "C.sub.1-6alkyl" indicates
that the alkyl group has from 1 to 6 carbon atoms.
[0054] "Alkyl" is a linear or branched saturated monovalent
hydrocarbon. For example, an alkyl group can have 1 to 10 carbon
atoms (i.e., (C.sub.1-10)alkyl) or 1 to 8 carbon atoms (i.e.,
(Cis)alkyl) or 1 to 6 carbon atoms (i.e., (C.sub.1-6 alkyl) or 1 to
4 carbon atoms (i.e., (C.sub.1-4)alkyl). Examples of alkyl groups
include, but are not limited to, methyl (Me, --CH.sub.3), ethyl
(Et, --CH.sub.2CH.sub.3), 1-propyl (n-Pr, n-propyl,
--CH.sub.2CH.sub.2CH.sub.3), 2-propyl (i-Pr, i-propyl,
--CH(CH.sub.3).sub.2), 1-butyl (n-Bu, n-butyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propyl (i-Bu,
i-butyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl (s-Bu, s-butyl,
--CH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propyl (t-Bu, t-butyl,
--C(CH.sub.3).sub.3), 1-pentyl (n-pentyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentyl
(--CH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butyl
(--C(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butyl
(--CH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butyl
(--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2), 2-methyl-1-butyl
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), 1-hexyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-hexyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 3-hexyl
(--CH(CH.sub.2CH.sub.3)(CH.sub.2CH.sub.2CH.sub.3)),
2-methyl-2-pentyl (--C(CH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.3),
3-methyl-2-pentyl (--CH(CH.sub.3)CH(CH.sub.3)CH.sub.2CH.sub.3),
4-methyl-2-pentyl (--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2),
3-methyl-3-pentyl (--C(CH.sub.3)(CH.sub.2CH.sub.3).sub.2),
2-methyl-3-pentyl (--CH(CH.sub.2CH.sub.3)CH(CH.sub.3).sub.2),
2,3-dimethyl-2-butyl (--C(CH.sub.3).sub.2CH(CH.sub.3).sub.2),
3,3-dimethyl-2-butyl (--CH(CH.sub.3)C(CH.sub.3).sub.3, and octyl
(--(CH.sub.2).sub.7CH.sub.3).
[0055] "Alkenyl" is a linear or branched monovalent hydrocarbon
radical with at least one carbon-carbon double bond. For example,
an alkenyl group can have 2 to 8 carbon atoms (i.e., C.sub.2-8
alkenyl), or 2 to 6 carbon atoms (i.e., C.sub.2-6 alkenyl) or 2 to
4 carbon atoms (i.e., C.sub.2-4 alkenyl). Examples of suitable
alkenyl groups include, but are not limited to, ethylene or vinyl
(--CH.dbd.CH.sub.2), allyl (--CH.sub.2CH.dbd.CH.sub.2), 5-hexenyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH.sub.2), and 3-hexenyl
(--CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2CH.sub.2).
[0056] "Alkynyl" is a linear or branched monovalent hydrocarbon
radical with at least one carbon-carbon triple bond. For example,
an alkynyl group can have 2 to 8 carbon atoms (i.e., C.sub.2-8
alkyne) or 2 to 6 carbon atoms (i.e., C.sub.2-6 alkynyl) or 2 to 4
carbon atoms (i.e., C.sub.2-4 alkynyl). Examples of alkynyl groups
include, but are not limited to, acetylenyl (--C.ident.CH),
propargyl (--CH.sub.2C.ident.CH), and
--CH.sub.2--C.ident.C--CH.sub.3.
[0057] The term "halo" or "halogen" as used herein refers to fluoro
(--F), chloro (--Cl), bromo (--Br) and iodo (--I).
[0058] The term "haloalkyl" as used herein refers to an alkyl as
defined herein, wherein one or more hydrogen atoms of the alkyl are
independently replaced by a halo substituent, which may be the same
or different. For example, C.sub.1-8haloalkyl is a C.sub.1-8alkyl
wherein one or more of the hydrogen atoms of the C.sub.1-8alkyl
have been replaced by a halo substituent. Examples of haloalkyl
groups include but are not limited to fluoromethyl,
fluorochloromethyl, difluoromethyl, difluorochloromethyl,
trifluoromethyl, 1,1,1-trifluoroethyl and pentafluoroethyl.
[0059] The term "heteroalkyl" as used herein refers to an alkyl as
defined herein, wherein one or more of the carbon atoms of the
alkyl are replaced by an O, S, or NR.sup.q, wherein each R.sup.q is
independently H or C.sub.1-6alkyl. For example,
C.sub.1-8heteroalkyl intends a heteroalkyl of one to eight carbons
wherein one or more carbon atoms is replaced by a heteroatom (e.g.,
O, S, NR.sup.q, OH, SH or N(R.sup.q).sub.2), which may the same or
different. Examples of heteroalkyls include but are not limited to
methoxymethyl, ethoxymethyl, methoxy, 2-hydroxyethyl and
N,N'-dimethylpropylamine. A heteroatom of a heteroalkyl may
optionally be oxidized or alkylated. A heteroatom may be placed at
any interior position of the heteroalkyl group or at a position at
which the group is attached to the remainder of the molecule.
Examples include, but are not limited to, --CH.sub.2OCH.sub.3,
--CH.sub.2CH.sub.2NHCH.sub.3,
--CH.sub.2CH.sub.2N(CH.sub.3)--CH.sub.3,
--CH.sub.2SCH.sub.2CH.sub.3, --S(O)CH.sub.3,
--CH.sub.2CH.sub.2S(O).sub.2CH.sub.3, --CHCHOCH.sub.3,
--CH.sub.2CHNOCH.sub.3, --CHCHN(CH.sub.3)CH.sub.3,
--CH.sub.2NHOCH.sub.3 and --CH.sub.2OS(CH.sub.3).sub.3
[0060] The term "aryl" as used herein refers to a single all carbon
aromatic ring or a multiple condensed all carbon ring system
wherein at least one of the rings is aromatic. For example, in
certain embodiments, an aryl group has 6 to 20 carbon atoms, 6 to
14 carbon atoms, or 6 to 12 carbon atoms. Aryl includes a phenyl
radical. Aryl also includes multiple condensed ring systems (e.g.,
ring systems comprising 2, 3 or 4 rings) having about 9 to 20
carbon atoms in which at least one ring is aromatic and wherein the
other rings may be aromatic or not aromatic (i.e., carbocycle).
Such multiple condensed ring systems are optionally substituted
with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle
portion of the multiple condensed ring system. The rings of the
multiple condensed ring system can be connected to each other via
fused, spiro and bridged bonds when allowed by valency
requirements. It is also to be understood that when reference is
made to a certain atom-range membered aryl (e.g., 6-10 membered
aryl), the atom range is for the total ring atoms of the aryl. For
example, a 6-membered aryl would include phenyl and a 10-membered
aryl would include naphthyl and 1, 2, 3, 4-tetrahydronaphthyl.
Non-limiting examples of aryl groups include, but are not limited
to, phenyl, indenyl, naphthyl, 1, 2, 3, 4-tetrahydronaphthyl,
anthracenyl, and the like.
[0061] The term "heteroaryl" as used herein refers to a single
aromatic ring that has at least one atom other than carbon in the
ring, wherein the atom is selected from the group consisting of
oxygen, nitrogen and sulfur; "heteroaryl" also includes multiple
condensed ring systems that have at least one such aromatic ring,
which multiple condensed ring systems are further described below.
Thus, "heteroaryl" includes single aromatic rings of from about 1
to 6 carbon atoms and about 1-4 heteroatoms selected from the group
consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen
atoms may also be present in an oxidized form provided the ring is
aromatic. Exemplary heteroaryl ring systems include but are not
limited to pyridyl, pyrimidinyl, oxazolyl or furyl. "Heteroaryl"
also includes multiple condensed ring systems (e.g., ring systems
comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined
above, is condensed with one or more rings selected from
heteroaryls (to form for example 1,8-naphthyridinyl), heterocycles,
(to form for example 1,2,3,4-tetrahydro-1,8-naphthyridinyl),
carbocycles (to form for example 5,6,7,8-tetrahydroquinolyl) and
aryls (to form for example indazolyl) to form the multiple
condensed ring system. Thus, a heteroaryl (a single aromatic ring
or multiple condensed ring system) has about 1-20 carbon atoms and
about 1-6 heteroatoms within the heteroaryl ring. Such multiple
condensed ring systems may be optionally substituted with one or
more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or
heterocycle portions of the condensed ring. The rings of the
multiple condensed ring system can be connected to each other via
fused, spiro and bridged bonds when allowed by valency
requirements. It is to be understood that the individual rings of
the multiple condensed ring system may be connected in any order
relative to one another. It is to be understood that the point of
attachment for a heteroaryl or heteroaryl multiple condensed ring
system can be at any suitable atom of the heteroaryl or heteroaryl
multiple condensed ring system including a carbon atom and a
heteroatom (e.g., a nitrogen). It also to be understood that when a
reference is made to a certain atom-range membered heteroaryl
(e.g., a 5 to 10 membered heteroaryl), the atom range is for the
total ring atoms of the heteroaryl and includes carbon atoms and
heteroatoms. For example, a 5-membered heteroaryl would include a
thiazolyl and a 10-membered heteroaryl would include a quinolinyl.
Exemplary heteroaryls include but are not limited to pyridyl,
pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl,
indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl,
oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl,
benzoxazolyl, indazolyl, quinoxalyl, quinazolyl,
5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl,
thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one,
triazolyl, 4,5,6,7-tetrahydro-1H-indazole and
3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole.
[0062] The term "cycloalkyl" refers to a single saturated or
partially unsaturated all carbon ring having 3 to 20 annular carbon
atoms (i.e., C.sub.3-20 cycloalkyl), for example from 3 to 12
annular atoms, for example from 3 to 10 annular atoms. The term
"cycloalkyl" also includes multiple condensed, saturated and
partially unsaturated all carbon ring systems (e.g., ring systems
comprising 2, 3 or 4 carbocyclic rings). Accordingly, cycloalkyl
includes multicyclic carbocyles such as a bicyclic carbocycles
(e.g., bicyclic carbocycles having about 6 to 12 annular carbon
atoms such as bicyclo[3.1.0]hexane and bicyclo[2.1.1]hexane), and
polycyclic carbocycles (e.g tricyclic and tetracyclic carbocycles
with up to about 20 annular carbon atoms). The rings of a multiple
condensed ring system can be connected to each other via fused,
spiro and bridged bonds when allowed by valency requirements.
Non-limiting examples of monocyclic cycloalkyl include cyclopropyl,
cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl,
1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl,
1-cyclohex-2-enyl and 1-cyclohex-3-enyl.
[0063] The term "heterocyclyl" or "heterocycle" as used herein
refers to a single saturated or partially unsaturated non-aromatic
ring or a non-aromatic multiple ring system that has at least one
heteroatom in the ring (i.e., at least one annular heteroatom
selected from oxygen, nitrogen, and sulfur). Unless otherwise
specified, a heterocyclyl group has from 5 to about 20 annular
atoms, for example from 3 to 12 annular atoms, for example from 5
to 10 annular atoms. Thus, the term includes single saturated or
partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings)
having from about 1 to 6 annular carbon atoms and from about 1 to 3
annular heteroatoms selected from the group consisting of oxygen,
nitrogen and sulfur in the ring. The rings of the multiple
condensed ring system can be connected to each other via fused,
spiro and bridged bonds when allowed by valency requirements.
Heterocycles include, but are not limited to, azetidine, aziridine,
imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine,
piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone,
tetrahydrofuran, tetrahydrothiophene, dihydropyridine,
tetrahydropyridine, quinuclidine, N-bromopyrrolidine,
N-chloropiperidine, and the like.
[0064] The term "oxo" as used herein refers to .dbd.O.
[0065] As used herein, "treatment" or "treating" is an approach for
obtaining beneficial or desired results. For purposes of the
present disclosure, beneficial or desired results include, but are
not limited to, alleviation of a symptom and/or diminishment of the
extent of a symptom and/or preventing a worsening of a symptom
associated with a disease or condition. In one embodiment,
"treatment" or "treating" includes one or more of the following: a)
inhibiting the disease or condition (e.g., decreasing one or more
symptoms resulting from the disease or condition, and/or
diminishing the extent of the disease or condition); b) slowing or
arresting the development of one or more symptoms associated with
the disease or condition (e.g., stabilizing the disease or
condition, delaying the worsening or progression of the disease or
condition); and c) relieving the disease or condition, e.g.,
causing the regression of clinical symptoms, ameliorating the
disease state, delaying the progression of the disease, increasing
the quality of life, and/or prolonging survival.
[0066] A "compound of the present disclosure" includes compounds
disclosed herein, for example a compound of the present disclosure
includes compounds of Formula (J), (I), (Ia), (Ib), (II), (IIa),
(IIb), (III), (IIIa), (IIIb), and the compounds listed in Table 1.
A compound of the present disclosure also includes compounds of
Formula (J), (I), (Ia), (Ib), (II), (IIa), (IIb), (III), (IIIa),
(IIIb), (VI), (IVa), (IVb), (IVc), (IVd), the compounds of Examples
1-113, and the compounds listed in Tables 1 and 3. A compound of
the present disclosure also includes the compounds of Examples
1-118
[0067] As used herein, "delaying" development of a disease or
condition means to defer, hinder, slow, retard, stabilize and/or
postpone development of the disease or condition. This delay can be
of varying lengths of time, depending on the history of the disease
and/or individual being treated. As is evident to one skilled in
the art, a sufficient or significant delay can, in effect,
encompass prevention, in that the individual does not develop the
disease or condition. For example, a method that "delays"
development of AIDS is a method that reduces the probability of
disease development in a given time frame and/or reduces extent of
the disease in a given time frame, when compared to not using the
method. Such comparisons may be based on clinical studies, using a
statistically significant number of subjects. For example, the
development of AIDS can be detected using known methods, such as
confirming an individual's HIV.sup.+ status and assessing the
individual's T-cell count or other indication of AIDS development,
such as extreme fatigue, weight loss, persistent diarrhea, high
fever, swollen lymph nodes in the neck, armpits or groin, or
presence of an opportunistic condition that is known to be
associated with AIDS (e.g., a condition that is generally not
present in individuals with functioning immune systems but does
occur in AIDS patients). Development may also refer to disease
progression that may be initially undetectable and includes
occurrence, recurrence and onset.
[0068] As used herein, "prevention" or "preventing" refers to a
regimen that protects against the onset of the disease or disorder
such that the clinical symptoms of the disease do not develop.
Thus, "prevention" relates to administration of a therapy (e.g.,
administration of a therapeutic substance) to a subject before
signs of the disease are detectable in the subject (e.g.,
administration of a therapeutic substance to a subject in the
absence of detectable infectious agent (e.g., virus) in the
subject). The subject may be an individual at risk of developing
the disease or disorder, such as an individual who has one or more
risk factors known to be associated with development or onset of
the disease or disorder. Thus, in certain embodiments, the term
"preventing HBV infection" refers to administering to a subject who
does not have a detectable HBV infection an anti-HBV therapeutic
substance. It is understood that the subject for anti-HBV
preventative therapy may be an individual at risk of contracting
the HBV virus. Thus, in certain embodiments, the term "preventing
HIV infection" refers to administering to a subject who does not
have a detectable HIV infection an anti-HIV therapeutic substance.
It is understood that the subject for anti-HIV preventative therapy
may be an individual at risk of contracting the HIV virus.
[0069] As used herein, an "at risk" individual is an individual who
is at risk of developing a condition to be treated. An individual
"at risk" may or may not have detectable disease or condition, and
may or may not have displayed detectable disease prior to the
treatment of methods described herein. "At risk" denotes that an
individual has one or more so-called risk factors, which are
measurable parameters that correlate with development of a disease
or condition and are known in the art. An individual having one or
more of these risk factors has a higher probability of developing
the disease or condition than an individual without these risk
factor(s). For example, individuals at risk for AIDS are those
having HIV.
[0070] As used herein, the term "therapeutically effective amount"
or "effective amount" refers to an amount that is effective to
elicit the desired biological or medical response, including the
amount of a compound that, when administered to a subject for
treating a disease, is sufficient to effect such treatment for the
disease. The effective amount will vary depending on the compound,
the disease, and its severity and the age, weight, etc., of the
subject to be treated. The effective amount can include a range of
amounts. As is understood in the art, an effective amount may be in
one or more doses, i.e., a single dose or multiple doses may be
required to achieve the desired treatment endpoint. An effective
amount may be considered in the context of administering one or
more therapeutic agents, and a single agent may be considered to be
given in an effective amount if, in conjunction with one or more
other agents, a desirable or beneficial result may be or is
achieved. Suitable doses of any co-administered compounds may
optionally be lowered due to the combined action (e.g., additive or
synergistic effects) of the compounds.
[0071] As used herein, an "agonist" is a substance that stimulates
its binding partner, typically a receptor. Stimulation is defined
in the context of the particular assay, or may be apparent in the
literature from a discussion herein that makes a comparison to a
factor or substance that is accepted as an "agonist" or an
"antagonist" of the particular binding partner under substantially
similar circumstances as appreciated by those of skill in the art.
Stimulation may be defined with respect to an increase in a
particular effect or function that is induced by interaction of the
agonist or partial agonist with a binding partner and can include
allosteric effects.
[0072] As used herein, an "antagonist" is a substance that inhibits
its binding partner, typically a receptor. Inhibition is defined in
the context of the particular assay, or may be apparent in the
literature from a discussion herein that makes a comparison to a
factor or substance that is accepted as an "agonist" or an
"antagonist" of the particular binding partner under substantially
similar circumstances as appreciated by those of skill in the art.
Inhibition may be defined with respect to a decrease in a
particular effect or function that is induced by interaction of the
antagonist with a binding partner, and can include allosteric
effects.
[0073] As used herein, a "partial agonist" or a "partial
antagonist" is a substance that provides a level of stimulation or
inhibition, respectively, to its binding partner that is not fully
or completely agonistic or antagonistic, respectively. It will be
recognized that stimulation, and hence, inhibition is defined
intrinsically for any substance or category of substances to be
defined as agonists, antagonists, or partial agonists.
[0074] As used herein, "intrinsic activity" or "efficacy" relates
to some measure of biological effectiveness of the binding partner
complex. With regard to receptor pharmacology, the context in which
intrinsic activity or efficacy should be defined will depend on the
context of the binding partner (e.g., receptor/ligand) complex and
the consideration of an activity relevant to a particular
biological outcome. For example, in some circumstances, intrinsic
activity may vary depending on the particular second messenger
system involved. Where such contextually specific evaluations are
relevant, and how they might be relevant in the context of the
present disclosure, will be apparent to one of ordinary skill in
the art.
[0075] "Pharmaceutically acceptable excipient" includes without
limitation any adjuvant, carrier, excipient, glidant, sweetening
agent, diluent, preservative, dye/colorant, flavor enhancer,
surfactant, wetting agent, dispersing agent, suspending agent,
stabilizer, isotonic agent, solvent, or emulsifier which has been
approved by the United States Food and Drug Administration as being
acceptable for use in humans or domestic animals
[0076] As used herein, modulation of a receptor includes agonism,
partial agonism, antagonism, partial antagonism, or inverse agonism
of a receptor.
[0077] The nomenclature used herein to name the subject compounds
is illustrated in the Examples and elsewhere herein.
[0078] As used herein, "co-administration" includes administration
of unit dosages of the compounds disclosed herein before or after
administration of unit dosages of one or more additional
therapeutic agents, for example, administration of the compound
disclosed herein within seconds, minutes, or hours of the
administration of one or more additional therapeutic agents. For
example, in some embodiments, a unit dose of a compound of the
present disclosure is administered first, followed within seconds
or minutes by administration of a unit dose of one or more
additional therapeutic agents. Alternatively, in other embodiments,
a unit dose of one or more additional therapeutic agents is
administered first, followed by administration of a unit dose of a
compound of the present disclosure within seconds or minutes. In
some embodiments, a unit dose of a compound of the present
disclosure is administered first, followed, after a period of hours
(e.g., 1-12 hours), by administration of a unit dose of one or more
additional therapeutic agents. In other embodiments, a unit dose of
one or more additional therapeutic agents is administered first,
followed, after a period of hours (e.g., 1-12 hours), by
administration of a unit dose of a compound of the present
disclosure.
[0079] Provided are also pharmaceutically acceptable salts,
hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of
the compounds described herein. "Pharmaceutically acceptable" or
"physiologically acceptable" refer to compounds, salts,
compositions, dosage forms and other materials which are useful in
preparing a pharmaceutical composition that is suitable for
veterinary or human pharmaceutical use.
[0080] The compounds of described herein may be prepared and/or
formulated as pharmaceutically acceptable salts. Pharmaceutically
acceptable salts are non-toxic salts of a free base form of a
compound that possesses the desired pharmacological activity of the
free base. These salts may be derived from inorganic or organic
acids or bases. For example, a compound that contains a basic
nitrogen may be prepared as a pharmaceutically acceptable salt by
contacting the compound with an inorganic or organic acid.
Non-limiting examples of pharmaceutically acceptable salts include
sulfates, pyrosulfates, bisulfates, sulfites, bisulfites,
phosphates, monohydrogen-phosphates, dihydrogenphosphates,
metaphosphates, pyrophosphates, chlorides, bromides, iodides,
acetates, propionates, decanoates, caprylates, acrylates, formates,
isobutyrates, caproates, heptanoates, propiolates, oxalates,
malonates, succinates, suberates, sebacates, fumarates, maleates,
butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates,
methylbenzoates, dinitrobenzoates, hydroxybenzoates,
methoxybenzoates, phthalates, sulfonates, methylsulfonates,
propylsulfonates, besylates, xylenesulfonates,
naphthalene-1-sulfonates, naphthalene-2-sulfonates, phenylacetates,
phenylpropionates, phenylbutyrates, citrates, lactates,
.gamma.-hydroxybutyrates, glycolates, tartrates, and mandelates.
Lists of other suitable pharmaceutically acceptable salts are found
in Remington: The Science and Practice of Pharmacy, 21.sup.st
Edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa.,
2006.
[0081] Examples of "pharmaceutically acceptable salts" of the
compounds disclosed herein also include salts derived from an
appropriate base, such as an alkali metal (for example, sodium,
potassium), an alkaline earth metal (for example, magnesium),
ammonium and NX.sub.4.sup.+ (wherein X is C.sub.1-C.sub.4 alkyl).
Also included are base addition salts, such as sodium or potassium
salts.
[0082] Provided are also compounds described herein or
pharmaceutically acceptable salts, isomers, or a mixture thereof,
in which from 1 to n hydrogen atoms attached to a carbon atom may
be replaced by a deuterium atom or D, in which n is the number of
hydrogen atoms in the molecule. As known in the art, the deuterium
atom is a non-radioactive isotope of the hydrogen atom. Such
compounds may increase resistance to metabolism, and thus may be
useful for increasing the half-life of the compounds described
herein or pharmaceutically acceptable salts, isomer, or a mixture
thereof when administered to a mammal. See, e.g., Foster,
"Deuterium Isotope Effects in Studies of Drug Metabolism", Trends
Pharmacol. Sci., 5(12):524-527 (1984). Such compounds are
synthesized by means well known in the art, for example by
employing starting materials in which one or more hydrogen atoms
have been replaced by deuterium.
[0083] Examples of isotopes that can be incorporated into the
disclosed compounds also include isotopes of hydrogen, carbon,
nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such
as .sup.2H, .sup.3H, .sup.11C, .sup.13C, .sup.14C, .sup.13N,
.sup.15N, .sup.15O, .sup.17O, .sup.18O, .sup.31P, .sup.32P, 35S,
.sup.18F, .sup.36Cl, .sup.123I, and .sup.125I, respectively.
Substitution with positron emitting isotopes, such as .sup.11C,
.sup.18F, .sup.15O and .sup.13N, can be useful in Positron Emission
Topography (PET) studies for examining substrate receptor
occupancy. Isotopically-labeled compounds of Formula (I), can
generally be prepared by conventional techniques known to those
skilled in the art or by processes analogous to those described in
the Examples as set out below using an appropriate
isotopically-labeled reagent in place of the non-labeled reagent
previously employed.
[0084] The compounds of the embodiments disclosed herein, or their
pharmaceutically acceptable salts may contain one or more
asymmetric centers and may thus give rise to enantiomers,
diastereomers, and other stereoisomeric forms that may be defined,
in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)-
or (L)-for amino acids. The present disclosure is meant to include
all such possible isomers, as well as their racemic and optically
pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)-
and (L)-isomers may be prepared using chiral synthons or chiral
reagents, or resolved using conventional techniques, for example,
chromatography and fractional crystallization. Conventional
techniques for the preparation/isolation of individual enantiomers
include chiral synthesis from a suitable optically pure precursor
or resolution of the racemate (or the racemate of a salt or
derivative) using, for example, chiral high pressure liquid
chromatography (HPLC). When the compounds described herein contain
olefinic double bonds or other centres of geometric asymmetry, and
unless specified otherwise, it is intended that the compounds
include both E and Z geometric isomers. Likewise, all tautomeric
forms are also intended to be included.
[0085] A "stereoisomer" refers to a compound made up of the same
atoms bonded by the same bonds but having different
three-dimensional structures, which are not interchangeable. The
present disclosure contemplates various stereoisomers and mixtures
thereof and includes "enantiomers", which refers to two
stereoisomers whose molecules are non-superimposable mirror images
of one another.
[0086] A "tautomer" refers to a proton shift from one atom of a
molecule to another atom of the same molecule. The present
disclosure includes tautomers of any said compounds.
[0087] A "solvate" is formed by the interaction of a solvent and a
compound. Solvates of salts of the compounds described herein are
also provided. Hydrates of the compounds described herein are also
provided.
[0088] A "prodrug" includes any compound that becomes a compound
described herein when administered to a subject, e.g., upon
metabolic processing of the prodrug.
[0089] The terms "combination antiretroviral therapy" ("cART")
refers to combinations or "cocktails" of antiretroviral medications
used to treat human viral infections, including HIV infections. As
used herein, the terms "combination antiretroviral therapy" and
"cART include combinations and regimens often referred to as Highly
Active Antiretroviral Therapy (HAART). HAART and cART combinations
and regimens commonly include multiple, often two or more, drugs
such as nucleoside reverse transcriptase inhibitors (NRTIs),
non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease
inhibitors (PIs), fusion inhibitors, CCR5 agonists, and/or
integrase inhibitors.
[0090] The terms "latent HIV reservoir", "HIV latent reservoir",
"HIV reservoir", "latent reservoir", and "latent HIV infection"
refer to a condition in which resting CD4+T lymphocytes or other
cells are infected with HIV but are not actively producing HIV. The
presently inactive HIV infected cells are referred to as "latently
infected cells". Antiretroviral therapy (ART) can reduce the level
of HIV in the blood to an undetectable level, while latent
reservoirs of HIV continue to survive. When a latently infected
cell is reactivated, the cell begins to produce HIV (HIV
replication).
II. COMPOUNDS
[0091] The present disclosure provides a compound of Formula
(J):
##STR00004##
[0092] or a pharmaceutically acceptable salt thereof, wherein:
[0093] X is N or CR.sup.10; [0094] R.sup.1 is selected from the
group consisting of hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0095] R.sup.2 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b,
--S(O).sub.1-2R.sup.a and OR.sup.a, wherein C.sub.1-6alkyl is
optionally substituted with 1 to 5 R.sup.20 groups; [0096] R.sup.3
is selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups; [0097] R.sup.4 is C.sub.1-12 alkyl which is
optionally substituted with 1 to 5 substituents independently
selected from halogen, --OR.sup.a, --NR.sup.aR.sup.b, CN,
--C(O)R.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b,
--OC(O)NR.sup.aR.sup.b, --NR.sup.aC(O)R.sup.b,
--NR.sup.aC(O)NR.sup.b, --NR.sup.aC(O)OR.sup.b, --SR.sup.a,
--S(O).sub.1-2R.sup.a, --S(O).sub.2NR.sup.aR.sup.b,
--NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6haloalkyl,
C.sub.3-6cycloalkyl, 3 to 6 membered heterocyclyl wherein the 3 to
6 membered heterocyclyl has 1 to 3 heteroatoms selected from
oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5 to 10 membered
heteroaryl wherein the 5 to 10 membered heteroaryl has 1 to 3
heteroatoms selected from oxygen, nitrogen, and sulfur; [0098]
wherein each C.sub.3-6cycloalkyl, 3 to 6 membered heterocyclyl,
C.sub.6-10 aryl, and 5 to 10 membered heteroaryl is optionally
substituted with 1 to 5 R.sup.21 groups; [0099] R.sup.10 is
selected from hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups each R.sup.20 is independently selected from the group
consisting of halogen, C.sub.1-6haloalkyl, CN, --NR.sup.aR.sup.b,
S(O).sub.1-2R.sup.a, and OR.sup.a; [0100] each R.sup.21 is
independently selected from the group consisting of halogen,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, CN, --NR.sup.aR.sup.b,
S(O).sub.1-2R.sup.a, and OR.sup.a; and [0101] each R.sup.a and
R.sup.b are independently selected from the group consisting of
hydrogen and C.sub.1-6alkyl; wherein each C.sub.1-6alkyl is
optionally substituted with 1 to 5 substituents independently
selected from halogen, hydroxyl, amino, 5 to 10 membered heteroaryl
wherein the 5 to 10 membered heteroaryl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, and C.sub.1-6haloalkyl;
[0102] provided that when X is N, R.sup.1 is Cl, R.sup.2 is H and
R.sup.3 is H then R.sup.4 is not CH.sub.2CH.sub.2OMe or
CH.sub.2CH.sub.2SO.sub.2Me.
[0103] In certain embodiments of Formula (J), X is CR.sup.10. In
certain embodiments of Formula (J), X is N.
[0104] The present disclosure provides a compound of Formula
(I):
##STR00005##
[0105] or a pharmaceutically acceptable salt thereof, wherein:
[0106] R.sup.1 is selected from the group consisting of hydrogen,
halogen, C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b,
--S(O).sub.1-2R.sup.a, and OR.sup.a, wherein C.sub.1-6alkyl is
optionally substituted with 1 to 5 R.sup.20 groups; [0107] R.sup.2
is selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups; [0108] R.sup.3 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0109] R.sup.4 is C.sub.1-12 alkyl which is optionally
substituted with 1 to 5 substituents independently selected from
halogen, --OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a,
--C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b,
C.sub.1-6haloalkyl, C.sub.3-6cycloalkyl, 3 to 6 membered
heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3
heteroatoms selected from oxygen, nitrogen, and sulfur, C.sub.6-10
aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered
heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen,
and sulfur; [0110] wherein each C.sub.3-6cycloalkyl, 3 to 6
membered heterocyclyl, C.sub.6-10 aryl, and 5 to 10 membered
heteroaryl is optionally substituted with 1 to 5 R.sup.21 groups;
[0111] each R.sup.20 is independently selected from the group
consisting of halogen, C.sub.1-6haloalkyl, CN, --NR.sup.aR.sup.b,
S(O).sub.1-2R.sup.a, and OR.sup.a; [0112] each R.sup.21 is
independently selected from the group consisting of halogen,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, CN, --NR.sup.aR.sup.b,
S(O).sub.1-2R.sup.a, and OR.sup.a; and each R.sup.a and R.sup.b are
independently selected from the group consisting of H and
C.sub.1-6alkyl; wherein each C.sub.1-6alkyl is optionally
substituted with 1 to 5 substituents independently selected from
halogen, hydroxyl, amino, 5 to 10 membered heteroaryl wherein the 5
to 10 membered heteroaryl has 1 to 3 heteroatoms selected from
oxygen, nitrogen, and sulfur, and C.sub.1-6haloalkyl; [0113]
provided that when R.sup.1 is Cl, R.sup.2 is H and R.sup.3 is H
then R.sup.4 is not CH.sub.2CH.sub.2OMe or
CH.sub.2CH.sub.2SO.sub.2Me.
[0114] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is C.sub.1-8 alkyl which is optionally substituted with 1
to 5 substituents independently selected from the group consisting
of halogen, --OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a,
--C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b,
C.sub.1-6haloalkyl, C.sub.3-6cycloalkyl, 3 to 6 membered
heterocyclyl wherein the 3 to 6 membered heterocyclyl has 1 to 3
heteroatoms selected from oxygen, nitrogen, and sulfur, C.sub.6-10
aryl, and 5 to 10 membered heteroaryl wherein the 5 to 10 membered
heteroaryl has 1 to 3 heteroatoms selected from oxygen, nitrogen,
and sulfur; and wherein each C.sub.3-6cycloalkyl, 3 to 6 membered
heterocyclyl, C.sub.6-10 aryl, and 5 to 10 membered heteroaryl is
optionally substituted with 1 to 5 R.sup.21 groups.
[0115] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is C.sub.1-6 alkyl optionally substituted with 1 to 5
substituents independently selected from the group consisting of
halogen, --OR.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b,
--SR.sup.a, C.sub.1-6haloalkyl, C.sub.3-6cycloalkyl, 3 to 6
membered heterocyclyl, and C.sub.6-10 aryl; wherein each
C.sub.3-6cycloalkyl, 3 to 6 membered heterocyclyl, and C.sub.6-10
aryl is optionally substituted with 1 to 5 R.sup.21 groups. In
certain embodiments of a compound of Formula (J) or (I), R.sup.4 is
C.sub.3-8 alkyl optionally substituted with 1 to 5 substituents
independently selected from the group consisting of halogen,
--OR.sup.a, --C(O)OR.sup.a, --NR.sup.aC(O)R.sup.b, --SR.sup.a,
C.sub.1-6haloalkyl, C.sub.3-6cycloalkyl, 3 to 6 membered
heterocyclyl, and C.sub.6-10 aryl; wherein each
C.sub.3-6cycloalkyl, 3 to 6 membered heterocyclyl, and C.sub.6-10
aryl is optionally substituted with 1 to 5 R.sup.21 groups.
[0116] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is C.sub.1-6 alkyl optionally substituted with 1 to 3
substituents independently selected from the group consisting of
halogen, --OR.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b,
--SR.sup.a, --C.sub.1-3haloalkyl, C.sub.3-6cycloalkyl, 3 to 6
membered heterocyclyl and C.sub.6-10 aryl; wherein each
C.sub.3-6cycloalkyl and C.sub.6-10 aryl is optionally substituted
with 1 to 3 R.sup.21 groups. In certain embodiments of a compound
of Formula (J) or (I), R.sup.4 is C.sub.3-8 alkyl optionally
substituted with 1 to 3 substituents independently selected from
the group consisting of halogen, --OR.sup.a, --C(O)OR.sup.a,
--NR.sup.aC(O)R.sup.b, --SR.sup.a, --C.sub.1-3haloalkyl,
C.sub.3-6cycloalkyl, 3 to 6 membered heterocyclyl and C.sub.6-10
aryl; wherein each C.sub.3-6cycloalkyl and C.sub.6-10 aryl is
optionally substituted with 1 to 3 R.sup.21 groups.
[0117] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is C.sub.1-6 alkyl optionally substituted with 1 or 2
substituents independently selected halogen, --OR.sup.a,
C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b, --SR.sup.a,
C.sub.1-3haloalkyl, C.sub.3-6cycloalkyl, 3 to 6 membered
heterocyclyl and C.sub.6-10 aryl; wherein each C.sub.3-6cycloalkyl
and C.sub.6-10 aryl is optionally substituted with 1 to 3 R.sup.21
groups and wherein R.sup.a and R.sup.b are each independently
hydrogen or C.sub.1-4alkyl, wherein the C.sub.1-4 alkyl is
optionally substituted with --NH.sub.2, OH, or pyridyl. In certain
embodiments of a compound of Formula (J) or (I), R.sup.4 is
C.sub.3-8 alkyl which is optionally substituted with 1 or 2
substituents independently selected from the group consisting of
halogen, --OR.sup.a, --C(O)OR.sup.a, --NR.sup.aC(O)R.sup.b,
--SR.sup.a, C.sub.1-3haloalkyl, C.sub.3-6cycloalkyl, 3 to 6
membered heterocyclyl and C.sub.6-10 aryl; wherein each
C.sub.3-6cycloalkyl and C.sub.6-10 aryl is optionally substituted
with 1 to 3 R.sup.20 groups and wherein R.sup.a and R.sup.b are
each independently hydrogen or C.sub.1-4alkyl, wherein each
C.sub.1-4 alkyl is optionally substituted with --NH.sub.2, OH, or
pyridyl.
[0118] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is C.sub.1-6 alkyl optionally substituted with 1 or 2
substituents independently selected from the group consisting of
OH, CF.sub.3, --C(O)OH, --C(O)OCH.sub.3, --C(O)NH.sub.2, SCH.sub.3,
--C(O)NHCH.sub.3, --C(O)NHCH.sub.2CH.sub.2NH.sub.2,
--C(O)NHCH.sub.2CH.sub.2OH, --C(O)NHCH.sub.2-pyridyl, phenyl,
tetrahydrofuranyl, and cyclopropyl. In certain embodiments of a
compound of Formula (J) or (I), R.sup.4 is C.sub.3-8 alkyl which is
optionally substituted with 1 or 2 substituents independently
selected from OH, CF.sub.3, --C(O)OH, --C(O)OCH.sub.3, SCH.sub.3,
--NHC(O)CH.sub.3, --NHC(O)CH.sub.2CH.sub.2NH.sub.2,
--NHC(O)CH.sub.2CH.sub.2OH, --NHC(O)CH.sub.2-pyridyl, phenyl,
tetrahydrofuranyl, and cyclopropyl.
[0119] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is C.sub.3-6 alkyl optionally substituted with 1 or 2
substituents independently selected from the group consisting of
OH, CF.sub.3, --C(O)OH, --C(O)OCH.sub.3, --C(O)NH.sub.2, SCH.sub.3,
--C(O)NHCH.sub.3, --C(O)NHCH.sub.2CH.sub.2NH.sub.2,
--C(O)NHCH.sub.2CH.sub.2OH, and --C(O)NHCH.sub.2-pyridyl. In
certain embodiments of a compound of Formula (J) or (I), R.sup.4 is
C.sub.3-6 alkyl which is optionally substituted with 1 or 2
substituents independently selected from OH, CF.sub.3, --C(O)OH,
--C(O)OCH.sub.3, SCH.sub.3, --NHC(O)CH.sub.3,
--NHC(O)CH.sub.2CH.sub.2NH.sub.2, --NHC(O)CH.sub.2CH.sub.2OH,
--NHC(O)CH.sub.2-pyridyl, phenyl, tetrahydrofuranyl, and
cyclopropyl.
[0120] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is C.sub.1-6 alkyl which is optionally substituted with OH.
In certain embodiments of a compound of Formula (J) or (I), R.sup.4
is C.sub.3-8 alkyl which is optionally substituted with OH. In
certain embodiments of a compound of Formula (J) or (I), R.sup.4 is
C.sub.3-8 alkyl which is substituted with --NHC(O)CH.sub.3.
[0121] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is C.sub.3-6 alkyl which is optionally substituted with OH.
In certain embodiments of a compound of Formula (J) or (I), R.sup.4
is C.sub.3-6 alkyl which is substituted with --NHC(O)CH.sub.3.
[0122] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 has at least one chiral center. In certain embodiments, the
at least one chiral center is in the S configuration. In certain
embodiments, the at least one chiral center is in the R
configuration.
[0123] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00006## ##STR00007##
[0124] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00008## ##STR00009## ##STR00010## ##STR00011##
[0125] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00012## ##STR00013##
[0126] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00014##
[0127] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00015##
[0128] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00016##
[0129] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00017## ##STR00018## ##STR00019##
[0130] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00020## ##STR00021##
[0131] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00022## ##STR00023##
[0132] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00024##
[0133] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00025##
[0134] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00026##
[0135] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00027##
[0136] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00028##
[0137] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00029##
[0138] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00030##
[0139] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00031##
[0140] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of:
##STR00032##
[0141] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is selected from the group consisting of
##STR00033## ##STR00034##
[0142] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is
##STR00035##
[0143] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is
##STR00036##
[0144] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is
##STR00037##
[0145] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is
##STR00038##
[0146] In certain embodiments of a compound of Formula (J) or (I),
R.sup.4 is
##STR00039##
[0147] In certain embodiments, the compound of Formula (J) or (I)
is a compound of Formula (II)
##STR00040##
[0148] or a pharmaceutically acceptable salt thereof, wherein:
[0149] R.sup.5 is selected from the group consisting of hydrogen,
halogen, and methyl; [0150] R.sup.6 is selected from the group
consisting of hydrogen, halogen, and methyl; or R.sup.5 and R.sup.6
together form an oxo group; [0151] R.sup.7 is selected from the
group consisting of hydrogen, halogen, OR.sup.a and
NR.sup.aR.sup.b; [0152] R.sup.8 is selected from the group
consisting of hydrogen and methyl; [0153] R.sup.9 is selected from
the group consisting of C.sub.1-4 alkyl, C.sub.3-5cycloalkyl, and
--S--C.sub.1-4alkyl; [0154] R.sup.a and R.sup.b are independently
selected from the group consisting of hydrogen and C.sub.1-6alkyl;
wherein each C.sub.1-6alkyl is optionally substituted with 1 to 3
substituents independently selected from the group consisting of
halogen, hydroxyl, and pyridyl; and R.sup.1, R.sup.2, and R.sup.3
are as otherwise defined herein.
[0155] For example, in Formula (II), (IIa), and (IIb), R.sup.1 is
selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups; R.sup.2 is selected from the group consisting
of hydrogen, halogen, C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b,
--S(O).sub.1-2R.sup.a and OR.sup.a, wherein C.sub.1-6alkyl is
optionally substituted with 1 to 5 R.sup.20 groups; and R.sup.3 is
selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups;
[0156] In certain embodiments, the compound of Formula (II) is a
compound of Formula (IIa)
##STR00041##
[0157] In certain embodiments, the compound of Formula (II) is a
compound of Formula (IIb)
##STR00042##
[0158] In certain embodiments of the compound of Formula (II),
(IIa), or (IIb), R.sup.5 is hydrogen; R.sup.6 is hydrogen; or
R.sup.5 and R.sup.6 together form an oxo group; R.sup.7 is OR.sup.a
or NR.sup.aR.sup.b; R.sup.8 is hydrogen; R.sup.9 is C.sub.1-4
alkyl, cyclopropyl or --SCH.sub.3; R.sup.a and R.sup.b are
independently selected from the group consisting of hydrogen and
C.sub.1-4alkyl; wherein each C.sub.1-4alkyl is optionally
substituted with 1 to 3 substituents independently selected from
halogen, hydroxyl, pyrid-2-yl, and CF.sub.3, and R.sup.1, R.sup.2,
and R.sup.3 are as otherwise defined herein. In certain
embodiments, R.sup.a and R.sup.b are hydrogen. In certain
embodiments, R.sup.7 is OH or NH.sub.2. In certain embodiments,
R.sup.1 and R.sup.2 are hydrogen.
[0159] In certain embodiments of a compound of Formula (IIa),
##STR00043##
is selected from
##STR00044##
[0160] In certain embodiments of a compound of Formula (IIa),
##STR00045##
is selected from
##STR00046##
[0161] In certain embodiments of a compound of formula (IIb),
##STR00047##
is selected from
##STR00048##
[0162] In certain embodiments of a compound of formula (IIb),
##STR00049##
is selected from
##STR00050##
[0163] In certain embodiments of the compound of Formula (II),
(IIa), or (IIb), R.sup.5 is hydrogen, R.sup.6 is hydrogen, or
R.sup.5 and R.sup.6 together form an oxo group, R.sup.7 is OR.sup.a
or NR.sup.aR.sup.b, R.sup.8 is hydrogen, R.sup.9 is C.sub.1-4alkyl,
cyclopropyl or --SCH3, and R.sup.a and R.sup.b are independently
selected from the group consisting of hydrogen and C.sub.1-4alkyl;
wherein each C.sub.1-4alkyl is optionally substituted with 1 to 3
substituents independently selected from halogen, hydroxyl,
pyrid-2-yl, and CF.sub.3. In certain embodiments of the compound of
Formula (II), (IIa), or (IIb), R.sup.7 is OH or NH.sub.2.
[0164] In certain embodiments of a compound of Formula (J), Formula
(I), or Formula (II), the compound is a compound of Formula
(III)
##STR00051##
wherein [0165] R.sup.5 is hydrogen; [0166] R.sup.6 is hydrogen; or
R.sup.5 and R.sup.6 together form an oxo group; [0167] R.sup.7 is
selected from the group consisting of OR.sup.a and NR.sup.aR.sup.b;
[0168] R.sup.a and R.sup.b are independently selected from the
group consisting of hydrogen and C.sub.1-3alkyl; wherein each
C.sub.1-3alkyl is optionally substituted with 1 to 3 substituents
independently selected from the group consisting of halogen and
hydroxyl and R.sup.1, R.sup.2, and R.sup.3 are as otherwise defined
herein.
[0169] In certain embodiments the compound of Formula (III) is a
compound of Formula (IIIa)
##STR00052##
[0170] In certain embodiments the compound of Formula (III) is a
compound of Formula (IIIb)
##STR00053##
[0171] In certain embodiments of the compound of Formula (III),
(IIIa), or (IIIb), R.sup.5 and R.sup.6 are both hydrogen and
R.sup.7 is OR.sup.a, wherein R.sup.a is hydrogen or C.sub.1-3alkyl.
In certain embodiments of the compound of Formula (III), (IIIa), or
(IIIb), R.sup.5 and R.sup.6 are both hydrogen and R.sup.7 is OH. In
certain embodiments of the compound of Formula (III), (IIIa), or
(IIIb), R.sup.1, R.sup.2, R.sup.5, and R.sup.6 are each hydrogen,
and R.sup.7 is OH.
[0172] In certain embodiments of the compound of Formula (III),
(IIIa), or (IIIb), R.sup.5 and R.sup.6 together form an oxo group
and R.sup.7 is selected from the group consisting of OR.sup.a and
NR.sup.aR.sup.b, wherein R.sup.a and R.sup.b are independently
selected from the group consisting of hydrogen and C.sub.1-3alkyl.
In certain embodiments of the compound of Formula (III), (IIIa), or
(IIIb), R.sup.5 and R.sup.6 together form an oxo group and R.sup.7
is selected from the group consisting of OR.sup.a and
NR.sup.aR.sup.b, wherein R.sup.a and R.sup.b are independently
selected from the group consisting of hydrogen and methyl.
[0173] In certain embodiments of a compound of Formula (J), or
Formula (I), the compound is a compound of Formula (IV):
##STR00054##
[0174] The R.sup.1, R.sup.2, and R.sup.3 groups of Formula (IV) are
as defined above for Formula (J) or (I). The R.sup.11, R.sup.12 and
R.sup.13 groups are as defined above for R.sup.4 in Formula (J) or
Formula (I).
[0175] In certain embodiments, the compound of Formula (IV), or a
pharmaceutically acceptable salt thereof, is a compound of Formula
(IVa):
##STR00055##
[0176] In certain embodiments, the compound of Formula (IV), or a
pharmaceutically acceptable salt thereof, is a compound of Formula
(IVb):
##STR00056##
[0177] The groups R.sup.1, R.sup.2, R.sup.3, R.sup.11, R.sup.12 and
R.sup.13 of Formula (IVa) and (IVb) are as defined for Formula (J),
(I) or (IV) above, or as defined below, or any combination
thereof.
[0178] R.sup.1 of Formula (IV), (IVa) and (IVb) can be any suitable
group selected from hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups. In certain embodiments, R.sup.1 is selected from hydrogen,
halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl
is optionally substituted with 1 to 5 R.sup.20 groups. In certain
embodiments, R.sup.1 can be hydrogen, halogen, and C.sub.1-3 alkyl,
wherein C.sub.1-3 alkyl is optionally substituted with 1 to 5
halogen groups. In certain embodiments, R.sup.1 can be hydrogen,
fluoro, chloro, bromo, methyl or ethyl, wherein each methyl or
ethyl group is optionally substituted with 1 to 5 halogen groups.
In certain embodiments, R.sup.1 can be hydrogen, fluoro, chloro,
bromo, methyl or ethyl, wherein each methyl or ethyl group is
optionally substituted with 1 to 5 fluoro groups. In certain
embodiments, R.sup.1 can be hydrogen, methyl, fluoro, chloro, and
CF.sub.3. In certain embodiments, R.sup.1 can be hydrogen. In
certain embodiments, R.sup.1 is selected from hydrogen, halogen,
NH.sub.2, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6
alkyl is optionally substituted with 1 to 5 R.sup.20 groups.
[0179] R.sup.2 of Formula (IV), (IVa) and (IVb) can be any suitable
group selected from hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups. In certain embodiments, R.sup.2 is selected from hydrogen,
halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl
optionally substituted with 1 to 5 R.sup.20 groups. In certain
embodiments, R.sup.2 is selected from hydrogen, halogen, C.sub.1-3
alkyl, CN and OR.sup.a, wherein C.sub.1-3 alkyl is optionally
substituted with 1 to 5 halogen groups. In certain embodiments,
R.sup.2 is selected from hydrogen, methyl, ethyl, fluoro, chloro,
bromo, CF.sub.3, CN, OH, OMe, and OEt. In certain embodiments,
R.sup.2 is selected from hydrogen, methyl, fluoro, and chloro. In
certain embodiments, R.sup.2 is selected from hydrogen and fluoro.
In certain embodiments, R.sup.2 is selected from hydrogen, halogen,
NH.sub.2, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6
alkyl is optionally substituted with 1 to 5 R.sup.20 groups. In
certain embodiments, R.sup.2 is selected from hydrogen, methyl,
ethyl, NH.sub.2, fluoro, chloro, bromo, CF.sub.3, CN, OH, OMe, and
OEt.
[0180] R.sup.3 of Formula (IV), (IVa) and (IVb) can be any suitable
group selected from hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups. In certain embodiments, R.sup.3 is selected from hydrogen,
halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl
is optionally substituted with 1 to 5 R.sup.20 groups. In certain
embodiments, R.sup.3 can be selected from hydrogen, halogen, and
C.sub.1-3 alkyl. In certain embodiments, R.sup.3 can be selected
from hydrogen, methyl, fluoro, and chloro. In certain embodiments,
R.sup.3 can be selected from hydrogen and methyl. In certain
embodiments, R.sup.3 is selected from hydrogen, halogen, NH.sub.2,
C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl is
optionally substituted with 1 to 5 R.sup.20 groups.
[0181] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein R.sup.1 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b,
--S(O).sub.1-2R.sup.a, and OR.sup.a, wherein C.sub.1-6alkyl is
optionally substituted with 1 to 5 R.sup.20 groups, R.sup.2 is
selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups, and R.sup.3 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups.
[0182] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein R.sup.1 is selected from the group consisting of
hydrogen, halogen, and C.sub.1-3 alkyl, wherein C.sub.1-3 alkyl is
optionally substituted with 1 to 5 halogen groups, R.sup.2 is
selected from the group consisting of hydrogen, halogen, C.sub.1-3
alkyl, CN and OR.sup.a, wherein C.sub.1-3 alkyl is optionally
substituted with 1 to 5 halogen groups, and R.sup.3 is selected
from the group consisting of hydrogen, halogen, and C.sub.1-3
alkyl.
[0183] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein R.sup.1 is selected from the group consisting of
hydrogen, methyl, fluoro, chloro, and CF.sub.3, R.sup.2 is selected
from the group consisting of hydrogen, methyl, ethyl, fluoro,
chloro, bromo, CF.sub.3, CN, OH, OMe, and OEt, and R.sup.3 is
selected from the group consisting of hydrogen, methyl, fluoro, and
chloro.
[0184] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein R.sup.1 is selected from the group consisting of
hydrogen, methyl, fluoro, chloro, and CF.sub.3, R.sup.2 is selected
from the group consisting of hydrogen, methyl, ethyl, NH.sub.2,
fluoro, chloro, bromo, CF.sub.3, CN, OH, OMe, and OEt, and R.sup.3
is selected from the group consisting of hydrogen, methyl, fluoro,
and chloro.
[0185] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein R.sup.1 is hydrogen, R.sup.2 is selected from the
group consisting of hydrogen, methyl, ethyl, fluoro, chloro, and
bromo, and R.sup.3 is selected from the group consisting of
hydrogen and methyl.
[0186] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein R.sup.1 is hydrogen. R.sup.2 is selected from the
group consisting of hydrogen and fluoro, and R.sup.3 is selected
from the group consisting of hydrogen and methyl.
[0187] In certain embodiments, R.sup.11 of Formula (IV), (IVa) and
(IVb) can be any suitable group selected from hydrogen, C.sub.1-2
alkyl, C.sub.3-6 cycloalkyl, and C.sub.1-3 haloalkyl. In certain
embodiments, the compound of Formula (IV), (IVa) or (IVb), or a
pharmaceutically acceptable salt thereof, is the compound wherein
R.sup.11 is selected from the group consisting of hydrogen,
C.sub.1-2 alkyl and C.sub.1-2 haloalkyl. In certain embodiments,
the compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically
acceptable salt thereof, is the compound wherein R.sup.11 is
selected from the group consisting of C.sub.1-2 alkyl and C.sub.1-2
haloalkyl. In certain embodiments, the compound of Formula (IV),
(IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is
the compound wherein R.sup.11 can be selected from hydrogen,
methyl, ethyl or CF.sub.3. In certain embodiments, the compound of
Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, is the compound wherein R.sup.11 can be selected from
methyl, ethyl or CF.sub.3. In certain embodiments, the compound of
Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, is the compound wherein R.sup.11 can be selected from
hydrogen, methyl, or CF.sub.3. In certain embodiments, the compound
of Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable
salt thereof, is the compound wherein R.sup.11 can be selected from
methyl, or CF.sub.3. In certain embodiments, the compound of
Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, is the compound wherein R.sup.11 can be selected from
hydrogen or methyl. In certain embodiments, the compound of Formula
(IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, wherein R.sup.11 is selected from the group consisting of
methyl and CF.sub.3. In certain embodiments, the compound of
Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, is the compound wherein R.sup.11 is methyl. In certain
embodiments, the compound of Formula (IV), (IVa) or (IVb), or a
pharmaceutically acceptable salt thereof, is the compound wherein
R.sup.11 is hydrogen.
[0188] R.sup.12 of Formula (IV), (IVa) and (IVb) can be any
suitable group selected from C.sub.1-3 alkyl, halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-3 alkyl group is optionally substituted with 1
to 5 substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and
sulfur.
[0189] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, wherein
R.sup.12 can be selected from C.sub.1-2 alkyl,
--C(O)NR.sup.aR.sup.b, and 5 membered heteroaryl having 1 to 3
nitrogen heteroatoms, wherein C.sub.1-2 alkyl is optionally
substituted with 1 to 5 substituents independently selected from
halogen, --OH, --NR.sup.aR.sup.b, --NR.sup.aC(O)R.sup.b,
--NR.sup.aS(O).sub.2R.sup.b, and C.sub.1-3 haloalkyl, and each
R.sup.a and R.sup.b is independently selected from the group
consisting of hydrogen and C.sub.1-3 alkyl, wherein each C.sub.1-3
alkyl is optionally substituted with 1 to 3 substituents
independently selected from hydroxyl and amino. In certain
embodiments, the compound of Formula (IV), (IVa) or (IVb), or a
pharmaceutically acceptable salt thereof, wherein R.sup.12 is
C.sub.1-2 alkyl, optionally substituted with 1 to 3 substituents
independently selected from halogen, --OH, --NH.sub.2,
--NHC(O)--C.sub.1-3 alkyl, --NHS(O).sub.2--C.sub.1-3 alkyl, and
C.sub.1-3 haloalkyl. In certain embodiments, the compound of
Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, wherein R.sup.12 is methyl or ethyl, each optionally
substituted with 1 or 2 substituents independently selected from
halogen, --OH, --NH.sub.2, --NHC(O)--C.sub.1-3 alkyl, and C.sub.1-3
haloalkyl. In certain embodiments, the compound of Formula (IV),
(IVa) or (IVb), or a pharmaceutically acceptable salt thereof,
wherein R.sup.12 is methyl or ethyl, wherein the methyl or ethyl is
substituted with 1 or 2 substituents independently selected from
--OH and --NHC(O)CH.sub.3. In certain embodiments, the compound of
Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, wherein R.sup.12 can be selected from CH.sub.2OH,
CH.sub.2CH.sub.2OH, CH(Me)OH, CH(CH.sub.2F)OH, CH(CHF.sub.2)OH,
CH(CF.sub.3)OH, CF.sub.3, CH.sub.2NH.sub.2, CH.sub.2NHC(O)Me,
CH(CH.sub.2F)NHC(O)Me, CH.sub.2NHS(O).sub.2Me, C(O)NH.sub.2,
C(O)NHMe, C(O)NH--CH.sub.2CH.sub.2OH,
C(O)NH--CH.sub.2CH.sub.2NH.sub.2, C(O)NH-(pyridin-2-ylmethyl),
imidazolyl, and triazolyl. In certain embodiments, the compound of
Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, wherein R.sup.12 can be selected from CH.sub.2OH,
CH(Me)OH, CH(CH.sub.2F)OH, and CH.sub.2NHC(O)Me. In certain
embodiments, the compound of Formula (IV), (IVa) or (IVb), or a
pharmaceutically acceptable salt thereof, wherein R.sup.12 can be
selected from CH.sub.2OH, CH(Me)OH, and CH.sub.2NHC(O)Me. In
certain embodiments, the compound of Formula (IV), (IVa) or (IVb),
or a pharmaceutically acceptable salt thereof, wherein R.sup.12 is
--CH.sub.2OH or --CH.sub.2NC(O)CH.sub.3.
[0190] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, wherein
R.sup.12 is C.sub.1-2 alkyl substituted with --NR.sup.aC(O)R.sup.b,
wherein each R.sup.a and R.sup.b is independently selected from the
group consisting of hydrogen and C.sub.1-3 alkyl, wherein each
C.sub.1-3 alkyl is optionally substituted with 1 to 3 substituents
independently selected from hydroxyl and amino.
[0191] R.sup.13 of Formula (IV), (IVa) and (IVb) can be any
suitable group selected from C.sub.1-6 alkyl, halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-6 alkyl is optionally substituted with 1 to 5
substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and
sulfur.
[0192] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein R.sup.13 is C.sub.3-6 alkyl optionally substituted
with 1 to 2 substituents independently selected from halogen and
--OH. In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein R.sup.13 is C.sub.3-6 alkyl optionally substituted
with 1 to 2 halogen substituents. In certain embodiments, the
compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically
acceptable salt thereof, is the compound wherein R.sup.13 is
C.sub.3-6 alkyl. Representative C.sub.3-6 alkyl groups for R.sup.13
include, but are not limited to, n-propyl, iso-propyl, n-butyl,
sec-butyl, iso-butyl, tert-butyl, n-pentyl, tert-pentyl, neopentyl,
isopentyl, sec-pentyl and 3-pentyl. In certain embodiments, the
compound of Formula (IV), (IVa) or (IVb), or a pharmaceutically
acceptable salt thereof, is the compound wherein R.sup.13 is
propyl, butyl or pentyl. In certain embodiments, the compound of
Formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt
thereof, is the compound wherein R.sup.13 is n-propyl, n-butyl or
n-pentyl. In certain embodiments, the compound of Formula (IV),
(IVa) or (IVb), or a pharmaceutically acceptable salt thereof, is
the compound wherein R.sup.13 is propyl or butyl.
[0193] R.sup.20 of Formula (IV), (IVa) and (IVb) can be any
suitable group selected from halogen, C.sub.1-6haloalkyl, CN,
--NR.sup.aR.sup.b, S(O).sub.1-2R.sup.a, and OR.sup.a. In certain
embodiments, each R.sup.20 can independently be selected from
halogen, CN, --NR.sup.aR.sup.b, and OR.sup.a. In certain
embodiments, each R.sup.20 can independently be selected from
halogen, CN, --NR.sup.aR.sup.b, and OR.sup.a. In certain
embodiments, each R.sup.20 can independently be halogen. In certain
embodiments, each R.sup.20 can independently be selected from
fluoro, chloro, bromo, CN, --NH.sub.2, OH, OMe, and OEt. In certain
embodiments, each R.sup.20 can independently be selected from
fluoro and chloro.
[0194] R.sup.a and R.sup.b of Formula (IV), (IVa) and (IVb) can
each independently be any suitable group selected from the group
consisting of hydrogen and C.sub.1-6alkyl; wherein each
C.sub.1-6alkyl is optionally substituted with 1 to 5 substituents
independently selected from halogen, hydroxyl, amino, 5 to 10
membered heteroaryl wherein the 5 to 10 membered heteroaryl has 1
to 3 heteroatoms selected from oxygen, nitrogen, and sulfur, and
C.sub.1-6haloalkyl. In certain embodiments, R.sup.a and R.sup.b can
each independently be selected from hydrogen and C.sub.1-3 alkyl,
wherein each C.sub.1-3 alkyl is optionally substituted with 1 to 3
substituents independently selected from halogen, hydroxyl, amino,
and C.sub.1-6 haloalkyl. In certain embodiments, R.sup.a and
R.sup.b can each independently be selected from hydrogen and
C.sub.1-3 alkyl, wherein each C.sub.1-3 alkyl is optionally
substituted with 1 to 3 substituents independently selected from
hydroxyl and amino. In certain embodiments, R.sup.a and R.sup.b can
each independently be selected from hydrogen and C.sub.1-3 alkyl,
wherein each C.sub.1-3 alkyl is optionally substituted with 1
substituent selected from hydroxyl and amino. In certain
embodiments, R.sup.a and R.sup.b can each independently be selected
from hydrogen and C.sub.1-3 alkyl. In certain embodiments, R.sup.a
and R.sup.b can each independently be selected from hydrogen,
methyl, ethyl, propyl, butyl, CF.sub.3, CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2CF.sub.3, CH.sub.2OH, CH.sub.2CH.sub.2OH,
CH.sub.2NH.sub.2, and CH.sub.2CH.sub.2NH.sub.2. In certain
embodiments, R.sup.a and R.sup.b can each independently be selected
from hydrogen, methyl, ethyl, CF.sub.3, CH.sub.2OH,
CH.sub.2CH.sub.2OH, CH.sub.2NH.sub.2, and CH.sub.2CH.sub.2NH.sub.2.
In certain embodiments, R.sup.a and R.sup.b can each independently
be selected from hydrogen, methyl, ethyl, CH.sub.2CH.sub.2OH, and
CH.sub.2CH.sub.2NH.sub.2. In certain embodiments, R.sup.a and
R.sup.b can each independently be selected from hydrogen, methyl
and ethyl. In certain embodiments, R.sup.a and R.sup.b can each
independently be selected from hydrogen and methyl.
[0195] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein: [0196] R.sup.1 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0197] R.sup.2 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b,
--S(O).sub.1-2R.sup.a and OR.sup.a, wherein C.sub.1-6alkyl is
optionally substituted with 1 to 5 R.sup.20 groups; [0198] R.sup.3
is selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups; [0199] R.sup.11 is selected from the group
consisting of hydrogen, C.sub.1-2 alkyl, C.sub.3-6 cycloalkyl, and
C.sub.1-3 haloalkyl; [0200] R.sup.12 is selected from C.sub.1-3
alkyl, halogen, --OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a,
--C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-3 alkyl group is optionally substituted with 1
to 5 substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0201] R.sup.13 is selected from C.sub.1-6 alkyl, halogen,
--OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-6 alkyl is optionally substituted with 1 to 5
substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0202] each R.sup.20 is independently selected from the group
consisting of halogen, CN, --NR.sup.aR.sup.b, and OR.sup.a; and
[0203] each R.sup.a and R.sup.b is independently selected from the
group consisting of hydrogen and C.sub.1-3 alkyl, wherein each
C.sub.1-3 alkyl is optionally substituted with 1 to 3 substituents
independently selected from halogen, hydroxyl, amino, and C.sub.1-6
haloalkyl.
[0204] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein: [0205] R.sup.1 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6alkyl, CN,
--NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and OR.sup.a, wherein
C.sub.1-6alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0206] R.sup.2 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b,
--S(O).sub.1-2R.sup.a and OR.sup.a, wherein C.sub.1-6alkyl is
optionally substituted with 1 to 5 R.sup.20 groups; [0207] R.sup.3
is selected from the group consisting of hydrogen, halogen,
C.sub.1-6alkyl, CN, --NR.sup.aR.sup.b, --S(O).sub.1-2R.sup.a, and
OR.sup.a, wherein C.sub.1-6alkyl is optionally substituted with 1
to 5 R.sup.20 groups; [0208] R.sup.11 is selected from the group
consisting of C.sub.1-2 alkyl, C.sub.3-6 cycloalkyl, and C.sub.1-3
haloalkyl; [0209] R.sup.12 is selected from C.sub.1-3 alkyl,
halogen, --OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a,
--C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-3 alkyl group is optionally substituted with 1
to 5 substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0210] R.sup.13 is selected from C.sub.1-6 alkyl, halogen,
--OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-6 alkyl is optionally substituted with 1 to 5
substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0211] each R.sup.20 is independently selected from the group
consisting of halogen, CN, --NR.sup.aR.sup.b, and OR.sup.a; and
[0212] each R.sup.a and R.sup.b is independently selected from the
group consisting of hydrogen and C.sub.1-3 alkyl, wherein each
C.sub.1-3 alkyl is optionally substituted with 1 to 3 substituents
independently selected from halogen, hydroxyl, amino, and C.sub.1-6
haloalkyl.
[0213] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein: [0214] R.sup.1 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a,
wherein C.sub.1-6 alkyl is optionally substituted with 1 to 5
R.sup.20 groups; [0215] R.sup.2 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a,
wherein C.sub.1-6 alkyl optionally substituted with 1 to 5 R.sup.20
groups; [0216] R.sup.3 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein
C.sub.1-6 alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0217] R.sup.11 is selected from the group consisting of
hydrogen, C.sub.1-2 alkyl, C.sub.3-6 cycloalkyl, and C.sub.1-3
haloalkyl; [0218] R.sup.12 is selected from C.sub.1-3 alkyl,
halogen, --OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a,
--C(O)OR.sup.a, --C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-3 alkyl group is optionally substituted with 1
to 5 substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0219] R.sup.13 is selected from C.sub.1-6 alkyl, halogen,
--OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-6 alkyl is optionally substituted with 1 to 5
substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0220] each R.sup.20 is independently selected from the group
consisting of halogen, CN, --NR.sup.aR.sup.b, and OR.sup.a; and
[0221] each R.sup.a and R.sup.b is independently selected from the
group consisting of hydrogen and C.sub.1-3 alkyl, wherein each
C.sub.1-3 alkyl is optionally substituted with 1 to 3 substituents
independently selected from halogen, hydroxyl, amino, and C.sub.1-6
haloalkyl.
[0222] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, is the
compound wherein: [0223] R.sup.1 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a,
wherein C.sub.1-6 alkyl is optionally substituted with 1 to 5
R.sup.20 groups; [0224] R.sup.2 is selected from the group
consisting of hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a,
wherein C.sub.1-6 alkyl optionally substituted with 1 to 5 R.sup.20
groups; [0225] R.sup.3 is selected from the group consisting of
hydrogen, halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein
C.sub.1-6 alkyl is optionally substituted with 1 to 5 R.sup.20
groups; [0226] R.sup.11 is selected from the group consisting of
C.sub.1-2 alkyl, C.sub.3-6 cycloalkyl, and C.sub.1-3 haloalkyl;
[0227] R.sup.12 is selected from C.sub.1-3 alkyl, halogen,
--OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-3 alkyl group is optionally substituted with 1
to 5 substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-3
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0228] R.sup.13 is selected from C.sub.1-6 alkyl, halogen,
--OR.sup.a, --NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.1-2R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur,
wherein the C.sub.1-6 alkyl is optionally substituted with 1 to 5
substituents independently selected from halogen, --OR.sup.a,
--NR.sup.aR.sup.b, CN, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --OC(O)NR.sup.aR.sup.b,
--NR.sup.aC(O)R.sup.b, --NR.sup.aC(O)NR.sup.b,
--NR.sup.aC(O)OR.sup.b, --SR.sup.a, --S(O).sub.12R.sup.a,
--S(O).sub.2NR.sup.aR.sup.b, --NR.sup.aS(O).sub.2R.sup.b, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, 3 to 6 membered heterocyclyl
wherein the 3 to 6 membered heterocyclyl has 1 to 3 heteroatoms
selected from oxygen, nitrogen, and sulfur, C.sub.6-10 aryl, and 5
to 10 membered heteroaryl wherein the 5 to 10 membered heteroaryl
has 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur;
[0229] each R.sup.20 is independently selected from the group
consisting of halogen, CN, --NR.sup.aR.sup.b, and OR.sup.a; and
[0230] each R.sup.a and R.sup.b is independently selected from the
group consisting of hydrogen and C.sub.1-3 alkyl, wherein each
C.sub.1-3 alkyl is optionally substituted with 1 to 3 substituents
independently selected from halogen, hydroxyl, amino, and C.sub.1-6
haloalkyl.
[0231] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, wherein
R.sup.11 is methyl or CF.sub.3, R.sup.12 is --CH.sub.2OH,
--CH(Me)OH or --CH.sub.2NHC(O)CH.sub.3, and R.sup.13 is selected
from the group consisting of propyl, butyl and pentyl.
[0232] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, wherein
R.sup.11 is methyl or CF.sub.3, R.sup.12 is --CH.sub.2OH,
--CH(Me)OH, CH.sub.2NHCH(CH.sub.3)(CF.sub.3) or
--CH.sub.2NHC(O)CH.sub.3, and R.sup.13 is selected from the group
consisting of propyl, butyl and pentyl.
[0233] In certain embodiments, the compound of Formula (IV), (IVa)
or (IVb), or a pharmaceutically acceptable salt thereof, wherein
R.sup.11 is methyl, R.sup.12 is --CH.sub.2OH or
--CH.sub.2NHC(O)CH.sub.3, and R.sup.13 is selected from the group
consisting of propyl and butyl.
[0234] In certain embodiments, the compound of Formula (IV), or a
pharmaceutically acceptable salt thereof, wherein the moiety
##STR00057##
is
##STR00058##
[0235] In certain embodiments, the compound of Formula (IV), or a
pharmaceutically acceptable salt thereof, wherein the moiety
##STR00059##
is
##STR00060##
[0236] In certain embodiments, the compound of Formula (IV) or
(IVa), or a pharmaceutically acceptable salt thereof, wherein the
moiety
##STR00061##
is
##STR00062##
[0237] In certain embodiments, the compound of Formula (IV) or
(IVa), or a pharmaceutically acceptable salt thereof, wherein the
moiety
##STR00063##
is
##STR00064##
[0238] In certain embodiments, the compound of Formula (IV) or
(IVa), or a pharmaceutically acceptable salt thereof, wherein the
moiety is
##STR00065##
[0239] In certain embodiments, the compound of Formula (IV) or
(IVa), or a pharmaceutically acceptable salt thereof, wherein the
moiety
##STR00066##
is
##STR00067##
[0240] In certain embodiments, the compound of Formula (IV) or
(IVa), or a pharmaceutically acceptable salt thereof, wherein the
moiety
##STR00068##
can also be drawn as the moiety
##STR00069##
[0241] In certain embodiments, the compound of Formula (IV) or
(IVb), or a pharmaceutically acceptable salt thereof, wherein the
moiety
##STR00070##
is
##STR00071##
[0242] In certain embodiments, the compound of Formula (IV) or
(IVb), or a pharmaceutically acceptable salt thereof, wherein the
moiety
##STR00072##
can also be drawn as the moiety
##STR00073##
[0243] In certain embodiments, the compound of Formula (IV) or
(IVa), or a pharmaceutically acceptable salt thereof, is a compound
of Formula (IVc)
##STR00074##
[0244] The R.sup.2, R.sup.12 and R.sup.13 groups of Formula (IVc)
are as defined above for Formula (J), (I), (IV) or (IVa), or any
combination thereof. For example, R.sup.2 can be selected from
hydrogen, halogen, C.sub.1-3 alkyl, CN and OR.sup.a, wherein
C.sub.1-3 alkyl is optionally substituted with 1 to 5 halogen
groups, R.sup.12 can be selected from C.sub.1-2 alkyl,
--C(O)NR.sup.aR.sup.b, and 5 membered heteroaryl having 1 to 3
nitrogen heteroatoms, wherein C.sub.1-2 alkyl is optionally
substituted with 1 to 5 substituents independently selected from
halogen, --OH, --NR.sup.aR.sup.b, --NR.sup.aC(O)R.sup.b,
--NR.sup.aS(O).sub.2R.sup.b, and C.sub.1-3 haloalkyl, and R.sup.13
can be C.sub.3-6 alkyl optionally substituted with 1 to 2
substituents independently selected from halogen and --OH. In
certain embodiments, the compound of Formula (IV), (IVa), or (IVc),
or a pharmaceutically acceptable salt thereof, is a compound
wherein R.sup.2 can be selected from hydrogen, methyl, ethyl,
fluoro, chloro, bromo, CF.sub.3, CN, OH, OMe, and OEt, and R.sup.12
can be selected CH.sub.2OH, CH.sub.2CH.sub.2OH, CH(Me)OH,
CH(CH.sub.2F)OH, CH(CHF.sub.2)OH, CH(CF.sub.3)OH, CF.sub.3,
CH.sub.2NH.sub.2, CH.sub.2NHC(O)Me, CH(CH.sub.2F)NHC(O)Me,
CH.sub.2NHS(O).sub.2Me, C(O)NH.sub.2, C(O)NHMe,
C(O)NH--CH.sub.2CH.sub.2OH, C(O)NH--CH.sub.2CH.sub.2NH.sub.2,
C(O)NH-(pyridin-2-ylmethyl), imidazolyl, and triazolyl, and
R.sup.13 can be propyl, butyl or pentyl. In certain embodiments,
the compound of Formula (IV), (IVa), or (IVc), or a
pharmaceutically acceptable salt thereof, is a compound wherein
R.sup.2 can be selected from hydrogen, methyl, fluoro, and chloro,
and R.sup.12 can be selected CH.sub.2OH, CH(Me)OH, CH(CH.sub.2F)OH,
and CH.sub.2NHC(O)Me, and R.sup.13 can be propyl, butyl or pentyl.
In certain embodiments, the compound of Formula (IV), (IVa), or
(IVc), or a pharmaceutically acceptable salt thereof, is a compound
wherein R.sup.2 is hydrogen or fluoro, R.sup.12 is --CH.sub.2OH or
--CH.sub.2NHC(O)CH.sub.3, and R.sup.13 is selected from propyl and
butyl. In certain embodiments, the compound of Formula (IV), (IVa),
or (IVc), or a pharmaceutically acceptable salt thereof, is a
compound wherein R.sup.2 is hydrogen, chloro, or fluoro, R.sup.12
is --CH.sub.2OH or --CH.sub.2NHC(O)CH.sub.3, and R.sup.13 is
selected from butyl or pentyl.
[0245] In certain embodiments, the compound of Formula (IV) or
(IVa), or a pharmaceutically acceptable salt thereof, is a compound
of Formula (IVd)
##STR00075##
[0246] The R.sup.1, R.sup.2, R.sup.3, R.sup.11, R.sup.13, R.sup.a
and R.sup.b groups of Formula (IVd) can be as defined above for
Formula (J), (I), (IV), or (IVa), or any combination thereof.
R.sup.12a can be any suitable group selected from hydrogen,
C.sub.1-2 alkyl and C.sub.1-3 haloalkyl. In certain embodiments,
the compound of Formula (IV), (IVa) or (IVd), or a pharmaceutically
acceptable salt thereof, is a compound wherein R.sup.12a can be
selected from hydrogen, C.sub.1-2 alkyl and C.sub.1-3 haloalkyl. In
certain embodiments, the compound of Formula (IV), (IVa) or (IVd),
or a pharmaceutically acceptable salt thereof, is a compound
wherein R.sup.12a can be selected from hydrogen, methyl, ethyl and
CF.sub.3. In certain embodiments, the compound of Formula (IV),
(IVa) or (IVd), or a pharmaceutically acceptable salt thereof, is a
compound wherein R.sup.12a can be hydrogen.
[0247] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, is the compound wherein
R.sup.1 is selected from the group consisting of hydrogen, halogen,
C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl is
optionally substituted with 1 to 5 R.sup.20 groups, R.sup.2 is
selected from the group consisting of hydrogen, halogen, C.sub.1-6
alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl optionally
substituted with 1 to 5 R.sup.20 groups, R.sup.3 is selected from
the group consisting of hydrogen, halogen, C.sub.1-6 alkyl, CN, and
OR.sup.a, wherein C.sub.1-6 alkyl is optionally substituted with 1
to 5 R.sup.20 groups, R.sup.11 is C.sub.1-2 alkyl or CF.sub.3,
R.sup.12a is selected from the group consisting of hydrogen,
C.sub.1-2 alkyl and C.sub.1-3 haloalkyl, R.sup.13 is C.sub.3-6
alkyl optionally substituted with 1 to 2 halogen substituents, each
R.sup.20 is independently selected from the group consisting of
halogen, C.sub.1-6haloalkyl, CN, --NR.sup.aR.sup.b,
S(O).sub.1-2R.sup.a, and OR.sup.a, and each R.sup.a and R.sup.b is
independently selected from the group consisting of hydrogen and
C.sub.1-3 alkyl, wherein each C.sub.1-3 alkyl is optionally
substituted with 1 to 3 substituents independently selected from
halogen, hydroxyl, amino, and C.sub.1-6 haloalkyl.
[0248] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, is the compound wherein
R.sup.1 is selected from the group consisting of hydrogen, halogen,
and C.sub.1-3 alkyl, R.sup.2 is selected from the group consisting
of hydrogen, halogen, and C.sub.1-3 alkyl, R.sup.3 is selected from
the group consisting of hydrogen, halogen, and C.sub.1-3 alkyl,
R.sup.11 is C.sub.1-2 alkyl or CF.sub.3, R.sup.12a is selected from
the group consisting of hydrogen, C.sub.1-2 alkyl and C.sub.1-3
haloalkyl, R.sup.13 is C.sub.3-6 alkyl optionally substituted with
1 to 2 halogen substituents, and each R.sup.a and R.sup.b is
independently selected from the group consisting of hydrogen and
C.sub.1-3 alkyl, wherein each C.sub.1-3 alkyl is optionally
substituted with 1 to 3 substituents independently selected from
halogen, hydroxyl, amino, and C.sub.1-6 haloalkyl.
[0249] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, has the structure:
##STR00076##
wherein R.sup.2 is selected from the group consisting of hydrogen,
methyl, fluoro, and chloro, R.sup.3 is selected from the group
consisting of hydrogen and methyl, R.sup.12a is selected from the
group consisting of hydrogen, C.sub.1-2 alkyl and C.sub.1-3
haloalkyl, R.sup.13 is C.sub.3-6 alkyl, and R.sup.b is methyl or
ethyl, each optionally substituted with hydroxyl or amino.
[0250] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, has the structure:
##STR00077##
wherein R.sup.2 is selected from the group consisting of hydrogen,
methyl, fluoro, and chloro, R.sup.12a is selected from the group
consisting of hydrogen, C.sub.1-2 alkyl and C.sub.1-3 haloalkyl,
R.sup.13 is C.sub.3-6 alkyl, and R.sup.b is methyl or ethyl, each
optionally substituted with hydroxyl or amino. In certain
embodiments, R.sup.2 and R.sup.13 can be as defined above for
Formula (J), (I), (IV), or (IVa), or any combination thereof.
[0251] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, has the structure:
##STR00078##
wherein R.sup.3 is selected from the group consisting of hydrogen
and methyl, R.sup.12a is selected from the group consisting of
hydrogen, C.sub.1-2 alkyl and C.sub.1-3 haloalkyl, R.sup.13 is
C.sub.3-6 alkyl, and R.sup.b is methyl or ethyl, each optionally
substituted with hydroxyl or amino.
[0252] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, has the structure:
##STR00079##
wherein R.sup.13 is C.sub.3-6 alkyl. R.sup.1, R.sup.2 and R.sup.3
can be as defined above for Formula (J), (I), (IV), (IVa) or
(IVd).
[0253] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, has the structure:
##STR00080##
wherein R.sup.2 is selected from the group consisting of hydrogen
and F, and R.sup.13 is C.sub.3-6 alkyl. In certain embodiments,
R.sup.2 and R.sup.13 can be as defined above for Formula (J), (I),
(IV), or (IVa), or any combination thereof.
[0254] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, has the structure:
##STR00081##
wherein R.sup.2 is selected from the group consisting of hydrogen,
Cl, and F, and R.sup.13 is C.sub.3-6 alkyl. In certain embodiments,
R.sup.2 and R.sup.13 can be as defined above for Formula (J), (I),
(IV), or (IVa), or any combination thereof.
[0255] In certain embodiments, the compound of Formula (IVd), or a
pharmaceutically acceptable salt thereof, has the structure:
##STR00082##
wherein R.sup.3 is selected from the group consisting of hydrogen
and methyl, and R.sup.13 is C.sub.3-6 alkyl.
[0256] In certain embodiments, the compound of Formula (J), (I), or
(IV), is selected from:
##STR00083##
or a pharmaceutically acceptable salt thereof.
[0257] In certain embodiments, the compound of Formula (J), (I), or
(IV), is selected from:
##STR00084##
or a pharmaceutically acceptable salt thereof.
[0258] In certain embodiments, the compound of Formula (J), (I), or
(IV), or a pharmaceutically acceptable salt thereof, is a compound
of the following formula:
##STR00085##
wherein R.sup.1 is selected from the group consisting of hydrogen,
halogen, C.sub.1-6 alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl
is optionally substituted with 1 to 5 R.sup.20 groups, R.sup.2 is
selected from the group consisting of hydrogen, halogen, C.sub.1-6
alkyl, CN, and OR.sup.a, wherein C.sub.1-6 alkyl optionally
substituted with 1 to 5 R.sup.20 groups, R.sup.3 is selected from
the group consisting of hydrogen, halogen, C.sub.1-6 alkyl, CN, and
OR.sup.a, wherein C.sub.1-6 alkyl is optionally substituted with 1
to 5 R.sup.20 groups, R.sup.12a is selected from the group
consisting of hydrogen, C.sub.1-2 alkyl and C.sub.1-3 haloalkyl,
R.sup.13 is C.sub.3-6 alkyl optionally substituted with 1 to 2
halogen substituents, each R.sup.20 is independently selected from
the group consisting of halogen, C.sub.1-6haloalkyl, CN,
--NR.sup.aR.sup.b, S(O).sub.1-2R.sup.a, and OR.sup.a, and each
R.sup.a and R.sup.b is independently selected from the group
consisting of hydrogen and C.sub.1-3 alkyl, wherein each C.sub.1-3
alkyl is optionally substituted with 1 to 3 substituents
independently selected from halogen, hydroxyl, amino, and C.sub.1-6
haloalkyl.
[0259] In certain embodiments, the compound of Formula (J), (I), or
(IV), or a pharmaceutically acceptable salt thereof, is a compound
of the following formula:
##STR00086##
wherein R.sup.1 is selected from the group consisting of hydrogen,
halogen, and C.sub.1-3 alkyl, R.sup.2 is selected from the group
consisting of hydrogen, halogen, and C.sub.1-3 alkyl, R.sup.3 is
selected from the group consisting of hydrogen, halogen, and
C.sub.1-3 alkyl, R.sup.12a is selected from the group consisting of
hydrogen, C.sub.1-2 alkyl and C.sub.1-3 haloalkyl, R.sup.13 is
C.sub.3-6 alkyl optionally substituted with 1 to 2 halogen
substituents, and each R.sup.a and R.sup.b is independently
selected from the group consisting of hydrogen and C.sub.1-3 alkyl,
wherein each C.sub.1-3 alkyl is optionally substituted with 1 to 3
substituents independently selected from halogen, hydroxyl, amino,
and C.sub.1-6 haloalkyl.
[0260] In certain embodiments, the compound of Formula (J), (I), or
(IV), or a pharmaceutically acceptable salt thereof, is a compound
of the following formula:
##STR00087##
wherein R.sup.13 is C.sub.3-6 alkyl. R.sup.1, R.sup.2 and R.sup.3
can be as defined above for Formula (J), (I), (IV), (IVa) or
(IVd).
[0261] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.1 is hydrogen,
halogen, or C.sub.1-6alkyl optionally substituted with 1 to 5
R.sup.20 groups. In certain embodiments of a compound of Formula
(J), (I), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa),
(IVb), or (IVd), R.sup.1 is hydrogen, halogen, or C.sub.1-6alkyl
optionally substituted with 1 to 5 R.sup.20 groups.
[0262] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.1 is hydrogen,
halogen, or C.sub.1-3alkyl optionally substituted with 1 to 5
halogens. In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb) or
(IVd), R.sup.1 is hydrogen, halogen, or C.sub.1-3alkyl optionally
substituted with 1 to 5 halogens.
[0263] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.1 is hydrogen,
Cl, CH.sub.3, or CF.sub.3. In certain embodiments of a compound of
Formula (J), (I), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV),
(IVa), (IVb) or (IVd), R.sup.1 is hydrogen, Cl, CH.sub.3, or
CF.sub.3.
[0264] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.2 is hydrogen,
halogen, CN, or C.sub.1-6alkyl optionally substituted with 1 to 5
R.sup.20 groups. In certain embodiments of a compound of Formula
(J), (I), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa),
(IVb), (IVc), or (IVd), R.sup.2 is hydrogen, halogen, CN, or
C.sub.1-6alkyl optionally substituted with 1 to 5 R.sup.20
groups.
[0265] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.2 is hydrogen,
halogen, CN or C.sub.1-3alkyl optionally substituted with 1 to 5
halogens. In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb),
(IVc), or (IVd), R.sup.2 is hydrogen, halogen, CN or C.sub.1-3alkyl
optionally substituted with 1 to 5 halogens.
[0266] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.2 is hydrogen,
CH.sub.3, --CH.sub.2CH.sub.3, F, Br, Cl, or CN. In certain
embodiments of a compound of Formula (J), (I), (II), (IIa), (IIb),
(III), (IIIa), (IIIb), (IV), (IVa), (IVb), (IVc), or (IVd), R.sup.2
is hydrogen, CH.sub.3, --CH.sub.2CH.sub.3, F, Br, Cl, or CN.
[0267] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.3 is hydrogen,
halogen, or C.sub.1-6alkyl optionally substituted with 1 to 5
R.sup.20 groups. In certain embodiments of a compound of Formula
(J), (I), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa),
(IVb) or (IVd), R.sup.3 is hydrogen, halogen, or C.sub.1-6alkyl
optionally substituted with 1 to 5 R.sup.20 groups.
[0268] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.3 is hydrogen,
halogen, or C.sub.1-3alkyl optionally substituted with 1 to 5
R.sup.20 groups. In certain embodiments of a compound of Formula
(J), (I), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa),
(IVb) or (IVd), R.sup.3 is hydrogen, halogen, or C.sub.1-3alkyl
optionally substituted with 1 to 5 R.sup.20 groups.
[0269] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.3 is hydrogen,
Cl, or CH.sub.3. In certain embodiments of a compound of Formula
(J), (I), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa),
(IVb) or (IVd), R.sup.3 is hydrogen, Cl, or CH.sub.3.
[0270] In certain embodiments of a compound of Formula (J),
R.sup.10 is hydrogen, F, Cl, or CH.sub.3.
[0271] In certain embodiments of a compound of Formula (J),
R.sup.10 is hydrogen.
[0272] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.1, R.sup.2, and
R.sup.3 are hydrogen. In certain embodiments of a compound of
Formula (J), (I), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV),
(IVa), (IVb), ((IVc), or (IVd), R.sup.1, R.sup.2, and R.sup.3 are
hydrogen.
[0273] In certain embodiments of a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), or (IIIb), R.sup.1 and R.sup.3
are hydrogen and R.sup.2 is F. In certain embodiments of a compound
of Formula (J), (I), (II), (IIa), (IIb), (III), (IIIa), (IIIb),
(IV), (IVa), (IVb), (IVc), or (IVd), R.sup.1 and R.sup.3 are
hydrogen and R.sup.2 is F.
[0274] It is understood that each of the variables (e.g. R.sup.1,
R.sup.2, R.sup.3, R.sup.4) may be combined with any other variables
for Formula (J), (I), (II), (IIa) or (IIb) (e.g. R.sup.1, R.sup.2,
R.sup.3, R.sup.4). Further, in instances describing a compound of
Formula (J) or (I), it is understood that the variables also
describe compounds of other formulae (e.g. Formula (II), (IIa),
(IIb), (III), (IIIa), and (IIIb)) which fall within the scope of
Formula (J) or (I).
[0275] It is understood that any variable for R.sup.1 of Formula
(J), (I), (II), (IIa), (IIb), (III), (IIIa), or (IIIb) may be
combined with any variable of R.sup.4 in Formula (J), (I), (II),
(IIa), (IIb), (III), (IIIa), or (IIIb), the same as if each and
every combination were specifically and individually listed. For
example, in one variation of Formula (J) or (I), R.sup.1 is
hydrogen, Cl, CH.sub.3 or CF.sub.3, and R.sup.4 is C.sub.1-6 alkyl
which is optionally substituted with 1 or 2 substituents
independently selected from OH, CF.sub.3, --C(O)OH,
--C(O)OCH.sub.3, --C(O)NH.sub.2, SCH.sub.3, --C(O)NHCH.sub.3,
--C(O)NHCH.sub.2CH.sub.2NH.sub.2, --C(O)NHCH.sub.2CH.sub.2OH,
--C(O)NHCH.sub.2-pyridyl, phenyl, tetrahydrofuranyl, and
cyclopropyl
[0276] It is understood that any variable for R.sup.2 of Formula
(J), (I), (II), (IIa), (IIb), (III), (IIIa), or (IIIb) may be
combined with any variable of R.sup.4 in Formula (J), (I), (II),
(IIa), (IIb), (III), (IIIa), or (IIIb), the same as if each and
every combination were specifically and individually listed. For
example, in one variation of Formula (J) or (I), R.sup.2 is
hydrogen, CH.sub.3, --CH.sub.2CH.sub.3, F, Br, Cl, or CN, and
R.sup.4 is C.sub.1-6 alkyl which is optionally substituted with 1
or 2 substituents independently selected from OH, CF.sub.3,
--C(O)OH, --C(O)OCH.sub.3, --C(O)NH.sub.2, SCH.sub.3,
--C(O)NHCH.sub.3, --C(O)NHCH.sub.2CH.sub.2NH.sub.2,
--C(O)NHCH.sub.2CH.sub.2OH, --C(O)NHCH.sub.2-pyridyl, phenyl,
tetrahydrofuranyl, and cyclopropyl.
[0277] It is understood that any variable for R.sup.3 of Formula
(J), (I), (II), (IIa), (IIb), (III), (IIIa), or (IIIb) may be
combined with any variable of R.sup.4 in Formula (J), (I), (II),
(IIa), (IIb), (III), (IIIa), or (IIIb), the same as if each and
every combination were specifically and individually listed. For
example, in one variation of Formula (J) or (I), R.sup.3 is
hydrogen, Cl, or CH.sub.3, and R.sup.4 is C.sub.1-6 alkyl which is
optionally substituted with 1 or 2 substituents independently
selected from OH, CF.sub.3, --C(O)OH, --C(O)OCH.sub.3,
--C(O)NH.sub.2, SCH.sub.3, --C(O)NHCH.sub.3,
--C(O)NHCH.sub.2CH.sub.2NH.sub.2, --C(O)NHCH.sub.2CH.sub.2OH,
--C(O)NHCH.sub.2-pyridyl, phenyl, tetrahydrofuranyl, and
cyclopropyl.
[0278] In certain embodiments, the compound of Formula (J) or (I),
or a pharmaceutically acceptable salt thereof, has one or more
features selected from: [0279] (a) R.sup.4 is C.sub.1-6 alkyl which
is optionally substituted with 1 or 2 substituents independently
selected halogen, --OR.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.aR.sup.b, --SR.sup.a, C.sub.1-3haloalkyl,
C.sub.3-6cycloalkyl, 3 to 6 membered heterocyclyl and C.sub.6-10
aryl; wherein each C.sub.3-6cycloalkyl and C.sub.6-10 aryl is
optionally substituted with 1 to 3 R.sup.21 groups and wherein
R.sup.a and R.sup.b are each independently hydrogen or
C.sub.1-4alkyl, wherein each C.sub.1-4 alkyl is optionally
substituted with --NH.sub.2, OH, or pyridyl; [0280] (b) R.sup.1 is
hydrogen, halogen, or C.sub.1-6alkyl optionally substituted with 1
to 5 R.sup.20 groups; [0281] (c) R.sup.2 is hydrogen, halogen, CN,
or C.sub.1-6alkyl optionally substituted with 1 to 5 R.sup.20
groups; and [0282] (d) R.sup.3 is hydrogen, halogen, or
C.sub.1-3alkyl optionally substituted with 1 to 5 R.sup.20 groups.
In certain embodiments, the compound of Formula (J) or (I), or a
pharmaceutically acceptable salt thereof has two or more features
selected from (a)-(d), as listed above. In certain embodiments, the
compound of Formula (J) or (I), or a pharmaceutically acceptable
salt thereof has three or more features selected from (a)-(d), as
listed above. In certain embodiments, the compound of Formula (J)
or (I), or a pharmaceutically acceptable salt thereof has four
features selected from (a)-(d), as listed above.
[0283] In certain embodiments, the compound of Formula (J) or (I),
or a pharmaceutically acceptable salt thereof has one or more
features selected from: [0284] (e) R.sup.4 is C.sub.1-6 alkyl which
is optionally substituted with 1 or 2 substituents independently
selected from OH, CF.sub.3, --C(O)OH, --C(O)OCH.sub.3,
--C(O)NH.sub.2, SCH.sub.3, --C(O)NHCH.sub.3,
--C(O)NHCH.sub.2CH.sub.2NH.sub.2, --C(O)NHCH.sub.2CH.sub.2OH,
--C(O)NHCH.sub.2-pyridyl, phenyl, tetrahydrofuranyl, and
cyclopropyl. [0285] (f) R.sup.1 is hydrogen, halogen, or
C.sub.1-3alkyl optionally substituted with 1 to 5 halogens; [0286]
(g) R.sup.2 is hydrogen, halogen, CN or C.sub.1-3alkyl optionally
substituted with 1 to 5 halogens; and [0287] (h) R.sup.3 is
hydrogen, halogen, or C.sub.1-3alkyl. In certain embodiments, the
compound of Formula (J) or (I), or a pharmaceutically acceptable
salt thereof has two or more features selected from (e)-(h), as
listed above. In certain embodiments, the compound of Formula (J)
or (I), or a pharmaceutically acceptable salt thereof has three or
more features selected from (e)-(h), as listed above. In certain
embodiments, the compound of Formula (J) or (I), or a
pharmaceutically acceptable salt thereof has two or more features
selected from (e)-(h), as listed above.
[0288] In certain embodiments, the compound of Formula (J) or (I)
is selected from:
##STR00088## ##STR00089## ##STR00090## ##STR00091##
##STR00092##
or a pharmaceutically acceptable salt thereof.
[0289] In certain embodiments, the compound of Formula (J) or (I)
is selected from:
##STR00093## ##STR00094## ##STR00095## ##STR00096##
or a pharmaceutically acceptable salt thereof.
[0290] In certain embodiments, the compound of Formula (J) or (I)
is selected from:
##STR00097##
or a pharmaceutically acceptable salt thereof.
[0291] In certain embodiments, the compound of Formula (J) is
selected from:
##STR00098##
or a pharmaceutically acceptable salt thereof.
[0292] In certain embodiments, the compound of Formula (J) or (I)
is selected from:
##STR00099## ##STR00100## ##STR00101## ##STR00102## ##STR00103##
##STR00104## ##STR00105## ##STR00106## ##STR00107##
##STR00108##
or a pharmaceutically acceptable salt thereof.
[0293] In certain embodiments, the compound of Formula (J), (I),
(IV), or (IVa) is selected from:
##STR00109##
or a pharmaceutically acceptable salt thereof.
[0294] In certain embodiments, the compound of Formula (J), (I),
(IV), or (IVa) is selected from:
##STR00110##
or a pharmaceutically acceptable salt thereof.
[0295] In certain embodiments, the compound of Formula (J), (I),
(IV), or (IVa) is selected from:
##STR00111##
or a pharmaceutically acceptable salt thereof.
[0296] In certain embodiments, the compound of Formula (J), (I),
(IV), or (IVa) is selected from:
##STR00112##
or a pharmaceutically acceptable salt thereof.
[0297] In certain embodiments, the compound of Formula (J), (I),
(IV), or (IVa) is selected from:
##STR00113## ##STR00114##
or a pharmaceutically acceptable salt thereof.
[0298] As used herein, "a compound of Formula (I)" includes
compounds for Formula (II) (IIa), (IIb), (III), (IIIa), (IIIb),
(IV), (IVa), (IVb), (IVc), or (IVd).
III. COMPOSITIONS
[0299] In certain embodiments, the present disclosure provides a
pharmaceutical composition comprising a compound of the present
disclosure (e.g.
[0300] a compound of Formula (J), (I), (II), (IIa), (IIb), (III),
(IIIa), (IIIb), (IV), (IVa), (IVb), (IVc), or (IVd)), or a
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable excipient.
[0301] In certain embodiments, the pharmaceutical composition
comprises one or more additional therapeutic agent, as more fully
set forth below.
[0302] Pharmaceutical compositions comprising the compounds
disclosed herein, or pharmaceutically acceptable salts thereof, may
be prepared with one or more pharmaceutically acceptable excipients
which may be selected in accord with ordinary practice. Tablets may
contain excipients including glidants, fillers, binders and the
like. Aqueous compositions may be prepared in sterile form, and
when intended for delivery by other than oral administration
generally may be isotonic. All compositions may optionally contain
excipients such as those set forth in the Rowe et al, Handbook of
Pharmaceutical Excipients, 6.sup.th edition, American Pharmacists
Association, 2009. Excipients can include ascorbic acid and other
antioxidants, chelating agents such as EDTA, carbohydrates such as
dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose,
stearic acid and the like. In certain embodiments, the composition
is provided as a solid dosage form, including a solid oral dosage
form.
[0303] The compositions include those suitable for various
administration routes, including oral administration. The
compositions may be presented in unit dosage form and may be
prepared by any of the methods well known in the art of pharmacy.
Such methods include the step of bringing into association the
active ingredient (e.g., a compound of the present disclosure or a
pharmaceutical salt thereof) with one or more pharmaceutically
acceptable excipients. The compositions may be prepared by
uniformly and intimately bringing into association the active
ingredient with liquid excipients or finely divided solid
excipients or both, and then, if necessary, shaping the product.
Techniques and formulations generally are found in Remington: The
Science and Practice of Pharmacy, 21.sup.st Edition, Lippincott
Williams and Wilkins, Philadelphia, Pa., 2006.
[0304] Compositions described herein that are suitable for oral
administration may be presented as discrete units (a unit dosage
form) including but not limited to capsules, cachets or tablets
each containing a predetermined amount of the active ingredient. In
one embodiment, the pharmaceutical composition is a tablet.
[0305] Pharmaceutical compositions disclosed herein comprise one or
more compounds disclosed herein, or a pharmaceutically acceptable
salt thereof, together with a pharmaceutically acceptable excipient
and optionally other therapeutic agents. Pharmaceutical
compositions containing the active ingredient may be in any form
suitable for the intended method of administration. When used for
oral use for example, tablets, troches, lozenges, aqueous or oil
suspensions, dispersible powders or granules, emulsions, hard or
soft capsules, syrups or elixirs may be prepared. Compositions
intended for oral use may be prepared according to any method known
to the art for the manufacture of pharmaceutical compositions and
such compositions may contain one or more excipients including
sweetening agents, flavoring agents, coloring agents and preserving
agents, in order to provide a palatable preparation. Tablets
containing the active ingredient in admixture with non-toxic
pharmaceutically acceptable excipients which are suitable for
manufacture of tablets are acceptable. These excipients may be, for
example, inert diluents, such as calcium or sodium carbonate,
lactose, lactose monohydrate, croscarmellose sodium, povidone,
calcium or sodium phosphate; granulating and disintegrating agents,
such as maize starch, or alginic acid; binding agents, such as
cellulose, microcrystalline cellulose, starch, gelatin or acacia;
and lubricating agents, such as magnesium stearate, stearic acid or
talc. Tablets may be uncoated or may be coated by known techniques
including microencapsulation to delay disintegration and adsorption
in the gastrointestinal tract and thereby provide a sustained
action over a longer period. For example, a time delay material
such as glyceryl monostearate or glyceryl distearate alone or with
a wax may be employed.
[0306] The amount of active ingredient that may be combined with
the inactive ingredients to produce a dosage form may vary
depending upon the intended treatment subject and the particular
mode of administration. For example, in some embodiments, a dosage
form for oral administration to humans may contain approximately 1
to 1000 mg of active material formulated with an appropriate and
convenient amount of a pharmaceutically acceptable excipient. In
certain embodiments, the pharmaceutically acceptable excipient
varies from about 5 to about 95% of the total compositions
(weight:weight).
[0307] In certain embodiments, a composition comprising a compound
of the present disclosure (e.g. a compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb),
(IVc), or (IVd)), or a pharmaceutically acceptable salt thereof in
one variation does not contain an agent that affects the rate at
which the active ingredient is metabolized. Thus, it is understood
that compositions comprising a compound of the present disclosure
in one aspect do not comprise an agent that would affect (e.g.,
slow, hinder or retard) the metabolism of a compound of the present
disclosure or any other active ingredient administered separately,
sequentially or simultaneously with a compound of the present
disclosure. It is also understood that any of the methods, kits,
articles of manufacture and the like detailed herein in one aspect
do not comprise an agent that would affect (e.g., slow, hinder or
retard) the metabolism of a compound of the present disclosure or
any other active ingredient administered separately, sequentially
or simultaneously with a compound of the present disclosure.
IV. METHODS
[0308] The present disclosure provides for methods of treating
diseases or conditions that are responsive to the modulation of
toll-like receptors (e.g. TLR-8 receptors). While not wishing to be
bound by any one theory, the presently disclosed compounds are
believed to modulate TLR-8 receptors as agonists. As is understood
by those of skill in the art, modulators of TLR-8 may, to some
degree, modulate other toll-like receptors (e.g. TLR-7). As such,
in certain embodiments, the compounds disclosed herein may also
modulate TLR-7 to a measureable degree. In certain embodiments,
those compounds that modulate TLR-8 to a higher degree than TLR-7
are considered selective modulators of TLR-8. Exemplary methods of
measuring the each compounds respective modulation of TLR-7 and
TLR-8 are described in the Examples provided herein. In certain
embodiments, the compounds disclosed herein are selective
modulators of TLR-8.
[0309] In certain embodiments, a method of modulating TLR-8 is
provided, comprising administering a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, to an
individual (e.g. a human).
[0310] In certain embodiments, a method of modulating TLR-8 in
vitro is provided.
[0311] In certain embodiments, the present disclosure provides a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, for use as a research tool, e.g., for use
in identifying modulators of TLR-8
[0312] In certain embodiments, the present disclosure provides
methods for the treatment or prevention of diseases or conditions
in an individual (e.g. a human) in need thereof, comprising
administering a compound of the present disclosure or a
pharmaceutically acceptable salt thereof. In certain embodiments,
the methods comprise administering one or more additional
therapeutic agents. Treatment with a compound of the present
disclosure typically results in the stimulation of an immune
response to the particular disease or condition being treated.
Diseases or conditions contemplated by the present disclosure
include those affected by the modulation of toll-like receptors
(e.g. TLR-8). In certain embodiments, a method of treating or
preventing a disease or condition responsive to the modulation of
TLR-8 is provided, comprising administering to a human a
therapeutically effective amount of a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof.
Exemplary diseases, disorders and conditions include but are not
limited to conditions involving autoimmunity, inflammation,
allergy, asthma, graft rejection, graft versus host disease (GvHD),
infectious diseases, cancer, and immunodeficiency.
[0313] In certain embodiments, infectious diseases include diseases
such as hepatitis A, hepatitis B (HBV), hepatitis C (HCV),
hepatitis D (HDV), HIV, human papillomavirus (HPV), respiratory
syncytial virus (RSV), severe acute respiratory syndrome (SARS),
influenza, parainfluenza, cytomegalovirus, dengue, herpes simplex
virus-1, herpes simplex virus-2, leishmania infection, and
respiratory syncytial virus. In certain embodiments, infectious
diseases include diseases such as hepatitis A, hepatitis B (HBV),
hepatitis D (HDV), HIV, human papillomavirus (HPV), respiratory
syncytial virus (RSV), severe acute respiratory syndrome (SARS),
influenza, parainfluenza, cytomegalovirus, dengue, herpes simplex
virus-1, herpes simplex virus-2, leishmania infection, and
respiratory syncytial virus.
[0314] In certain embodiments, a method of treating or preventing a
viral infection is provided, comprising administering to an
individual (e.g. a human) a therapeutically effective amount a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof. In one embodiment, the method can be used
to induce an immune response against multiple epitopes of a viral
infection in a human. Induction of an immune response against viral
infection can be assessed using any technique that is known by
those of skill in the art for determining whether an immune
response has occurred. Suitable methods of detecting an immune
response for the present disclosure include, among others,
detecting a decrease in viral load or antigen in a subject's serum,
detection of IFN-gamma-secreting peptide specific T cells, and
detection of elevated levels of one or more liver enzymes, such as
alanine transferase (ALT) and aspartate transferase (AST). In one
embodiment, the detection of IFN-gamma-secreting peptide specific T
cells is accomplished using an ELISPOT assay. Another embodiment
includes reducing the viral load associated with HBV infection,
including a reduction as measured by PCR testing.
[0315] In certain embodiments, the present invention provides a
method for enhancing the efficacy of a vaccine by co-administering
with the vaccine, a therapeutically effective amount of a compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, to an individual (e.g. a human). In certain embodiments,
the compound of the present disclosure or a pharmaceutically
acceptable salt thereof, may be co-administered with a vaccine to
boost the immune response by allowing the production of a higher
amount of antibodies or by allowing a longer lasting protection. In
certain embodiments, the compounds of the present disclosure, or a
pharmaceutically acceptable salt thereof, may be used as vaccine
adjuvants to increase the efficacy and response to the immunization
with a particular antigen. In certain embodiments, co-administering
the compounds of the present disclosure, or a pharmaceutically
acceptable salt thereof, with a vaccine, may influence the way a
vaccine's antigen is presented to the immune system and enhance the
vaccine's efficacy.
[0316] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, for use
in medical therapy is provided. In certain embodiments, a compound
of the present disclosure or a pharmaceutically acceptable salt
thereof, for use in treating or preventing a disease or condition
responsive to the modulation of TLR-8, is provided. In certain
embodiments, the disease or condition is a viral infection as set
forth herein.
[0317] In certain embodiments, the use of a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, for the
manufacture of a medicament for treating or preventing a disease or
condition responsive to the modulation of TLR-8, is provided.
[0318] In certain embodiments, the present disclosure also provides
methods for treating a hepatitis B viral infection, comprising
administering to an individual (e.g. a human) infected with
hepatitis B virus a therapeutically effective amount a compound of
the present disclosure or a pharmaceutically acceptable salt
thereof. Typically, the individual is suffering from a chronic
hepatitis B infection, although it is within the scope of the
present disclosure to treat people who are acutely infected with
HBV.
[0319] The present disclosure also provides methods for treating a
hepatitis C viral infection, comprising administering to an
individual (e.g. a human) infected with hepatitis C virus a
therapeutically effective amount a compound of the present
disclosure or a pharmaceutically acceptable salt thereof.
Typically, the individual is suffering from a chronic hepatitis C
infection, although it is within the scope of the present
disclosure to treat people who are acutely infected with HCV.
[0320] Treatment of HBV or HCV in accordance with the present
disclosure typically results in the stimulation of an immune
response against HBV or HCV in an individual (e.g. a human) being
infected with HBV or HCV, respectively, and a consequent reduction
in the viral load of HBV or HCV in the infected individual.
Examples of immune responses include production of antibodies
(e.g., IgG antibodies) and/or production of cytokines, such as
interferons, that modulate the activity of the immune system. The
immune system response can be a newly induced response, or can be
boosting of an existing immune response. In particular, the immune
system response can be seroconversion against one or more HBV or
HCV antigens.
[0321] As described more fully herein, compounds of the present
disclosure can be administered with one or more additional
therapeutic agent(s) to an individual (e.g. a human) infected with
HBV or HCV. The additional therapeutic agent(s) can be administered
to the infected individual (e.g.a human) at the same time as a
compound of the present disclosure or before or after
administration of a compound of the present disclosure. For
example, in certain embodiments, when used to treat or prevent HCV,
a compound of the present disclosure may be administered with one
or more additional therapeutic agent(s) selected from the group
consisting of interferons, ribavirin or its analogs, HCV NS3
protease inhibitors, HCV NS4 protease inhibitors, HCV NS3/NS4
protease inhibitors, alpha-glucosidase 1 inhibitors,
hepatoprotectants, nucleoside or nucleotide inhibitors of HCV NS5B
polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV
NS5A inhibitors, TLR-7 agonists, cyclophilin inhibitors, HCV IRES
inhibitors, pharmacokinetic enhancers, and other drugs for treating
HCV, or mixtures thereof. Specific examples are more fully
described below.
[0322] Further, in certain embodiments, when used to treat or
prevent HBV, a compound of the present disclosure may be
administered with one or more additional therapeutic agent(s)
selected from the group consisting of HBV DNA polymerase
inhibitors, toll-like receptor 7 modulators, toll-like receptor 8
modulators, Toll-like receptor 7 and 8 modulators, Toll-like
receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors,
compounds targeting HbcAg, cyclophilin inhibitors, HBV therapeutic
vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors,
NTCP inhibitors, antisense oligonucleotide targeting viral mRNA,
short interfering RNAs (siRNA), hepatitis B virus E antigen
inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies
including HBV antibodies targeting the surface antigens of the
hepatitis B virus, thymosin agonists, cytokines, nucleoprotein
inhibitors (HBV core or capsid protein inhibitors), stimulators of
retinoic acid-inducible gene 1, stimulators of NOD2, recombinant
thymosin alpha-1 and hepatitis B virus replication inhibitors, and
combinations thereof. Specific examples are more fully described
below.
[0323] In certain embodiments, the present disclosure provides a
method for ameliorating a symptom associated with an HBV infection
or HCV infection, wherein the method comprises administering to an
individual (e.g. a human) infected with hepatitis B virus or
hepatitis C virus a therapeutically effective amount of a compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, wherein the therapeutically effective amount is sufficient
to ameliorate a symptom associated with the HBV infection or HCV
infection. Such symptoms include the presence of HBV virus
particles (or HCV virus particles) in the blood, liver
inflammation, jaundice, muscle aches, weakness and tiredness.
[0324] In certain embodiments, the present disclosure provides a
method for reducing the rate of progression of a hepatitis B viral
infection or a hepatitis C virus infection, in an individual (e.g.
a human), wherein the method comprises administering to an
individual (e.g. a human) infected with hepatitis B virus or
hepatitis C virus a therapeutically effective amount of a compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, wherein the therapeutically effective amount is sufficient
to reduce the rate of progression of the hepatitis B viral
infection or hepatitis C viral infection. The rate of progression
of the infection can be followed by measuring the amount of HBV
virus particles or HCV virus particles in the blood.
[0325] In certain embodiments, the present disclosure provides a
method for reducing the viral load associated with HBV infection or
HCV infection, wherein the method comprises administering to an
individual (e.g. a human) infected with HBV or HCV a
therapeutically effective amount of a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, wherein
the therapeutically effective amount is sufficient to reduce the
HBV viral load or the HCV viral load in the individual.
[0326] In certain embodiments, the present disclosure provides a
method of inducing or boosting an immune response against hepatitis
B virus or hepatitis C virus in an individual (e.g. a human),
wherein the method comprises administering a therapeutically
effective amount of a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, to the individual,
wherein a new immune response against hepatitis B virus or
hepatitis C virus is induced in the individual, or a preexisting
immune response against hepatitis B virus or hepatitis C virus is
boosted in the individual. Seroconversion with respect to HBV or
HCV can be induced in the individual. Examples of immune responses
include production of antibodies, such as IgG antibody molecules,
and/or production of cytokine molecules that modulate the activity
of one or more components of the human immune system.
[0327] In certain embodiments, an immune response can be induced
against one or more antigens of HBV or HCV. For example, an immune
response can be induced against the HBV surface antigen (HBsAg), or
against the small form of the HBV surface antigen (small S
antigen), or against the medium form of the HBV surface antigen
(medium S antigen), or against a combination thereof. Again by way
of example, an immune response can be induced against the HBV
surface antigen (HBsAg) and also against other HBV-derived
antigens, such as the core polymerase or x-protein.
[0328] Induction of an immune response against HCV or HBV can be
assessed using any technique that is known by those of skill in the
art for determining whether an immune response has occurred.
Suitable methods of detecting an immune response for the present
disclosure include, among others, detecting a decrease in viral
load in a individual's serum, such as by measuring the amount of
HBV DNA or HCV DNA in a subject's blood using a PCR assay, and/or
by measuring the amount of anti-HBV antibodies, or anti-HCV
antibodies, in the subject's blood using a method such as an
ELISA.
[0329] In certain embodiments, a compound of a compound of the
present disclosure (e.g. a compound of Formula (I)), or a
pharmaceutically acceptable salt thereof, for use in treating or
preventing a HBV infection is provided. In certain embodiments, a
compound of the present disclosure (e.g. a compound of Formula
(I)), or a pharmaceutically acceptable salt thereof, for use in
treating or preventing a HCV infection is provided. In certain
embodiments, a compound of the present disclosure (e.g. a compound
of Formula (I)), or a pharmaceutically acceptable salt thereof, for
the manufacture of a medicament for treating or preventing a HBV
infection is provided. In certain embodiments, a compound of the
present disclosure (e.g. a compound of Formula (I)), or a
pharmaceutically acceptable salt thereof, for the manufacture of a
medicament for treating or preventing a HCV infection is
provided.
[0330] In certain embodiments, the present disclosure also provides
methods for treating a Retroviridae viral infection (e.g., an HIV
viral infection) in an individual (e.g., a human), comprising
administering a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, to the individual.
[0331] In certain embodiments, the present disclosure also provides
methods for treating a HIV infection (e.g. a HIV-1 infection),
comprising administering to an individual (e.g. a human) infected
with HIV virus a therapeutically effective amount of a compound of
the present disclosure, or a pharmaceutically acceptable salt
thereof. In certain embodiments, the individual in need thereof is
a human who has been infected with HIV. In certain embodiments, the
individual in need thereof is a human who has been infected with
HIV but who has not developed AIDS. In certain embodiments, the
individual in need thereof is an individual at risk for developing
AIDS. In certain embodiments, the individual in need thereof is a
human who has been infected with HIV and who has developed
AIDS.
[0332] In certain embodiments, a method for treating or preventing
an HIV viral infection in an individual (e.g., a human), comprising
administering a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, to the individual is
provided.
[0333] In certain embodiments, a method for inhibiting the
replication of the HIV virus, treating AIDS or delaying the onset
of AIDS in an individual (e.g., a human), comprising administering
a compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, to the individual is provided.
[0334] In certain embodiments, a method for preventing an HIV
infection in an individual (e.g., a human), comprising
administering a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, to the individual is
provided. In certain embodiments, the individual is at risk of
contracting the HIV virus, such as an individual who has one or
more risk factors known to be associated with of contracting the
HIV virus.
[0335] In certain embodiments, a method for treating an HIV
infection in an individual (e.g., a human), comprising
administering a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, to the individual is
provided.
[0336] In certain embodiments, a method for treating an HIV
infection in an individual (e.g., a human), comprising
administering to the individual in need thereof a therapeutically
effective amount of a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more additional
therapeutic agents selected from the group consisting of HIV
protease inhibiting compounds, HIV non-nucleoside inhibitors of
reverse transcriptase, HIV nucleoside inhibitors of reverse
transcriptase, HIV nucleotide inhibitors of reverse transcriptase,
HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120
inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and
other drugs for treating HIV, and combinations thereof is
provided.
[0337] In certain embodiments, a compound of the present invention
is administered to a patient where active HIV gene expression has
been suppressed by administration of antiretroviral therapy
(including combination antiretroviral therapy" or "cART").
[0338] In certain embodiments, a method of reducing the latent HIV
reservoir in a human infected with HIV is provided, the method
comprising administering to the human a pharmaceutically effective
amount of a compound of the present disclosure. In certain
embodiments, the method further comprises administering one or more
anti-HIV agents. In certain embodiments, the method further
comprises administering antiretroviral therapy (including
combination antiretroviral therapy" or "cART"). In certain
embodiments, active HIV gene expression in the human has been
suppressed by administration of antiretroviral therapy (including
combination antiretroviral therapy" or "cART").
[0339] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof for use
in medical therapy of an HIV viral infection (e.g. HIV-1 or the
replication of the HIV virus (e.g. HIV-1) or AIDS or delaying the
onset of AIDS in an individual (e.g., a human)) is provided.
[0340] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof for use
in the manufacture of a medicament for treating an HIV viral
infection or the replication of the HIV virus or AIDS or delaying
the onset of AIDS in an individual (e.g., a human). One embodiment
provides a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, for use in the
prophylactic or therapeutic treatment of an HIV infection or AIDS
or for use in the therapeutic treatment or delaying the onset of
AIDS is provided.
[0341] In certain embodiments, the use of a compound of the present
disclosure (e.g. a compound of Formula (I)), or a pharmaceutically
acceptable salt thereof, for the manufacture of a medicament for an
HIV virus infection in an individual (e.g., a human) is provided.
In certain embodiments, a compound of the present disclosure (e.g.
a compound of Formula (I)), or a pharmaceutically acceptable salt
thereof, for use in the prophylactic or therapeutic treatment of an
HIV virus infection is provided.
[0342] In certain embodiments, in the methods of use, the
administration is to an individual (e.g., a human) in need of the
treatment. In certain embodiments, in the methods of use, the
administration is to an individual (e.g., a human) who is at risk
of developing AIDS.
[0343] Provided herein is a compound of the present disclosure
(e.g. a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, for use in therapy. In one embodiment, the compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, is for use in a method of treating an HIV viral infection
or the replication of the HIV virus or AIDS or delaying the onset
of AIDS in an individual (e.g., a human).
[0344] Also provided herein is a compound of the present disclosure
(e.g. a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, for use in a method of treating or preventing HIV in
an individual in need thereof. In certain embodiments, the
individual in need thereof is a human who has been infected with
HIV. In certain embodiments, the individual in need thereof is a
human who has been infected with HIV but who has not developed
AIDS. In certain embodiments, the individual in need thereof is an
individual at risk for developing AIDS. In certain embodiments, the
individual in need thereof is a human who has been infected with
HIV and who has developed AIDS.
[0345] Also provided herein is a compound of the present disclosure
(e.g. a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, for use in the therapeutic treatment or delaying the
onset of AIDS.
[0346] Also provided herein is a compound of the present disclosure
(e.g. a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, for use in the prophylactic or therapeutic treatment
of an HIV infection.
[0347] In certain embodiments, the HIV infection is an HIV-1
infection.
[0348] Additionally, the compounds of this disclosure are useful in
the treatment of cancer or tumors (including dysplasias, such as
uterine dysplasia). These includes hematological malignancies, oral
carcinomas (for example of the lip, tongue or pharynx), digestive
organs (for example esophagus, stomach, small intestine, colon,
large intestine, or rectum), peritoneum, liver and biliary
passages, pancreas, respiratory system such as larynx or lung
(small cell and non-small cell), bone, connective tissue, skin
(e.g., melanoma), breast, reproductive organs (fallopian tube,
uterus, cervix, testicles, ovary, or prostate), urinary tract
(e.g., bladder or kidney), brain and endocrine glands such as the
thyroid. In summary, the compounds of this disclosure are employed
to treat any neoplasm, including not only hematologic malignancies
but also solid tumors of all kinds. In certain embodiments, the
compounds are useful for treating a form of cancer selected from
ovarian cancer, breast cancer, head and neck cancer, renal cancer,
bladder cancer, hepatocellular cancer, and colorectal cancer.
[0349] Hematological malignancies are broadly defined as
proliferative disorders of blood cells and/or their progenitors, in
which these cells proliferate in an uncontrolled manner.
Anatomically, the hematologic malignancies are divided into two
primary groups: lymphomas--malignant masses of lymphoid cells,
primarily but not exclusively in lymph nodes, and
leukemias--neoplasm derived typically from lymphoid or myeloid
cells and primarily affecting the bone marrow and peripheral blood.
The lymphomas can be sub-divided into Hodgkin's Disease and
Non-Hodgkin's lymphoma (NHL). The later group comprises several
distinct entities, which can be distinguished clinically (e.g.
aggressive lymphoma, indolent lymphoma), histologically (e.g.
follicular lymphoma, mantle cell lymphoma) or based on the origin
of the malignant cell (e.g. B lymphocyte, T lymphocyte). Leukemias
and related malignancies include acute myelogenous leukemia (AML),
chronic myelogenous leukemia (CML), acute lymphoblastic leukemia
(ALL) and chronic lymphocytic leukemia (CLL). Other hematological
malignancies include the plasma cell dyscrasias including multiple
myeloma, and the myelodysplastic syndromes.
[0350] In certain embodiments, the compounds of the present
disclosure are useful in the treatment of B-cell lymphoma,
lymphoplasmacytoid lymphoma, fallopian tube cancer, head and neck
cancer, ovarian cancer, and peritoneal cancer.
[0351] In certain embodiments, the compounds of the present
disclosure are useful in the treatment of hepatocellular carcinoma,
gastric cancer, and/or colorectal cancer. In certain embodiments,
the compounds of the present disclosure are useful in the treatment
of prostate cancer, breast cancer, and/or ovarian cancer. In
certain embodiments, the compounds of the present disclosure are
useful in the treatment of recurrent or metastatic squamous cell
carcinoma.
[0352] In certain embodiments, a method of treating a
hyperproliferative disease, comprising administering to an
individual (e.g. a human) in need thereof a therapeutically
effective amount of a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is provided. In certain
embodiments, the hyperproliferative disease is cancer. In certain
embodiments, the cancer is a solid tumor. In certain embodiments,
the cancer is selected from ovarian cancer, breast cancer, head and
neck cancer, renal cancer, bladder cancer, hepatocellular cancer,
and colorectal cancer. In certain embodiments, the cancer is a
lymphoma. In certain embodiments, the cancer is Hodgkin's lymphoma.
In certain embodiments, the cancer is non-Hodgkin's lymphoma. In
certain embodiments, the cancer is B-cell lymphoma. In certain
embodiments, the cancer is selected from B-cell lymphoma; fallopian
tube cancer, head and neck cancer, ovarian cancer and peritoneal
cancer. In certain embodiments, the method further comprises
administering one or more additional therapeutic agents as more
fully described herein.
[0353] In certain mebodiments, the cancer is prostate cancer,
breast cancer, ovarian cancer, hepatocellular carcinoma, gastric
cancer, colorectal cancer and/or recurrent or metastatic squamous
cell carcinoma. In certain mebodiments, the cancer is prostate
cancer, breast cancer, and/or ovarian cancer. In certain
embodiments, the cancer is hepatocellular carcinoma, gastric
cancer, and/or colorectal cancer. In certain embodiments, the
cancer is recurrent or metastatic squamous cell carcinoma.
V. ADMINISTRATION
[0354] In some embodiments, in the methods of use, the
administration is to an individual (e.g., a human) in need of the
treatment.
[0355] Additional examples of diseases, disorders, or conditions
include psoriasis, systemic lupus erythematosusand allergic
rhinitis
[0356] In one embodiment, the compound of the present disclosure,
or a pharmaceutically acceptable salt thereof, is for use in a
method of treating a hyperproliferative disease (e.g. cancer) in an
individual (e.g., a human).
[0357] Also provided herein is the use of a compound of the present
disclosure (e.g. a compound of Formula (I)) or a pharmaceutically
acceptable salt thereof for the manufacture of a medicament for
treating a hyperproliferative disease (e.g. cancer) is
provided.
VI. ADMINISTRATION
[0358] One or more of the compounds of the present disclosure (also
referred to herein as the active ingredients), can be administered
by any route appropriate to the condition to be treated. Suitable
routes include oral, rectal, nasal, topical (including buccal and
sublingual), transdermal, vaginal and parenteral (including
subcutaneous, intramuscular, intravenous, intradermal, intrathecal
and epidural), and the like. It will be appreciated that the
preferred route may vary with for example the condition of the
recipient. An advantage of certain compounds disclosed herein is
that they are orally bioavailable and can be dosed orally.
[0359] A compound of the present disclosure, such as a compound of
Formula (I), may be administered to an individual in accordance
with an effective dosing regimen for a desired period of time or
duration, such as at least about one month, at least about 2
months, at least about 3 months, at least about 6 months, or at
least about 12 months or longer. In one variation, the compound is
administered on a daily or intermittent schedule for the duration
of the individual's life.
[0360] The dosage or dosing frequency of a compound of the present
disclosure may be adjusted over the course of the treatment, based
on the judgment of the administering physician.
[0361] The compound may be administered to an individual (e.g., a
human) in an effective amount. In certain embodiments, the compound
is administered once daily.
[0362] In certain embodiments, methods for treating or preventing a
disease or condition in a human are provided, comprising
administering to the human a therapeutically effective amount of a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, in combination with a therapeutically
effective amount of one or more (e.g., one, two, three, four, one
or two, one to three, or one to four) additional therapeutic
agents. As modulators of TLR-8 may be used in the treatment of
various diseases or condutions, the particular identity of the
additional therapeutic agents will depend on the particular disease
or condition being treated.
[0363] The compound of Formula (J), (I), (II), (IIa), (IIb), (III),
(IIIa), (IIIb), (IV), (IVa), (IVb), (IVc), or (IVd) can be
administered by any useful route and means, such as by oral or
parenteral (e.g., intravenous) administration. Therapeutically
effective amounts of the compound of Formula (J), (I), (II), (IIa),
(IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb), (IVc), or (IVd)
are from about 0.00001 mg/kg body weight per day to about 10 mg/kg
body weight per day, such as from about 0.0001 mg/kg body weight
per day to about 10 mg/kg body weight per day, or such as from
about 0.001 mg/kg body weight per day to about 1 mg/kg body weight
per day, or such as from about 0.01 mg/kg body weight per day to
about 1 mg/kg body weight per day, or such as from about 0.05 mg/kg
body weight per day to about 0.5 mg/kg body weight per day, or such
as from about 0.3 .mu.g to about 30 mg per day, or such as from
about 30 .mu.g to about 300 .mu.g per day.
[0364] A compound of the present disclosure (e.g., any compound of
Formula (I)) may be combined with one or more additional
therapeutic agents in any dosage amount of the compound of the
present disclosure (e.g., from 1 mg to 1000 mg of compound).
Therapeutically effective amounts of the compound of Formula (J),
(I), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb),
(IVc), or (IVd), are from about 0.01 mg per dose to about 1000 mg
per dose, such as from about 0.01 mg per dose to about 100 mg per
dose, or such as from about 0.1 mg per dose to about 100 mg per
dose, or such as from about 1 mg per dose to about 100 mg per dose,
or such as from about 1 mg per dose to about 10 mg per dose. Other
therapeutically effective amounts of the compound of Formula (J),
(I), (II), (IIa), (lib), (III), (IIIa), (IIIb), (IV), (IVa), (IVb),
(IVc), or (IVd) are about 1 mg per dose, or about 2, 3, 4, 5, 6, 7,
8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,
85, 90, 95, or about 100 mg per dose. Other therapeutically
effective amounts of the compound of Formula (J), (I), (II), (IIa),
(IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb), (IVc), or (IVd)
are about 100 mg per dose, or about 125, 150, 175, 200, 225, 250,
275, 300, 350, 400, 450, or about 500 mg per dose. A single dose
can be administered hourly, daily, or weekly. For example, a single
dose can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16
or once every 24 hours. A single dose can also be administered once
every 1 day, 2, 3, 4, 5, 6, or once every 7 days. A single dose can
also be administered once every 1 week, 2, 3, or once every 4
weeks. In certain embodiments, a single dose can be administered
once every week. A single dose can also be administered once every
month.
[0365] The frequency of dosage of the compound of Formula (J), (I),
(II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb),
(IVc), or (IVd) will be determined by the needs of the individual
patient and can be, for example, once per day or twice, or more
times, per day. Administration of the compound continues for as
long as necessary to treat the HBV or HCV infection. For example,
Compound I can be administered to a human being infected with HBV
or HCV for a period of from 20 days to 180 days or, for example,
for a period of from 20 days to 90 days or, for example, for a
period of from 30 days to 60 days.
[0366] Administration can be intermittent, with a period of several
or more days during which a patient receives a daily dose of the
compound of Formula (J), (I), (II), (IIa), (IIb), (III), (IIIa),
(IIIb), (IV), (IVa), (IVb), (IVc), or (IVd), followed by a period
of several or more days during which a patient does not receive a
daily dose of the compound. For example, a patient can receive a
dose of the compound every other day, or three times per week.
Again by way of example, a patient can receive a dose of the
compound each day for a period of from 1 to 14 days, followed by a
period of 7 to 21 days during which the patient does not receive a
dose of the compound, followed by a subsequent period (e.g., from 1
to 14 days) during which the patient again receives a daily dose of
the compound. Alternating periods of administration of the
compound, followed by non-administration of the compound, can be
repeated as clinically required to treat the patient.
[0367] In one embodiment, pharmaceutical compositions comprising a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, in combination with one or more (e.g.,
one, two, three, four, one or two, one to three, or one to four)
additional therapeutic agents, and a pharmaceutically acceptable
excipient are provided.
[0368] In one embodiment, kits comprising a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, in
combination with one or more (e.g., one, two, three, four, one or
two, one to three, or one to four) additional therapeutic agents
are provided.
[0369] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with one, two, three, four or more additional therapeutic
agents. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with two additional therapeutic agents. In other
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with three
additional therapeutic agents. In further embodiments, a compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, is combined with four additional therapeutic agents. The
one, two, three, four or more additional therapeutic agents can be
different therapeutic agents selected from the same class of
therapeutic agents, and/or they can be selected from different
classes of therapeutic agents.
[0370] In certain embodiments, when a compound of the present
disclosure is combined with one or more additional therapeutic
agents as described herein, the components of the composition are
administered as a simultaneous or sequential regimen. When
administered sequentially, the combination may be administered in
two or more administrations.
[0371] In certain embodiments, a compound of the present disclosure
is combined with one or more additional therapeutic agents in a
unitary dosage form for simultaneous administration to a patient,
for example as a solid dosage form for oral administration.
[0372] In certain embodiments, a compound of the present disclosure
is administered with one or more additional therapeutic agents.
Co-administration of a compound of the present disclosure with one
or more additional therapeutic agents generally refers to
simultaneous or sequential administration of a compound of the
present disclosure and one or more additional therapeutic agents,
such that therapeutically effective amounts of the compound
disclosed herein and one or more additional therapeutic agents are
both present in the body of the patient.
[0373] Co-administration includes administration of unit dosages of
the compounds disclosed herein before or after administration of
unit dosages of one or more additional therapeutic agents, for
example, administration of the compound disclosed herein within
seconds, minutes, or hours of the administration of one or more
additional therapeutic agents. For example, in some embodiments, a
unit dose of a compound of the present disclosure is administered
first, followed within seconds or minutes by administration of a
unit dose of one or more additional therapeutic agents.
Alternatively, in other embodiments, a unit dose of one or more
additional therapeutic agents is administered first, followed by
administration of a unit dose of a compound of the present
disclosure within seconds or minutes. In some embodiments, a unit
dose of a compound of the present disclosure is administered first,
followed, after a period of hours (e.g., 1-12 hours), by
administration of a unit dose of one or more additional therapeutic
agents. In other embodiments, a unit dose of one or more additional
therapeutic agents is administered first, followed, after a period
of hours (e.g., 1-12 hours), by administration of a unit dose of a
compound of the present disclosure.
VII. COMBINATION THERAPY FOR HBV
[0374] In certain embodiments, a method for treating or preventing
an HBV infection in a human having or at risk of having the
infection is provided, comprising administering to the human a
therapeutically effective amount of a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, in
combination with a therapeutically effective amount of one or more
(e.g., one, two, three, four, one or two, one to three or one to
four) additional therapeutic agents. In one embodiment, a method
for treating an HBV infection in a human having or at risk of
having the infection is provided, comprising administering to the
human a therapeutically effective amount of a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
in combination with a therapeutically effective amount of one or
more (e.g., one, two, three, four, one or two, one to three or one
to four) additional therapeutic agents.
[0375] In certain embodiments, the present disclosure provides a
method for treating an HBV infection, comprising administering to a
patient in need thereof a therapeutically effective amount of a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, in combination with a therapeutically
effective amount of one or more additional therapeutic agents which
are suitable for treating an HBV infection. In certain embodiments,
one or more additional therapeutic agents includes, for example,
one, two, three, four, one or two, one to three or one to four
additional therapeutic agents.
[0376] In the above embodiments, the additional therapeutic agent
may be an anti-HBV agent. For example, in some embodiments, the
additional therapeutic agent is selected from the group consisting
of HBV combination drugs, HBV DNA polymerase inhibitors,
immunomodulators, toll-like receptor modulators (modulators of
TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9,
TLR-10, TLR-11, TLR-12 and TLR-13), interferon alpha receptor
ligands, hyaluronidase inhibitors, recombinant IL-7, hepatitis B
surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B
core antigen (HbcAg), cyclophilin inhibitors, HBV therapeutic
vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors,
NTCP (Na+-taurocholate cotransporting polypeptide) inhibitors,
antisense oligonucleotide targeting viral mRNA, short interfering
RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators,
inhibitors of ribonucleotide reductase, hepatitis B virus E antigen
inhibitors, recombinant scavenger receptor A (SRA) proteins, Src
kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short
synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV
antibodies targeting the surface antigens of the hepatitis B virus
and bispecific antibodies and "antibody-like" therapeutic proteins
(such as DARTs.RTM., Duobodies.RTM., Bites.RTM., XmAbs.RTM.,
TandAbs.RTM., Fab derivatives), CCR2 chemokine antagonists,
thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or
capsid protein inhibitors), stimulators of retinoic acid-inducible
gene 1, stimulators of NOD2, stimulators of NOD1, Arginase-1
inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta
receptor activators, Natural Killer Cell Receptor 2B4 inhibitors,
Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors,
cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD137
inhibitors, Killer cell lectin-like receptor subfamily G member 1
inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator
inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors,
PEG-Interferon Lambda, recombinant thymosin alpha-1, BTK
inhibitors, modulators of TIGIT, modulators of CD47, modulators of
SIRPalpha, modulators of ICOS, modulators of CD27, modulators of
CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4,
modulators of B7-H4, modulators of B7-H3, modulators of NKG2A,
modulators of GITR, modulators of CD160, modulators of HEVEM,
modulators of CD161, modulators of Axl, modulators of Mer,
modulators of Tyro, gene modifiers or editors such as CRISPR
(including CRISPR Cas9), zinc finger nucleases or synthetic
nucleases (TALENs), Hepatitis B virus replication inhibitors,
compounds such as those disclosed in U.S. Publication No.
2010/0143301 (Gilead Sciences), U.S. Publication No. 2011/0098248
(Gilead Sciences), U.S. Publication No. 2009/0047249 (Gilead
Sciences), U.S. Pat. No. 8,722,054 (Gilead Sciences), U.S.
Publication No. 2014/0045849 (Janssen), U.S. Publication No.
2014/0073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221
(Janssen), WO2014/128189 (Janssen), U.S. Publication No.
2014/0350031 (Janssen), WO2014/023813 (Janssen), U.S. Publication
No. 2008/0234251 (Array Biopharma), U.S. Publication No.
2008/0306050 (Array Biopharma), U.S. Publication No. 2010/0029585
(Ventirx Pharma), U.S. Publication No. 2011/0092485 (Ventirx
Pharma), US2011/0118235 (Ventirx Pharma), U.S. Publication No.
2012/0082658 (Ventirx Pharma), U.S. Publication No. 2012/0219615
(Ventirx Pharma), U.S. Publication No. 2014/0066432 (Ventirx
Pharma), U.S. Publication No. 2014/0088085 (Ventirx Pharma), U.S.
Publication No. 2014/0275167 (Novira Therapeutics), U.S.
Publication No. 2013/0251673 (Novira Therapeutics), U.S. Pat. No.
8,513,184 (Gilead Sciences), U.S. Publication No. 2014/0030221
(Gilead Sciences), U.S. Publication No. 2013/0344030 (Gilead
Sciences), U.S. Publication No. 2013/0344029 (Gilead Sciences),
U.S. Publication No. 2014/0343032 (Roche), WO2014037480 (Roche),
U.S. Publication No. 2013/0267517 (Roche), WO2014131847 (Janssen),
WO2014033176 (Janssen), WO2014033170 (Janssen), WO2014033167
(Janssen), U.S. Publication No. 2014/0330015 (Ono Pharmaceutical),
U.S. Publication No. 2013/0079327 (Ono Pharmaceutical), U.S.
Publication No. 2013/0217880 (Ono pharmaceutical), and other drugs
for treating HBV, and combinations thereof. In some embodiments,
the additional therapeutic agent is further selected from hepatitis
B surface antigen (HBsAg) secretion or assembly inhibitors,
TCR-like antibodies, IDO inhibitors, cccDNA epigenetic modifiers,
IAPs inhibitors, SMAC mimetics, and compounds such as those
disclosed in US20100015178 (Incyte),
[0377] In certain embodiments, the additional therapeutic is
selected from the group consisting of HBV combination drugs, HBV
DNA polymerase inhibitors, toll-like receptor 7 modulators,
toll-like receptor 8 modulators, Toll-like receptor 7 and 8
modulators, Toll-like receptor 3 modulators, interferon alpha
receptor ligands, HBsAg inhibitors, compounds targeting HbcAg,
cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic
vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense
oligonucleotide targeting viral mRNA, short interfering RNAs
(siRNA), hepatitis B virus E antigen inhibitors, HBx inhibitors,
cccDNA inhibitors, HBV antibodies including HBV antibodies
targeting the surface antigens of the hepatitis B virus, thymosin
agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid
protein inhibitors), stimulators of retinoic acid-inducible gene 1,
stimulators of NOD2, stimulators of NOD1, recombinant thymosin
alpha-1, BTK inhibitors, and hepatitis B virus replication
inhibitors, and combinations thereof. In certain embodiments, the
additional therapeutic is selected from hepatitis B surface antigen
(HBsAg) secretion or assembly inhibitors and IDO inhibitors.
[0378] In certain embodiments a compound of the present disclosure
(e.g. a compound of Formula (I)) is formulated as a tablet, which
may optionally contain one or more other compounds useful for
treating HBV. In certain embodiments, the tablet can contain
another active ingredient for treating HBV, such as HBV DNA
polymerase inhibitors, immunomodulators, toll-like receptor
modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6,
TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), modulators
of tlr7, modulators of tlr8, modulators of tlr7 and tlr8,
interferon alpha receptor ligands, hyaluronidase inhibitors,
hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting
hepatitis B core antigen (HbcAg), cyclophilin inhibitors, HBV viral
entry inhibitors, NTCP (Na+-taurocholate cotransporting
polypeptide) inhibitors, endonuclease modulators, inhibitors of
ribonucleotide reductase, hepatitis B virus E antigen inhibitors,
Src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, CCR2
chemokine antagonists, thymosin agonists, nucleoprotein inhibitors
(HBV core or capsid protein inhibitors), stimulators of retinoic
acid-inducible gene 1, stimulators of NOD2, stimulators of NOD1,
Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin
beta receptor activators, Natural Killer Cell Receptor 2B4
inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160
inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors,
CD137 inhibitors, Killer cell lectin-like receptor subfamily G
member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte
attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1
inhibitors, BTK inhibitors, modulators of TIGIT, modulators of
CD47, modulators of SIRP alpha, modulators of ICOS, modulators of
CD27, modulators of CD70, modulators of OX40, modulators of NKG2D,
modulators of Tim-4, modulators of B7-H4, modulators of B7-H3,
modulators of NKG2A, modulators of GITR, modulators of CD160,
modulators of HEVEM, modulators of CD161, modulators of Axl,
modulators of Mer, modulators of Tyro, and Hepatitis B virus
replication inhibitors, and combinations thereof. In certain
embodiments, the tablet can contain another active ingredient for
treating HBV, such as hepatitis B surface antigen (HBsAg) secretion
or assembly inhibitors, cccDNA epigenetic modifiers, IAPs
inhibitors, SMAC mimetics, and IDO inhibitors.
[0379] In certain embodiments, such tablets are suitable for once
daily dosing.
[0380] In certain embodiments, the additional therapeutic agent is
selected from one or more of: [0381] (1) Combination drugs selected
from the group consisting of tenofovir disoproxil
fumarate+emtricitabine (TRUVADA.RTM.); adefovir+clevudine and
GBV-015, as well as combination drugs selected from
ABX-203+lamivudine+PEG-IFNalpha, ABX-203+adefovir+PEG-IFNalpha, and
INO-9112+RG7944 (INO-1800); [0382] (2) HBV DNA polymerase
inhibitors selected from the group consisting of besifovir,
entecavir (Baraclude.RTM.), adefovir (Hepsera.RTM.), tenofovir
disoproxil fumarate (Viread.RTM.), tenofovir alafenamide,
tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate,
tenofovir alafenamide hemifumarate, tenofovir dipivoxil, tenofovir
dipivoxil fumarate, tenofovir octadecyloxyethyl ester, telbivudine
(Tyzeka.RTM.), pradefovir, Clevudine, emtricitabine (Emtriva.RTM.),
ribavirin, lamivudine (Epivir-HBV.RTM.), phosphazide, famciclovir,
SNC-019754, FMCA, fusolin, AGX-1009 and metacavir, as well as HBV
DNA polymerase inhibitors selected from AR-II-04-26 and HS-10234;
[0383] (3) Immunomodulators selected from the group consisting of
rintatolimod, imidol hydrochloride, ingaron, dermaVir, plaquenil
(hydroxychloroquine), proleukin, hydroxyurea, mycophenolate mofetil
(MPA) and its ester derivative mycophenolate mofetil (MMF), WF-10,
ribavirin, IL-12, polymer polyethyleneimine (PEI), Gepon, VGV-1,
MOR-22, BMS-936559 and IR-103, as well as immunomodulators selected
from INO-9112, polymer polyethyleneimine (PEI), Gepon, VGV-1,
MOR-22, BMS-936559, RO-7011785, RO-6871765 and IR-103; [0384] (4)
Toll-like receptor 7 modulators selected from the group consisting
of GS-9620, GSK-2245035, imiquimod, resiquimod, DSR-6434, DSP-3025,
IMO-4200, MCT-465, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X,
TMX-202 RG-7863 and RG-7795; [0385] (5) Toll-like receptor 8
modulators selected from the group consisting of motolimod,
resiquimod, 3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463;
[0386] (6) Toll-like receptor 3 modulators selected from the group
consisting of rintatolimod, poly-ICLC, MCT-465, MCT-475, Riboxxon,
Riboxxim and ND-1.1; [0387] (7) Interferon alpha receptor ligands
selected from the group consisting of interferon alpha-2b (Intron
A.RTM.), pegylated interferon alpha-2a (Pegasys.RTM.), interferon
alpha 1b (Hapgen.RTM.), Veldona, Infradure, Roferon-A,
YPEG-interferon alfa-2a (YPEG-rhIFNalpha-2a), P-1101, Algeron,
Alfarona, Ingaron (interferon gamma), rSIFN-co (recombinant super
compound interferon), Ypeginterferon alfa-2b (YPEG-rhIFNalpha-2b),
MOR-22, peginterferon alfa-2b (PEG-Intron.RTM.), Bioferon,
Novaferon, Inmutag (Inferon), Multiferon.RTM., interferon
alfa-nl(Humoferon.RTM.), interferon beta-1a (Avonex.RTM.),
Shaferon, interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b
(BioGeneric Pharma), interferon-alpha 2 (CJ), Laferonum, VIPEG,
BLAUFERON-B, BLAUFERON-A, Intermax Alpha, Realdiron, Lanstion,
Pegaferon, PDferon-B PDferon-B, interferon alfa-2b (IFN,
Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano,
Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A,
Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon
alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC,
Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun
Institute of Biological Products), Anterferon, Shanferon,
Layfferon, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai,
Pegstat, rHSA-IFN alpha-2b and Interapo (Interapa); [0388] (8)
Hyaluronidase inhibitors selected from the group consisting of
astodrimer; [0389] (9) Modulators of IL-10; [0390] (10) HBsAg
inhibitors selected from the group consisting of HBF-0259,
PBHBV-001, PBHBV-2-15, PBHBV-2-1, REP 9AC, REP-9C and REP 9AC', as
well as HBsAg inhibitors selected from REP-9, REP-2139,
REP-2139-Ca, REP-2165, REP-2055, REP-2163, REP-2165, REP-2053,
REP-2031 and REP-006 and REP-9AC' [0391] (11) Toll like receptor 9
modulators selected from CYT003, as well as Toll like receptor 9
modulators selected from CYT-003, IMO-2055, IMO-2125, IMO-3100,
IMO-8400, IMO-9200, agatolimod, DIMS-9054, DV-1179, AZD-1419,
MGN-1703, and CYT-003-QbG10; [0392] (12) Cyclophilin inhibitors
selected from the group consisting of OCB-030, SCY-635 and NVP-018;
[0393] (13) HBV Prophylactic vaccines selected from the group
consisting of Hexaxim, Heplisav, Mosquirix, DTwP-HBV vaccine,
Bio-Hep-B, D/T/P/HBV/M (LBVP-0101; LBVW-0101), DTwP-Hepb-Hib-IPV
vaccine, Heberpenta L, DTwP-HepB-Hib, V-419, CVI-HBV-001,
Tetrabhay, hepatitis B prophylactic vaccine (Advax Super D),
Hepatrol-07, GSK-223192A, Engerix B.RTM., recombinant hepatitis B
vaccine (intramuscular, Kangtai Biological Products), recombinant
hepatitis B vaccine (Hansenual polymorpha yeast, intramuscular,
Hualan Biological Engineering), Bimmugen, Euforavac, Eutravac,
anrix-DTaP--IPV-Hep B, Infanrix-DTaP--IPV-Hep B-Hib, Pentabio
Vaksin DTP--HB-Hib, Comvac 4, Twinrix, Euvax-B, Tritanrix HB,
Infanrix Hep B, Comvax, DTP-Hib-HBV vaccine, DTP-HBV vaccine, Yi
Tai, Heberbiovac HB, Trivac HB, GerVax, DTwP-Hep B-Hib vaccine,
Bilive, Hepavax-Gene, SUPERVAX, Comvac5, Shanvac-B, Hebsulin,
Recombivax HB, Revac B mcf, Revac B+, Fendrix, DTwP-HepB-Hib,
DNA-001, Shan6, rhHBsAG vaccine, and DTaP-rHB-Hib vaccine; [0394]
(14) HBV Therapeutic vaccines selected from the group consisting of
HBsAG-HBIG complex, Bio-Hep-B, NASVAC, abi-HB (intravenous),
ABX-203, Tetrabhay, GX-110E, GS-4774, peptide vaccine
(epsilonPA-44), Hepatrol-07, NASVAC (NASTERAP), IMP-321, BEVAC,
Revac B mcf, Revac B+, MGN-1333, KW-2, CVI-HBV-002, AltraHepB,
VGX-6200, FP-02, TG-1050, NU-500, HBVax, im/TriGrid/antigen
vaccine, Mega-CD40L-adjuvanted vaccine, HepB-v, NO-1800,
recombinant VLP-based therapeutic vaccine (HBV infection, VLP
Biotech), AdTG-17909, AdTG-17910 AdTG-18202, ChronVac-B, and Lm
HBV, as well as HBV Therapeutic vaccines selected from FP-02.2 and
RG7944 (INO-1800); [0395] (15) HBV viral entry inhibitor selected
from the group consisting of Myrcludex B; [0396] (16) Antisense
oligonucleotide targeting viral mRNA selected from the group
consisting of ISIS-HBVRx; [0397] (17) short interfering RNAs
(siRNA) selected from the group consisting of TKM-HBV (TKM-HepB),
ALN-HBV, SR-008, ddRNAi and ARC-520; [0398] (18) Endonuclease
modulators selected from the group consisting of PGN-514; [0399]
(19) Inhibitors of ribonucleotide reductase selected from the group
consisting of Trimidox; [0400] (20) Hepatitis B virus E antigen
inhibitors selected from the group consisting of wogonin; [0401]
(21) HBV antibodies targeting the surface antigens of the hepatitis
B virus selected from the group consisting of GC-1102, XTL-17,
XTL-19, XTL-001, KN-003 and fully human monoclonal antibody therapy
(hepatitis B virus infection, Humabs BioMed), as well as HBV
antibodies targeting the surface antigens of the hepatitis B virus
selected from IV Hepabulin SN; [0402] (22) HBV antibodies including
monoclonal antibodies and polyclonal antibodies selected from the
group consisting of Zutectra, Shang Sheng Gan Di, Uman Big
(Hepatitis B Hyperimmune), Omri-Hep-B, Nabi-HB, Hepatect CP,
HepaGam B, igantibe, Niuliva, CT-P24, hepatitis B immunoglobulin
(intravenous, pH4, HBV infection, Shanghai RAAS Blood Products) and
Fovepta (BT-088); [0403] (23) CCR2 chemokine antagonists selected
from the group consisting of propagermanium; [0404] (24) Thymosin
agonists selected from the group consisting of Thymalfasin; [0405]
(25) Cytokines selected from the group consisting of recombinant
IL-7, CYT-107, interleukin-2 (IL-2, Immunex); recombinant human
interleukin-2 (Shenzhen Neptunus) and celmoleukin, as well as
cytokines selected from IL-15, IL-21, IL-24; [0406] (26)
Nucleoprotein inhibitors (HBV core or capsid protein inhibitors)
selected from the group consisting of NVR-1221, NVR-3778, BAY
41-4109, morphothiadine mesilate and DVR-23; [0407] (27)
Stimulators of retinoic acid-inducible gene 1 selected from the
group consisting of SB-9200, SB-40, SB-44, ORI-7246, ORI-9350,
ORI-7537, ORI-9020, ORI-9198 and ORI-7170; [0408] (28) Stimulators
of NOD2 selected from the group consisting of SB-9200; [0409] (29)
Recombinant thymosin alpha-1 selected from the group consisting of
NL-004 and PEGylated thymosin alpha 1; [0410] (30) Hepatitis B
virus replication inhibitors selected from the group consisting of
isothiafludine, IQP-HBV, RM-5038 and Xingantie; [0411] (31) PI3K
inhibitors selected from the group consisting of idelalisib,
AZD-8186, buparlisib, CLR-457, pictilisib, neratinib, rigosertib,
rigosertib sodium, EN-3342, TGR-1202, alpelisib, duvelisib,
UCB-5857, taselisib, XL-765, gedatolisib, VS-5584, copanlisib, CAI
orotate, perifosine, RG-7666, GSK-2636771, DS-7423, panulisib,
GSK-2269557, GSK-2126458, CUDC-907, PQR-309, INCB-040093,
pilaralisib, BAY-1082439, puquitinib mesylate, SAR-245409, AMG-319,
RP-6530, ZSTK-474, MLN-1117, SF-1126, RV-1729, sonolisib,
LY-3023414, SAR-260301 and CLR-1401; [0412] (32) cccDNA inhibitors
selected from the group consisting of BSBI-25; [0413] (33) PD-L1
inhibitors selected from the group consisting of MEDI-0680,
RG-7446, durvalumab, KY-1003, KD-033, MSB-0010718C, TSR-042,
ALN-PDL, STI-A1014 and BMS-936559; [0414] (34) PD-1 inhibitors
selected from the group consisting of nivolumab, pembrolizumab,
pidilizumab, BGB-108 and mDX-400; [0415] (35) BTK inhibitors
selected from the group consisting of ACP-196, dasatinib,
ibrutinib, PRN-1008, SNS-062, ONO-4059, BGB-3111, MSC-2364447,
X-022, spebrutinib, TP-4207, HM-71224, KBP-7536, AC-0025; [0416]
(36) Other drugs for treating HBV selected from the group
consisting of gentiopicrin (gentiopicroside), nitazoxanide,
birinapant, NOV-205 (Molixan; BAM-205), Oligotide, Mivotilate,
Feron, levamisole, Ka Shu Ning, Alloferon, WS-007, Y-101 (Ti Fen
Tai), rSIFN-co, PEG-IIFNm, KW-3, BP-Inter-014, oleanolic acid,
HepB-nRNA, cTP-5 (rTP-5), HSK-II-2, HEISCO-106-1, HEISCO-106,
Hepbarna, IBPB-006IA, Hepuyinfen, DasKloster 0014-01, Jiangantai
(Ganxikang), picroside, GA5 NM-HBV, DasKloster-0039, hepulantai,
IMB-2613, TCM-800B and ZH-2N, as well as other drugs for treating
HBV selected from reduced glutathione, and RO-6864018; and [0417]
(37) The compounds disclosed in US20100143301 (Gilead Sciences),
US20110098248 (Gilead Sciences), US20090047249 (Gilead Sciences),
U.S. Pat. No. 8,722,054 (Gilead Sciences), US20140045849 (Janssen),
US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221
(Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen),
WO2014/023813 (Janssen), US20080234251 (Array Biopharma),
US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma),
US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma),
US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma),
US20140066432 (Ventirx Pharma), US20140088085 (VentirxPharma),
US20140275167 (Novira therapeutics), US20130251673 (Novira
therapeutics), U.S. Pat. No. 8,513,184 (Gilead Sciences),
US20140030221 (Gilead Sciences), US20130344030 (Gilead Sciences),
US20130344029 (Gilead Sciences), US20140343032 (Roche),
WO2014037480 (Roche), US20130267517 (Roche), WO2014131847
(Janssen), WO2014033176 (Janssen), WO2014033170 (Janssen),
WO2014033167 (Janssen), US20140330015 (Ono pharmaceutical),
US20130079327 (Ono pharmaceutical), and US20130217880 (Ono
pharmaceutical), and the compounds disclosed in US20100015178
(Incyte).
[0418] Also included in the list above are: [0419] (38) IDO
inhibitors selected from the group consisting of epacadostat
(INCB24360), F-001287, resminostat (4SC-201), SN-35837, NLG-919,
GDC-0919, and indoximod; [0420] (39) Arginase inhibitors selected
from CB-1158, C-201, and resminostat; and [0421] (40) Cytotoxic
T-lymphocyte-associated protein 4 (ipi4) inhibitors selected from
ipilumimab, belatacept, PSI-001, PRS-010, tremelimumab, and
JHL-1155.
[0422] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with one, two, three, four or more additional therapeutic
agents. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with two additional therapeutic agents. In other
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with three
additional therapeutic agents. In further embodiments, a compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, is combined with four additional therapeutic agents. The
one, two, three, four or more additional therapeutic agents can be
different therapeutic agents selected from the same class of
therapeutic agents, and/or they can be selected from different
classes of therapeutic agents.
[0423] In a specific embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with an HBV DNA polymerase inhibitor. In another specific
embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with an HBV
DNA polymerase inhibitor and at least one additional therapeutic
agent selected from the group consisting of: immunomodulators,
toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3,
TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12
and TLR-13), interferon alpha receptor ligands, hyaluronidase
inhibitors, recombinant IL-7, HBsAg inhibitors, compounds targeting
HbcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV
prophylactic vaccines HBV viral entry inhibitors, NTCP inhibitors,
antisense oligonucleotide targeting viral mRNA, short interfering
RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators,
inhibitors of ribonucleotide reductase, Hepatitis B virus E antigen
inhibitors, recombinant scavenger receptor A (SRA) proteins, src
kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short
synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV
antibodies targeting the surface antigens of the hepatitis B virus
and bispecific antibodies and "antibody-like" therapeutic proteins
(such as DARTs.RTM., Duobodies.RTM., Bites.RTM., XmAbs.RTM.,
TandAbs.RTM., Fab derivatives), CCR2 chemokine antagonists,
thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or
capsid protein inhibitors), stimulators of retinoic acid-inducible
gene 1, stimulators of NOD2, stimulators of NOD1, Arginase-1
inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta
receptor activators, Natural Killer Cell Receptor 2B4 inhibitors,
Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors,
cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD137
inhibitors, Killer cell lectin-like receptor subfamily G member 1
inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator
inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors,
PEG-Interferon Lambda, recombinant thymosin alpha-1, BTK
inhibitors, modulators of TIGIT, modulators of CD47, modulators of
SIRPalpha, modulators of ICOS, modulators of CD27, modulators of
CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4,
modulators of B7-H4, modulators of B7-H3, modulators of NKG2A,
modulators of GITR, modulators of CD160, modulators of HEVEM,
modulators of CD161, modulators of Axl, modulators of Mer,
modulators of Tyro, gene modifiers or editors such as CRISPR
(including CRISPR Cas9), zinc finger nucleases or synthetic
nucleases (TALENs), and Hepatitis B virus replication inhibitors.
In certain embodiments the at least one additional therapeutic
agent is further selected from hepatitis B surface antigen (HBsAg)
secretion or assembly inhibitors, TCR-like antibodies, cccDNA
epigenetic modifiers, IAPs inhibitors, SMAC mimetics, and IDO
inhibitors.
[0424] In another specific embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with an HBV DNA polymerase inhibitor and at least one
additional therapeutic agent selected from the group consisting of:
HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA
inhibitors, HBV antibodies targeting the surface antigens of the
hepatitis B virus, short interfering RNAs (siRNA), miRNA gene
therapy agents, short synthetic hairpin RNAs (sshRNAs), and
nucleoprotein inhibitors (HBV core or capsid protein
inhibitors).
[0425] In another specific embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with an HBV DNA polymerase inhibitor, one or two
additional therapeutic agents selected from the group consisting
of: immunomodulators, toll-like receptor modulators (modulators of
TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9,
TLR-10, TLR-11, TLR-12 and TLR-13), HBsAg inhibitors, HBV
therapeutic vaccines, HBV antibodies including HBV antibodies
targeting the surface antigens of the hepatitis B virus and
bispecific antibodies and "antibody-like" therapeutic proteins
(such as DARTs.RTM., Duobodies.RTM., Bites.RTM., XmAbs.RTM.,
TandAbs.RTM., Fab derivatives), cyclophilin inhibitors, stimulators
of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1
inhibitors, Arginase-1 inhibitors, PI3K inhibitors and stimulators
of NOD2, and one or two additional therapeutic agents selected from
the group consisting of: HBV viral entry inhibitors, NTCP
inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies
targeting the surface antigens of the hepatitis B virus, short
interfering RNAs (siRNA), miRNA gene therapy agents, short
synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV
core or capsid protein inhibitors). In certain embodiments one or
two additional therapeutic agents is further selected from
hepatitis B surface antigen (HBsAg) secretion or assembly
inhibitors, TCR-like antibodies, and IDO inhibitors.
[0426] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with one, two, three, four or more additional therapeutic
agents selected from adefovir (Hepsera.RTM.), tenofovir disoproxil
fumarate+emtricitabine (TRUVADA.RTM.), tenofovir disoproxil
fumarate (Viread.RTM.), entecavir (Baraclude.RTM.), lamivudine
(Epivir-HBV.RTM.), tenofovir alafenamide, tenofovir, tenofovir
disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide
hemifumarate, telbivudine (Tyzeka.RTM.), Clevudine.RTM.,
emtricitabine (Emtriva.RTM.), peginterferon alfa-2b
(PEG-Intron.RTM.), Multiferon.RTM., interferon alpha 1b
(Hapgen.RTM.), interferon alpha-2b (Intron A.RTM.), pegylated
interferon alpha-2a (Pegasys.RTM.), interferon alfa-nl
(Humoferon.RTM.), ribavirin, interferon beta-la (Avonex.RTM.),
Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A,
Oligotide, Zutectra, Shaferon, interferon alfa-2b (AXXO),
Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron,
interferon-alpha 2 (CJ), BEVAC, Laferonum, VIPEG, BLAUFERON-B,
BLAUFERON-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon,
PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma),
alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep,
interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon,
interferon alfa-2b (Amega), interferon alfa-2b (Virchow),
peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon,
Urifron, interferon alfa-2b (Changchun Institute of Biological
Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2,
Immunex), recombinant human interleukin-2 (Shenzhen Neptunus),
Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, INTEFEN, SINOGEN,
Fukangtai, Alloferon and celmoleukin
[0427] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with entecavir (Baraclude.RTM.), adefovir (Hepsera.RTM.),
tenofovir disoproxil fumarate (Viread.RTM.), tenofovir alafenamide,
tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate,
tenofovir alafenamide hemifumarate, telbivudine (Tyzeka.RTM.) or
lamivudine (Epivir-HBV.RTM.)
[0428] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with entecavir (Baraclude.RTM.), adefovir (Hepsera.RTM.),
tenofovir disoproxil fumarate (Viread.RTM.), tenofovir alafenamide
hemifumarate, telbivudine (Tyzeka.RTM.) or lamivudine
(Epivir-HBV.RTM.).
[0429] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof is
combined with a PD-1 inhibitor. In a particular embodiment, a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof is combined with a PD-L1 inhibitor. In a
particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof is combined with an IDO
inhibitor. In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof is
combined with an IDO inhibitor and a PD-1 inhibitor. In a
particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with an IDO
inhibitor and a PD-L1 inhibitor. In a particular embodiment, a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, is combined with a TLR7 modulator, such as
GS-9620.
[0430] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with a TLR7 modulator and an IDO inhibitor. In a
particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a TLR7
modulator such as GS-9620 and an IDO inhibitor such as
epacadostat.
[0431] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with
(4-amino-2-butoxy-8-({3-[(pyrrolidin-1-yl)methyl]phenyl}methyl)-7,8-dihyd-
ropteridin-6(5H)-one) or a pharmaceutically acceptable salt
thereof.
[0432] As used herein, GS-9620
(4-amino-2-butoxy-8-({3-[(pyrrolidin-1-yl)methyl]phenyl}methyl)-7,8-dihyd-
ropteridin-6(5H)-one), includes pharmaceutically acceptable salts
thereof. J. Med. Chem., 2013, 56 (18), pp 7324-7333.
[0433] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with a first additional therapeutic agent selected from
the group consisting of: entecavir (Baraclude.RTM.), adefovir
(Hepsera.RTM.), tenofovir disoproxil fumarate (Viread.RTM.),
tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir
alafenamide fumarate, tenofovir alafenamide hemifumarate,
telbivudine (Tyzeka.RTM.) or lamivudine (Epivir-HBV.RTM.) and at
least one additional therapeutic agent selected from the group
consisting of immunomodulators, toll-like receptor modulators
(modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7,
TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), interferon alpha
receptor ligands, hyaluronidase inhibitors, recombinant IL-7, HBsAg
inhibitors, compounds targeting HbcAg, cyclophilin inhibitors, HBV
Therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry
inhibitors, NTCP inhibitors, antisense oligonucleotide targeting
viral mRNA, short interfering RNAs (siRNA), miRNA gene therapy
agents, endonuclease modulators, inhibitors of ribonucleotide
reductase, Hepatitis B virus E antigen inhibitors, recombinant
scavenger receptor A (SRA) proteins, src kinase inhibitors, HBx
inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs
(sshRNAs), HBV antibodies including HBV antibodies targeting the
surface antigens of the hepatitis B virus and bispecific antibodies
and "antibody-like" therapeutic proteins (such as DARTs.RTM.,
Duobodies.RTM., Bites.RTM., XmAbs.RTM., TandAbs.RTM., Fab
derivatives), CCR2 chemokine antagonists, thymosin agonists,
cytokines, nucleoprotein inhibitors (HBV core or capsid protein
inhibitors), stimulators of retinoic acid-inducible gene 1,
stimulators of NOD2, stimulators of NOD1, recombinant thymosin
alpha-1, Arginase-1 inhibitors, STING agonists, PI3K inhibitors,
lymphotoxin beta receptor activators, Natural Killer Cell Receptor
2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160
inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors,
CD137 inhibitors, Killer cell lectin-like receptor subfamily G
member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte
attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1
inhibitors, PEG-Interferon Lambd, BTK inhibitors, modulators of
TIGIT, modulators of CD47, modulators of SIRPalpha, modulators of
ICOS, modulators of CD27, modulators of CD70, modulators of OX40,
modulators of NKG2D, modulators of Tim-4, modulators of B7-H4,
modulators of B7-H3, modulators of NKG2A, modulators of GITR,
modulators of CD160, modulators of HEVEM, modulators of CD161,
modulators of Axl, modulators of Mer, modulators of Tyro, gene
modifiers or editors such as CRISPR (including CRISPR Cas9), zinc
finger nucleases or synthetic nucleases (TALENs), a and Hepatitis B
virus replication inhibitors. In certain embodiments, the at least
one additional therapeutic agent is further selected from hepatitis
B surface antigen (HBsAg) secretion or assembly inhibitors,
TCR-like antibodies, IDO inhibitors, cccDNA epigenetic modifiers,
IAPs inhibitors, and SMAC mimetics.
[0434] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with a first additional therapeutic agent selected from
the group consisting of: entecavir (Baraclude.RTM.), adefovir
(Hepsera.RTM.), tenofovir disoproxil fumarate (Viread.RTM.),
tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir
alafenamide fumarate, tenofovir alafenamide hemifumarate,
telbivudine (Tyzeka.RTM.) or lamivudine (Epivir-HBV.RTM.) and at
least a one additional therapeutic agent selected from the group
consisting of peginterferon alfa-2b (PEG-Intron.RTM.),
Multiferon.RTM., interferon alpha 1b (Hapgen.RTM.), interferon
alpha-2b (Intron A.RTM.), pegylated interferon alpha-2a
(Pegasys.RTM.), interferon alfa-nl(Humoferon.RTM.), ribavirin,
interferon beta-1a (Avonex.RTM.), Bioferon, Ingaron, Inmutag
(Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon,
interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b
(BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), BEVAC,
Laferonum, VIPEG, BLAUFERON-B, BLAUFERON-A, Intermax Alpha,
Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN,
Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano,
Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A,
Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon
alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC,
Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun
Institute of Biological Products), Anterferon, Shanferon, MOR-22,
interleukin-2 (IL-2, Immunex), recombinant human interleukin-2
(Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai,
INTEFEN, SINOGEN, Fukangtai, Alloferon and celmoleukin.
[0435] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with a first additional therapeutic agent selected from
the group consisting of: entecavir (Baraclude.RTM.), adefovir
(Hepsera.RTM.), tenofovir disoproxil fumarate (Viread.RTM.),
tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir
alafenamide fumarate, tenofovir alafenamide hemifumarate,
telbivudine (Tyzeka.RTM.) or lamivudine (Epivir-HBV.RTM.) and at
least one additional therapeutic agent selected from the group
consisting of HBV viral entry inhibitors, NTCP inhibitors, HBx
inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface
antigens of the hepatitis B virus, short interfering RNAs (siRNA),
miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs),
and nucleoprotein inhibitors (HBV core or capsid protein
inhibitors).
[0436] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with a first additional therapeutic agent selected from
the group consisting of: entecavir (Baraclude.RTM.), adefovir
(Hepsera.RTM.), tenofovir disoproxil fumarate (Viread.RTM.),
tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir
alafenamide fumarate, tenofovir alafenamide hemifumarate,
telbivudine (Tyzeka.RTM.) or lamivudine (Epivir-HBV.RTM.), one or
two additional therapeutic agents selected from the group
consisting of: immunomodulators, toll-like receptor modulators
(modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7,
TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), HBsAg inhibitors,
HBV therapeutic vaccines, HBV antibodies including HBV antibodies
targeting the surface antigens of the hepatitis B virus and
bispecific antibodies and "antibody-like" therapeutic proteins
(such as DARTs.RTM., Duobodies.RTM., Bites.RTM., XmAbs.RTM.,
TandAbs.RTM., Fab derivatives), cyclophilin inhibitors, stimulators
of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1
inhibitors, Arginase-1 inhibitors, PI3K inhibitors and stimulators
of NOD2, and one or two additional therapeutic agents selected from
the group consisting of: HBV viral entry inhibitors, NTCP
inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies
targeting the surface antigens of the hepatitis B virus, short
interfering RNAs (siRNA), miRNA gene therapy agents, short
synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV
core or capsid protein inhibitors). In certain embodiments, the one
or two additional therapeutic agents is further selected from
hepatitis B surface antigen (HBsAg) secretion or assembly
inhibitors, TCR-like antibodies, and IDO inhibitors.
[0437] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with 5-30 mg tenofovir alafenamide fumarate, tenofovir
alafenamide hemifumarate, or tenofovir alafenamide. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with 5-10;
5-15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30 mg tenofovir
alafenamide fumarate, tenofovir alafenamide hemifumarate, or
tenofovir alafenamide. In certain embodiments, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is combined with 10 mg tenofovir alafenamide fumarate, tenofovir
alafenamide hemifumarate, or tenofovir alafenamide. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with 25 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide. A compound of the present disclosure
(e.g., a compound of Formula (I)) may be combined with the agents
provided herein in any dosage amount of the compound (e.g., from 50
mg to 500 mg of compound) the same as if each combination of
dosages were specifically and individually listed. A compound of
the present disclosure (e.g., a compound of Formula (I)) may be
combined with the agents provided herein in any dosage amount of
the compound (e.g. from about 1 mg to about 150 mg of compound) the
same as if each combination of dosages were specifically and
individually listed.
[0438] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with 100-400 mg tenofovir disoproxil fumarate, tenofovir
disoproxil hemifumarate, or tenofovir disoproxil. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with 100-150;
100-200, 100-250; 100-300; 100-350; 150-200; 150-250; 150-300;
150-350; 150-400; 200-250; 200-300; 200-350; 200-400; 250-350;
250-400; 350-400 or 300-400 mg tenofovir disoproxil fumarate,
tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In
certain embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with 300 mg
tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate,
or tenofovir disoproxil. In certain embodiments, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is combined with 250 mg tenofovir disoproxil fumarate, tenofovir
disoproxil hemifumarate, or tenofovir disoproxil. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with 150 mg
tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate,
or tenofovir disoproxil. A compound of the present disclosure
(e.g., a compound of Formula (I)) may be combined with the agents
provided herein in any dosage amount of the compound (e.g., from 50
mg to 500 mg of compound) the same as if each combination of
dosages were specifically and individually listed. A compound of
the present disclosure (e.g., a compound of Formula (I)) may be
combined with the agents provided herein in any dosage amount of
the compound (e.g., from about 1 mg to about 150 mg of compound)
the same as if each combination of dosages were specifically and
individually listed.
[0439] Also provided herein is a compound of the present disclosure
(e.g., a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, and one or more additional active ingredients for
treating HBV, for use in a method of treating or preventing
HBV.
[0440] Also provided herein is a compound of the present disclosure
(e.g., a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, for use in a method of treating or preventing HBV,
wherein the compound, or a pharmaceutically acceptable salt thereof
is administered simultaneously, separately or sequentially with one
or more additional therapeutic agents fort for treating HBV.
VIII. COMBINATION THERAPY FOR HCV
[0441] In certain embodiments, a method for treating or preventing
an HCV infection in a human having or at risk of having the
infection is provided, comprising administering to the human a
therapeutically effective amount of a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, in
combination with a therapeutically effective amount of one or more
(e.g., one, two, three, one or two, or one to three) additional
therapeutic agents. In one embodiment, a method for treating an HCV
infection in a human having or at risk of having the infection is
provided, comprising administering to the human a therapeutically
effective amount of a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more (e.g., one, two,
three, one or two, or one to three) additional therapeutic
agents.
[0442] In certain embodiments, the present disclosure provides a
method for treating an HCV infection, comprising administering to a
patient in need thereof a therapeutically effective amount of a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, in combination with a therapeutically
effective amount of one or more additional therapeutic agents which
are suitable for treating an HCV infection.
[0443] In the above embodiments, the additional therapeutic agent
may be an anti-HCV agent. For example, in some embodiments, the
additional therapeutic agent is selected from the group consisting
of interferons, ribavirin or its analogs, HCV NS3 protease
inhibitors, HCV NS4 protease inhibitors, HCV NS3/NS4 protease
inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants,
nucleoside or nucleotide inhibitors of HCV NS5B polymerase,
non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A
inhibitors, TLR-7 agonists, cyclophilin inhibitors, HCV IRES
inhibitors, and pharmacokinetic enhancers, compounds such as those
disclosed in US2010/0310512, US2013/0102525, and WO2013/185093, or
combinations thereof.
[0444] In certain embodiments a compound of the present disclosure
(e.g., a compound of Formula (I)) is formulated as a tablet, which
may optionally contain one or more other compounds useful for
treating HCV. In certain embodiments, the tablet can contain
another active ingredient for treating HCV, such as interferons,
ribavirin or its analogs, HCV NS3 protease inhibitors, HCV NS4
protease inhibitors, HCV NS3/NS4 protease inhibitors,
alpha-glucosidase 1 inhibitors, hepatoprotectants, nucleoside or
nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside
inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7
agonists, cyclophilin inhibitors, HCV IRES inhibitors, and
pharmacokinetic enhancers, or combinations thereof.
[0445] In certain embodiments, such tablets are suitable for once
daily dosing.
[0446] In certain embodiments, the additional therapeutic agent is
selected from one or more of: [0447] (1) Interferons selected from
the group consisting of pegylated rIFN-alpha 2b (PEG-Intron),
pegylated rIFN-alpha 2a (Pegasys), rIFN-alpha 2b (Intron A),
rIFN-alpha 2a (Roferon-A), interferon alpha (MOR-22, OPC-18,
Alfaferone, Alfanative, Multiferon, subalin), interferon alfacon-1
(Infergen), interferon alpha-nl (Wellferon), interferon alpha-n3
(Alferon), interferon-beta (Avonex, DL-8234), interferon-omega
(omega DUROS, Biomed 510), albinterferon alpha-2b (Albuferon), IFN
alpha XL, BLX-883 (Locteron), DA-3021, glycosylated interferon
alpha-2b (AVI-005), PEG-Infergen, PEGylated interferon lambda
(PEGylated IL-29), or belerofon, IFN alpha-2b XL, rIFN-alpha 2a,
consensus IFN alpha, infergen, rebif, pegylated IFN-beta, oral
interferon alpha, feron, reaferon, intermax alpha, r-IFN-beta, and
infergen+actimmuneribavirin and ribavirin analogs, e.g., rebetol,
copegus, VX-497, and viramidine (taribavirin); [0448] (2) Ribavirin
and its analogs selected from the group consisting of ribavirin
(Rebetol, Copegus), and taribavirin (Viramidine); [0449] (3) NS5A
inhibitors selected from the group consisting of Compound A. 1
(described below), Compound A.2 (described below), Compound A.3
(described below), ABT-267, Compound A.4 (described below),
JNJ-47910382, daclatasvir (BMS-790052), ABT-267, Samatasvir,
MK-8742, MK-8404, EDP-239, IDX-719, PPI-668, GSK-2336805, ACH-3102,
A-831, A-689, AZD-2836 (A-831), AZD-7295 (A-689), and BMS-790052;
[0450] (4) NS5B polymerase inhibitors selected from the group
consisting of sofosbuvir (GS-7977), Compound A.5 (described below),
Compound A.6 (described below), ABT-333, Compound A.7 (described
below), ABT-072, Compound A.8 (described below), tegobuvir
(GS-9190), GS-9669, TMC647055, ABT-333, ABT-072, setrobuvir
(ANA-598), IDX-21437, filibuvir (PF-868554), VX-222, IDX-375,
IDX-184, IDX-102, BI-207127, valopicitabine (NM-283), PSI-6130
(R1656), PSI-7851, BCX-4678, nesbuvir (HCV-796), BILB 1941,
MK-0608, NM-107, R7128, VCH-759, GSK625433, XTL-2125, VCH-916,
JTK-652, MK-3281, VBY-708, A848837, GL59728, A-63890, A-48773,
A-48547, BC-2329, BMS-791325, BILB-1941, AL-335, AL-516 and
ACH-3422; [0451] (5) Protease (NS3, NS3-NS4) inhibitors selected
from the group consisting of Compound A.9, Compound A. 10, Compound
A. 11, ABT-450, Compound A. 12 (described below), simeprevir
(TMC-435), boceprevir (SCH-503034), narlaprevir (SCH-900518),
vaniprevir (MK-7009), MK-5172, danoprevir (ITMN-191), sovaprevir
(ACH-1625), neceprevir (ACH-2684), Telaprevir (VX-950), VX-813,
VX-500, faldaprevir (BI-201335), asunaprevir (BMS-650032),
BMS-605339, VBY-376, PHX-1766, YH5531, BILN-2065, and BILN-2061;
[0452] (6) Alpha-glucosidase 1 inhibitors selected from the group
consisting of celgosivir (MX-3253), Miglitol, and UT-231B; [0453]
(7) Hepatoprotectants selected from the group consisting of
emericasan (IDN-6556), ME-3738, GS-9450 (LB-84451), silibilin, and
MitoQ; [0454] (8) TLR-7 agonists selected from the group consisting
of imiquimod, 852A, GS-9524, ANA-773, ANA-975, AZD-8848 (DSP-3025),
and SM-360320; [0455] (9) Cyclophillin inhibitors selected from the
group consisting of DEBIO-025, SCY-635, and NIM811; [0456] (10) HCV
IRES inhibitors selected from the group consisting of MCI-067;
[0457] (11) Pharmacokinetic enhancers selected from the group
consisting of BAS-100, SPI-452, PF-4194477, TMC-41629, GS-9350,
GS-9585, and roxythromycin; and [0458] (12) Other anti-HCV agents
selected from the group consisting of thymosin alpha 1 (Zadaxin),
nitazoxanide (Alinea, NTZ), BIVN-401 (virostat), PYN-17 (altirex),
KPE02003002, actilon (CPG-10101), GS-9525, KRN-7000, civacir,
GI-5005, XTL-6865, BIT225, PTX-111, ITX2865, TT-033i, ANA 971,
NOV-205, tarvacin, EHC-18, VGX-410C, EMZ-702, AVI 4065, BMS-650032,
BMS-791325, Bavituximab, MDX-1106 (ONO-4538), Oglufanide, VX-497
(merimepodib) NIM811, benzimidazole derivatives,
benzo-1,2,4-thiadiazine derivatives, and phenylalanine
derivatives;
[0459] Compound A. 1 is an inhibitor of the HCV NS5A protein and is
represented by the following chemical structure:
##STR00115##
(see, e.g., U.S. Application Publication No. 20100310512 A1).
[0460] Compound A.2 is an NS5A inhibitor and is represented by the
following chemical structure:
##STR00116##
[0461] Compound A.3 is an NS5A inhibitor and is represented by the
following chemical structure:
##STR00117##
[0462] Compound A.4 is an NS5A inhibitor and is represented by the
following chemical structure:
##STR00118##
(see U.S. Application Publication No. 2013/0102525 and references
therein.)
[0463] Compound A.5 is an NS5B Thumb II polymerase inhibitor and is
represented by the following chemical structure:
##STR00119##
[0464] Compound A.6 is a nucleotide inhibitor prodrug designed to
inhibit replication of viral RNA by the HCV NS5B polymerase, and is
represented by the following chemical structure:
##STR00120##
[0465] Compound A.7 is an HCV polymerase inhibitor and is
represented by the following structure:
##STR00121##
(see U.S. Application Publication No. 2013/0102525 and references
therein).
[0466] Compound A.8 is an HCV polymerase inhibitor and is
represented by the following structure:
##STR00122##
(see U.S. Application Publication No. 2013/0102525 and references
therein).
[0467] Compound A.9 is an HCV protease inhibitor and is represented
by the following chemical structure:
##STR00123##
[0468] Compound A. 10 is an HCV protease inhibitor and is
represented by the following chemical structure:
##STR00124##
[0469] Compound A.11 is an HCV protease inhibitor and is
represented by the following chemical structure:
##STR00125##
[0470] Compound A. 12 is an HCV protease inhibitor and is
represented by the following chemical structure:
##STR00126##
(see U.S. Application Publication No. 2013/0102525 and references
therein).
[0471] In one embodiment, the additional therapeutic agent used in
combination with the pharmaceutical compositions as described
herein is a HCV NS3 protease inhibitor. Non-limiting examples
include the following:
##STR00127##
[0472] In another embodiment, the additional therapeutic agent used
in combination with the pharmaceutical compositions as described
herein is a cyclophillin inhibitor, including for example, a
cyclophilin inhibitor disclosed in WO2013/185093. Non-limiting
examples in addition to those listed above include the
following:
##STR00128## ##STR00129##
and stereoisomers and mixtures of stereoisomers thereof.
[0473] In a specific embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with a HCV NSSB polymerase inhibitor. In a specific
embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a HCV
NS5B polymerase inhibitor and a HCV NS5A inhibitor. In another
specific embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a HCV
NS5B polymerase inhibitor, a HCV NS3 protease inhibitor and a HCV
NS5A inhibitor. In another specific embodiment, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is combined with a HCV NS5B polymerase inhibitor, a HCV NS4
protease inhibitor and a HCV NS5A inhibitor. In another specific
embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a HCV
NS5B polymerase inhibitor, a HCV NS3/NS4 protease inhibitor and a
HCV NS5A inhibitor. In another specific embodiment, a compound of
the present disclosure, or a pharmaceutically acceptable salt
thereof, is combined with a HCV NS3 protease inhibitor and a HCV
NS5A inhibitor. In another specific embodiment, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is combined with a HCV NS4 protease inhibitor and a HCV NS5A
inhibitor. In another specific embodiment, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is combined with a HCV NS3/NS4 protease inhibitor and a HCV NS5A
inhibitor. In another specific embodiment, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is combined with a HCV NS3 protease inhibitor, a pharmacokinetic
enhancer and a HCV NS5A inhibitor. In another specific embodiment,
a compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, is combined with a HCV NS4 protease
inhibitor, a pharmacokinetic enhancer and a HCV NS5A inhibitor. In
another specific embodiment, a compound of the present disclosure,
or a pharmaceutically acceptable salt thereof, is combined with a
HCV NS3/NS4 protease inhibitor, a pharmacokinetic enhancer and a
HCV NS5A inhibitor.
[0474] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with one, two, three, four or more additional therapeutic
agents selected from simeprevir, MK-8742, MK-8408, MK-5172,
ABT-450, ABT-267, ABT-333, sofosbuvir, sofosbuvir+ledipasvir,
sofosbuvir+GS-5816, sofosbuvir+GS-9857+ledipasvir,
ABT-450+ABT-267+ritonavir, ABT-450+ABT-267+ribavirin+ritonavir,
ABT-450+ABT-267+ribavirin+ABT-333+ritonavir, ABT-530+ABT-493,
MK-8742+MK-5172, MK-8408+MK-3682+MK-5172, MK-8742+MK-3682+MK-5172,
daclatasvir, interferon, pegylated interferon, ribavirin,
samatasvir, MK-3682, ACH-3422, AL-335, IDX-21437, IDX-21459,
tegobuvir, setrobuvir, valopicitabine, boceprevir, narlaprevir,
vaniprevir, danoprevir, sovaprevir, neceprevir, telaprevir,
faldaprevir, asunaprevir, ledipasvir, GS-5816, GS-9857, ACH-3102,
ACH-3422+ACH-3102, ACH-3422+sovaprevir+ACH-3102, asunaprevir,
asunaprevir+daclatasvir, AL-516, and vedroprevir.
[0475] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
co-administered with simeprevir. In certain embodiments, a compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, is co-administered with MK-8742 or MK-8408. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
MK-5172. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
co-administered with ABT-450, ABT-267, or ABT-333. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
Viekirat (a combination of ABT-450, ABT-267, and ritonavir). In
certain embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
daclatasvir. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
co-administered with sofosbuvir. In certain embodiments, a compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, is co-administered with Harvoni (sofosbuvir+ledipasvir).
In certain embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
sofosbuvir and GS-5816. In certain embodiments, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is co-administered with sofosbuvir+GS-9857+ledipasvir. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
ABT-450+ABT-267+ribavirin+ritonavir. In certain embodiments, a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, is co-administered with
ABT-450+ABT-267+ribavirin+ABT-333+ritonavir. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
ABT-530+ABT-493. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
co-administered with MK-8408+MK-3682+MK-5172. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
MK-8742+MK-5172. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
co-administered with MK-3682. In certain embodiments, a compound of
the present disclosure, or a pharmaceutically acceptable salt
thereof, is co-administered with ACH-3422. In certain embodiments,
a compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, is co-administered with AL-335. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
ACH-3422+ACH-3102. In certain embodiments, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is co-administered with ACH-3422+sovaprevir+ACH-3102. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
GS-5816. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
co-administered with GS-9857. In certain embodiments, a compound of
the present disclosure, or a pharmaceutically acceptable salt
thereof, is co-administered with IDX-21459. In certain embodiments,
a compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, is co-administered with boceprevir. In
certain embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is co-administered with
ledipasvir. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
co-administered with AL-516.
[0476] In various methods, Compound A.1 is administered in an
amount ranging from about 10 mg/day to about 200 mg/day. For
example, the amount of Compound A.1 can be about 30 mg/day, about
45 mg/day, about 60 mg/day, about 90 mg/day, about 120 mg/day,
about 135 mg/day, about 150 mg/day, about 180 mg/day. In some
methods, Compound A. 1 is administered at about 90 mg/day. In
various methods, Compound A.2 is administered in an amount ranging
from about 50 mg/day to about 800 mg/day. For example, the amount
of Compound A.2 can be about 100 mg/day, about 200 mg/day, or about
400 mg/day. In some methods, the amount of Compound A.3 is about 10
mg/day to about 200 mg/day. For example, the amount of Compound A.3
can be about 25 mg/day, about 50 mg/day, about 75 mg/day, or about
100 mg/day.
[0477] In various methods, sofosbuvir is administered in an amount
ranging from about 10 mg/day to about 1000 mg/day. For example, the
amount of sofosbuvir can be about 100 mg/day, about 200 mg/day,
about 300 mg/day, about 400 mg/day, about 500 mg/day, about 600
mg/day, about 700 mg/day, about 800 mg/day. In some methods,
sofosbuvir is administered at about 400 mg/day.
[0478] Also provided herein is a compound of the present disclosure
(e.g., a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, and one or more additional therapeutic agents for
treating HCV, for use in a method of treating or preventing
HCV.
[0479] Also provided herein is a compound of the present disclosure
(e.g., a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, for use in a method of treating or preventing HCV,
wherein the compound or a pharmaceutically acceptable salt thereof
is administered simultaneously, separately or sequentially with one
or more additional therapeutic agents for treating HCV.
IX. COMBINATION THERAPY FOR HIV
[0480] In certain embodiments, a method for treating or preventing
an HIV infection in a human having or at risk of having the
infection is provided, comprising administering to the human a
therapeutically effective amount of a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, in
combination with a therapeutically effective amount of one or more
(e.g., one, two, three, one or two, or one to three) additional
therapeutic agents. In one embodiment, a method for treating an HIV
infection in a human having or at risk of having the infection is
provided, comprising administering to the human a therapeutically
effective amount of a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more (e.g., one, two,
three, one or two, or one to three) additional therapeutic
agents.
[0481] In certain embodiments, the present disclosure provides a
method for treating an HIV infection, comprising administering to a
patient in need thereof a therapeutically effective amount of a
compound of the present disclosure, or a pharmaceutically
acceptable salt, thereof, in combination with a therapeutically
effective amount of one or more additional therapeutic agents which
are suitable for treating an HIV infection. In certain embodiments,
one or more additional therapeutic agents includes, for example,
one, two, three, four, one or two, one to three or one to four
additional therapeutic agents.
[0482] In the above embodiments, the additional therapeutic agent
may be an anti-HIV agent. For example, in some embodiments, the
additional therapeutic agent is selected from the group consisting
of HIV protease inhibitors, HIV non-nucleoside or non-nucleotide
inhibitors of reverse transcriptase, HIV nucleoside or nucleotide
inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV
non-catalytic site (or allosteric) integrase inhibitors, HIV entry
inhibitors (e.g., CCR5 inhibitors, gp41 inhibitors (i.e., fusion
inhibitors) and CD4 attachment inhibitors), CXCR4 inhibitors, gp120
inhibitors, G6PD and NADH-oxidase inhibitors, HIV vaccines, HIV
maturation inhibitors, latency reversing agents (e.g., histone
deacetylase inhibitors, proteasome inhibitors, protein kinase C
(PKC) activators, and BRD4 inhibitors), compounds that target the
HIV capsid ("capsid inhibitors"; e.g., capsid polymerization
inhibitors or capsid disrupting compounds, HIV nucleocapsid p7
(NCp7) inhibitors, HIV p24 capsid protein inhibitors),
pharmacokinetic enhancers, immune-based therapies (e.g., Pd-1
modulators, Pd-L1 modulators, toll like receptors modulators, IL-15
agonists), HIV antibodies, bispecific antibodies and
"antibody-like" therapeutic proteins (e.g., DARTs.RTM.,
Duobodies.RTM., Bites.RTM., XmAbs.RTM., TandAbs.RTM., Fab
derivatives) including those targeting HIV gpl20 or gp41,
combination drugs for HIV, HIV p17 matrix protein inhibitors, IL-13
antagonists, Peptidyl-prolyl cis-trans isomerase A modulators,
Protein disulfide isomerase inhibitors, Complement C5a receptor
antagonists, DNA methyltransferase inhibitor, HIV vif gene
modulators, HIV-1 viral infectivity factor inhibitors, TAT protein
inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators,
mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing
inhibitors, Rev protein inhibitors, Integrin antagonists,
Nucleoprotein inhibitors, Splicing factor modulators, COMM domain
containing protein 1 modulators, HIV Ribonuclease H inhibitors,
Retrocyclin modulators, CDK-9 inhibitors, Dendritic ICAM-3 grabbing
nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL
protein inhibitors, Complement Factor H modulators, Ubiquitin
ligase inhibitors, Deoxycytidine kinase inhibitors, Cyclin
dependent kinase inhibitors Proprotein convertase PC9 stimulators,
ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase
priming complex inhibitors, PI3K inhibitors, compounds such as
those disclosed in WO 2013/006738 (Gilead Sciences), US
2013/0165489 (University of Pennsylvania), WO 2013/091096A1
(Boehringer Ingelheim), WO 2009/062285 (Boehringer Ingelheim),
US20140221380 (Japan Tobacco), US20140221378 (Japan Tobacco), WO
2010/130034 (Boehringer Ingelheim), WO 2013/159064 (Gilead
Sciences), WO 2012/145728 (Gilead Sciences), WO2012/003497 (Gilead
Sciences), WO2014/100323 (Gilead Sciences), WO2012/145728 (Gilead
Sciences), WO2013/159064 (Gilead Sciences) and WO 2012/003498
(Gilead Sciences) and WO 2013/006792 (Pharma Resources), and other
drugs for treating HIV, and combinations thereof. In some
embodiments, the additional therapeutic agent is further selected
from Vif dimerization antagonists and HIV gene therapy.
[0483] In certain embodiments, the additional therapeutic is
selected from the group consisting of HIV protease inhibitors, HIV
non-nucleoside or non-nucleotide inhibitors of reverse
transcriptase, HIV nucleoside or nucleotide inhibitors of reverse
transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or
allosteric) integrase inhibitors, pharmacokinetic enhancers, and
combinations thereof.
[0484] In certain embodiments a compound of the present disclosure
is formulated as a tablet, which may optionally contain one or more
other compounds useful for treating HIV. In certain embodiments,
the tablet can contain another active ingredient for treating HIV,
such as HIV protease inhibitors, HIV non-nucleoside or
non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside
or nucleotide inhibitors of reverse transcriptase, HIV integrase
inhibitors, HIV non-catalytic site (or allosteric) integrase
inhibitors, pharmacokinetic enhancers, and combinations
thereof.
[0485] In certain embodiments, such tablets are suitable for once
daily dosing.
[0486] In certain embodiments, the additional therapeutic agent is
selected from one or more of: [0487] (1) Combination drugs selected
from the group consisting of ATRIPLA.RTM. (efavirenz+tenofovir
disoproxil fumarate+emtricitabine), COMPLERA.RTM. (EVIPLERA.RTM.,
rilpivirine+tenofovir disoproxil fumarate+emtricitabine),
STRIBILD.RTM. (elvitegravir+cobicistat+tenofovir disoproxil
fumarate+emtricitabine), dolutegravir+abacavir sulfate+lamivudine,
TRIUMEQ.RTM. (dolutegravir+abacavir+lamivudine),
lamivudine+nevirapine+zidovudine, dolutegravir+rilpivirine,
atazanavir sulfate+cobicistat, darunavir+cobicistat,
efavirenz+lamivudine+tenofovir disoproxil fumarate, tenofovir
alafenamide hemifumarate+emtricitabine+cobicistat+elvitegravir,
Vacc-4x+romidepsin, darunavir+tenofovir alafenamide
hemifumarate+emtricitabine+cobicistat, APH-0812,
raltegravir+lamivudine, KALETRA.RTM. (ALUVIA.RTM.,
lopinavir+ritonavir), atazanavir sulfate+ritonavir, COMBIVIR.RTM.
(zidovudine+lamivudine, AZT+3TC), EPZICOM.RTM. (Livexa.RTM.,
abacavir sulfate+lamivudine, ABC+3TC), TRIZIVIR.RTM. (abacavir
sulfate+zidovudine+lamivudine, ABC+AZT+3TC), TRUVADA.RTM.
(tenofovir disoproxil fumarate+emtricitabine, TDF+FTC),
tenofovir+lamivudine and lamivudine+tenofovir disoproxil fumarate,
as well as combinations drugs selected from
dolutegravir+rilpivirine hydrochloride, atazanavir+cobicistat,
tenofovir alafenamide hemifumarate+emtricitabine, tenofovir
alafenamide+emtricitabine, tenofovir alafenamide
hemifumarate+emtricitabine+rilpivirine, tenofovir
alafenamide+emtricitabine+rilpivirine,
doravirine+lamivudine+tenofovir disoproxil fumarate,
doravirine+lamivudine+tenofovir disoproxil; [0488] (2) HIV protease
inhibitors selected from the group consisting of amprenavir,
atazanavir, fosamprenavir, fosamprenavir calcium, indinavir,
indinavir sulfate, lopinavir, ritonavir, nelfinavir, nelfinavir
mesylate, saquinavir, saquinavir mesylate, tipranavir, brecanavir,
darunavir, DG-17, TMB-657 (PPL-100) and TMC-310911; [0489] (3) HIV
non-nucleoside or non-nucleotide inhibitors of reverse
transcriptase selected from the group consisting of delavirdine,
delavirdine mesylate, nevirapine, etravirine, dapivirine,
doravirine, rilpivirine, efavirenz, KM-023, VM-1500, lentinan and
AIC-292; [0490] (4) HIV nucleoside or nucleotide inhibitors of
reverse transcriptase selected from the group consisting of
VIDEX.RTM. and VIDEX.RTM. EC (didanosine, ddl), zidovudine,
emtricitabine, didanosine, stavudine, zalcitabine, lamivudine,
censavudine, abacavir, abacavir sulfate, amdoxovir, elvucitabine,
alovudine, phosphazid, fozivudine tidoxil, apricitabine, amdoxovir,
KP-1461, fosalvudine tidoxil, tenofovir, tenofovir disoproxil,
tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate,
tenofovir alafenamide, tenofovir alafenamide hemifumarate,
tenofovir alafenamide fumarate, adefovir, adefovir dipivoxil, and
festinavir; [0491] (5) HIV integrase inhibitors selected from the
group consisting of curcumin, derivatives of curcumin, chicoric
acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid,
derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid,
derivatives of aurintricarboxylic acid, caffeic acid phenethyl
ester, derivatives of caffeic acid phenethyl ester, tyrphostin,
derivatives of tyrphostin, quercetin, derivatives of quercetin,
raltegravir, elvitegravir, dolutegravir and cabotegravir, as well
as HIV integrase inhibitors selected from JTK-351; [0492] (6) HIV
non-catalytic site, or allosteric, integrase inhibitors (NCINI)
selected from the group consisting of CX-05168, CX-05045 and
CX-14442; [0493] (7) HIV gp41 inhibitors selected from the group
consisting of enfuvirtide, sifuvirtide and albuvirtide; [0494] (8)
HIV entry inhibitors selected from the group consisting of
cenicriviroc; [0495] (9) HIV gp120 inhibitors selected from the
group consisting of Radha-108 (Receptol) and BMS-663068; [0496]
(10) CCR5 inhibitors selected from the group consisting of
aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO-140, Adaptavir
(RAP-101), TBR-220 (TAK-220), nifeviroc (TD-0232), TD-0680, and
vMIP (Haimipu); [0497] (11) CD4 attachment inhibitors selected from
the group consisting of ibalizumab; [0498] (12) CXCR4 inhibitors
selected from the group consisting of plerixafor, ALT-1188, vMIP
and Haimipu; [0499] (13) Pharmacokinetic enhancers selected from
the group consisting of cobicistat and ritonavir; [0500] (14)
Immune-based therapies selected from the group consisting of
dermaVir, interleukin-7, plaquenil (hydroxychloroquine), proleukin
(aldesleukin, IL-2), interferon alfa, interferon alfa-2b,
interferon alfa-n3, pegylated interferon alfa, interferon gamma,
hydroxyurea, mycophenolate mofetil (MPA) and its ester derivative
mycophenolate mofetil (MMF), WF-10, ribavirin, IL-2, IL-12, polymer
polyethyleneimine (PEI), Gepon, VGV-1, MOR-22, BMS-936559,
toll-like receptors modulators (TLR-1, TLR-2, TLR-3, TLR-4, TLR-5,
TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13),
rintatolimod and IR-103; [0501] (15) HIV vaccines selected from the
group consisting of peptide vaccines, recombinant subunit protein
vaccines, live vector vaccines, DNA vaccines, virus-like particle
vaccines (pseudovirion vaccine), CD4-derived peptide vaccines,
vaccine combinations, rgp120 (AIDSVAX), ALVAC HIV (vCP1521)/AIDSVAX
B/E (gp120) (RV144), Remune, ITV-1, Contre Vir, Ad5-ENVA-48,
DCVax-001 (CDX-2401), PEP-6409, Vacc-4x, Vacc-C5, VAC-3S,
multiclade DNA recombinant adenovirus-5 (rAd5), Pennvax-G, VRC-HIV
MAB060-00-AB, AVX-101, Tat Oyi vaccine, AVX-201, HIV-LAMP-vax,
Ad35, Ad35-GRIN, NAcGM3/VSSP ISA-51, poly-ICLC adjuvanted vaccines,
TatImmune, GTU-multiHIV (FIT-06), AGS-004,
gp140[delta]V2.TV1+MF-59, rVSVIN HIV-1 gag vaccine, SeV-Gag
vaccine, AT-20, DNK-4, Ad35-GRIN/ENV, TBC-M4, HIVAX, HIVAX-2,
NYVAC-HIV-PT1, NYVAC-HIV-PT4, DNA-HIV-PT123, Vichrepol,
rAAV1-PG9DP, GOVX-B11, GOVX-B21, ThV-01, TUTI-16, VGX-3300,
TVI-HIV-1, Ad-4 (Ad4-env Clade C+Ad4-mGag), EN41-UGR7C, EN41-FPA2,
PreVaxTat, TL-01, SAV-001, AE-H, MYM-V101, CombiHIVvac, ADVAX,
MYM-V201, MVA-CMDR, ETV-01 and DNA-Ad5 gag/pol/nef/nev (HVTN505),
as well as HIV vaccines selected from monomeric gp120 HIV-1 subtype
C vaccine (Novartis), HIV-TriMix-mRNA, MVATG-17401, ETV-01,
CDX-1401, and rcAd26.MOS1.HIV-Env; [0502] (16) HIV antibodies,
bispecific antibodies and "antibody-like" therapeutic proteins
(such as DARTs.RTM., Duobodies.RTM., Bites.RTM., XmAbs.RTM.,
TandAbs.RTM., Fab derivatives) including BMS-936559, TMB-360 and
those targeting HIV gp120 or gp41 selected from the group
consisting of bavituximab, UB-421, C2F5, C2G12, C4E10,
C2F5+C2G12+C4E10, 3-BNC-117, PGT145, PGT121, MDX010 (ipilimumab),
VRC01, A32, 7B2, 10E8 and VRC07, as well as HIV antibodies such as
VRC-07-523; [0503] (17) latency reversing agents selected from the
group consisting of Histone deacetylase inhibitors such as
Romidepsin, vorinostat, panobinostat; Proteasome inhibitors such as
Velcade; protein kinase C (PKC) activators such as Indolactam,
Prostratin, Ingenol B and DAG-lactones, Ionomycin, GSK-343, PMA,
SAHA, BRD4 inhibitors, IL-15, JQ1, disulfram, and amphotericin B;
[0504] (18) HIV nucleocapsid p7 (NCp7) inhibitors selected from the
group consisting of azodicarbonamide; [0505] (19) HIV maturation
inhibitors selected from the group consisting of BMS-955176 and
GSK-2838232; [0506] (20) PI3K inhibitors selected from the group
consisting of idelalisib, AZD-8186, buparlisib, CLR-457,
pictilisib, neratinib, rigosertib, rigosertib sodium, EN-3342,
TGR-1202, alpelisib, duvelisib, UCB-5857, taselisib, XL-765,
gedatolisib, VS-5584, copanlisib, CAI orotate, perifosine, RG-7666,
GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458,
CUDC-907, PQR-309, INCB-040093, pilaralisib, BAY-1082439,
puquitinib mesylate, SAR-245409, AMG-319, RP-6530, ZSTK-474,
MLN-1117, SF-1126, RV-1729, sonolisib, LY-3023414, SAR-260301 and
CLR-1401; [0507] (21) the compounds disclosed in WO 2004/096286
(Gilead Sciences), WO 2006/110157 (Gilead Sciences), WO 2006/015261
(Gilead Sciences), WO 2013/006738 (Gilead Sciences), US
2013/0165489 (University of Pennsylvania), US20140221380 (Japan
Tobacco), US20140221378 (Japan Tobacco), WO 2013/006792 (Pharma
Resources), WO 2009/062285 (Boehringer Ingelheim), WO 2010/130034
(Boehringer Ingelheim), WO 2013/091096A1 (Boehringer Ingelheim), WO
2013/159064 (Gilead Sciences), WO 2012/145728 (Gilead Sciences),
WO2012/003497 (Gilead Sciences), WO2014/100323 (Gilead Sciences),
WO2012/145728 (Gilead Sciences), WO2013/159064 (Gilead Sciences)
and WO 2012/003498 (Gilead Sciences); and [0508] (22) other drugs
for treating HIV selected from the group consisting of BanLec,
MK-8507, AG-1105, TR-452, MK-8591, REP 9, CYT-107, alisporivir,
NOV-205, IND-02, metenkefalin, PGN-007, Acemannan, Gamimune,
Prolastin, 1,5-dicaffeoylquinic acid, BIT-225, RPI-MN, VSSP,
Hlviral, IMO-3100, SB-728-T, RPI-MN, VIR-576, HGTV-43, MK-1376,
rHIV7-shl-TAR-CCR5RZ, MazF gene therapy, BlockAide, ABX-464,
SCY-635, naltrexone and PA-1050040 (PA-040); and other drugs for
treating HIV selected from AAV-eCD4-Ig gene therapy, TEV-90110,
TEV-90112, TEV-90111, TEV-90113, deferiprone, and HS-10234.
[0509] In certain embodiments, the additional therapeutic agent is
a compound disclosed in US 2014-0221356 (Gilead Sciences, Inc.) for
example
(2R,5S,13aR)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13-
a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-c-
arboxamide,
(2S,5R,13aS)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13-
a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-c-
arboxamide,
(1S,4R,12aR)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-dioxo-1,2,3,4,6,8,12,12-
a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazine-9-carboxamide,
(1R,4S,12aR)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-1,2,3,4,6,8,12-
,12a-octahydro-1,4-methanodipyrido[1,2-a:
1',2'-d]pyrazine-9-carboxamide,
(2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13-
,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1-
0-carboxamide, and
(1R,4S,12aR)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-dioxo-1,2,3,4,6,8,12,12-
a-octahydro-1,4-methanodipyrido[1,2-a:
1',2'-d]pyrazine-9-carboxamide, US2015-0018298 (Gilead Sciences,
Inc.) and US2015-0018359 (Gilead Sciences, Inc.),
[0510] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with one, two, three, four or more additional therapeutic
agents. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with two additional therapeutic agents. In other
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with three
additional therapeutic agents. In further embodiments, a compound
of the present disclosure, or a pharmaceutically acceptable salt
thereof, is combined with four additional therapeutic agents. The
one, two, three, four or more additional therapeutic agents can be
different therapeutic agents selected from the same class of
therapeutic agents, and/or they can be selected from different
classes of therapeutic agents.
[0511] In a specific embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with an HIV nucleoside or nucleotide inhibitor of reverse
transcriptase and an HIV non-nucleoside inhibitor of reverse
transcriptase. In another specific embodiment, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is combined with an HIV nucleoside or nucleotide inhibitor of
reverse transcriptase, and an HIV protease inhibiting compound. In
a further embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with an HIV
nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV
non-nucleoside inhibitor of reverse transcriptase, and an HIV
protease inhibiting compound. In an additional embodiment, a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, is combined with an HIV nucleoside or
nucleotide inhibitor of reverse transcriptase, an HIV
non-nucleoside inhibitor of reverse transcriptase, and a
pharmacokinetic enhancer. In certain embodiments, a compound of the
present disclosure, or a pharmaceutically acceptable salt thereof,
is combined with one or more additional therapeutic agents selected
from HIV nucleoside inhibitor of reverse transcriptase, an
integrase inhibitor, and a pharmacokinetic enhancer. In another
embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with two HIV
nucleoside or nucleotide inhibitors of reverse transcriptase.
[0512] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with one, two, three, four or more additional therapeutic
agents selected from Triumeq.RTM.
(dolutegravir+abacavir+lamivudine), dolutegravir+abacavir
sulfate+lamivudine, raltegravir, Truvada.RTM. (tenofovir disoproxil
fumarate+emtricitabine, TDF+FTC), maraviroc, enfuvirtide,
Epzicom.RTM. (Livexa.RTM., abacavir sulfate+lamivudine, ABC+3TC),
Trizivir.RTM. (abacavir sulfate+zidovudine+lamivudine,
ABC+AZT+3TC), adefovir, adefovir dipivoxil, Stribild.RTM.
(elvitegravir+cobicistat+tenofovir disoproxil
fumarate+emtricitabine), rilpivirine, rilpivirine hydrochloride,
Complera.RTM. (Eviplera.RTM., rilpivirine+tenofovir disoproxil
fumarate+emtricitabine), Cobicistat, Atripla.RTM.
(efavirenz+tenofovir disoproxil fumarate+emtricitabine),
atazanavir, atazanavir sulfate, dolutegravir, elvitegravir,
Aluvia.RTM. (Kaletra.RTM., lopinavir+ritonavir), ritonavir,
emtricitabine, atazanavir sulfate+ritonavir, darunavir, lamivudine,
Prolastin, fosamprenavir, fosamprenavir calcium, efavirenz,
Combivir.RTM. (zidovudine+lamivudine, AZT+3TC), etravirine,
nelfinavir, nelfinavir mesylate, interferon, didanosine, stavudine,
indinavir, indinavir sulfate, tenofovir+lamivudine, zidovudine,
nevirapine, saquinavir, saquinavir mesylate, aldesleukin,
zalcitabine, tipranavir, amprenavir, delavirdine, delavirdine
mesylate, Radha-108 (Receptol), Hlviral, lamivudine+tenofovir
disoproxil fumarate, efavirenz+lamivudine+tenofovir disoproxil
fumarate, phosphazid, lamivudine+nevirapine+zidovudine, abacavir,
abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir
disoproxil fumarate, tenofovir alafenamide and tenofovir
alafenamide hemifumarate. In certain embodiments, the one, two,
three, four or more additional therapeutic agents are further
selected from raltegravir+lamivudine, atazanavir
sulfate+cobicistat, atazanavir+cobicistat, darunavir+cobicistat,
darunavir+cobicistat, atazanavir sulfate+cobicistat,
atazanavir+cobicistat.
[0513] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with one, two, three, four or more additional therapeutic
agents selected from Triumeq.RTM.
(dolutegravir+abacavir+lamivudine), dolutegravir+abacavir
sulfate+lamivudine, raltegravir, Truvada.RTM. (tenofovir disoproxil
fumarate+emtricitabine, TDF+FTC), maraviroc, enfuvirtide,
Epzicom.RTM. (Livexa.RTM., abacavir sulfate+lamivudine, ABC+3TC),
Trizivir.RTM. (abacavir sulfate+zidovudine+lamivudine,
ABC+AZT+3TC), adefovir, adefovir dipivoxil, Stribild.RTM.
(elvitegravir+cobicistat+tenofovir disoproxil
fumarate+emtricitabine), rilpivirine, rilpivirine hydrochloride,
Complera.RTM. (Eviplera.RTM., rilpivirine+tenofovir disoproxil
fumarate+emtricitabine), cobicistat, Atripla.RTM.
(efavirenz+tenofovir disoproxil fumarate+emtricitabine),
atazanavir, atazanavir sulfate, dolutegravir, elvitegravir,
Aluvia.RTM. (Kaletra.RTM., lopinavir+ritonavir), ritonavir,
emtricitabine, atazanavir sulfate+ritonavir, darunavir, lamivudine,
Prolastin, fosamprenavir, fosamprenavir calcium, efavirenz,
Combivir.RTM. (zidovudine+lamivudine, AZT+3TC), etravirine,
nelfinavir, nelfinavir mesylate, interferon, didanosine, stavudine,
indinavir, indinavir sulfate, tenofovir+lamivudine, zidovudine,
nevirapine, saquinavir, saquinavir mesylate, aldesleukin,
zalcitabine, tipranavir, amprenavir, delavirdine, delavirdine
mesylate, Radha-108 (Receptol), Hlviral, lamivudine+tenofovir
disoproxil fumarate, efavirenz+lamivudine+tenofovir disoproxil
fumarate, phosphazid, lamivudine+nevirapine+zidovudine,
(2R,5S,13aR)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13-
a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-c-
arboxamide,
(2S,5R,13aS)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13-
a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-c-
arboxamide,
(1S,4R,12aR)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-dioxo-1,2,3,4,6,8,12,12-
a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazine-9-carboxamide,
(1R,4S,12aR)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-1,2,3,4,6,8,12-
,12a-octahydro-1,4-methanodipyrido[1,2-a:
1',2'-d]pyrazine-9-carboxamide,
(2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13-
,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1-
0-carboxamide, and
(1R,4S,12aR)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-dioxo-1,2,3,4,6,8,12,12-
a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazine-9-carboxamide
abacavir, abacavir sulfate, tenofovir, tenofovir disoproxil,
tenofovir disoproxil fumarate, tenofovir alafenamide and tenofovir
alafenamide hemifumarate.
[0514] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with abacavir sulfate, tenofovir, tenofovir disoproxil,
tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate,
tenofovir alafenamide or tenofovir alafenamide hemifumarate.
[0515] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with tenofovir, tenofovir disoproxil, tenofovir disoproxil
fumarate, tenofovir alafenamide, or tenofovir alafenamide
hemifumarate.
[0516] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with a first additional therapeutic agent selected from
the group consisting of: abacavir sulfate, tenofovir, tenofovir
disoproxil, tenofovir disoproxil fumarate, tenofovir alafenamide,
and tenofovir alafenamide hemifumarate and a second additional
therapeutic agent selected from the group consisting of
emtricitabine and lamivudine.
[0517] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with a first additional therapeutic agent selected from
the group consisting of: tenofovir, tenofovir disoproxil, tenofovir
disoproxil fumarate, tenofovir alafenamide, and tenofovir
alafenamide hemifumarate and a second additional therapeutic agent,
wherein the second additional therapeutic agent is
emtricitabine.
[0518] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with 5-30 mg tenofovir alafenamide fumarate, tenofovir
alafenamide hemifumarate, or tenofovir alafenamide and 200 mg
emtricitabine. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with 5-10; 5-15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30
mg tenofovir alafenamide fumarate, tenofovir alafenamide
hemifumarate, or tenofovir alafenamide and 200 mg emtricitabine. In
certain embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with 10 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide and 200 mg emtricitabine. In certain
embodiments, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with 25 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide and 200 mg emtricitabine. A compound of
the present disclosure (e.g., a compound of formula (I)) may be
combined with the agents provided herein in any dosage amount of
the compound (e.g., from 1 mg to 500 mg of compound) the same as if
each combination of dosages were specifically and individually
listed.
[0519] In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with 200-400 mg tenofovir disoproxil fumarate, tenofovir
disoproxil hemifumarate, or tenofovir disoproxil and 200 mg
emtricitabine. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with 200-250; 200-300; 200-350; 250-350; 250-400; 350-400;
300-400; or 250-400 mg tenofovir disoproxil fumarate, tenofovir
disoproxil hemifumarate, or tenofovir disoproxil and 200 mg
emtricitabine. In certain embodiments, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with 300 mg tenofovir disoproxil fumarate, tenofovir
disoproxil hemifumarate, or tenofovir disoproxil and 200 mg
emtricitabine. A compound of the present disclosure (e.g., a
compound of formula (I)) may be combined with the agents provided
herein in any dosage amount of the compound (e.g., from 50 mg to
500 mg of compound) the same as if each combination of dosages were
specifically and individually listed. A compound of the present
disclosure (e.g., a compound of Formula (I)) may be combined with
the agents provided herein in any dosage amount of the compound
(e.g. from about 1 mg to about 150 mg of compound) the same as if
each combination of dosages were specifically and individually
listed.
[0520] In certain embodiments a compound of the present disclosure,
or a pharmaceutically acceptable salt thereof, is combined with
(2R,5S,13aR)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13-
a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,
l1-b][1,3]oxazepine-10-carboxamide,
(2S,5R,13aS)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13-
a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-c-
arboxamide,
(1S,4R,12aR)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-dioxo-1,2,3,4,6,8,12,12-
a-octahydro-1,4-methanodipyrido[1,2-a:
1',2'-d]pyrazine-9-carboxamide,
(1R,4S,12aR)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-1,2,3,4,6,8,12-
,12a-octahydro-1,4-methanodipyrido[1,2-a:
1',2'-d]pyrazine-9-carboxamide,
(2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13-
,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1-
0-carboxamide, or
(1R,4S,12aR)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-dioxo-1,2,3,4,6,8,12,12-
a-octahydro-1,4-methanodipyrido[1,2-a:
1',2'-d]pyrazine-9-carboxamide.
[0521] Also provided herein is a compound the present disclosure
(e.g., a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, and one or more additional therapeutic agents for
treating HIV, for use in a method of treating or preventing
HIV.
[0522] Also provided herein is a compound of the present disclosure
(e.g., a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, for use in a method of treating or preventing HIV,
wherein the compound or a pharmaceutically acceptable salt thereof
is administered simultaneously, separately or sequentially with one
or more additional therapeutic agents for treating HIV.
[0523] In certain embodiments, a method for treating
hyperproliferative disorders such as cancer in a human is provided,
comprising administering to the human a therapeutically effective
amount of a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more (e.g., one, two,
three, one or two, or one to three) additional therapeutic agents.
In one embodiment, a method for treating hyperproliferative
disorders such as cancer in a human is provided, comprising
administering to the human a therapeutically effective amount of a
compound of the present disclosure, or a pharmaceutically
acceptable salt thereof, in combination with a therapeutically
effective amount of one or more (e.g., one, two, three, one or two,
or one to three) additional therapeutic agents.
X. COMBINATION THERAPY FOR CANCER
[0524] In certain embodiments, the present disclosure provides a
method for treating hyperproliferative disorders such as cancer,
comprising administering to a patient in need thereof a
therapeutically effective amount of a compound of the present
disclosure, or a pharmaceutically acceptable salt, thereof, in
combination with a therapeutically effective amount of one or more
additional therapeutic agents which are suitable for treating
hyperproliferative disorders such as cancer.
[0525] In the above embodiments, the additional therapeutic agent
may be an anti-cancer agent. For example, in some embodiments, the
additional therapeutic agent is selected from the group consisting
of chemotherapeutic agents, immunotherapeutic agents,
radiotherapeutic agents, anti-neoplastic agents, anti-hormonal
agents, anti-angiogenic agents, anti-fibrotic agents, therapeutic
antibodies, tyrosine kinase inhibitors, JAK inhibitors, Hedgehog
inhibitors, HDAC inhibitors, Discoidin domain receptor (DDR)
inhibitors, MMP9 inhibitors, LOXL inhibitors, ASK1 inhibitors, PI3K
inhibitors, BTK inhibitors, SYK inhibitors, mTOR inhibitors, AKT
inhibitors, Mitogen or Extracellular Regulated Kinase (MEK)
inhibitors, blockers of Raf kinases (rafk), CDK inhibitors, JNK
inhibitors, MAPK inhibitors, Raf inhibitors, ROCK inhibitors, Tie2
inhibitors, Myo-inositol signaling inhibitors, phospholipase C
blockers, anti-CD19 antibodies, anti-CD20 antibodies, anti-MN-14
antibodies, Anti-TRAIL DR4 and DR5 antibodies, anti-CD74
antibodies, cancer vaccines based upon the genetic makeup of an
individual patient's tumor, IDH1 inhibitors, BRD4 inhibitors, TPL2
inhibitors; A2B inhibitors; TBK1 inhibitors; IKK inhibitors; BCR
inhibitors, agents inhibiting the RAS/RAF/ERK pathway, protein
kinase C (PKC) modulators, modulators of growth factor receptors
such as epidermal growth factor receptor (EGFr), platelet derived
growth factor receptor (PDGFr), erbB2, erbB4, ret, vascular
endothelial growth factor receptor (VEGFr), tyrosine kinase with
immunoglobulin-like and epidermal growth factor homology domains
(TIE-2), insulin growth factor-I (IGFI) receptor, macrophage colony
stimulating factor (cfms), BTK, ckit, cmet, fibroblast growth
factor (FGF) receptors, Trk receptors (TrkA, TrkB, and TrkC),
ephrin (eph) receptors, and the RET protooncogene, modulators of
tyrosine kinases including cSrc, Lck, Fyn, Yes, cAbl, FAK (Focal
adhesion kinase) and Bcr-Abl, modulators of PKB family kinases,
modulators of TGF beta receptor kinases, inhibitors of Ras oncogene
including inhibitors of famesyltransferase, geranyl-geranyl
transferase, and CAAX proteases, anti-sense oligonucleotides,
ribozymes, Bcl-2 family protein inhibitors, proteasome inhibitors,
Heat shock protein HSP90 inhibitors, combination drugs and
immunotherapy, and other drugs for treating hyperproliferative
disorders such as cancer, and combinations thereof.
[0526] In certain embodiments a compound of the present disclosure
is formulated as a tablet, which may optionally contain one or more
other compounds useful for treating cancer. In certain embodiments,
the tablet can contain another active ingredient for treating
cancer, such as chemotherapeutic agents, immunotherapeutic agents,
radiotherapeutic agents, anti-neoplastic agents, anti-fibrotic
agents, anti-hormonal agents, anti-angiogenic agents, Tyrosine
kinase inhibitors, JAK inhibitors, Hedgehog inhibitors, HDAC
inhibitors, Discoidin domain receptor (DDR) inhibitors, MMP9
inhibitors, LOXL inhibitors, ASK1 inhibitors, PI3K inhibitors, BTK
inhibitors, SYK inhibitors, mTOR inhibitors, AKT inhibitors,
Mitogen or Extracellular Regulated Kinase (MEK) inhibitors,
blockers of Raf kinases (rafk), CDK inhibitors, JNK inhibitors,
MAPK inhibitors, Raf inhibitors, ROCK inhibitors, Tie2 inhibitors,
Myo-inositol signaling inhibitors, phospholipase C blockers, IDH1
inhibitors, BRD4 inhibitors, TPL2 inhibitors; A2B inhibitors; TBK1
inhibitors; IKK inhibitors; BCR inhibitors, agents inhibiting the
RAS/RAF/ERK pathway, protein kinase C (PKC) modulators, modulators
of growth factor receptors such as epidermal growth factor receptor
(EGFr), platelet derived growth factor receptor (PDGFr), erbB2,
erbB4, ret, vascular endothelial growth factor receptor (VEGFr),
tyrosine kinase with immunoglobulin-like and epidermal growth
factor homology domains (TIE-2), insulin growth factor-I (IGFI)
receptor, macrophage colony stimulating factor (cfms), BTK, ckit,
cmet, fibroblast growth factor (FGF) receptors, Trk receptors
(TrkA, TrkB, and TrkC), ephrin (eph) receptors, and the RET
protooncogene, modulators of tyrosine kinases including cSrc, Lck,
Fyn, Yes, cAbl, FAK (Focal adhesion kinase) and Bcr-Abl, modulators
of PKB family kinases, modulators of TGF beta receptor kinases,
inhibitors of Ras oncogene including inhibitors of
farnesyltransferase, geranyl-geranyl transferase, and CAAX
proteases, anti-sense oligonucleotides, ribozymes, Bcl-2 family
protein inhibitors, proteasome inhibitors, Heat shock protein HSP90
inhibitors, combination drugs and immunotherapy, and other drugs
for treating hyperproliferative disorders such as cancer, and
combinations thereof.
[0527] In certain embodiments, such tablets are suitable for once
daily dosing. In certain embodiments, the additional therapeutic
agent is selected from one or more of: [0528] (1) Chemotherapeutic
agents selected from the group consisting of:
anti-metabolites/anti-cancer agents, such as pyrimidine analogs
(floxuridine, capecitabine, and cytarabine); purine analogs, folate
antagonists and related inhibitors, antiproliferative/antimitotic
agents including natural products such as vinca alkaloid
(vinblastine, vincristine) and microtubule such as taxane
(paclitaxel, docetaxel), vinblastin, nocodazole, epothilones and
navelbine, epidipodophyllotoxins (etoposide, teniposide); DNA
damaging agents (actinomycin, amsacrine, busulfan, carboplatin,
chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin,
daunorubicin, doxorubicin, epirubicin, iphosphamide, melphalan,
merchlorehtamine, mitomycin, mitoxantrone, nitrosourea,
procarbazine, taxol, taxotere, teniposide, etoposide,
triethylenethiophosphoramide); antibiotics such as dactinomycin
(actinomycin D), daunorubicin, doxorubicin (adriamycin),
idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin
(mithramycin) and mitomycin; enzymes (L-asparaginase which
systemically metabolizes L-asparagine and deprives cells which do
not have the capacity to synthesize their own asparagine);
antiplatelet agents; antiproliferative/antimitotic alkylating
agents such as nitrogen mustards cyclophosphamide and analogs,
melphalan, chlorambucil), and (hexamethylmelamine and thiotepa),
alkyl nitrosoureas (BCNU) and analogs, streptozocin,
trazenes-dacarbazinine (DTIC); antiproliferative/antimitotic
antimetabolites such as folic acid analogs (methotrexate); platinum
coordination complexes (cisplatin, oxiloplatinim, carboplatin),
procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones,
hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide,
nilutamide) and aromatase inhibitors (letrozole, anastrozole);
anticoagulants (heparin, synthetic heparin salts and other
inhibitors of thrombin); fibrinolytic agents (such as tissue
plasminogen activator, streptokinase and urokinase), aspirin,
dipyridamole, ticlopidine, clopidogrel; antimigratory agents;
antisecretory agents (breveldin); immunosuppressives tacrolimus,
sirolimus azathioprine, mycophenolate; compounds (TNP-470,
genistein) and growth factor inhibitors (vascular endothelial
growth factor inhibitors, fibroblast growth factor inhibitors);
angiotensin receptor blocker, nitric oxide donors; anti-sense
oligonucleotides; cell cycle inhibitors and differentiation
inducers (tretinoin); inhibitors, topoisomerase inhibitors
(doxorubicin (adriamycin), daunorubicin, dactinomycin, eniposide,
epirubicin, idarubicin, irinotecan and mitoxantrone, topotecan,
irinotecan), corticosteroids (cortisone, dexamethasone,
hydrocortisone, methylpednisolone, prednisone, and prednisolone);
growth factor signal transduction kinase inhibitors; dysfunction
inducers, toxins such as Cholera toxin, ricin, Pseudomonas
exotoxin, Bordetella pertussis adenylate cyclase toxin, or
diphtheria toxin, and caspase activators, chromatin, alkylating
agents such as thiotepa and cyclophosphamide (Cytoxan, Endoxan,
Endoxana, Cyclostin), alkyl sulfonates such as busulfan,
improsulfan and piposulfan; aziridines such as benzodopa,
carboquone, meturedopa, and uredopa; emylerumines and
memylamelamines including alfretamine, triemylenemelamine,
triethylenephosphoramide, triethylenethiophosphoramide and
trimemylolomelamine; acetogenins (especially bullatacin and
bullatacinone); a camptothecin (including synthetic analogue
topotecan); bryostatin; callystatin; CC-1065 (including its
adozelesin, carzelesin and bizelesin synthetic analogues);
cryptophycins (articularly cryptophycin 1 and cryptophycin 8);
dolastatin; duocarmycin (including the synthetic analogues, KW-2189
and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil,
chlomaphazine, cholophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,
novembichin, phenesterine, prednimustine, trofosfamide, uracil
mustard; nitrosoureas such as carmustine, chlorozotocin,
foremustine, lomustine, nimustine, ranimustine; antibiotics such as
the enediyne antibiotics (e.g., calicheamicin, especially
calicheamicin gammaII and calicheamicin phiI1, see, e.g., Agnew,
Chem. Intl. Ed. Engl, 33:183-186 (1994); dynemicin, including
dynemicin A; bisphosphonates, such as clodronate; an esperamicin;
as well as neocarzinostatin chromophore and related chromoprotein
enediyne antibiotic chromomophores), aclacinomysins, actinomycin,
authramycin, azaserine, bleomycins, cactinomycin, carabicin,
carrninomycin, carzinophilin, chromomycins, dactinomycin,
daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin
(including morpholino-doxorubicin, cyanomorpholino-doxorubicin,
2-pyrrolino-doxorubicin, PEGylated liposomal doxorubicin and
deoxydoxorubicin), epirubicin, esorubicin, idarubicin,
marcellomycin, mitomycins such as mitomycin C, mycophenolic acid,
nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin,
quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,
ubenimex, zinostatin, zorubicin; anti-metabolites such as
methotrexate and 5-fluorouracil (5-FU); folic acid analogues such
as demopterin, methotrexate, pteropterin, trimetrexate; purine
analogs such as fludarabine, 6-mercaptopurine, thiamiprine,
thioguanine; pyrimidine analogues such as ancitabine, azacitidine,
6-azauridine, carmofur, dideoxyuridine, doxifluridine, enocitabine,
floxuridine; androgens such as calusterone, dromostanolone
propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals
such as aminoglutethimide, mitotane, trilostane; folic acid
replinisher such as frolinic acid; aceglatone; aldophosphamide
glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil;
bisantrene; edatraxate; defofamine; demecolcine; diaziquone;
elformthine; elliptinium acetate; an epothilone; etoglucid; gallium
nitrate; hydroxyurea; lentinan; leucovorin; lonidamine;
maytansinoids such as maytansine and ansamitocins; mitoguazone;
mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet;
pirarubicin; losoxantrone; fluoropyrimidine; folinic acid;
podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK(r);
razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid;
triaziquone; 2,2',2''-tricUorotriemylamine; trichothecenes
(especially T-2 toxin, verracurin A, roridin A and anguidine);
urethane; vindesine; dacarbazine; mannomustine; mitobronitol;
mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
cyclophosphamide; thiopeta; taxoids, paclitaxel (Taxol) and
docetaxel (Taxotere); chlorambucil; gemcitabine (Gemzar);
6-thioguanine; mercaptopurine; methotrexate; platinum analogs such
as cisplatin and carboplatin; platinum; ifosfamide; mitroxantrone;
vancristine; vinorelbine (Navelbine); novantrone; teniposide;
edatrexate; daunomycin; aminopterin; xeoloda; ibandronate; CPT-11;
topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO);
retinoids such as retinoic acid; capecitabine and FOLFIRI
(fluorouracil, leucovorin, and irinotecan); [0529] (2)
Anti-hormonal agents selected from the group consisting of:
anti-estrogens and selective estrogen receptor modulators (SERMs),
including, for example, tamoxifen (including Nolvadex), raloxifene,
droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018,
onapristone, and toremifene; inhibitors of the enzyme aromatase,
which regulates estrogen production in the adrenal glands, such as,
for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate,
exemestane, formestane, fadrozole, vorozole, letrozole and
anastrozole, and anti-androgens such as flutamide, nilutamide,
bicalutamide, leuprolide, and goserelin; [0530] (3) Anti-angiogenic
agents selected from the group consisting of: retinoid acid and
derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN, ENDOSTATIN,
suramin, squalamine, tissue inhibitors of metalloproteinase-1,
tissue inhibitors of metalloproteinase-2, plasminogen activator
inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived
inhibitors, paclitaxel (nab-paclitaxel), platelet factor 4,
protamine sulphate (clupeine), sulphated chitin derivatives
(prepared from queen crab shells), sulphated polysaccharide
peptidoglycan complex (sp-pg), staurosporine, modulators of matrix
metabolism, including for example, proline analogs
((1-azetidine-2-carboxylic acid (LACA), cishydroxyproline,
d,I-3,4-dehydroproline, thiaproline, .alpha.-dipyridyl,
beta-aminopropionitrile fumarate,
4-propyl-5-(4-pyridinyl)-2(3h)-oxazolone; methotrexate,
mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chimp-3,
chymostatin, beta-cyclodextrin tetradecasulfate, eponemycin;
fumagillin, gold sodium thiomalate, d-penicillamine (CDPT),
beta-1-anticollagenase-serum, alpba-2-antiplasmin, bisantrene,
lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid
disodium or "CCA", thalidomide; angiostatic steroid,
cargboxynaminolmidazole; metalloproteinase inhibitors such as BB94,
antibodies, preferably monoclonal antibodies against these
angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF
isoforms, VEGF-C, HGF/SF, Ang-1/Ang-2 and the compounds disclosed
in Ferrara N. and Alitalo, K. "Clinical application of angiogenic
growth factors and their inhibitors" (1999) Nature Medicine
5:1359-1364; [0531] (4) Anti-fibrotic agents selected from the
group consisting of: beta-aminoproprionitrile (BAPN), primary
amines reacting with the carbonyl group of the active site of the
lysyl oxidases, and more particularly those which produce, after
binding with the carbonyl, a product stabilized by resonance, such
as the following primary amines: emylenemamine, hydrazine,
phenylhydrazine, and their derivatives, semicarbazide, and urea
derivatives, aminonitriles, such as beta-aminopropionitrile (BAPN),
or 2-nitroethylamine, unsaturated or saturated haloamines, such as
2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine,
3-bromopropylamine, p-halobenzylamines, selenohomocysteine lactone,
copper chelating agents, indirect inhibitors such as compounds
blocking the aldehyde derivatives originating from the oxidative
deamination of the lysyl and hydroxylysyl residues by the lysyl
oxidases, such as the thiolamines, in particular D-penicillamine,
or its analogues such as 2-amino-5-mercapto-5-methylhexanoic acid,
D-2-amino-3-methyl-3-((2-acetamidoethyl)dithio)butanoic acid,
p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid,
sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane
sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sulphanate,
sodium-4-mercaptobutanesulphinate trihydrate, the compounds
disclosed in U.S. Pat. Nos. 4,965,288, 4,997,854, 4,943,593,
5,021,456; 5,5059,714; 5,120,764; 5,182,297; 5,252,608 and U.S.
Patent Application No. 2004/0248871; [0532] (5) Therapeutic
antibodies selected from the group consisting of: abagovomab,
adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab,
anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab,
bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab,
cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab,
daratumumab, drozitumab, duligotumab, dusigitumab, detumomab,
dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab,
ertumaxomab, etaracizumab, farietuzumab, ficlatuzumab, figitumumab,
flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab,
glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab,
inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab,
lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab,
matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab,
namatumab, naptumomab, necitumumab, nimotuzumab, nofetumomabn,
ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab,
oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab,
pertuzumab, pintumomab, pritumumab, racotumomab, radretumab,
rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab,
siltuximab, simtuzumab, solitomab, tacatuzumab, taplitumomab,
tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab,
tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab,
zalutumumab, alemtuzumab, veltuzumab, apolizumab, bevacizumab,
epratuzumab, tositumomab, galiximab, ibritumomab, lumiliximab,
milatuzumab, obinutuzumab, ofatumumab, CC49 and 3F8, wherein the
antibody may be further labeled or combined with a radioisotope
particle, such as indium In 111, yttrium Y 90, iodine I-131; [0533]
(6); JAK inhibitors selected from the group consisting of:
ruxolitinib, fedratinib, tofacitinib, baricitinib, lestaurtinib,
pacritinib, momelotinib, XL019, AZD1480, INCB039110, LY2784544,
BMS911543, and NS018; [0534] (7) Hedgehog inhibitors selected from
the group consisting of: saridegib; [0535] (8) Histone deacetylase
(HDAC) inhibitors selected from the group consisting of:
pracinostat, romidepsin, vorinostat and panobinostat; [0536] (9)
Tyrosine kinase inhibitors selected from the group consisting of:
lestaurtinib, gefitinib, erlotinib and sunitinib; [0537] (10)
Discoidin domain receptor (DDR) inhibitors selected from the group
consisting of: the inhibitors disclosed in US2009/0142345,
US2011/0287011, WO2013/027802, WO2013/034933, and U.S. Provisional
Application No. 61/705,044; [0538] (11) MMP9 inhibitors selected
from the group consisting of: marimastat (BB-2516), cipemastat (Ro
32-3555), and the inhibitors described in WO2012/027721; [0539]
(12) LOXL inhibitors selected from the group consisting of: the
antibodies described in WO2009/017833, the antibodies described in
WO2009/017833, WO2009/035791 and WO/2011/097513; [0540] (13) ASK1
inhibitors selected from the group consisting of: the compounds
described in WO2011/008709 and WO/2013/112741; [0541] (14) PI3K
inhibitors selected from the group consisting of: the compounds
described in U.S. Pat. No. 7,932,260, U.S. Provisional Application
Nos. 61/543,176; 61/581,528; 61/745,429; 61/745,437; and
61/835,333, PI3K II, TGR-1202, AMG-319, GSK2269557, X-339, X-414,
RP5090, KAR4141, XL499, OXY111A, duvelisib, IPI-443, GSK2636771,
BAY 10824391, TGX221, RG-7666, CUDC-907, PQR-309, DS-7423,
panulisib, AZD-8186, CLR-457, pictilisib, neratinib, rigosertib,
rigosertib sodium, EN-3342, UCB-5857, taselisib, INCB-040093,
pilaralisib, BAY-1082439, puquitinib mesylate, XL-765, gedatolisib,
VS-5584, copanlisib, CAI orotate, alpelisib, buparlisib, BAY
80-6946, BYL719, PX-866, RG7604, MLN1117, WX-037, AEZS-129, PA799,
ZSTK474, RP-6530, AS252424, LY294002, TG100115, LY294002, BEZ235,
XL147 (SAR245408), SAR-245409, GDC-0941, BKM120, CH5132799, XL756,
MLN-1117, SF-1126, RV-1729, sonolisib, GDC-0980, CLR-1401,
perifosine and wortmannin; [0542] (15) BTK inhibitors selected from
the group consisting of: ibrutinib, HM71224, ONO-4059 and CC-292;
[0543] (16) SYK inhibitors selected from the group consisting of:
tamatinib (R406), fostamatinib (R788), PRT062607, BAY-61-3606,
NVP-QAB 205 AA, R112, R343, and the compounds described in U.S.
Pat. No. 8,450,321;
[0544] (17) mTOR inhibitors selected from the group consisting of:
temsirolimus, everolimus, ridaforolimus, deforolimus, OSI-027,
AZD2014, CC-223, RAD001, LY294002, BEZ235, rapamycin, Ku-0063794,
and PP242; [0545] (18) AKT inhibitors selected from the group
consisting of: perifosine, MK-2206, GDC-0068 and GSK795; [0546]
(19) MEK inhibitors selected from the group consisting of:
trametinib, selumetinib, cobimetinib, MEK162, PD-325901, PD-035901,
AZD6244, and CI-1040; [0547] (20) CDK inhibitors selected from the
group consisting of: AT-7519, alvocidib, palbociclib and SNS-032;
[0548] (21) JNK inhibitors selected from the group consisting of:
CC-401; [0549] (22) MAPK inhibitors selected from the group
consisting of: VX-702, SB203580 and SB202190; [0550] (23) Raf
inhibitors selected from the group consisting of: PLX4720; [0551]
(24) ROCK inhibitors selected from the group consisting of: Rho-15;
[0552] (25) Tie2 inhibitors selected from the group consisting of:
AMG-Tie2-1; [0553] (26) Myo-inositol signaling inhibitors such as
phospholipase C blockers and Myoinositol analogues described in
Powis, G., and Kozikowski A., (1994) New Molecular Targets for
Cancer Chemotherapy ed., Paul Workman and David Kerr, CRC press
1994, London; [0554] (27) Bcl-2 family protein inhibitors selected
from the group consisting of: ABT-263, ABT-199 and ABT-737; [0555]
(28) IKK inhibitors selected from the group consisting of:
BMS-345541; [0556] (29) Proteasome inhibitors selected from the
group consisting of: bortezomib; [0557] (30) Protein kinase C (PKC)
inhibitors selected from the group consisting of: bryostatin 1 and
enzastaurin; [0558] (31) Heat shock protein HSP90 inhibitors
selected from the group consisting of: Geldanamycin; [0559] (32)
Combination drugs selected from the group consisting of: FR
(fludarabine, rituximab), FCR (fludarabine, cyclophosphamide,
rituximab), R-CHOP (rituximab plus CHOP), R-CVP (rituximab plus
CVP), R-FCM (rituximab plus FCM), R-ICE (rituximab-ICE), CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisone), CVP
(cyclophosphamide, vincristine and prednisone), FCM (fludarabine,
cyclophosphamide, mitoxantrone), hyperCVAD (hyperfractionated
cyclophosphamide, vincristine, doxorubicin, dexamethasone,
methotrexate, cytarabine), ICE (iphosphamide, carboplatin and
etoposide), MCP (mitoxantrone, chlorambucil, and prednisolone), and
R MCP (R MCP); and [0560] (33) other drugs for treating cancer
selected from the group consisting of aldesleukin, alvocidib,
CHIR-12.12, ha20, tiuxetan, PRO131921, SGN-40, WT-1 analog peptide
vaccine, WT1 126-134 peptide vaccine, autologous human
tumor-derived HSPPC-96, GTOP-99 (MyVax.RTM.), antineoplaston AS2-1,
antineoplaston A10, anti-thymocyte globulin, beta alethine, arsenic
trioxide, amifostine, aminocamptothecin, lenalidomide, caspofungin,
clofarabine, ixabepilone, cladribine, chlorambucil, Curcumin,
vinorelbine, tipifamib, tanespimycin, sildenafil citrate,
denileukin diftitox, simvastatin, epoetin alfa, fenretinide,
filgrastim, mesna, mitoxantrone, lenalidomide, fludarabine,
mycophenolate mofetil, nelarabine, octreotide, oxaliplatin,
pegfilgrastim, recombinant interleukin-12, recombinant
interleukin-11, recombinant flt3 ligand, recombinant human
thrombopoietin, sargramostim, lymphokine-activated killer cells,
omega-3 fatty acids, recombinant interferon alfa, therapeutic
allogeneic lymphocytes and cyclosporine analogs.
[0561] In a particular embodiment, a compound of the present
disclosure, or a pharmaceutically acceptable salt thereof, is
combined with one, two, three, four or more additional therapeutic
agents selected from ibrutinib, aldesleukin, alvocidib,
antineoplaston AS2-1, antineoplaston A10, anti-thymocyte globulin,
amifostine trihydrate, aminocamptothecin, arsenic trioxide, beta
alethine, ABT-263, ABT-199, ABT-737, BMS-345541, bortezomib,
bryostatin 1, busulfan, carboplatin, campath-1H, CC-5103,
carmustine, caspofungin acetate, clofarabine, cisplatin, Cladribine
(Leustarin), Chlorambucil (Leukeran), Curcumin, cyclosporine,
Cyclophosphamide (Cyloxan, Endoxan, Endoxana, Cyclostin),
denileukin diftitox, dexamethasone, DT PACE, docetaxel, dolastatin
10, Doxorubicin (Adriamycin.RTM., Adriblastine), doxorubicin
hydrochloride, enzastaurin, epoetin alfa, etoposide, everolimus
(RAD001), fenretinide, filgrastim, melphalan, mesna, flavopiridol,
fludarabine (Fludara), Geldanamycin (17 AAG), ifosfamide,
irinotecan hydrochloride, ixabepilone, lenalidomide
(Revlimid.RTM.), lymphokine-activated killer cells, melphalan,
methotrexate, mitoxantrone hydrochloride, motexafin gadolinium,
mycophenolate mofetil, nelarabine, oblimersen Obatoclax,
oblimersen, octreotide acetate, omega-3 fatty acids, oxaliplatin,
paclitaxel, PD0332991, PEGylated liposomal doxorubicin
hydrochloride, pegfilgrastim, Pentstatin (Nipent), perifosine,
Prednisolone, Prednisone, selicilib, recombinant interferon alfa,
recombinant interleukin-12, recombinant interleukin-11, recombinant
flt3 ligand, recombinant human thrombopoietin, rituximab,
sargramostim, sildenafil citrate, simvastatin, sirolimus, Styryl
sulphones, tacrolimus, tanespimycin, temsirolimus, thalidomide,
therapeutic allogeneic lymphocytes, thiotepa, tipifamib,
Vincristine, vincristine sulfate, vinorelbine ditartrate,
Vorinostat (SAHA), vorinostat, FR (fludarabine, rituximab), CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisone), CVP
(cyclophosphamide, vincristine and prednisone), FCM (fludarabine,
cyclophosphamide, mitoxantrone), FCR (fludarabine,
cyclophosphamide, rituximab), hyperCVAD (hyperfractionated
cyclophosphamide, vincristine, doxorubicin, dexamethasone,
methotrexate, cytarabine), ICE (iphosphamide, carboplatin and
etoposide), MCP (mitoxantrone, chlorambucil, and prednisolone),
R-CHOP (rituximab plus CHOP), R-CVP (rituximab plus CVP), R-FCM
(rituximab plus FCM), R-ICE (rituximab-ICE), and R MCP (R MCP).
[0562] Any of the methods of treatment provided may be used to
treat cancer at various stages. By way of example, the cancer stage
includes but is not limited to early, advanced, locally advanced,
remission, refractory, reoccurred after remission and
progressive.
[0563] In addition, the subject may be a human who is undergoing
one or more standard therapies, such as chemotherapy, radiotherapy,
immunotherapy, surgery, or combination thereof. Accordingly, one or
more anti-cancer agents may be administered before, during, or
after administration of chemotherapy, radiotherapy, immunotherapy,
surgery or combination thereof.
[0564] The therapeutic treatments can be supplemented or combined
with any of the abovementioned therapies with stem cell
transplantation or treatment. One example of modified approach is
radioimmunotherapy, wherein a monoclonal antibody is combined with
a radioisotope particle, such as indium In 111, yttrium Y 90,
iodine 1-131. Examples of combination therapies include, but are
not limited to, Iodine-131 tositumomab (Bexxar.RTM.), Yttrium-90
ibritumomab tiuxetan (Zevalin.RTM.), Bexxar.RTM. with CHOP.
[0565] Other therapeutic procedures include peripheral blood stem
cell transplantation, autologous hematopoietic stem cell
transplantation, autologous bone marrow transplantation, antibody
therapy, biological therapy, enzyme inhibitor therapy, total body
irradiation, infusion of stem cells, bone marrow ablation with stem
cell support, in vitro-treated peripheral blood stem cell
transplantation, umbilical cord blood transplantation, immunoenzyme
technique, pharmacological study, low-LET cobalt-60 gamma ray
therapy, bleomycin, conventional surgery, radiation therapy, and
nonmyeloablative allogeneic hematopoietic stem cell
transplantation.
[0566] Also provided herein is a compound of the present disclosure
(e.g., a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, and one or more additional therapeutic agents for
treating cancer, for use in a method of treating cancer.
[0567] Also provided herein is a compound of the present disclosure
(e.g., a compound of Formula (I)), or a pharmaceutically acceptable
salt thereof, for use in a method of treating cancer, wherein the
compound or a pharmaceutically acceptable salt thereof is
administered simultaneously, separately or sequentially with one or
more additional therapeutic agents for treating cancer.
XI. KITS
[0568] The present disclosure provides a kit comprising a compound
of the present disclosure or a pharmaceutically acceptable salt
thereof. The kit may further comprise instructions for use, e.g.,
for use in modulating a toll-like receptor (e.g. TLR-8), such as
for use in treating a disease, disorder, or condition. In certain
embodiments the use is for treating a HIV, HBV, or HCV infection.
In certain embodiments the use is for treating a HBV infection. The
instructions for use are generally written instructions, although
electronic storage media (e.g., magnetic diskette or optical disk)
containing instructions are also acceptable.
[0569] The present disclosure also provides a pharmaceutical kit
comprising one or more containers comprising a compound of the
present disclosure or a pharmaceutically acceptable salt thereof.
Optionally associated with such container(s) can be a notice in the
form prescribed by a governmental agency regulating the
manufacture, use or sale of pharmaceuticals, which notice reflects
approval by the agency for the manufacture, use or sale for human
administration. Each component (if there is more than one
component) can be packaged in separate containers or some
components can be combined in one container where cross-reactivity
and shelf life permit. The kits may be in unit dosage forms, bulk
packages (e.g., multi-dose packages) or sub-unit doses. Kits may
also include multiple unit doses of the compounds and instructions
for use and be packaged in quantities sufficient for storage and
use in pharmacies (e.g., hospital pharmacies and compounding
pharmacies).
XII. COMPOUND PREPARATION
[0570] Also provided are articles of manufacture comprising a unit
dosage of a compound of the present disclosure or a
pharmaceutically acceptable salt thereof, in suitable packaging for
use in the methods described herein. Suitable packaging is known in
the art and includes, for example, vials, vessels, ampules,
bottles, jars, flexible packaging and the like. An article of
manufacture may further be sterilized and/or sealed.
[0571] The embodiments are also directed to processes and
intermediates useful for preparing the subject compounds or
pharmaceutically acceptable salts thereof.
[0572] Many general references providing commonly known chemical
synthetic schemes and conditions useful for synthesizing the
disclosed compounds are available (see, e.g., Smith, March's
Advanced Organic Chemistry: Reactions, Mechanisms, and Structure,
7.sup.th edition, Wiley-Interscience, 2013.)
[0573] Compounds as described herein can be purified by any of the
means known in the art, including chromatographic means, such as
high performance liquid chromatography (HPLC), preparative thin
layer chromatography, flash column chromatography and ion exchange
chromatography. Any suitable stationary phase can be used,
including normal and reversed phases as well as ionic resins. Most
typically the disclosed compounds are purified via silica gel
and/or alumina chromatography. See, e.g., Introduction to Modem
Liquid Chromatography, 2nd ed., ed. L. R. Snyder and J. J.
Kirkland, John Wiley and Sons, 1979; and Thin Layer Chromatography,
E. Stahl (ed.), Springer-Verlag, New York, 1969.
[0574] During any of the processes for preparation of the subject
compounds, it may be necessary and/or desirable to protect
sensitive or reactive groups on any of the molecules concerned.
This may be achieved by means of conventional protecting groups as
described in standard works, such as T. W. Greene and P. G. M.
Wuts, "Protective Groups in Organic Synthesis," 4.sup.th ed.,
Wiley, New York 2006. The protecting groups may be removed at a
convenient subsequent stage using methods known from the art.
XIII. EXAMPLES
[0575] Exemplary chemical entities useful in methods of the
embodiments will now be described by reference to illustrative
synthetic schemes for their general preparation herein and the
specific examples that follow. Artisans will recognize that, to
obtain the various compounds herein, starting materials may be
suitably selected so that the ultimately desired substituents will
be carried through the reaction scheme with or without protection
as appropriate to yield the desired product. Alternatively, it may
be necessary or desirable to employ, in the place of the ultimately
desired substituent, a suitable group that may be carried through
the reaction scheme and replaced as appropriate with the desired
substituent. Furthermore, one of skill in the art will recognize
that the transformations shown in the schemes below may be
performed in any order that is compatible with the functionality of
the particular pendant groups. Each of the reactions depicted in
the general schemes is preferably run at a temperature from about
0.degree. C. to the reflux temperature of the organic solvent used.
Unless otherwise specified, the variables are as defined above in
reference to Formulas (I) or (J).
[0576] Representative syntheses of compounds of the present
disclosure are described in schemes below, and the particular
examples that follow.
[0577] Scheme 1 shows a representative synthesis of the compounds
of the embodiments. The methodology is compatible with a wide
variety of functionalities.
##STR00130##
[0578] In Scheme 1, compounds of formula A1 (where R.sup.1,
R.sup.2, and R.sup.3 are as defined herein or are suitably
protected derivatives of R.sup.1, R.sup.2, and R.sup.3) are
converted to the corresponding 4-amino,2-chloro heterocycle by
reaction with a nuclephilic amine in the presence of a suitable
base (such as DIPEA) at room temperature. The compound of formula
A2 is then treated with 2,4-dimethoxybenzylamine at elevated
temperature resulting in a 2,4-diaminopyrimidine of formula A3. In
cases where R.sup.1, R.sup.2, and R.sup.3 is a diversifiable
chemical group such as Cl or Br, further replacement of R.sup.1,
R.sup.2, and R.sup.3 by a variety of methods including cyanation,
nucleophilic aromatic displacement, and metal catalyzed cross
coupling reactions such as Suzuki couplings is carried out to
provide products of formula A4. Treatment with a suitable acid
(such as trifluoroacetic acid) leads to certain compounds of
Formula (I) or (J). Where suitable, other leaving groups may be
used in place of the C1 group(s) of A1.
##STR00131##
[0579] 2,4-dichloro pyrido-pyrimidines of formula A1 (where
R.sup.1, R.sup.2, and R.sup.3 are as defined herein or are suitably
protected derivatives of R.sup.1, R.sup.2, and R.sup.3) are
converted to the corresponding 4-amino,2-chloro heterocycle by
reaction with an amino acid ester (such as L-norvaline methyl
ester) in the presence of a suitable base (such as DIPEA) at room
temperature to provide a compound of formula B1, where G is an the
sidechain of the amino acid. The compound of formula B1 is then
treated with 2,4-dimethoxybenzylamine in a microwave reactor at a
suitable temperature (such as about 135.degree. C.), resulting in a
2,4-diaminopyrimidine of formula B2. Hydrolysis of the ester group
via treatment with a suitable base (such as aqueous KOH/THF)
provides product of formula B3 where Z is hydroxyl. Further
reaction of the resulting carboxylic acid leads to modification of
Z via HATU-promoted amide formation with various amines. Protecting
group removal with a suitable acid (such as trifluoroacetic acid)
at room temperature then leads to certain compounds of Formula (J)
or (I).
[0580] Scheme 3 shows a representative synthesis of the compounds
of the embodiments. The methodology is compatible with a wide
variety of functionalities.
##STR00132##
[0581] An amide of formula C1 (where R.sup.1, R.sup.2, and R.sup.3
are as defined herein or are suitably protected derivatives of
R.sup.1, R.sup.2, and R.sup.3, and Z.sup.1 is NH.sup.2 or O-alkyl)
is converted to a compound of formula C2, under suitable reaction
conditions. For example, the compound of formula C1 is contacted
with chloroformamidine hydrochloride under suitable conditions to
provide C2. The hydroxyl group may be further modified, for example
by introducing any suitable leaving group, such as a tosyl group,
prior to contacting with R.sup.4--NH.sub.2. Alternatively,
R.sup.4--NH.sub.2 may be directly coupled to C2 im the presence of
a suitable coupling agent, for example, BOP reagent, under suitable
conditions.
[0582] Additionally, a compound of Formula A1 (where R.sup.1,
R.sup.2, and R.sup.3 are as defined herein or are suitably
protected derivatives of R.sup.1, R.sup.2, and R.sup.3) may be
prepared as described in the scheme below. It is understood that A1
may be further modified to prepare compounds of Formula (I) as more
fully described herein.
##STR00133##
[0583] As described above C1 is contacted with a suitable agent,
such as triphosgene and dioxane, to result in a compound of D1. The
compound D1 may be further halogenated under suitable conditions,
such as treatment with POCl.sub.3 and PCl.sub.5, to provide a
compound of formula A1.
[0584] In certain instances, the above processes further involve
the step of forming a salt of a compound of the present disclosure.
Embodiments are directed to the other processes described herein;
and to the product prepared by any of the processes described
herein.
[0585] Except as otherwise noted, the methods and techniques of the
present embodiments are generally performed according to
conventional methods well known in the art and as described in
various general and more specific references that are cited and
discussed throughout the present specification. See, e.g., Loudon,
Organic Chemistry, 5.sup.th edition, New York: Oxford University
Press, 2009; Smith, March's Advanced Organic Chemistry: Reactions,
Mechanisms, and Structure, 7.sup.th edition, Wiley-Interscience,
2013.
[0586] The Examples provided herein describe the synthesis of
compounds disclosed herein as well as intermediates used to prepare
the compounds. It is to be understood that individual steps
described herein may be combined. It is also to be understood that
separate batches of a compound may be combined and then carried
forth in the next synthetic step.
[0587] In the following description of the Examples, specific
embodiments are described. These embodiments are described in
sufficient detail to enable those skilled in the art to practice
certain embodiments of the present disclosure. Other embodiments
may be utilized and logical and other changes may be made without
departing from the scope of the disclosure. The following
description is, therefore, not intended to limit the scope of the
present disclosure.
[0588] The methods of the present invention generally provide a
specific enantiomer or diastereomer as the desired product,
although the stereochemistry of the enantiomer or diastereomer was
not determined in all cases. When the stereochemistry of the
specific stereocenter in the enantiomer or diastereomer is not
determined, the compound is drawn without showing any
stereochemistry at that specific stereocenter even though the
compound can be substantially enantiomerically or
disatereomerically pure.
Example 1
##STR00134##
[0589] Synthesis of
N.sup.4-butyl-N.sup.2-(2,4-dimethoxybenzyl)pyrido[3,2-d]pyrimidine-2,4-di-
amine (1A)
[0590] To a solution of 2,4-dichloropyrido[3,2-d]pyrimidine
(CAS#39551-54-7, supplied by Astatech, Inc.) (50 mg, 0.25 mmol) in
THF (2 mL) was added butan-1-amine (0.03 mL, 0.28 mmol) and
N,N-diisopropylethylamine (0.13 ml, 0.75 mmol). After stirring at
room temperature for 30 minutes, 2,4-dimethoxybenzylamine (0.19 ml,
1.25 mmol) and N,N-diisopropylethylamine (0.13 ml, 0.75 mmol) were
added and the mixture was heated to 100.degree. C. After 16 hours,
the reaction was cooled to room temperature, diluted with ethyl
acetate, washed with water and brine, dried over Na2SO4, and
concentrated in vacuo. The product (1A) was obtained after flash
chromatography. MS (m/z): 368.14 [M+H].sup.+.
Synthesis of N.sup.4-butylpyrido[3,2-d]pyrimidine-2,4-diamine
(1B)
[0591] 1A was dissolved in trifluoroacetic acid (3 mL). After 30
minutes, the reaction was diluted with water and methanol. After 60
minutes, the mixture was concentrated in vacuo. The residue was
then co-evaporated with methanol three times and filtered in
methanol to afford the title product 1B as a trifluoroacetic acid
salt. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. 8.59 (dd,
J=4.4, 1.4 Hz, 1H), 7.82 (dd, J=8.5, 1.4 Hz, 1H), 7.72 (dd, J=8.5,
4.4 Hz, 1H), 3.66 (t, J=7.3 Hz, 2H), 1.78-1.62 (m, 2H), 1.43 (dq,
J=14.7, 7.4 Hz, 2H), 0.98 (t, J=7.4 Hz, 3H). MS (m/z): 218.10
[M+H].sup.+. .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.6.
Example 2
##STR00135##
[0592] Synthesis of
N.sup.2-(2,4-dimethoxybenzyl)-N.sup.4-(pentan-2-yl)pyrido[3,2-d]pyrimidin-
e-2,4-diamine (2A)
[0593] 2A was synthesized following the procedure described above
for preparation of 1A, replacing butan-1-amine with 2-aminopentane.
MS (m/z) 382.17 [M+H].sup.+.
Synthesis of
N.sup.4-(pentan-2-yl)pyrido[3,2-d]pyrimidine-2,4-diamine (2B)
[0594] 2B was prepared following the procedure described for 1B to
yield the title compound (2B) as its TFA salt. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.61 (dd, J=4.4, 1.4 Hz, 1H), 7.84 (dd,
J=8.5, 1.4 Hz, 1H), 7.74 (dd, J=8.5, 4.4 Hz, 1H), 4.60-4.46 (m,
1H), 1.74 (dtd, J=13.5, 8.3, 6.7 Hz, 1H), 1.68-1.55 (m, 1H), 1.44
(d, J=7.4 Hz, 2H), 1.32 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.4 Hz, 3H).
MS (m/z) 232.11 [M+H].sup.+. 19F NMR (377 MHz, Methanol-d4) .delta.
-77.5.
##STR00136##
Synthesis of
(S)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
4-methylpentan-1-ol (3A)
[0595] 3A was synthesized following the above procedure for 1A,
replacing butan-1-amine with (S)-(+)-leucinol. MS (m/z) 412.19
[M+H].sup.+.
Synthesis of
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-4-methylpentan-1-ol
(3B)
[0596] 3B was synthesized using the procedure described above for
the preparation of 1B to yield the title compound (3B) as its TFA
salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.62 (dd, J=4.4,
1.3 Hz, 1H), 7.84 (dd, J=8.5, 1.4 Hz, 1H), 7.74 (dd, J=8.5, 4.4 Hz,
1H), 4.74-4.58 (m, 1H), 3.71 (h, J=6.2 Hz, 2H), 1.76-1.58 (m, 2H),
1.52 (tq, J=10.6, 3.5 Hz, 1H), 0.98 (t, J=6.4 Hz, 6H). MS (m/z)
262.15 [M+H].sup.+. .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-77.6
Example 4
##STR00137##
[0597] Synthesis of
(S)-3-cyclopropyl-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidi-
n-4-yl)amino)propan-1-ol (4A)
[0598] 4A was prepared using the procedure described above for the
preparation of 1A, replacing butan-1-amine with
(2S)-2-amino-3-cyclopropylpropan-1-ol HCl salt. MS (m/z) 410.20
[M+H].sup.+
Synthesis of
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-3-cyclopropylpropan-1-o-
l (4B)
[0599] 4B was synthesized following the procedure described above
for 1B to yield the title compound (4B) as its TFA salt. .sup.1H
NMR (400 MHz, Methanol-d.sub.4) .delta. 8.62 (dd, J=4.4, 1.3 Hz,
1H), 7.85 (dd, J=8.5, 1.4 Hz, 1H), 7.75 (dd, J=8.5, 4.4 Hz, 1H),
4.63 (dq, J=7.3, 5.5 Hz, 1H), 3.81 (d, J=5.2 Hz, 2H), 1.65 (h,
J=7.1 Hz, 2H), 0.78 (dddd, J=15.0, 10.1, 5.1, 2.1 Hz, 1H), 0.45
(dddd, J=11.1, 9.4, 7.9, 4.6 Hz, 2H), 0.19-0.07 (m, 2H). MS (m/z)
260.15 [M+H].sup.+. .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-77.6
Example 5
##STR00138##
[0600] Synthesis of (S)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)penta-
noate (5A)
[0601] 5A was prepared following the general procedure described
above for 1A, replacing butan-1-amine with (S)-methyl
2-aminopentanoate. MS (m/z) 426.19 [M+H].sup.+.
Synthesis of (S)-methyl
2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)pentanoate (5B)
[0602] 5B was prepared following the procedure described above for
lB to yield the title compound (5B) as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d.sub.4) .delta. 8.66 (dd, J=4.4, 1.4 Hz, 1H),
7.88 (dd, J=8.5, 1.4 Hz, 1H), 7.79 (dd, J=8.5, 4.4 Hz, 1H), 5.02
(dd, J=8.7, 5.3 Hz, 1H), 3.78 (s, 3H), 2.13-1.92 (m, 2H), 1.56-1.39
(m, 2H), 0.99 (t, J=7.4 Hz, 3H). MS (m/z) 276.13 [M+H].sup.+.
.sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.8.
Example 6
##STR00139##
[0603] Synthesis of
(S)-2-((8-chloro-2-((2,4-dimethoxybenzyl)amino)-6-methylpyrido[3,2-d]pyri-
midin-4-yl)amino)pentan-1-ol (6A)
[0604] 6A was prepared following the procedure described above for
1A, replacing butan-1-amine with (S)-methyl 2-aminopentanoate and
instead starting from
2,4,8-trichloro-6-methylpyrido[3,2-d]pyrimidine in place of
2,4-dichloropyrido[3,2-d]pyrimidine. MS (m/z) 446.20
[M+H].sup.+.
Synthesis of
(S)-2-((2-amino-8-chloro-6-methylpyrido[3,2-d]pyrimidin-4-yl)amino)pentan-
-1-ol (6B)
[0605] 6B was prepared following the procedure described above for
1B to yield the title compound (6B) as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d.sub.4) .delta. 7.84 (s, 1H), 4.55 (ddd,
J=12.6, 7.2, 5.2 Hz, 1H), 3.75 (d, J=5.3 Hz, 3H), 1.79-1.67 (m,
3H), 1.51-1.35 (m, 3H), 0.98 (t, J=7.4 Hz, 4H). MS (m/z) 296.18
[M+H].sup.+. .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.6.
Example 7
##STR00140##
[0607] Compound 7,
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-phenylethanol,
was prepared following the procedure for compound 1B reported
above, instead replacing butan-1-amine with
(S)-2-amino-2-phenylethanol to yield the title compound (7) as its
TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.68 (dd,
J=4.3, 1.5 Hz, 1H), 7.84 (dd, J=8.5, 1.5 Hz, 1H), 7.77 (dd, J=8.5,
4.4 Hz, 1H), 7.49-7.43 (m, 2H), 7.38-7.31 (m, 2H), 7.31-7.24 (m,
1H), 5.57 (dd, J=7.4, 4.8 Hz, 1H), 4.12-3.93 (m, 2H). .sup.19F NMR
(376 MHz, Methanol-d4) .delta. -77.7. MS (m/z) 282.1
[M+H].sup.+.
Example 8
##STR00141##
[0609] Compound 8,
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol, was
prepared following the procedure for the synthesis of compound 1B
reported above, instead replacing butan-1-amine with
(R)-2-aminopentan-1-ol to yield the title compound (8) as its TFA
salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.64 (dd, J=4.4,
1.4 Hz, 1H), 7.83 (dd, J=8.5, 1.5 Hz, 1H), 7.76 (dd, J=8.5, 4.4 Hz,
1H), 4.55 (dq, J=7.4, 5.4 Hz, 1H), 3.78-3.69 (m, 2H), 1.77-1.65 (m,
2H), 1.52-1.36 (m, 2H), 0.98 (t, J=7.3 Hz, 3H). .sup.19F NMR (376
MHz, Methanol-d4) .delta. -77.56. MS (m/z) 248.1 [M+H].sup.+.
Example 9
##STR00142##
[0611] Compound 9,
(2S,3S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylpentan-1-ol-
, was prepared following the procedure for compound 1B reported
above, instead replacing butan-1-amine with
(2S,3S)-2-amino-3-methylpentan-1-ol to yield the title compound (9)
as its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.64
(dd, J=4.4, 1.4 Hz, 1H), 7.84 (dd, J=8.5, 1.4 Hz, 1H), 7.76 (dd,
J=8.5, 4.4 Hz, 1H), 4.39 (dt, J=8.1, 5.0 Hz, 1H), 3.83 (d, J=5.0
Hz, 2H), 1.97-1.82 (m, 1H), 1.58 (dddd, J=16.8, 11.2, 7.6, 3.8 Hz,
1H), 1.33-1.16 (m, 2H), 1.03 (d, J=6.8 Hz, 3H), 0.94 (t, J=7.4 Hz,
3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta. -77.71. MS (m/z)
262.1 [M+H].sup.+.
Example 10
##STR00143##
[0613] Compound 10,
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-4-(methylthio)butan-1-o-
l, was prepared following the 2 step procedure for compound 1B
reported above, replacing butan-1-amine with
(S)-2-amino-4-(methylthio)butan-1-ol to yield the title compound
(10) as its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta.
8.64 (dd, J=4.4, 1.4 Hz, 1H), 7.83 (dd, J=8.5, 1.4 Hz, 1H), 7.76
(dd, J=8.5, 4.4 Hz, 1H), 4.66 (dq, J=8.1, 5.4 Hz, 1H), 3.76 (d,
J=5.3 Hz, 2H), 2.65-2.52 (m, 2H), 2.11-1.98 (m, 5H). .sup.19F NMR
(376 MHz, Methanol-d4) .delta. -77.63. MS (m/z) 280.1
[M+H].sup.+.
Example 11
##STR00144##
[0615] Compound 11,
N.sup.4-pentylpyrido[3,2-d]pyrimidine-2,4-diamine, was prepared
following the procedure for compound 1B reported above, instead
replacing butan-1-amine with n-pentylamine to yield the title
compound (11) as its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4)
.delta. 8.62 (dd, J=4.4, 1.4 Hz, 1H), 7.81 (dd, J=8.5, 1.4 Hz, 1H),
7.74 (dd, J=8.5, 4.4 Hz, 1H), 3.67 (dd, J=7.8, 6.8 Hz, 2H),
1.80-1.66 (m, 2H), 1.49-1.32 (m, 4H), 0.99-0.85 (m, 3H). .sup.19F
NMR (376 MHz, Methanol-d4) .delta. -77.58. MS (m/z) 232.1
[M+H].sup.+.
Example 12
##STR00145##
[0617] Compound 12,
2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)ethanol, was prepared
following the procedure for compound 1B reported above, instead
replacing butan-1-amine with ethanolamine to yield the title
compound (12) as its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4)
.delta. 8.64 (dd, J=4.3, 1.5 Hz, 1H), 7.88-7.72 (m, 2H), 3.82 (d,
J=2.3 Hz, 4H). .sup.19F NMR (376 MHz, Methanol-d4) .delta. -77.58.
MS (m/z) 206.0 [M+H].sup.+.
Example 13
##STR00146##
[0619] Compound 13,
3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)propan-1-ol, was
prepared following the 2 step procedure for compound 1B reported
above, instead replacing butan-1-amine with propanolamine to yield
the title compound (13) as its TFA salt. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.62 (td, J=4.6, 1.4 Hz, 1H), 7.87-7.70 (m,
2H), 3.80 (dt, J=11.7, 6.8 Hz, 2H), 3.70 (t, J=6.0 Hz, 2H),
2.00-1.88 (m, 2H). .sup.19F NMR (376 MHz, Methanol-d4) .delta.
-77.58. MS (m/z) 220.1 [M+H].sup.+.
Example 14
##STR00147##
[0621] Compound 14,
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol, was
prepared following the procedure for compound 1B reported above,
instead replacing butan-1-amine with (S)-2-aminohexan-1-ol to yield
the title compound (14) as its TFA salt. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.63 (dd, J=4.4, 1.4 Hz, 1H), 7.84 (dd, J=8.5,
1.4 Hz, 1H), 7.76 (dd, J=8.5, 4.4 Hz, 1H), 4.53 (dq, J=8.6, 5.4 Hz,
1H), 3.79-3.68 (m, 2H), 1.87-1.61 (m, 2H), 1.52-1.31 (m, 4H),
1.01-0.85 (m, 3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta.
-77.63. MS (m/z) 262.2 [M+H].sup.+.
Example 15
##STR00148##
[0623] Compound 15,
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol, was
prepared following the procedure for compound 1B reported above,
instead replacing butan-1-amine with (R)-2-aminohexan-1-ol to yield
the title compound (15) as its TFA salt. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.66-8.59 (m, 1H), 7.84 (dd, J=8.5, 1.4 Hz,
1H), 7.77 (td, J=8.8, 4.4 Hz, 1H), 4.59-4.42 (m, 1H), 3.81-3.68 (m,
2H), 1.90-1.65 (m, 2H), 1.49-1.35 (m, 4H), 1.03-0.82 (m, 3H).
.sup.19F NMR (376 MHz, Methanol-d4) .delta. -77.60. MS (m/z) 262.2
[M+H].sup.+.
Example 16
##STR00149##
[0625] Compound 16,
N.sup.4-((tetrahydrofuran-2-yl)methyl)pyrido[3,2-d]pyrimidine-2,4-diamine-
, was prepared following the procedure for compound 1B reported
above, instead replacing butan-1-amine with
(tetrahydrofuran-2-yl)-methanamine to yield the title compound (16)
as its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.62
(dd, J=4.4, 1.4 Hz, 1H), 7.83 (dd, J=8.5, 1.4 Hz, 1H), 7.75 (dd,
J=8.5, 4.4 Hz, 1H), 4.24 (qd, J=6.8, 4.8 Hz, 1H), 3.93 (dt, J=8.3,
6.5 Hz, 1H), 3.84-3.68 (m, 3H), 2.16-1.82 (m, 3H), 1.71 (ddt,
J=11.6, 8.0, 6.5 Hz, 1H). .sup.19F NMR (376 MHz, Methanol-d4)
.delta. -77.50. MS (m/z) 246.1 [M+H].sup.+.
Example 17
##STR00150##
[0627] Compound 17,
2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)propane-1,3-diol, was
prepared following the procedure for compound 1B reported above,
instead replacing butan-1-amine with 2-aminopropane-1,3-diol to
yield the title compound (17) as its TFA salt. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.64 (dd, J=4.4, 1.4 Hz, 1H), 7.85 (dd,
J=8.5, 1.4 Hz, 1H), 7.77 (dd, J=8.5, 4.4 Hz, 1H), 4.54 (p, J=5.5
Hz, 1H), 3.84 (d, J=5.5 Hz, 4H). .sup.19F NMR (376 MHz,
Methanol-d4) .delta. -77.66. MS (m/z) 236.1 [M+H].sup.+.
Example 18
##STR00151##
[0628] Synthesis of 3-amino-5-bromopicolinamide (18B)
[0629] To a solution of 3-amino-5-bromopicolinic acid 18A (300 mg,
1.38 mmol, 1 equiv.) in DMF (11 ml, 0.1 M) was added HATU (598 mg,
1.57 mmol, 1.1 equiv.) followed by DIPEA (0.48 mL, 2.76 mmol, 2
equiv.) and ammonium hydroxide (0.8 mL, 5.55 mmol, 4 equiv.). The
mixture was allowed to stir overnight. Water (50 mL) was added and
the mixture then extracted with EtOAc (3 times). The organic layer
was separated, dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The product (18B) was obtained
after flash chromatography. MS (m/z): 216.8 [M+H].sup.+
Synthesis of 2-amino-7-bromopyrido[3,2-d]pyrimidin-4-ol (18C)
[0630] To a flask containing 3-amino-5-bromopicolinamide (18B) (205
mg, 0.1 mmol, 1 equiv.) was added chloroformamadine hydrochloride
(140 mg, 1.3 equiv.). The mixture was heated to 165.degree. C.
overnight. It was allowed to cool to room temperature, then
filtered and washed with water and ethyl ether. The residue was
allowed to air dry to furnish
2-amino-7-bromopyrido[3,2-d]pyrimidin-4-ol (1C) which was used
without further purification. MS (m/z): 239.9 [M+H].sup.+
Synthesis of
N-(7-bromo-4-hydroxypyrido[3,2-d]pyrimidin-2-yl)acetamide (18D)
[0631] To a flask containing
2-amino-7-bromopyrido[3,2-d]pyrimidin-4-ol (1C) (155 mg, 0.64 mmol,
1 equiv.) was added acetic anhydride (3 mL). The mixture was heated
to 115.degree. C. for 4 hrs. It was concentrated under reduced
pressure. It was filtered and washed with diethyl ether and hexane
and allowed to air dry to obtain
N-(7-bromo-4-hydroxypyrido[3,2-d]pyrimidin-2-yl)acetamide (18D). MS
(m/z): 282.9 [M+H]..sup.+
Synthesis of
N-(7-bromo-4-chloropyrido[3,2-d]pyrimidin-2-yl)acetamide (18E)
[0632] Into a solution of
N-(7-bromo-4-hydroxypyrido[3,2-d]pyrimidin-2-yl)acetamide (18D)
(200 mg, 0.71 mmol, 1 equiv.) was added acetonitrile (2 ml) and
POCl.sub.3 (1 ml) followed by DIPEA (0.12 mL, 0.71 mmol., 1
equiv.). The mixture was refluxed for 6 hours. The mixture was
concentrated under reduced pressure. To it was added water (20 mL)
then extracted with EtOAc (3 times). The organic layer was
separated, dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to afford the title product
N-(7-bromo-4-chloropyrido[3,2-d]pyrimidin-2-yl)acetamide (18E). MS
(m/z): 298.9 [M+H].
Synthesis of
(S)-2-((2-amino-7-bromopyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(18F)
[0633] To a solution of
N-(7-bromo-4-chloropyrido[3,2-d]pyrimidin-2-yl)acetamide (18E) (215
mg, 0.71 mmol, 1 equiv.) was added DMF (1.5 ml) followed by DIPEA
(0.38 mL, 2.1 mmol, 3 equiv.) and (S)-(+)-2-Amino-1-pentanol (55
mg, 3.6 mmol, 5 equiv.). The reaction was allowed to stir
overnight. It was concentrated under reduced pressure and purified
by reverse phase HPLC to furnish the title compound (18F) as its
TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.41 (d, J=2.0
Hz, 1H), 7.83 (d, J=2.0 Hz, 1H), 4.34 (dd, J=8.5, 5.4 Hz, 1H),
3.65-3.53 (m, 3H), 1.67-1.49 (m, 3H), 1.41-1.24 (m, 3H), 0.86 (t,
J=7.4 Hz, 5H). .sup.19F NMR (377 MHz, CD.sub.3sOD) 6-77.52. MS
(m/z): 368.2 [M+H].
Example 19
##STR00152##
[0634] Synthesis of 2,4,7-trichloropyrido[3,2-d]pyrimidine
(19B)
[0635] Into a microwave vial was added
pyrido[3,2-d]pyrimidine-2,4-diol (19A) (200 mg, 1.2 mmol, 1 equiv.)
is added POCl.sub.3 (2.5 mL) and PCl.sub.5 (1.53 g, 7.4 mmol, 6
equiv.). The mixture was heated to 160.degree. C. for 3 hr in
microwave reactor. The reaction mixture was concentrated under
reduced pressure and partitioned between EtOAc and H.sub.2O. The
organics were separated, dried, and removed in vacuo. The residue
purified by column chromatography on silica to provide the title
compound. MS (m/z): 236.6[M+H].sup.+.
Synthesis of
(S)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(19C)
[0636] To a solution of 2,4,7-trichloropyrido[3,2-d]pyrimidine
(19B) (160 mg, 0.68 mmol, 1 equiv.) was added dioxane (4 ml)
followed by DIPEA (0.18 mL, 1.2 mmol, 1.5 equiv.) and
(S)-(+)-2-Amino-1-pentanol (85 mg, 0.82 mmol, 1.1 equiv.). The
reaction was allowed to stir for an hr. It was concentrated under
reduced pressure and used as is to provide the title compound. MS
(m/z): 301.1[M+H].sup.+.
Synthesis of
(S)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)pentan-1-ol (19D)
[0637] To a solution of
(R)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(19C) (206 mg, 0.68 mmol, 1 equiv.) was added dioxane (4 ml)
followed by DIPEA (0.24 mL, 1.4 mmol, 2 equiv.) and
2,4-demethoxybenzylamine (0.30 mL, 2.0 mmol, 3 equiv.). The
reaction was allowed heated at 120.degree. C. overnight. The
reaction mixture was partitioned between EtOAc and H.sub.2O. The
organics were separated, dried, and removed in vacuo. The residue
purified by column chromatography on silica to provide the title
compound. MS (m/z): 432.2 [M+H]..sup.+
Synthesis of
(S)-2-((2-amino-7-chloropyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(19E)
[0638] Into a solution of
(S)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)pentan-1-ol (19D) (35 mg, 0.08 mmol, 1 equiv.) was added
DCM (2 mL) and TFA (0.5 mL). After 3 hours the reaction mixture was
concentrated under reduced pressure and purified by reverse phase
HPLC to furnish the title compound (19E) as its TFA salt. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 8.48 (d, J=2.0 Hz, 1H), 7.78 (d,
J=2.1 Hz, 1H), 4.48 (dd, J=8.6, 5.3 Hz, 1H), 3.93-3.74 (m, 2H),
3.71 (d, J=5.2 Hz, 3H), 1.77-1.57 (m, 2H), 1.50-1.36 (m, 1H), 1.28
(s, 2H), 0.97 (t, J=7.4 Hz, 4H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.59 (d, J=80.2 Hz). MS (m/z): 282.1
[M+H]..sup.+
General Scheme for Examples 20-22
##STR00153##
[0639] Example 20
##STR00154##
[0640] Synthesis of
(S)-2-((2-((2,4-dimethoxybenzyl)amino)-7-methylpyrido[3,2-d]pyrimidin-4-y-
l)amino)pentan-1-ol (19F)
[0641] Into a vial containing
(S)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)pentan-1-ol (19D) (25 mg, 0.06 mmol, 1 equiv.) was added
methylboronic acid (8 mg, 0.14 mmol, 2.5 equiv.), potassium
phosphate tribasic (37 mg, 0.17 mmol, 3 equiv.),
palladium(0)-tetrakis(triphenylphosphine) (7 mg, 0.006 mmol, 0.1
equiv.) along with dioxane (2 mL) and water (2 mL). The mixture is
heated to 150.degree. C. for 1 hr in a microwave reactor. The
reaction mixture was partitioned between EtOAc and H.sub.2O. The
organics were separated, dried, and removed in vacuo to furnish the
title compound which was used directly. MS (m/z): 474.3
[M+H]..sup.+
Synthesis of
(S)-2-((2-amino-7-methylpyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(20)
[0642] Into the a flask containing 19F was added THF (2 mL), water
(2 mL) followed by 2,3-dichloro-5,6-dicyanobenzoquinone (26 mg,
20.11 mmol, 2 equiv.) After stirring overnight, the reaction
mixture was partitioned between EtOAc and H.sub.2O. The organics
were separated, dried, and removed in vacuo. Purification was
carried out using flash column chromatography to furnish the title
compound (20). .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.35 (d,
J=1.1 Hz, 1H), 7.49 (s, 1H), 4.54-4.34 (m, 1H), 3.70 (d, J=5.0 Hz,
2H), 1.84-1.61 (m, 2H), 1.56-1.35 (m, 2H), 0.97 (t, J=7.3 Hz, 3H).
MS (m/z): 262.1 [M+H]..sup.+
Example 21
##STR00155##
[0644] Synthesis of
(S)-2-((2-amino-7-ethylpyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(21) was prepared according to the procedure used for 20, instead
using ethylboronic acid in place of methylboronic acid. .sup.1H NMR
(400 MHz, Methanol-d4) .delta. 8.65-8.30 (m, 1H), 7.62 (s, 1H),
4.61-4.38 (m, 1H), 3.80-3.64 (m, 2H), 2.84 (q, J=7.6 Hz, 2H), 1.71
(tdd, J=8.3, 6.5, 2.2 Hz, 2H), 1.43 (dddd, J=12.4, 7.4, 5.1, 2.5
Hz, 2H), 1.39-1.23 (m, 4H), 0.97 (t, J=7.3 Hz, 3H). MS (m/z): 276.2
[M+H].sup.+.
Example 22
##STR00156##
[0646] Synthesis of
(S)-2-amino-4-((1-hydroxypentan-2-yl)amino)pyrido[3,2-d]pyrimidine-7-carb-
onitrile (22) was prepared according to the two step procedure used
for 20, instead using Zn(CN).sub.2 in place of methylboronic acid.
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.93 (d, J=1.7 Hz, 1H), 7.24
(d, J=1.7 Hz, 1H), 2.95-2.68 (m, 3H), 0.76 (d, J=7.3 Hz, 2H), 0.47
(d, J=7.6 Hz, 1H), 0.02 (t, J=7.4 Hz, 4H). MS (m/z): 273.3
[M+H].
Example 23
##STR00157##
[0647] Synthesis of
(R)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(23A)
[0648] To a solution of 2,4,7-trichloropyrido[3,2-d]pyrimidine
(19B) (45 mg, 0.19 mmol, 1 equiv.) was added dioxane (4 ml)
followed by DIPEA (41 .mu.L, 0.23 mmol, 1.2 equiv.) and
(R)-(-)-2-Amino-1-hexanol 97% (24.7 mg, 0.21 mmol, 1.1 equiv.). The
reaction was allowed to stir for an hr. It was concentrated under
reduced pressure and used as is to provide the title compound. MS
(m/z): 316.2[M+H]..sup.+
Synthesis of
(R)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (23B)
[0649] To a solution of
(R)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(23A) (60 mg, 0.19 mmol, 1 equiv.) was added dioxane (4 ml)
followed by DIPEA (68 .mu.L, 0.38 mmol, 2 equiv.) and
2,4-demethoxybenzylamine (85 .mu.L, 3.0 mmol, 3 equiv.). The
reaction was allowed heated at 120.degree. C. overnight. The
reaction mixture partitioned between EtOAc and H.sub.2O. The
organics were separated, dried, and removed in vacuo. The residue
purified by column chromatography on silica to provide the title
compound. MS (m/z): 446.9 [M+H]..sup.+
Synthesis
(R)-2-((2-amino-7-chloropyrido[3,2-d]pyrimidin-4-yl)amino)hexan--
1-ol (23C)
[0650] To a solution of
(R)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (20B) (50 mg, 0.11 mmol, 1 equiv.) was added DCM
(2 mL) and TFA (0.5 mL). After 3 hours the reaction mixture was
concentrated under reduced pressure and purified by reverse phase
HPLC to furnish the title compound (23C) as its TFA salt. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 8.60 (d, J=2.1 Hz, 1H), 7.90 (d,
J=2.1 Hz, 1H), 4.58-4.44 (m, 1H), 3.79-3.63 (m, 3H), 1.86-1.61 (m,
2H), 1.52-1.24 (m, 5H), 1.01-0.79 (m, 4H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.61. MS (m/z): 296.2 [M+H]..sup.+
Example 24
##STR00158##
[0651] Synthesis of methyl 3-amino-6-bromo-5-fluoropicolinate
(24B)
[0652] To a solution of methyl 3-amino-5-fluoropicolinate (24A)
(270 mg, 0.22 mmol, 1 equiv.) was added acetonitrile (5 mL) and
N-bromosuccinimide (310 mg, 0.24 mmol, 1.1 equiv.). The reaction
was allowed to stir at room temperature overnight. The reaction
mixture partitioned between EtOAc and H.sub.2O. The organics were
separated, dried, and removed in vacuo. The residue purified by
column chromatography on silica to provide the title compound. MS
(m/z): 250.2 [M+H]..sup.+
Synthesis of 2-amino-6-chloro-7-fluoropyrido[3,2-d]pyrimidin-4-ol
(24C)
[0653] To a flask containing methyl
3-amino-6-bromo-5-fluoropicolinate (24B) (200 mg, 0.80 mmol, 1
equiv.) was added chloroformamadine hydrochloride (185 mg, 1.61
mmol, 2 equiv.). The mixture was heated to 165.degree. C.
overnight. It was allowed to cool down to room temperature it was
filtered and washed with water and ethyl ether. The residue was
allowed to air dry to provide the title compound (24C).
Approximately, 25% of the product is the corresponding side product
2-amino-6-bromo-7-fluoropyrido[3,2-d]pyrimidin-4-ol. The material
was used without further purification. MS (m/z): 260.0
[M+H]..sup.+
Synthesis of Synthesis of
2-amino-6-chloro-7-fluoropyrido[3,2-d]pyrimidin-4-ol (24D)
[0654] To a flask
2-amino-6-chloro-7-fluoropyrido[3,2-d]pyrimidin-4-ol (24C) (50 mg,
0.23 mmol, 1 equiv.) is added
(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate 97% (BOP Reagent) (123 mg, 0.28 mmol, 10.2
equiv.), (S)-(+)-2-Amino-1-pentanol, 97% (48 mg, 0.47 mmol, 2
equiv.) and DBU (105 .mu.L, 0.70 mmol, 3 equiv.) and DMF (3 mL).
The mixture was allowed to stir at room temperature overnight and
purified by reverse phase HPLC to furnish the title compound (24D)
as its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta.
7.86-7.63 (m, 1H), 4.64-4.47 (m, 1H), 3.72 (d, J=5.5 Hz, 2H),
1.82-1.61 (m, 3H), 1.56-1.35 (m, 2H), 0.97 (t, J=7.4 Hz, 3H).
.sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.54, -110.63 (d,
J=8.2 Hz). MS (m/z): 300.2 [M+H].sup.+.
Example 25
##STR00159##
[0655] Synthesis of
N.sup.4-butyl-8-methylpyrido[3,2-d]pyrimidine-2,4-diamine (25E)
[0656] Beginning from intermediate 25A, treatment with 1.05 equiv
butan-1-amine in THF/DIPEA at RT gave 25B, which was concentrated
to a residue and carried forward directly. Heating with excess
2,4-dimethoxybenzylamine in THF/DIPEA led to compound 25 C, with
characteristic MS (m/z): 416.2 [M+H].+Following the procedure
reported by Hasnik et. al in Synthesis, 2009, 1309-1317, instead of
the expected 6-methylation via potassium methyl trifluoroborate,
protonolysis of the intermediate heteroaryl-Pd complex led mainly
to isolation of 25D, and finally to
N.sup.4-butyl-8-methylpyrido[3,2-d]pyrimidine-2,4-diamine 25E upon
treatment of 25D in excess TFA and final purification via HPLC to
provide the title compound (25E) as its TFA salt. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.48 (d, J=1.1 Hz, 1H), 7.61 (d, J=1.1
Hz, 1H), 3.67 (d, J=7.2 Hz, 2H), 2.52 (s, 3H), 1.75-1.68 (m, 2H),
1.46-1.35 (m, 2H), 0.98 (t, J=7.3 Hz, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.6. MS (m/z): 232.1 [M+H]..sup.+
Example 26
##STR00160##
[0657] Synthesis of
(S)-2-((2-amino-8-methylpyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(26E)
[0658] Beginning from intermediate 25A and following the synthetic
sequence reported above for the synthesis of 25E, but instead using
L-norvalinol in place of butan-1-amine, 26E was obtained as its TFA
salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.50 (d, J=4.6 Hz,
1H), 7.63 (dq, J=4.5, 0.8 Hz, 1H), 4.60-4.49 (m, 1H), 3.78-3.70 (m,
2H), 2.53 (s, 3H), 1.81-1.64 (m, 2H), 1.52-1.34 (m, 2H), 0.97 (t,
J=7.3 Hz, 3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.7.
MS (m/z): 262.2 [M+H].sup.+
Example 27
##STR00161##
[0659] Synthesis of
(S)-2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(27C)
[0660] To a solution of 2,4-dichloropyrido[3,2-d]pyrimidine (160
mg, 0.68 mmol, 1 equiv.) was added THF (4 ml) followed by DIPEA
(0.18 mL, 1.2 mmol, 1.5 equiv.) and (S)-(+)-2-amino-1-pentanol (85
mg, 0.82 mmol, 1.1 equiv.). The reaction was allowed to stir for
1h. The reaction was concentrated under reduced pressure and used
as is to provide 27A. MS (m/z): 267.1[M+H].
Synthesis of
(S)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)p-
entan-1-ol (27B)
[0661] To a solution of
(S)-2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol (27A)
(206 mg, 0.68 mmol, 1 equiv.) was added is added THF (4 ml)
followed by DIPEA (0.24 mL, 1.4 mmol, 2 equiv.) and
2,4-dimethoxybenzylamine (0.30 mL, 2.0 mmol, 3 equiv.). The
reaction was heated at 135.degree. C. via microwave reactor for 30
minutes. The reaction mixture was partitioned between EtOAc and
H.sub.2O. The organics were separated, dried, and removed in vacuo.
The residue was purified by column chromatography on silica to
provide 27B. MS (m/z): 398.2 [M+H]..sup.+
Synthesis of
(S)-2-((2-amino-[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol (27C)
[0662] Into a solution of
(S)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)p-
entan-1-ol (27B) (35 mg, 0.08 mmol, 1 equiv.) was added DCM (2 mL)
and TFA (0.5 mL). After 3 hours the reaction mixture was
concentrated under reduced pressure and purified by reverse phase
HPLC to furnish the title compound (27C) as its TFA salt. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 8.65 (dd, J=4.3, 1.5 Hz, 1H),
7.85-7.73 (m, 2H), 4.55 (s, 1H), 3.76-3.70 (m, 2H), 1.77-1.66 (m,
2H), 1.44 (td, J=7.3, 4.2 Hz, 2H), 0.98 (t, J=7.4 Hz, 3H). .sup.19F
NMR (377 MHz, Methanol-d4) .delta. -77.6. MS (m/z): 248.2
[M+H].sup.+
Example 28
##STR00162##
[0664] Following the general procedure described above for the
synthesis of 1B, 2,4-dichloropyrido[3,2-d]pyrimidine was instead
reacted with 1.1 equiv (S)-1,1,1-trifluoropentan-2-amine in place
of 1-butan-amine and then carried through the steps as reported
above in Example 1 to provide
(S)-N.sup.4-(1,1,1-trifluoropentan-2-yl)pyrido[3,2-d]pyrimidine-2,4-diami-
ne (28). .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.87 (s, 1H), 8.67
(dd, J=4.4, 1.5 Hz, 1H), 7.95-7.81 (m, 2H), 5.13 (t, J=8.9 Hz, 1H),
2.21-2.10 (m, 1H), 1.74 (dd, J=12.1, 7.1 Hz, 1H), 1.44-1.36 (m,
1H), 1.27 (dq, J=13.7, 7.1 Hz, 1H), 0.89 (t, J=7.3 Hz, 3H).
.sup.19F NMR (377 MHz, Methanol-d4) .delta. -73.9, -74.1. MS (m/z):
286.1 [M+H].sup.+.
Example 29
##STR00163##
[0666] Following the general procedure described above for the
synthesis of 1B, 2,4-dichloropyrido[3,2-d]pyrimidine was instead
reacted with 1.1 equiv 4,4,4-trifluorobutylamine in place of
1-butan-amine and then carried through the steps as reported above
for Example 1 to provide
N.sup.4-(4,4,4-trifluorobutyl)pyrido[3,2-d]pyrimidine-2,4-diamine
(29) after HPLC purification as its TFA salt. .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 9.74 (t, J=6.0 Hz, 1H), 8.63 (dd, J=4.4, 1.4 Hz,
1H), 8.18-7.50 (m, 2H), 3.62 (q, J=6.7 Hz, 1H), 2.39-2.27 (m, 1H),
1.93-1.84 (m, 1H). .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-65.5, 75.6. MS (m/z): 272.1 [M+H].sup.+
Example 30
##STR00164##
[0667] Synthesis of
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)pentanamide
(30B)
[0668] Beginning from 50 mg of the intermediate compound 5A
previously described above, treatment with 1 equiv. aq. KOH in
THF/MEOH (4 mL) for 1h gave, upon removal of solvent, intermediate
30A, MS (m/z): 399.1 [M+H].sup.+. 30A was treated with 1.5 equiv
HATU and 3 equiv DIPEA in 2 mL DMF, with quenching by excess
2,4-dimethoxybenzylamine (DMB) to provide the intermediate amide.
After global DMB removal via TFA treatment, HPLC purification of
the product residue provided title compound 30B as its TFA salt.
.sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. 8.67 (ddd, J=9.2,
4.3, 1.5 Hz, 1H), 7.89-7.73 (m, 2H), 4.00-3.59 (m, 1H), 2.81 (s,
2H), 2.22-1.79 (m, 2H), 1.48 (tt, J=9.8, 7.4 Hz, 2H), 0.99 (t,
J=7.4 Hz, 3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.6.
MS (m/z): 261.1 [M+H].sup.+.
Example 31
##STR00165##
[0669] Synthesis of
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-N-methylpentanamide
(31)
[0670] 50 mg of 30A was treated with 1.5 equiv HATU and 3 equiv
DIPEA in 2 mL DMF, with quenching by 1.0 M methylamine in THF to
provide the intermediate methylamide. After standard DMB removal
via TFA treatment, HPLC purification of the product residue
provided title compound 31 as its TFA salt. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.68 (dd, J=4.3, 1.5 Hz, 1H), 7.89-7.76 (m,
2H), 4.85 (m, 1H), 2.76 (s, 3H), 2.08-1.85 (m, 2H), 1.45 (dddd,
J=16.5, 13.8, 11.5, 7.4 Hz, 2H), 0.98 (t, J=7.4 Hz, 3H). .sup.19F
NMR (377 MHz, Methanol-d4) .delta. -77.9. MS (m/z): 275.1
[M+H].sup.+
Example 32
##STR00166##
[0671] Synthesis of
N.sup.4-butyl-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine-2,4-diamine
(32)
[0672] Beginning from 10 mg compound 1B, the synthesis of which is
reported in Example 1, and proceeding with chemistry described by
Yining et al. in PNAS, 2011, 108, 14411, 1B was heated at
55.degree. C. in DMSO in the presence of 10 equivalents of zinc
trifluoromethane sulfinate and 10 equiv t-butylhydroperoxide 70%
aq. solution. After 24h, the reaction mixture was injected directly
onto HPLC for final purification to provide the title compound (32)
as the corresponding TFA salt. .sup.1H NMR (400 MHz, Methanol-d4)
.delta. 8.15 (d, J=8.7 Hz, 1H), 8.01 (dd, J=8.8, 0.8 Hz, 1H),
3.82-3.56 (m, 2H), 1.83-1.61 (m, 2H), 1.58-1.31 (m, 2H), 0.99 (t,
J=7.4 Hz, 3H). .sup.19F NMR (377 MHz, Methanol-d.sub.4) .delta.
-69.0, -77.6. MS (m/z): 286.1 [M+H].sup.+.
Example 33
##STR00167##
[0673] Synthesis of
(S)-2-((2-amino-6-methylpyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(33)
[0674] 50 mg compound 6B, (0.11 mmol, 1 equiv) in 10 mL (1:1
EtOH/EtOAc) was reacted with 28 mg 5% Pd/C at 70.degree. C. under 1
atm H.sub.2. After overnight, the reaction was filtered to remove
catalyst and the product chromatographed on silica gel, eluting at
25% MeOH/75% EtOAc to provide the title compound (33) as its TFA
salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 7.74 (d, J=8.6 Hz,
1H), 7.65 (d, J=8.6 Hz, 1H), 4.54 (ddd, J=12.4, 7.3, 5.2 Hz, 1H),
3.75 (d, J=5.2 Hz, 2H), 2.65 (s, 3H), 1.73 (q, J=7.5 Hz, 2H), 1.44
(ddt, J=14.6, 7.4, 4.2 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H). .sup.19F
NMR (377 MHz, Methanol-d4) .delta. -77.7. MS (m/z) 262.14
[M+H].sup.+.
Example 34
##STR00168##
[0675] Synthesis of
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-N-(2-hydroxyethyl)penta-
namide (34)
[0676] The title compound was synthesized in a similar fashion to
30B as reported in Example 30, instead replacing methanolic ammonia
with ethanolamine to provide the title compound (34) as its TFA
salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.68 (dd, J=4.3,
1.5 Hz, 1H), 7.86 (dd, J=8.6, 1.5 Hz, 1H), 7.80 (dd, J=8.5, 4.4 Hz,
1H), 4.88 (d, J=5.5 Hz, 1H), 3.27-3.22 (m, 2H), 2.11-1.90 (m, 3H),
1.70-1.40 (m, 5H), 1.00 (t, J=7.4 Hz, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.5. MS (m/z) 305.21 [M+H].sup.+.
Example 35
##STR00169##
[0677] Synthesis of
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-N-(2-hydroxy-2-methylpr-
opyl)pentanamide (35)
[0678] Compound (35) was synthesized in a similar fashion to 30B as
reported in Example 30, instead replacing methanolic ammonia with
1-amino-2-methyl-2-propanol to provide the title compound (35) as
its TFA salt. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. 8.67
(dd, J=4.4, 1.4 Hz, 1H), 7.87 (dd, J=8.5, 1.4 Hz, 1H), 7.79 (dd,
J=8.5, 4.4 Hz, 1H), 4.84-4.78 (m, 1H), 3.61 (td, J=5.9, 5.5, 1.5
Hz, 2H), 2.09-1.85 (m, 2H), 1.48 (dddd, J=18.0, 13.7, 9.7, 7.3 Hz,
2H), 1.29 (s, 6H), 0.99 (t, J=7.4 Hz, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.5. MS (m/z) 333.25 [M+H].sup.+
Example 36
##STR00170##
[0679] Synthesis of
(S)-N-(2-aminoethyl)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)pentana-
mide (36)
[0680] Compound 36 was synthesized in a similar fashion to 30B,
instead replacing methanolic ammonia with N-Boc-ethylenediamine.
Global deprotection with TFA furnished the title compound (36) as
its bis-TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.68
(dd, J=4.4, 1.4 Hz, 1H), 7.88 (dd, J=8.5, 1.4 Hz, 1H), 7.81 (dd,
J=8.5, 4.3 Hz, 1H), 4.92 (dd, J=8.6, 5.1 Hz, 1H), 3.56 (ddd,
J=13.9, 12.8, 6.7 Hz, 1H), 3.45 (dt, J=14.3, 6.1 Hz, 1H), 3.08
(hept, J=6.4 Hz, 2H), 2.13-2.00 (m, 1H), 2.00-1.85 (m, 1H),
1.55-1.41 (m, 2H), 0.99 (t, J=7.4 Hz, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.6. MS (m/z) 304.05 [M+H].sup.+.
Example 37
##STR00171##
[0681] Synthesis of
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-N-(pyridin-2-ylmethyl)p-
entanamide (37)
[0682] Compound 37 was synthesized in a similar fashion to 30B,
instead replacing methanolic ammonia with 2-picolylamine to provide
the title compound (37) as the bis TFA salt. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.69 (dd, J=4.4, 1.5 Hz, 1H), 8.65-8.62 (m,
1H), 8.22 (td, J=7.8, 1.7 Hz, 1H), 7.88 (dd, J=8.5, 1.4 Hz, 1H),
7.81 (dd, J=8.5, 4.4 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 7.67 (dd,
J=7.5, 5.7 Hz, 1H), 4.93 (dd, J=8.8, 5.2 Hz, 1H), 4.65 (s, 2H),
2.13-1.94 (m, 3H), 1.57-1.40 (m, 3H), 1.00 (t, J=7.4 Hz, 3H).
.sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.8. MS (m/z) 352.04
[M+H].sup.+.
Example 38
##STR00172##
[0683] Synthesis of
(R)-2-((8-chloro-2-((2,4-dimethoxybenzyl)amino)-6-methylpyrido[3,2-d]pyri-
midin-4-yl)amino)pentan-1-ol (38A)
[0684] 38A was synthesized in a similar fashion to 6A, instead
replacing (S)-norvalinol with (R)-2-aminopentanol and
2,4-dichloropyrido[3,2-d]pyrimidine with
2,4,8-trichloro-6-methylpyrido[3,2-d]pyrimidine. MS (m/z) 446.24
[M+H].sup.+.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-6-methylpyrido[3,2-d]pyrimidin-4-y-
l)amino)pentan-1-ol (38B)
[0685] 38B was synthesized in a similar fashion to 6B. MS (m/z)
412.22 [M+H].sup.+.
Synthesis of
(R)-2-((2-amino-6-methylpyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(38C)
[0686] Compound 38C was synthesized in a similar fashion to 33,
providing the title compound (38C) as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d4) .delta. 7.69 (d, J=8.5 Hz, 1H), 7.59 (d,
J=8.4 Hz, 1H), 4.49 (qd, J=7.9, 6.9, 4.1 Hz, 1H), 3.71 (d, J=5.0
Hz, 2H), 2.60 (s, 3H), 1.68 (q, J=7.5 Hz, 2H), 1.44-1.33 (m, 2H),
0.93 (t, J=7.3 Hz, 3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-77.3. MS (m/z) 262.15 [M+H].sup.+.
Example 39
##STR00173##
[0687] Synthesis of
(R)-2-((8-chloro-2-((2,4-dimethoxybenzyl)amino)-6-methylpyrido[3,2-d]pyri-
midin-4-yl)amino)hexan-1-ol (39A)
[0688] 39A was synthesized in a similar fashion to 1A, instead
replacing butan-1-amine with (R)-2-aminohexanol and
2,4-dichloropyrido[3,2-d]pyrimidine with
2,4,8-trichloro-6-methylpyrido[3,2-d]pyrimidine. MS (m/z)
460.21[M+H].sup.+.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-6-methylpyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (39B)
[0689] 39B was synthesized in a similar fashion to 33. MS (m/z)
426.24 [M+H].sup.+.
Synthesis of
(R)-2-((2-amino-6-methylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(39C)
[0690] Compound 39C was synthesized in a similar fashion to 1B to
provide the title compound (39C) as its TFA salt. .sup.1H NMR (400
MHz, Methanol-d.sub.4) .delta. 7.72 (d, J=8.5 Hz, 1H), 7.62 (d,
J=8.4 Hz, 1H), 4.50 (dt, J=8.4, 5.2 Hz, 1H), 3.73 (d, J=5.1 Hz,
2H), 2.63 (s, 3H), 1.80-1.67 (m, 2H), 1.44-1.32 (m, 5H), 0.93-0.86
(m, 3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.3. MS
(m/z) 276.17 [M+H].sup.+.
Example 40
##STR00174##
[0691] Synthesis of
(S)-2-((8-chloro-2-((2,4-dimethoxybenzyl)amino)-6-methylpyrido[3,2-d]pyri-
midin-4-yl)amino)hexan-1-ol (40A)
[0692] 40A was synthesized in a similar fashion to 1A, replacing
butan-1-amine with (S)-2-aminohexanol and
2,4-dichloropyrido[3,2-d]pyrimidine with
2,4,8-trichloro-6-methylpyrido[3,2-d]pyrimidine. MS (m/z)
460.26[M+H].sup.+.
Synthesis of
(S)-2-((2-((2,4-dimethoxybenzyl)amino)-6-methylpyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (40b)
[0693] 40b was synthesized in a similar fashion to 33. MS (m/z)
426.24 [M+H].sup.+.
Synthesis of
(S)-2-((2-amino-6-methylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(40C)
[0694] Compound 40C was synthesized in a similar fashion to 1B to
provide the title compound (40C) as its TFA salt. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 7.73 (d, J=8.6 Hz, 1H), 7.63 (d, J=8.6
Hz, 1H), 4.51 (dq, J=8.5, 6.1, 5.4 Hz, 1H), 3.75 (d, J=5.2 Hz, 2H),
2.64 (s, 3H), 1.84-1.65 (m, 3H), 1.38 (qd, J=8.0, 6.4, 2.9 Hz, 5H),
0.95-0.87 (m, 4H). .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-77.6. MS (m/z) 276.16 [M+H].sup.+.
Example 41
##STR00175##
[0695] N.sup.4-butyl-7-chloropyrido[3,2-d]pyrimidine-2,4-diamine
(41)
[0696] Compound 41 was synthesized following the procedure
described above for preparation of 19E, instead reacting
intermediate 19B with 1-butan-amine and proceeding with the
reported sequence to yield the title compound (41) as the TFA salt
after final HPLC purification. .sup.1H NMR (400 MHz, Methanol-d4)
.delta. 8.56 (d, J=2.1 Hz, 1H), 7.90 (d, J=2.0 Hz, 1H), 3.66 (t,
J=7.3 Hz, 2H), 1.76-1.64 (m, 2H), 1.59 (s, OH), 1.43 (dq, J=14.7,
7.4 Hz, 2H), 0.98 (t, J=7.4 Hz, 3H). .sup.19F NMR (376 MHz,
Methanol-d4) .delta. -77.55. MS (m/z) 252.2 [M+H].sup.+.
Example 42
##STR00176##
[0698]
(S)-2-((2-amino-7-methoxypyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-
-ol (42B) was prepared according to the following scheme:
##STR00177##
(S)-2-((2-((2,4-dimethoxybenzyl)amino)-7-methoxypyrido[3,2-d]pyrimidin-4--
yl)amino)pentan-1-ol (42A)
[0699] Into a vial containing
(S)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)pentan-1-ol (19D) (50 mg, 0.11 mmol, 1 equiv.) was added
NaOMe (65 .mu.L, 1.1 mmol, 10 equiv.) and methanol (2 mL). The
mixture was heated to 150.degree. C. for 30 min. in a microwave
reactor. The reaction mixture was partitioned between EtOAc and
H.sub.2O. The organic layer was separated, dried, and removed in
vacuo. The residue was purified by column chromatography on silica
to provide the title compound. MS (m/z): 428.2 [M+H]..sup.+
[0700] Compound 42B was synthesized via TFA treatment of 42A to
yield the title compound (42B) as the TFA salt after final HPLC
purification. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.32 (d,
J=2.5 Hz, 1H), 7.21 (d, J=2.5 Hz, 1H), 4.57-4.45 (m, 1H), 4.00 (s,
3H), 3.77-3.67 (m, 2H), 1.80-1.63 (m, 2H), 1.50-1.39 (m, 2H), 0.97
(t, J=7.4 Hz, 3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-77.52. MS (m/z) 278.2 [M+H].sup.+.
Example 43
##STR00178##
[0701] Synthesis of
(S)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)pentan-1-ol
(43C)
##STR00179##
[0703] Methyl 3-amino-5-fluoropicolinate (43A) (830 mg, 4.88 mmol),
chloroformamidine hydrochloride (1121.64 mg, 9.76 mmol), dimethyl
sulfone (4592.09 mg, 48.78 mmol) and a stir bar were charged into a
sealed pressure tube and heated to 160.degree. C. for 1 hour. At
this time reaction was allowed to cool, 50 mL of water was added
and the solution stirred with heating for 30 minutes. Precipitates
were filtered off and the mother liquor was purified by reverse
phase HPLC using ACN/H.sub.2O with 0.1% TFA as the eluent on a
Hydro-RP column with a 2 to 5% ACN gradient. Solvents were removed
under reduced pressure and the residue was azeotroped 2x with
methanol, 2x with DCM before sonication in ether. Precipitates were
filtered and air dried to afford 210 mg (23.9%) of
2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-ol (43B) as a white solid.
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.43 (d, J=2.5 Hz, 1H), 7.48
(dd, J=10.1, 2.5 Hz, 1H), 7.23 (s, 2H). .sup.19F NMR (376 MHz,
DMSO-d6) .delta. -75.15, -119.96. MS (m/z) 181.0 [M+H].sup.+.
[0704] Compound 43C was synthesized via a BOP-C1 promoted coupling
of 43B with (S)-norvalinol, which provided the title compound (43C)
as its TFA salt after final HPLC purification. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.56 (d, J=2.4 Hz, 1H), 7.61 (dd, J=8.8,
2.5 Hz, 1H), 4.56 (dq, J=12.7, 6.4, 6.0 Hz, 1H), 3.80-3.69 (m, 2H),
1.78 (ddd, J=18.8, 11.4, 3.7 Hz, 2H), 1.53-1.33 (m, 2H), 0.97 (t,
J=7.4 Hz, 3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.64,
-118.17 (d, J=8.8 Hz). MS (m/z) 266.2 [M+H].sup.+.
Example 44
##STR00180##
[0705]
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-o-
l (44)
[0706] Compound 44 was synthesized following the procedure
described above for preparation of 43C, instead reacting
intermediate 43B with (R)-norleucinol and proceeding with the above
reported sequence to yield the title compound (44) as the TFA salt
after final HPLC purification. .sup.1H NMR (400 MHz, Methanol-d4)
.delta. 8.57 (d, J=2.4 Hz, 1H), 7.60 (dd, J=8.8, 2.4 Hz, 1H), 4.53
(dq, J=8.7, 5.6 Hz, 1H), 3.72 (d, J=5.4 Hz, 2H), 1.72 (m, 2H),
1.52-1.28 (m, 4H), 1.04-0.82 (m, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.60, -118.13 (d, J=8.6 Hz). MS (m/z) 280.2
[M+H].sup.+.
Example 45
##STR00181##
[0707]
(S)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-o-
l (45)
[0708] Compound 45 was synthesized following the procedure
described above for preparation of 43C, instead reacting
intermediate 43B with (S)-norleucinol and proceeding with the above
reported sequence to yield the title compound (45) as the TFA salt
after final HPLC purification. .sup.1H NMR (400 MHz, Methanol-d4)
.delta. 8.57 (d, J=2.4 Hz, 1H), 7.60 (dd, J=8.8, 2.4 Hz, 1H), 4.53
(dq, J=8.7, 5.6 Hz, 1H), 3.72 (d, J=5.4 Hz, 2H), 1.72 (m, 2H),
1.52-1.28 (m, 4H), 1.04-0.82 (m, 3H). .sup.19F NMR (376 MHz,
Methanol-d4) .delta. -77.60, -118.13 (d, J=8.6 Hz). MS (m/z) 280.2
[M+H].sup.+.
Example 46
##STR00182##
[0709] Synthesis of
(R)-2-((2-amino-6,7-difluoroquinazolin-4-yl)amino)hexan-1-ol
(46C)
##STR00183##
[0711] 2-amino-6,7-difluoroquinazolin-4-ol (46B) was synthesized
following the procedure described above for preparation of 43B,
instead reacting intermediate 46A in place of 43A and proceeding
with the above reported sequence to yield the title compound (46C)
as the TFA salt after final HPLC purification. .sup.1H NMR (400
MHz, DMSO-d6).sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.83 (t,
J=9.7 Hz, 1H), 7.31-7.22 (m, 1H), 7.19 (s, 1H). .sup.19F NMR (376
MHz, DMSO-d.sub.6) .delta. -74.93, -128.78, -144.35. MS (m/z) 198.0
[M+H].sup.+.
[0712] Compound (46C) was synthesized via a BOP-Cl promoted
coupling of 46B with (R)-norleucinol, which provided the title
compound (46C) as its TFA salt after final HPLC purification.
.sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.29 (dd, J=11.0, 7.9
Hz, 1H), 7.35 (dd, J=10.6, 6.8 Hz, 1H), 4.67-4.53 (m, 1H),
3.80-3.59 (m, 2H), 1.77-1.63 (m, 2H), 1.49-1.30 (m, 4H), 0.91 (td,
J=7.0, 6.3, 2.2 Hz, 3H). .sup.19F NMR (376 MHz, Methanol-d4)
.delta. -77.71, -127.97 (ddd, J=21.5, 10.6, 7.9 Hz), -142.27 (ddd,
J=21.4, 11.0, 6.9 Hz). MS (m/z) 297.2 [M+H].sup.+.
Example 47
##STR00184##
[0714] (R)-2-((2-aminoquinazolin-4-yl)amino)hexan-1-ol (47B) was
synthesized via a BOP-Cl promoted coupling of 47A with
(R)-norleucinol, which provided the title compound (47B) as its TFA
salt after final HPLC purification. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.22 (ddd, J=8.3, 1.3, 0.6 Hz, 1H), 7.78 (ddd,
J=8.4, 7.3, 1.3 Hz, 1H), 7.50-7.33 (m, 2H), 4.71-4.56 (m, 1H),
3.80-3.61 (m, 2H), 1.81-1.64 (m, 2H), 1.47-1.31 (m, 4H), 0.92 (h,
J=3.2 Hz, 3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta. -77.69.
MS (m/z) 261.1 [M+H].sup.+.
Example 48
##STR00185##
[0716] Synthesis (S)-2-((2-aminoquinazolin-4-yl)amino)hexan-1-ol
(48) was prepared in a similar fashion to 47B, instead using
(S)-norleucinol in place of (R)-norleucinol. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.22 (ddd, J=8.3, 1.3, 0.6 Hz, 1H), 7.78 (ddd,
J=8.4, 7.3, 1.3 Hz, 1H), 7.50-7.33 (m, 2H), 4.71-4.56 (m, 1H),
3.80-3.61 (m, 2H), 1.81-1.64 (m, 2H), 1.47-1.31 (m, 4H), 0.92 (h,
J=3.2 Hz, 3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta. -77.69.
MS (m/z) 261.1 [M+H].sup.+.
Example 49
##STR00186##
[0717] Synthesis of (S)-tert-butyl
(2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)prop-
yl)carbamate (49A)
[0718] A solution of 2,4-dichloropyrido[3,2-d]pyrimidine (100 mg,
0.5 mmol) in THF (2 mL), was treated with (S)-tert-butyl
(2-aminopropyl)carbamate hydrochloride butan-1-amine
(CAS#959833-70-6, Fluorochem Ltd. UK), (0.03 mL, 0.56 mmol) and
N,N-diisopropylethylamine (0.25 mL, 1.15 mmol). The mixture was
stirred at rt for 30 minutes, 2,4-dimethoxybenzylamine (0.19 ml,
1.25 mmol) and N,N-diisopropylethylamine (0.13 mL, 0.75 mmol) were
added, and the mixture was heated to 100.degree. C. After 16 h, the
reaction was cooled to rt, diluted with EtOAc, washed with water
and brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated
in vacuo. The resulting residue was subjected to silica gel
chromatography eluting with 0-100% EtOAc in hexanes to provide,
after removal of volatiles in vacuo, compound 49A. LCMS (m/z):
469.18[M+H].sup.+.
Synthesis of
(S)-N.sup.4-(1-aminopropan-2-yl)pyrido[3,2-d]pyrimidine-2,4-diamine
(49)
[0719] 49A (50 mg, 0.11 mmol) was dissolved in TFA (3 mL). After 30
minutes, the reaction was diluted with water and methanol. After 60
minutes, the mixture was concentrated in vacuo. The residue was
then dissolved in methanol and filtered to provide, after removal
of volatiles in vacuo, compound 49 as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d.sub.4) .delta. 8.67 (ddd, J=9.0, 4.2, 1.6 Hz,
1H), 7.85-7.68 (m, 2H), 4.82 (m, 1H), 3.34 (d, 2H), 1.39 (d, 3H).
.sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.8. LCMS (m/z):
219.03 [M+H].sup.+; t.sub.R=0.29 min. (LC/MS HPLC method B).
Example 50
##STR00187##
[0720] Synthesis of (R)-2-(2-aminohexyl)isoindoline-1,3-dione
hydrochloride (50a)
[0721] To phthalimide 51c (180 mg, 0.53 mmol) was added 4N HCl in
dioxane (20 mL). The reaction was stirred at rt for 6 h and then
the volatiles were removed in vacuo to provide crude 50a which was
carried forward directly into the next step without further
purification. LCMS (m/z): 246.93 [M+H].sup.+.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)hexan-
oate (50b)
[0722] A solution of 2,4-dichloropyrido[3,2-d]pyrimidine (100 mg,
0.5 mmol) in THF (2 mL) was treated with 50a, (150 mg, 0.53 mmol)
and N,N-diisopropylethylamine (0.25 mL, 1.15 mmol). The mixture was
stirred at rt for 30 minutes, and 2,4-dimethoxybenzylamine (0.38
mL, 2.5 mmol) and N,N-diisopropylethylamine (0.13 mL, 0.75 mmol)
were added and the mixture was heated to 125.degree. C. After 24 h,
the reaction was cooled to rt, diluted with EtOAc (50 mL), washed
with water (25 mL), brine (25 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The resulting residue was
subjected to silica gel chromatography eluting with 0-100% EtOAc in
hexanes to give, after removal of volatiles in vacuo, compound
50b.
Synthesis of
(R)-N.sup.4-(1-aminohexan-2-yl)pyrido[3,2-d]pyrimidine-2,4-diamine
(50)
[0723] 50b (15 mg, 0.04 mmol) was dissolved in TFA (3 mL). After 60
minutes the mixture was concentrated to a residue in vacuo followed
by co-evaporation with MeOH, to provide the title compound 50 as
its bis-TFA salt. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.68
(m, 1H), 7.81-7.83 (m, 2H), 4.89 (m, 1H), 3.91 (m, 2H), 3.61 (m,
1H) 1.92-1.79 (m, 2H), 1.55-1.48 (m, 4H), 0.98 (t, J=7.4 Hz, 3H).
.sup.19F NMR (377 MHz, MeOH-d4) .delta. -77.9. LCMS (m/z): 261.14
[M+H].sup.+; t.sub.R=0.30 min.
Example 51
##STR00188## ##STR00189##
[0725] (R)-norleucinol (0.5 g, 4.3 mmol) was treated with
Boc.sub.2O (1.2 equiv, 5.2 mmol) and excess
N,N-diisopropylethylamine in DCM (20 mL). The reaction mixture was
stirred for 3h and then filtered through a silica gel plug. Removal
of the volatiles provided 51b as a crude residue that was used
without further purification. LCMS (m/z): 218.23 [M+H].sup.+.
[0726] Compound 51b (0.7 g, 3.22 mmol) was reacted with PPh.sub.3
(1.1 g, 3.9 mmol), phthalimide (573 mg, 3.9 mmol), and DIAD (810
mg, 4.0 mmol) in THF (30 mL). The mixture was stirred for 3 h, and
then partitioned between EtOAc (200 mL) and water (200 mL). The
organic layer was separated, washed with brine (100 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The residue
was subjected to silica gel chromatography eluting with 0-100%
EtOAc in hexanes to provide 51c. LCMS (m/z): 347.24
[M+H].sup.+.
[0727] Imide 51c (300 mg, 0.87 mmol) was treated with excess
hydrazine hydrate (0.2 mL, 6.25 mmol) in EtOH (30 mL) and refluxed
for 16 h. The mixture was concentrated in vacuo to provide
intermediate 51d as a crude residue that was carried forward
directly. Intermediate 51d (0.87 mmol) was dissolved in DCM (10 mL)
and treated with AcCl (0.1 mL, 1.2 mmol), followed by TEA (0.26 mL,
1.8 mmol). The mixture was stirred for 3 h, and then the reaction
was diluted with DCM (50 mL). The mixture was then washed with
water (50 mL), brine (50 mL), dried over Na.sub.2SO.sub.4, filtered
and then concentrated under reduced pressure to provide 51e. LCMS
(m/z): 259.21 [M+H].sup.+.
[0728] Intermediate 51e (0.3 g) was treated with 4N HCl in dioxanes
(20 mL) and stirred for 4 h at rt. The volatiles were removed in
vacuo to provide the hydrochloride 51f which was used without
further purification. LCMS (m/z): 159.45 [M+H].sup.+.
Synthesis of
(R)-N-(2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amin-
o)hexyl)acetamide (51a)
[0729] A solution of 2,4-dichloropyrido[3,2-d]pyrimidine (100 mg,
0.5 mmol) in THF (2 mL was treated with 51f, (200 mg, 0.53 mmol)
and N,N-diisopropylethylamine (0.25 mL, 1.15 mmol). After the
mixture was stirred for 30 minutes, 2,4-dimethoxybenzylamine (0.38
mL, 2.5 mmol) and N,N-diisopropylethylamine (0.13 mL, 0.75 mmol)
were added, and the mixture was heated to 115.degree. C. After
heating for 16 h, the reaction was cooled to rt, diluted with EtOAc
(100 mL), washed with water (100 mL), brine (100 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The resulting
residue was subjected to silica gel flash chromatography eluting
with 0-100% EtOAc in hexanes to provide 51a. LCMS (m/z): 453.33
[M+H].sup.+.
Synthesis of
(R)-N-(2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)hexyl)acetamide
(51)
[0730] 51a (60 mg, 0.133 mmol) was dissolved in TFA (3 mL). After
60 minutes, the mixture was concentrated in vacuo. The residue was
taken up in MeOH, filtered and concentrated in vacuo, to give the
title compound 51 as its TFA salt. .sup.1H NMR (400 MHz,
MeOH-d.sub.4) 8.65 (dd, J=4.3, 1.5 Hz, 1H), 7.86-7.73 (m, 2H),
4.68-4.55 (m, 4H), 3.59 (dd, J=13.9, 4.3 Hz, 4H), 3.34-3.23 (m,
3H), 1.88 (s, 3H), 1.78-1.67 (m, 2H), 1.39 (ddd, J=7.7, 5.1, 2.4
Hz, 4H), 0.91 (ddt, J=8.3, 4.7, 3.0 Hz, 3H). .sup.19F NMR (377 MHz,
MeOH-d4) .delta. -77.7. LCMS (m/z): 303.15 [M+H].sup.+;
t.sub.R=0.68 min. (LC/MS HPLC method B).
Example 52
##STR00190##
[0732] N-Boc-protected intermediate 51d (188 mg, 0.87 mmol) was
dissolved in DCM (10 mL) and treated with methanesulfonyl chloride
(0.78 .mu.L, 114 mg, 1 mmol) and TEA (0.26 mL, 1.8 mmol). After 3
h, EtOAc (100 mL) was added and the resulting mixture washed with
water (100 mL), brine (100 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo to provide 52b. LCMS (m/z):
295.24 [M+H].sup.+.
[0733] Following the synthesis of 51f from 51e, intermediate 52b
(0.87 mmol) was converted to the crude hydrochloride salt 52c which
was then carried forward without purification.
Synthesis of
(R)-N-(2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amin-
o)hexyl)methanesulfonamide (52A)
[0734] A solution of 2,4-dichloropyrido[3,2-d]pyrimidine (50 mg,
0.25 mmol) in THF (2 mL) was treated with crude 52c, (85 mg, 0.43
mmol) and N,N-diisopropylethylamine (0.25 mL, 1.15 mmol). The
mixture was stirred at rt for 30 minutes, 2,4-dimethoxybenzylamine
(0.19 mL, 1.25 mmol) and N,N-diisopropylethylamine (0.13 mL, 0.75
mmol) were added, and the mixture was heated to 115.degree. C.
After 16 h, the reaction was cooled to rt, diluted with EtOAc (100
mL), washed with de-ionised water (100 mL), brine (100 mL), dried
over Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
0-100% EtOAc in hexanes to provide 52A. LCMS (m/z): 489.25
[M+H].sup.+.
Synthesis of
(R)-N-(2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)hexyl)methanesulfonam-
ide (52)
[0735] 52A (30 mg, 0.06 mmol) was dissolved in TFA (3 mL). After 60
minutes, the mixture was concentrated in vacuo. The residue was
then diluted with MeOH, filtered, and concentrated in vacuo to
afford the title product 52 as its TFA salt. .sup.1H NMR (400 MHz,
MeOH-d.sub.4) .delta. 8.65 (dd, J=4.4, 1.4 Hz, 1H), 7.84 (dd,
J=8.5, 1.4 Hz, 1H), 7.76 (dd, J=8.5, 4.4 Hz, 1H), 4.58 (t, J=6.1
Hz, 1H), 3.52-3.26 (m, 2H), 2.93 (s, 3H), 1.75 (dd, J=9.6, 4.0 Hz,
2H), 1.39 (td, J=8.5, 7.6, 3.5 Hz, 4H), 0.91 (m, 3H). .sup.19F NMR
(377 MHz, MeOH-d4) .delta. -77.7. LCMS (m/z): 339.21 [M+H].sup.+;
t.sub.R=0.83 min. (LC/MS HPLC method B).
Example 53
##STR00191##
[0737] Compound 61C (0.22 g, 0.69 mmol) was mesylated following the
procedure for the formation of 61D but instead replacing acetyl
chloride with methanesulfonyl chloride (0.06 mL, 0.8 mmol) to give
a quantitative yield of the corresponding mesylated intermediate.
The resulting sulfonamide was then subjected to Pd/C hydrogenation
followed by N-BOC removal, as described in the preparation of 61E
from 61D to give the crude product 53A as its hydrochloride salt.
LCMS (m/z): 209.1 [M+H].sup.+.
Synthesis of
(R)-N-(2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amin-
o)-2-methylhexyl)methanesulfonamide (53B)
[0738] A solution of 2,4-dichloropyrido[3,2-d]pyrimidine (100 mg,
0.5 mmol) in THF (4 mL) was treated with crude 53A (0.69 mmol), and
N,N-diisopropylethylamine (0.5 mL, 2.3 mmol). After heating at
75.degree. C. for 4 h, 2,4-dimethoxybenzylamine (0.4 mL, 2.5 mmol)
and additional N,N-diisopropylethylamine (0.26 mL, 1.5 mmol) were
added and the mixture was heated to 115.degree. C. After 16 h, the
reaction was cooled to rt, diluted with EtOAc (100 mL), washed with
de-ionised water (100 mL), brine (100 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was subjected to silica gel chromatography eluting with
0-100% EtOAc to give 53B. LCMS (m/z): 503.28 [M+H].sup.+.
Synthesis of
(R)-N-(2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexyl)methan-
esulfonamide (53)
[0739] 53B (75 mg, 0.15 mmol) was dissolved in TFA (3 mL). After 60
minutes, the mixture was concentrated in vacuo. The residue was
dissolved in MeOH, filtered and volatiles removed in vacuo to
afford the title product 53, as its TFA salt. .sup.1H NMR (400 MHz,
MeOH-d.sub.4) .delta. 8.63 (dd, J=4.3, 1.4 Hz, 1H), 7.79 (dd,
J=8.4, 1.5 Hz, 1H), 7.73 (dd, J=8.4, 4.3 Hz, 1H), 3.78 (m, 2H),
2.93 (s, 3H), 2.25 (m, 1H), 1.82 (dd, J=9.6, 4.0 Hz, 2H), 1.56 (s,
3H), 1.37 (td, J=8.4, 7.5, 3.4 Hz, 4H), 0.93 (m, 3H). .sup.19F NMR
(377 MHz, MeOH-d4) .delta. -77.6. LCMS (m/z): 353.18 [M+H].sup.+;
t.sub.R=0.83 min. (LC/MS HPLC method B).
Example 54
##STR00192##
[0740] Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)hexan-
oate (54A)
[0741] To a solution of 2,4-dichloropyrido[3,2-d]pyrimidine
(CAS#39551-54-7, supplied by Astatech, Inc.) (500 mg, 2.5 mmol) in
THF (10 mL) was added D-norleucine methyl ester hydrochloride (454
mg, 2.5 mmol) and N,N-diisopropylethylamine (1.3 mL, 7.5 mmol).
After stirring at rt for 30 minutes, 2,4-dimethoxybenzylamine (1.9
mL, 12.5 mmol) and N,N-diisopropylethylamine (1.3 mL, 7.5 mmol)
were added and the mixture was heated to 100.degree. C. After 16 h,
the reaction was cooled to rt, diluted with EtOAc (100 mL), washed
with water (100 mL), brine (100 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The residue was subjected to
silica gel chromatography eluting with hexanes-EtOAc to provide
54A. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.33 (dd, J=4.2,
1.5 Hz, 1H), 7.68 (d, J=7.6 Hz, 1H), 7.43 (dd, J=8.5, 4.2 Hz, 1H),
7.28 (s, 1H), 6.46 (d, J=2.3 Hz, 1H), 6.41 (dd, J=8.2, 2.4 Hz, 1H),
4.88 (q, J=7.3 Hz, 1H), 4.59 (d, J=6.0 Hz, 2H), 3.85 (s, 3H), 3.79
(s, 3H), 3.75 (s, 3H), 2.04-1.95 (m, 1H), 1.88 (dq, J=14.8, 7.6 Hz,
1H), 1.40 (dddd, J=26.8, 15.8, 6.9, 2.6 Hz, 5H), 0.91 (t, J=7.1 Hz,
3H). LCMS (m/z): 440.49 [M+H].sup.+; t.sub.R=0.77 min. on LC/MS
Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)h-
exanoic acid (54B)
[0742] To a solution of 54A (750.7 mg, 1.71 mL) in THF (3.6 mL) and
MeOH (3.6 mL) was added iN KOH(a.sub.q) (3.6 mL). After 4 h, the
reaction was was neutralized to pH 7 using 1M HCl(a.sub.q).
Concentration of the mixture in vacuo afforded the crude product
54B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.34 (d, J=4.1 Hz,
1H), 7.77 (s, 1H), 7.61 (d, J=6.5 Hz, 1H), 7.53 (dd, J=8.5, 4.2 Hz,
1H), 7.10 (s, 1H), 6.53 (d, J=2.3 Hz, 1H), 6.42 (dd, J=7.9, 2.0 Hz,
1H), 4.65 (s, 1H), 4.44 (s, 2H), 3.81 (s, 3H), 3.71 (s, 3H), 1.90
(s, 2H), 1.30 (s, 4H), 0.84 (s, 3H). LCMS (m/z): 426.16
[M+H].sup.+; t.sub.R=0.67 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
N-(2-hydroxyethyl)hexanamide (54C)
[0743] To a solution of crude 54B (50 mg, 0.12 mmol),
N,N-diisopropylethylamine (0.15 mL, 0.86 mmol), and 2-aminoethanol
(0.05 mL, 0.59 mmol) in NMP (12 mL) was added HATU (96 mg, 0.25
mmol). After 16 h the mixture was subjected to preparative HPLC
(Synergi 4u Polar-RP 80A, Axia; 10% aq. acetonitrile-70% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient) to afford 54C as
its TFA salt. LCMS (m/z): 469.23 [M+H].sup.+; t.sub.R=0.70 min. on
LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-N-(2-hydroxyethyl)hexan-
amide (54)
[0744] To 54C (10 mg, 0.02 mmol) was added TFA (3 mL). After 4 h,
MeOH (2 mL) and water (2 mL) were added to the mixture. After 16 h,
the mixture was concentrated in vacuo and then co-evaporated with
MeOH three times. The residue was subjected to preparative HPLC
(Synergi 4u Polar-RP 80A, Axia; 10% aq. acetonitrile-60% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient) to give 54 as a
TFA salt. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.68 (dd,
J=4.4, 1.5 Hz, 1H), 7.86 (dd, J=8.5, 1.5 Hz, 1H), 7.80 (dd, J=8.5,
4.4 Hz, 1H), 4.81 (dd, J=8.2, 5.7 Hz, 1H), 3.66-3.56 (m, 2H),
3.43-3.32 (m, 2H), 2.12-1.90 (m, 2H), 1.49-1.36 (m, 4H), 0.98-0.89
(m, 3H). .sup.19F NMR (377 MHz, MeOH-d.sub.4) .delta. -77.83. LCMS
(m/z): 319.23 [M+H].sup.+; t.sub.R=0.49 min. on LC/MS Method A.
Example 55
##STR00193##
[0745] Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)h-
exan-1-ol (55A)
[0746] To a solution of 2,4-dichloropyrido[3,2-d]pyrimidine (500
mg, 2.5 mmol) in THF (15 mL) was added (R)-norleucinol (293 mg, 2.5
mmol) and N,N-diisopropylethylamine (1.3 m, 7.5 mmol). After
stirring at rt for 30 minutes, 2,4-dimethoxybenzylamine (1.9 mL,
12.5 mmol) and N,N-diisopropylethylamine (1.3 mL, 7.5 mmol) were
added and the mixture was heated to 100.degree. C. After 16 h, the
reaction was cooled to rt, diluted with EtOAc (100 mL), washed with
water (100 mL), brine (100 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The residue was subjected to
silica gel chromatography eluting with hexanes-EtOAc to give 55A.
.sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.32 (s, 1H), 7.74 (s,
1H), 7.46 (s, 1H), 6.49-6.37 (m, 3H), 4.60 (d, J=5.9 Hz, 3H), 3.86
(s, 5H), 3.79 (s, 5H), 1.55 (s, 2H), 1.45-1.33 (m, 6H), 0.91 (t,
J=7.0 Hz, 4H). LCMS (m/z): 412.20 [M+H].sup.+; t.sub.R=0.89 min. on
LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)h-
exanal (55B)
[0747] To a solution of 55A (100 mg, 0.24 mmol) in DCM (5 mL) at
0.degree. C. was added Dess-Martin periodinane (248 mg, 0.58 mmol).
The reaction was warmed to rt and stirred for 24 h. The reaction
was diluted with DCM (5 mL) and then quenched with a mixture of
sat. Na.sub.2S.sub.2O.sub.3(aq) (5 mL) and sat. NaHCO.sub.3(aq) (5
mL). The organic layer was separated and the aqueous layer was
extracted with DCM (2.times.10 mL). The combined organics were
washed with brine (100 mL), dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc to give 55B. LCMS (m/z):
410.19 [M+H].sup.+; t.sub.R=0.97 min. on LC/MS Method A.
Synthesis of
(R)-N.sup.4-(1-(1H-imidazol-2-yl)pentyl)-N.sup.2-(2,4-dimethoxybenzyl)pyr-
ido[3,2-d]pyrimidine-2,4-diamine (55C)
[0748] To a solution of 55B (50 mg, 0.12 mmol) in MeOH (2 mL) was
added gyloxal trimer dihydrate (12 mg, 0.06 mg) and ammonia in MeOH
(2M, 0.28 mL, 0.55 mmol). After 24 h, additional gyloxal trimer
dihydrate (12 mg, 0.06 mg) and ammonia in MeOH (2M, 0.28 mL, 0.55
mmol) were added. After 18 h, the mixture was concentrated in
vacuo. The residue was diluted with water (10 mL) and extracted
with EtOAc (4.times.10 mL). The combined organics were dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to afford the
crude 55C. LCMS (m/z): 448.15 [M+H].sup.+; t.sub.R=0.62 min. on
LC/MS Method A.
Synthesis of
(R)-N.sup.4-(1-(1H-imidazol-2-yl)pentyl)pyrido[3,2-d]pyrimidine-2,4-diami-
ne (55)
[0749] To 55C (50 mg, 0.11 mmol) was added TFA (2 mL). After 90
minutes, MeOH (2 mL) and water (2 mL) were added to the mixture.
After 16 h, the mixture was concentrated in vacuo and co-evaporated
with MeOH (.times.3). The residue was subjected to preparative HPLC
(Synergi 4u Polar-RP 80A, Axia; 10% aq. acetonitrile-60% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient) to give 55 as a
TFA salt .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.70 (dd,
J=4.4, 1.4 Hz, 1H), 7.93 (dd, J=8.5, 1.4 Hz, 1H), 7.83 (dd, J=8.5,
4.4 Hz, 1H), 7.52 (s, 2H), 5.92-5.71 (m, 1H), 2.30 (td, J=9.3, 8.7,
4.3 Hz, 2H), 1.64-1.34 (m, 4H), 0.95 (t, J=7.0 Hz, 3H). .sup.19F
NMR (377 MHz, MeOH-d.sub.4) .delta. -77.73. LCMS (m/z):
298.05[M+H].sup.+; t.sub.R=0.46 min. on LC/MS Method A.
Example 56
##STR00194##
[0750] Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)h-
exanamide (56A)
[0751] To a solution of 54B (50 mg, 0.12 mmol),
N,N-diisopropylethylamine (0.1 mL, 0.57 mmol), and ammonia in
dioxane (0.5 M, 1.2 mL, 0.59 mmol) in NMP (6 mL) was added HATU
(174 mg, 0.46 mmol). After 4 h the mixture was subjected to
preparative HPLC (Synergi 4u Polar-RP 80A, Axia; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient) to afford 56A as a TFA salt. LCMS (m/z): 425.18
[M+H].sup.+; t.sub.R=0.69 min. on LC/MS Method A.
Synthesis of
(R)-N.sup.4-(1-(4H-1,2,4-triazol-3-yl)pentyl)-N.sup.2-(2,4-dimethoxybenzy-
l)pyrido[3,2-d]pyrimidine-2,4-diamine (56B)
[0752] A mixture of 56A (70 mg, 0.17 mmol) and
N,N-dimethylformamide dimethyl acetal (2 mL, 16 mmol) was heated to
120.degree. C. After 2 h, the mixture was cooled to rt and
concentrated in vacuo. The crude residue was dissolved in AcOH (2
mL) and treated with hydrazine monohydrate (0.02 mL, 0.42 mmol).
The mixture was heated to 90.degree. C. for 24 h. The mixture was
concentrated in vacuo to afford the crude 56B which was used
without further purification. LCMS (m/z): 449.23 [M+H].sup.+;
t.sub.R=0.83 min. on LC/MS Method A.
Synthesis of
(R)-N.sup.4-(1-(4H-1,2,4-triazol-3-yl)pentyl)pyrido[3,2-d]pyrimidine-2,4--
diamine (56)
[0753] To crude 56B was added TFA (3 mL). After 60 minutes, the
mixture was concentrated in vacuo and the residue was diluted with
MeOH (3.5 mL) and water (3.5 mL). After 90 min., the mixture was
concentrated and then subjected to preparative HPLC (Synergi 4u
Polar-RP 80A, Axia; 10% aq. acetonitrile-60% aq. acetonitrile with
0.1% TFA, over 20 min. gradient) to afford 56 as a TFA salt.
.sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.67 (dd, J=4.4, 1.4
Hz, 1H), 8.47 (s, 1H), 7.86 (dd, J=8.5, 1.4 Hz, 1H), 7.79 (dd,
J=8.5, 4.4 Hz, 1H), 5.72 (dd, J=8.4, 6.3 Hz, 1H), 2.30-2.09 (m,
2H), 1.49-1.34 (m, 4H), 0.96-0.89 (m, 3H). .sup.19F NMR (377 MHz,
MeOH-d.sub.4) .delta. -77.98. LCMS (m/z): 299.15 [M+H].sup.+;
t.sub.R=0.62 min. on LC/MS Method A.
Example 57
##STR00195##
[0755] 2-Chloro-4-methyl-5-nitropyridine (10.0 g, 57.8 mmol) was
dissolved in EtOH (100 mL) and Raney nickel (3 g) was added. The
reaction mixture was stirred under H.sub.2 overnight. The mixture
was filtered, concentrated under vacuum, and washed with petroleum
ether/EtOAc=5:1 (50 mL) to give crude
6-chloro-4-methylpyridin-3-amine.
[0756] 6-Chloro-4-methylpyridin-3-amine (22.0 g, 154.9 mmol) was
dissolved in DMF (150 mL) and treated with NIS (41.8 g, 185.9
mmol). The reaction mixture was stirred at rt overnight, then water
(200 mL) was added, and the mixture was extracted with EtOAc
(3.times.200 mL). The combined organics were concentrated in vacuo
and the residue was subjected to silica gel flash chromatography
eluting with Et.sub.2zO-EtOAc to give
6-chloro-2-iodo-4-methylpyridin-3-amine. .sup.1H NMR (DMSO-d.sub.6,
400 MHz): .delta. 7.11 (s, 1H), 5.23 (s, 2H), 2.15 (s, 3H) ppm.
[0757] To a solution of 6-chloro-2-iodo-4-methylpyridin-3-amine
(30.0 g, 111.7 mmol) in MeOH (200 mL) was added Pd(dppf)Cl.sub.2
(4.09 g, 5.5 mmol), Et.sub.3N (45.1 g, 447 mmol) and the reaction
mixture was stirred at rt overnight. The residue was subjected to
silica gel chromatography eluting with Et.sub.2zO-EtOAc to give
6-chloro-2-iodo-4-methylpyridin-3-amine. .sup.1H NMR (DMSO-d.sub.6,
400 MHz): .delta. 7.33 (d, J=0.8, 1H), 6.74 (s, 2H), 3.82 (s, 3H),
3.18 (d, J=0.4, 3H) ppm.
[0758] To a solution of 6-chloro-2-iodo-4-methylpyridin-3-amine
(18.8 g, 94 mmol) in NH.sub.4OH (180 mL) was added MeOH (10 mL) and
the reaction mixture was stirred at rt overnight. The mixture was
filtered and the collected solid washed with petroleum ether/EtOAc
(5:1, 50 mL) to afford 3-amino-6-chloro-4-methylpicolinamide.
.sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta. 7.76 (s, 1H), 7.43 (s,
1H), 7.27 (s, 1H), 6.92 (s, 2H), 2.15 (s, 3H) ppm.
[0759] A solution of 3-amino-6-chloro-4-methylpicolinamide (10 g,
54.1 mmol) and CDI (8.02 g; 27.02 mmol) in 1,4-dioxane (200 mL) was
stirred at 110.degree. C. for 30 minutes. The mixture was filtered
and the collected solids were washed with EtOAc (30 mL). The
organics were concentrated in vacuo to give crude
6-chloro-8-methylpyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione. .sup.1H
NMR (CDCl.sub.3, 400 MHz) .delta. 7.70 (d, J=1.2 Hz, 1H), 2.76 (d,
J=0.8 Hz, 3H) ppm.
Synthesis of 2,4,6-trichloro-8-methylpyrido[3,2-d]pyrimidine
(25A)
[0760] A solution of
6-chloro-8-methylpyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione (32 g,
151.6 mmol) and N,N-diisopropylethylamine (50 mL) in POCl.sub.3
(320 mL) was stirred at 125.degree. C. overnight. The mixture was
concentrated in vacuo and the residue was subjected to silica gel
flash chromatography eluting with Et.sub.2O-EtOAc to give 25A.
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 7.70 (d, J=1.2 Hz, 1H),
2.76 (d, J=0.8 Hz, 3H) ppm.
##STR00196##
Synthesis of
(R)-2-((6-chloro-2-((2,4-dimethoxybenzyl)amino)-8-methylpyrido[3,2-d]pyri-
midin-4-yl)amino)hexan-1-ol (57A)
[0761] To a solution of 25A (50 mg, 0.20 mmol) in THF (15 mL) was
added D-norleucinol (24 mg, 0.20 mmol) and
N,N-diisopropylethylamine (1.1 mL, 6.0 mmol). After stirring at rt
for 30 minutes, 2,4-dimethoxybenzylamine (0.2 mL, 1.1 mmol) and
additional N,N-diisopropylethylamine (0.26 mL, 1.5 mmol) was added
and the mixture was heated to 100.degree. C. After 16 h, the
reaction was cooled to rt, diluted with EtOAc (100 mL), washed with
water (100 mL), brine (100 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The crude residue was subjected
to silica gel chromatography eluting with hexanes-EtOAc to provide
57A. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 7.30 (d, J=8.2 Hz,
1H), 7.25 (s, 1H), 6.75 (d, J=6.0 Hz, 1H), 6.46 (d, J=2.3 Hz, 1H),
6.41 (dd, J=8.2, 2.4 Hz, 1H), 5.39 (s, 1H), 4.57 (d, J=6.0 Hz, 2H),
3.85 (s, 4H), 3.81 (d, J=3.1 Hz, 1H), 3.79 (s, 4H), 3.68 (q, J=7.7,
7.2 Hz, 1H), 2.51 (s, 3H), 1.72-1.60 (m, 3H), 1.46-1.30 (m, 5H),
0.95-0.86 (m, 4H). LCMS (m/z): 460.25 [M+H].sup.+; t.sub.R=1.26
min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-8-methylpyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (57B)
[0762] A solution of 57A (35 mg, 0.08 mmol) in EtOAc (4 mL) and
EtOH (4 mL) was purged with Ar, and then Pd/C (Degussa 10 wt %, 25
mg) was added. The mixture was then purged with H.sub.2 and heated
to 70.degree. C. After 1 h, the reaction was cooled, purged with
Ar, filtered through Celite, and the Celite rinsed with EtOAc. The
organics were concentrated in vacuo and the residue was subjected
to silica gel chromatography eluting with EtOAc-MeOH to afford 57B.
LCMS (m/z): 426.16 [M+H].sup.+; t.sub.R=1.18 min. on LC/MS Method
A.
Synthesis of
(R)-2-((2-amino-8-methylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(57)
[0763] To 57B (21 mg, 0.05 mmol) was added TFA (3 mL). After 60
minutes, MeOH (5 mL) and water (5 mL) were added to the mixture.
After 4 h, the mixture was concentrated in vacuo and co-evaporated
with MeOH (.times.3). The residue was subjected to preparative HPLC
(Synergi 4u Polar-RP 80A, Axia; 10% aq. acetonitrile-70% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient) to provide 57 as
a TFA salt. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.50 (d,
J=4.6 Hz, 1H), 7.63 (dd, J=4.6, 1.0 Hz, 1H), 4.53 (dq, J=8.6, 5.2
Hz, 1H), 3.74 (d, J=5.3 Hz, 2H), 2.53 (d, J=0.8 Hz, 4H), 1.83-1.64
(m, 3H), 1.45-1.33 (m, 5H), 0.97-0.87 (m, 4H). .sup.19F NMR (377
MHz, MeOH-d.sub.4) .delta. -77.78. LCMS (m/z): 276.26 [M+H].sup.+;
t.sub.R=0.88 min. on LC/MS Method A.
Example 58
##STR00197##
[0764] Synthesis of
(S)-2-((2-amino-8-methylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(58)
[0765] 58 was synthesized in a 3 step procedure similar to that
described for Example 57, instead replacing D-norleucinol with
L-norleucinol (24 mg, 0.204 mmol), affording 58 as a TFA salt.
.sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.48 (d, J=4.6 Hz, 1H),
7.60 (dd, J=4.6, 1.0 Hz, 1H), 4.52 (dq, J=8.7, 5.4 Hz, 1H), 3.74
(d, J=5.8 Hz, 2H), 2.52 (d, J=0.8 Hz, 3H), 1.86-1.61 (m, 3H),
1.47-1.32 (m, 5H), 0.95-0.86 (m, 4H). .sup.19F NMR (377 MHz,
MeOH-d.sub.4) .delta. -77.64. LCMS (m/z): 276.17 [M+H].sup.+;
t.sub.R=0.88 min. on LC/MS Method A.
Example 59
##STR00198##
[0766] Synthesis of (R)-2-amino-2-methylhexan-1-ol (59A)
[0767] To (2R)-2-amino-2-methylhexanoic acid hydrochloride (250 mg,
1.4 mmol, supplied by Astatech) in THF (5 mL) was added
borane-tetrahydrofuran complex solution in THF (1M, 5.5 mL)
dropwise over 5 minutes. After 24 h, the reaction was quenched with
MeOH (1 mL) and concentrated in vacuo. The residue was diluted with
DCM, filtered, and concentrated in vacuo to afford crude 59A which
was carried forward into the next step directly. LCMS (m/z): 131.92
[M+H].sup.+; t.sub.R=0.58 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
2-methylhexan-1-ol (59B)
[0768] To a solution of 2,4-dichloropyrido[3,2-d]pyrimidine (50 mg,
0.25 mmol) in THF (10 mL) was added 59A (50 mg, 0.38 mmol) and
N,N-diisopropylethylamine (0.13 mL, 0.75 mmol). After stirring at
80.degree. C. for 18 h, 2,4-dimethoxybenzylamine (0.19 mL, 1.25
mmol) was added and the mixture was heated to 100.degree. C. After
18 h, the reaction was cooled to rt, diluted with EtOAc, washed
with water and brine, dried over Na.sub.2SO.sub.4, then filtered
and concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc to provide 59B. LCMS
(m/z): 426.21 [M+H].sup.+; t.sub.R=0.91 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol
(59)
[0769] To 59B was added TFA (3 mL). After 2 h, the reaction mixture
was concentrated in vacuo. The residue was subjected to preparative
HPLC (Synergi 4u Polar-RP 80A, Axia; 10% aq. acetonitrile-70% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient) to provide 59 as
a TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.62 (dd,
J=4.2, 1.6 Hz, 1H), 7.81 (dd, J=8.5, 1.6 Hz, 1H), 7.77 (dd, J=8.5,
4.2 Hz, 1H), 3.97 (d, J=11.2 Hz, 1H), 3.72 (d, J=11.2 Hz, 1H),
2.18-2.03 (m, 1H), 1.99-1.86 (m, 1H), 1.54 (s, 3H), 1.41-1.30 (m,
4H), 0.92 (t, J=6.9 Hz, 2H). .sup.19F NMR (377 MHz, MeOH-d.sub.4)
.delta. -77.98. LCMS (m/z): 276.13 [M+H].sup.+; t.sub.R=0.65 min.
on LC/MS Method A.
Example 60
##STR00199##
[0770] Synthesis of
(S)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol
(60)
[0771] Compound 60 was synthesized in a procedure similar to that
reported for 59, replacing (2R)-2-amino-2-methylhexanoic acid
hydrochloride with (2S)-2-amino-2-methylhexanoic acid hydrochloride
(250 mg, 1.38 mmol, supplied by Astatech, Inc.). Final purification
with preparative HPLC (Synergi 4u Polar-RP 80A, Axia; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient) provided 60 as a TFA salt. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 8.63 (dd, J=4.3, 1.5 Hz, 1H), 7.82 (dd,
J=8.5, 1.5 Hz, 1H), 7.77 (dd, J=8.5, 4.3 Hz, 1H), 3.98 (d, J=11.2
Hz, 1H), 3.73 (d, J=11.2 Hz, 1H), 2.19-2.04 (m, 1H), 2.01-1.88 (m,
1H), 1.55 (s, 3H), 1.50-1.29 (m, 4H), 0.93 (t, J=6.9 Hz, 3H).
.sup.19F NMR (377 MHz, MeOH-d.sub.4) .delta. -77.98. LCMS (m/z):
276.10 [M+H].sup.+; t.sub.R=0.65 min. on LC/MS Method A.
Example 61
##STR00200## ##STR00201##
[0772] Synthesis of (R)-tert-butyl
(1-hydroxy-2-methylhexan-2-yl)carbamate (61A)
[0773] To a solution of 59A (1 g, 7.6 mmol) in THF (35 mL) was
added sat. NaHCO.sub.3(aq) (35 mL) followed by di-tert-butyl
dicarbonate (3.33 g, 15.24 mmol). After 24 h, the organic solvents
were removed in vacuo. The resulting slurry was diluted with water
(50 mL), extracted with EtOAc (100 mL), washed with brine (10 mL),
dried over Na.sub.2SO.sub.4, and concentrated in vacuo. The residue
was subjected to silica gel chromatography using an ELSD eluting
with hexanes-EtOAc to provide 61A. LCMS (m/z): 231.61 [M+H].sup.+;
t.sub.R=1.09 min. on LC/MS Method A.
Synthesis of (R)-tert-butyl (2-methyl-1-oxohexan-2-yl)carbamate
(61B)
[0774] To a solution of 61A (2.1 g, 9.0 mmol) in DCM (100 mL) was
added Dess-Martin periodinane (5.7 g, 14 mmol). After 2 h the
reaction was quenched with sat. Na.sub.2S.sub.2O.sub.3(aq) (75 mL).
The mixture was separated and the aqueous layer was extracted with
DCM (100 mL). The combined organics were washed with water (100 mL)
and brine (100 mL), dried over Na.sub.2SO.sub.4, then filtered and
concentrated in vacuo. The residue was subjected to silica gel
chromatography using an ELSD eluting with hexanes-EtOAc to provide
61B. LCMS (m/z): 173.75 [M+H-(t-Bu)].sup.+; t.sub.R=1.18 min. on
LC/MS Method A.
Synthesis of (R)-tert-butyl
(1-(benzylamino)-2-methylhexan-2-yl)carbamate (61C)
[0775] To a solution of 61B (1.9 g, 8.4 mmol) in dry MeOH (50 mL)
was added benzylamine (1.0 mL, 8.35 mmol). After 18 h, sodium
borohydride (500 mg, 13 mmol) was added portionwise. At 60 minutes,
the mixture was concentrated in vacuo. The resulting residue was
dissolved in EtOAc (50 mL), washed with 1M NaOH.sub.(aq) (50 mL),
10% Rochelle's salt aq. solution (50 mL, solid supplied by
Sigma-Aldrich), and brine (50 mL), dried over Na.sub.2SO.sub.4,
then filtered and concentrated in vacuo to afford 61C. LCMS (m/z):
321.03 [M+H].sup.+; t.sub.R=0.94 min. on LC/MS Method A.
Synthesis of (R)-tert-butyl
(1-(N-benzylacetamido)-2-methylhexan-2-yl)carbamate (61D)
[0776] To a solution of 61C (2.2 g, 6.9 mmol) in THF (50 mL) was
added N,N-diisopropylethylamine (2.4 mL, 14 mmol) followed by
acetyl chloride (0.75 mL, 11 mmol). After 60 minutes, the mixture
was diluted with EtOAc (150 mL), washed with sat. NaHCO.sub.3(aq)
(100 mL) and brine (100 mL), dried over Na.sub.2SO.sub.4, then
filtered and concentrated in vacuo. The residue was subjected to
silica gel chromatography eluting with hexanes-EtOAc to provide
61D. LCMS (m/z): 362.82 [M+H].sup.+; t.sub.R=1.32 min. on LC/MS
Method A.
Synthesis of (R)-N-(2-amino-2-methylhexyl)acetamide (61E)
[0777] To a solution of 61D (2.0 g, 5.4 mmol) in EtOH (55 mL) and
hydrochloric acid solution in dioxane (4M, 2 mL) that was purged
with Ar, was added palladium hydroxide on carbon (20 wt %, 2.0 g).
The mixture was purged with H.sub.2 and heated to 60.degree. C.
After 24 h, the reaction mixture was filtered through Celite,
rinsed with EtOAc, and concentrated in vacuo to afford 61E as a HCl
salt. LCMS (m/z): 172.92 [M+H].sup.+; t.sub.R=0.50 min. on LC/MS
Method A.
Synthesis of
(R)-N-(2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin--
4-yl)amino)-2-methylhexyl)acetamide (61F)
[0778] To a solution of 2,4-dichloropyrido[3,2-d]pyrimidine (30 mg,
0.15 mmol) in THF (10 mL) was added 61E (25 mg, 0.15 mmol) and
N,N-diisopropylethylamine (0.08 mL, 0.44 mmol). After stirring at
80.degree. C. for 18 h, 2,4-dimethoxybenzylamine (0.1 mL, 0.73
mmol) was added and the mixture heated to 100.degree. C. After 18
h, the reaction was cooled to rt, diluted with EtOAc, washed with
water and brine, dried over Na.sub.2SO.sub.4, and concentrated in
vacuo. The residue was subjected to silica gel chromatography
eluting with EtOAc-MeOH to provide 61F. LCMS (m/z): 467.24
[M+H].sup.+; t.sub.R=1.02 min. on LC/MS Method A.
Synthesis of
(R)-N-(2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
yl)acetamide (61)
[0779] To 61F (33 mg, 0.07 mmol) was added TFA (3 mL). After 60
minutes, the mixture was concentrated in vacuo and co-evaporated
with MeOH (.times.3). The residue was suspended in MeOH, filtered,
and concentrated in vacuo to provide 61 as a TFA salt. .sup.1H NMR
(400 MHz, MeOH-d.sub.4) .delta. 8.63 (dd, J=4.4, 1.4 Hz, 1H), 7.84
(dd, J=8.5, 1.4 Hz, 1H), 7.76 (dd, J=8.5, 4.4 Hz, 1H), 3.95 (d,
J=14.0 Hz, 1H), 3.57 (d, J=14.0 Hz, 1H), 2.25-2.12 (m, 1H), 1.95
(s, 3H), 1.95-1.86 (m, 1H), 1.54 (s, 3H), 1.41-1.32 (m, 4H),
0.95-0.90 (m, 3H). .sup.19F NMR (377 MHz, MeOH-d.sub.4) .delta.
-77.77. LCMS (m/z): 317.24 [M+H].sup.+; t.sub.R=0.71 min. on LC/MS
Method A.
Example 62
##STR00202##
[0780] Synthesis of
(R)-N-(2-((6-chloro-2-((2,4-dimethoxybenzyl)amino)-8-methylpyrido[3,2-d]p-
yrimidin-4-yl)amino)-2-methylhexyl)acetamide (62A)
[0781] To a solution of 25A (37 mg, 0.15 mmol) in THF (5 mL) was
added 61E (25 mg, 0.15 mmol) and N,N-diisopropylethylamine (0.4 mL,
0.43 mmol). After stirring at 80.degree. C. for 18 h,
2,4-dimethoxybenzylamine (0.1 mL, 0.63 mmol) was added and the
mixture was heated to 100.degree. C. After 18 h, the reaction was
cooled to rt, diluted with EtOAc, washed with water (50 mL) and
brine (50 mL), dried over Na.sub.2SO.sub.4, then filtered and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with EtOAc-MeOH to provide 62A (49 mg, 75%).
LCMS (m/z): 515.17 [M+H].sup.+; t.sub.R=0.86 min. on LC/MS Method
A.
Synthesis of
(R)-N-(2-((2-((2,4-dimethoxybenzyl)amino)-8-methylpyrido[3,2-d]pyrimidin--
4-yl)amino)-2-methylhexyl)acetamide (62B)
[0782] To a solution of 62A (49 mg, 0.1 mmol) in EtOAc (4 mL) and
EtOH (4 mL) that was purged with Ar, was added Pd/C (Degussa 10 wt
%, 25 mg). The mixture was then purged with H.sub.2 and heated to
70.degree. C. After 1 h, the reaction was allowed to cool to rt,
purged with Ar, filtered through Celite, rinsed with EtOAc (50 mL),
and concentrated in vacuo to provide 62B (46 mg, 100%). LCMS (m/z):
481.25 [M+H].sup.+; t.sub.R=1.10 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-amino-8-methylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(62)
[0783] To 62B (46 mg, 0.1 mmol) was added TFA (3 mL). After 18 h,
the mixture was concentrated in vacuo and co-evaporated with MeOH
(3.times.10 mL). The residue was suspended in 10 mL MeOH, filtered,
and concentrated in vacuo to provide 62 as a TFA salt. .sup.1H NMR
(400 MHz, MeOH-d.sub.4) .delta. 8.48 (d, J=4.6 Hz, 1H), 7.61 (dd,
J=4.7, 1.0 Hz, 1H), 3.95 (d, J=14.0 Hz, 1H), 3.56 (d, J=14.0 Hz,
1H), 2.52 (d, J=0.8 Hz, 3H), 2.18 (ddd, J=13.5, 11.3, 4.5 Hz, 1H),
1.95 (s, 3H), 1.89 (ddd, J=13.5, 11.6, 4.8 Hz, 1H), 1.54 (s, 3H),
1.42-1.31 (m, 5H), 0.96-0.89 (m, 4H). .sup.19F NMR (377 MHz,
MeOH-d.sub.4) .delta. -77.85. LCMS (m/z): 331.16 [M+H].sup.+;
t.sub.R=0.79 min. on LC/MS Method A.
Example 63
##STR00203##
[0784] Synthesis of methyl 2-amino-2-methylhexanoate (63A)
[0785] To a mixture of (2R)-2-amino-2-methylhexanoic acid
hydrochloride (50 mg, 0.28 mmol) and (2S)-2-amino-2-methylhexanoic
acid hydrochloride (50 mg, 0.28 mmol) in MeOH (5.0 mL) was added
(trimethylsilyl) diazomethane in hexanes (2 M, 0.41 mL, 0.83 mmol)
dropwise. After 6 h, the reaction was quenched with AcOH (100
.mu.L). The mixture was concentrated in vacuo to provide 63A that
was used without further isolation. LCMS (m/z): 159.91 [M+H].sup.+;
t.sub.R=0.57 min. on LC/MS Method A.
Synthesis of methyl
2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin-4-yl)am-
ino)-2-methylhexanoate (63B)
[0786] To a solution of 84E (120 mg, 0.55 mmol) in THF (5 mL) was
added 63A (88 mg, 0.55 mmol) and N,N-diisopropylethylamine (0.3 mL,
1.7 mmol). After stirring at 80.degree. C. for 18 h, the reaction
was cooled to rt, diluted with EtOAc (50 mL), washed with water (50
mL) and brine (50 mL), dried over Na.sub.2SO.sub.4, then filtered
and concentrated in vacuo. The crude residue was then diluted with
THF (10 mL) and 2,4-dimethoxybenzylamine (0.4 mL, 2.6 mmol) and
N,N-diisopropylethylamine (0.3 mL, 1.7 mmol) were added. After
stirring at 100.degree. C. for 18 h, the reaction was cooled to rt,
diluted with EtOAc (50 mL), washed with water and brine, dried over
Na.sub.2SO.sub.4, then filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
hexanes-EtOAc to provide 63B. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.14 (d, J=2.5 Hz, 1H), 7.36 (s, 1H), 7.28-7.24 (m, 2H),
6.46 (d, J=2.3 Hz, 1H), 6.41 (dd, J=8.3, 2.4 Hz, 1H), 4.54 (dd,
J=6.2, 2.7 Hz, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 3.69 (s, 3H),
2.27-2.16 (m, 1H), 2.02 (s, 1H), 1.71 (s, 3H), 1.34-1.23 (m, 5H),
0.88 (t, J=6.9 Hz, 3H). .sup.19F NMR (376 MHz, Chloroform-d)
6-121.51 (d, J=422.9 Hz). LCMS (m/z): 472.21 [M+H].sup.+;
t.sub.R=0.91 min. on LC/MS Method A.
Synthesis of
2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin-4-yl)am-
ino)-2-methylhexan-1-ol (63C)
[0787] To a solution of 63B (104 mg, 0.22 mmol) in THF (5 mL) was
added lithium aluminum hydride in Et.sub.2O (2M, 0.30 mL, 0.60
mmol). After 5 h the reaction was quenched with H.sub.2O (1 mL) and
2M NaOH(a.sub.q), and then filtered. The mother liquor was then
diluted with EtOAc (30 mL), washed with sat. Rochelle's salt
solution (25 mL), H.sub.2O (25 mL), and brine (25 mL), dried over
Na.sub.2SO.sub.4, then filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
hexanes-EtOAc to provide 63C. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.12 (d, J=2.5 Hz, 1H), 7.32 (s, 1H), 7.28 (s, 1H), 6.46
(d, J=2.4 Hz, 1H), 6.42 (dd, J=8.2, 2.4 Hz, 1H), 4.57-4.52 (m, 2H),
3.84 (s, 3H), 3.79 (s, 4H), 3.75 (s, 2H), 1.92 (d, J=14.1 Hz, 1H),
1.74 (t, J=12.6 Hz, 1H), 1.40-1.37 (m, 3H), 1.32 (td, J=13.4, 12.4,
6.3 Hz, 4H), 0.91 (t, J=7.0 Hz, 3H). .sup.19F NMR (377 MHz,
Chloroform-d) 6-121.34. LCMS (m/z): 444.20 [M+H].sup.+;
t.sub.R=0.94 min. on LC/MS Method A.
Synthesis of
2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol
(63)
[0788] To 63C (22 mg, 0.05 mmol) was added TFA (3 mL). After 30
minutes, the reaction mixture was diluted with MeOH (5 mL). After
stirring for 18 h, the mixture was filtered and concentrated in
vacuo. Co-evaporation with MeOH (.times.3) provided 63 as a TFA
salt. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.53 (d, J=2.4
Hz, 1H), 8.20 (s, 1H), 7.65 (dd, J=8.8, 2.4 Hz, 1H), 3.95 (s, 1H),
3.70 (d, J=11.2 Hz, 1H), 2.09 (ddd, J=13.9, 10.9, 5.3 Hz, 1H),
1.96-1.86 (m, 1H), 1.53 (s, 3H), 1.42-1.28 (m, 6H), 0.95-0.87 (m,
3H). .sup.19F NMR (377 MHz, MeOH-d.sub.4) .delta. -77.47, -118.23
(d, J=8.6 Hz). LCMS (m/z): 294.12 [M+H].sup.+; t.sub.R=0.68 min. on
LC/MS Method A.
Example 64
##STR00204##
[0789] Synthesis of (S)-2-amino-2-methylhexan-1-ol (64A)
[0790] To (2S)-2-amino-2-methylhexanoic acid hydrochloride (250 mg,
1.4 mmol, supplied by Astatech) in THF (5 mL) was added
borane-tetrahydrofuran complex solution in THF (1M, 5.5 mL)
dropwise over 5 minutes. After 24 h, the reaction was quenched with
MeOH (1 mL) and concentrated in vacuo. The residue was taken up in
DCM (10 mL), filtered, and concentrated in vacuo to provide crude
64A. LCMS (m/z): 131.92 [M+H].sup.+; t.sub.R=0.57 min. on LC/MS
Method A.
Synthesis of
(S)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol (64)
[0791] To a solution of 43B (140 mg, 78 mmol) and 64A (125 mg, 0.95
mmol) in NMP (7.5 mL), was added DBU (0.35 mL, 2.4 mmol) followed
by BOP (419 mg, 0.95 mmol). After 16 h, the reaction mixture was
subjected to prep HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-50% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient) to provide, after removal of volatiles in vacuo, 64 as a
TFA salt. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.55 (d,
J=2.4 Hz, 1H), 8.22 (s, 1H), 7.64 (dd, J=8.7, 2.5 Hz, 1H), 3.97 (d,
J=11.2 Hz, 1H), 3.71 (d, J=11.2 Hz, 1H), 2.09 (ddd, J=13.9, 10.8,
5.2 Hz, 1H), 1.92 (ddd, J=13.6, 10.9, 5.4 Hz, 1H), 1.54 (s, 4H),
1.40-1.31 (m, 5H), 1.00-0.85 (m, 3H). .sup.19F NMR (377 MHz,
MeOH-d.sub.4) .delta. -77.62, -118.22 (d, J=8.7 Hz). LCMS (m/z)
294.09 [M+H].sup.+; t.sub.R=0.79 min. on LC/MS Method A.
Example 65
##STR00205##
[0792] Synthesis of
(R)-N-(2-((2-amino-7-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
yl)acetamide (65A)
[0793] To a solution of 19B (112 mg, 0.48 mmol) in THF (5 mL) was
added 61E (100 mg, 0.48 mmol) and N,N-diisopropylethylamine (0.25
mL, 1.4 mmol). After stirring at 80.degree. C. for 18 h,
2,4-dimethoxybenzylamine (0.75 mL, 5.0 mmol) was added and the
mixture was heated to 100.degree. C. After 18 h, the reaction was
cooled to rt, diluted with EtOAc (50 mL), washed with water (50 mL)
and brine (50 mL), dried over Na.sub.2SO.sub.4, then filtered and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc to provide 65A LCMS
(m/z): 509.30[M+H].sup.+; t.sub.R=0.89 min. on LC/MS Method A.
Synthesis of
(R)-N-(2-((2-amino-7-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
yl)acetamide (65)
[0794] To 65A (21 mg, 0.04 mmol) was added TFA (3 mL). After 30
minutes, the mixture was concentrated in vacuo and the residue
co-evaporated with MeOH (10 mL.times.3). The resulting residue was
suspended in MeOH (10 mL), filtered, and concentrated in vacuo to
provide 65 as a TFA salt. .sup.1H NMR (400 MHz, MeOH-d.sub.4)
.delta. 8.59 (d, J=2.1 Hz, 1H), 8.58 (s, 1H), 7.91 (d, J=2.1 Hz,
1H), 3.93 (d, J=14.0 Hz, 1H), 3.52 (d, J=14.0 Hz, 1H), 2.22-2.10
(m, 1H), 1.96 (s, 3H), 1.95-1.87 (m, 1H), 1.54 (s, 3H), 1.34 (dd,
J=7.5, 3.9 Hz, 5H), 0.94-0.89 (m, 3H). .sup.19F NMR (377 MHz,
MeOH-d.sub.4) .delta. -77.91. LCMS (m/z): 351.29 [M+H].sup.+;
t.sub.R=0.69 min. on LC/MS Method A.
Example 66
##STR00206##
[0795] Synthesis of
(R)-N-(2-((2-((2,4-dimethoxybenzyl)amino)-7-methylpyrido[3,2-d]pyrimidin--
4-yl)amino)-2-methylhexyl)acetamide (66A)
[0796] To 65A (128 mg, 0.26 mmol) in 1,4-dioxane (10 mL) and water
(10 mL) was added methylboronic acid (61 mg, 1.0 mmol),
tetrakis(triphenylphosphine)palladium(0) (51 mg, 0.05 mmol), and
potassium phosphate tribasic (163 mg, 0.77 mmol). The reaction
mixture was heated to 150.degree. C. in a microwave reactor for 30
minutes. The reaction mixture was diluted with water (50 mL) and
extracted with EtOAc (3.times.25 mL). The combined organics were
washed with water (50 mL) and brine (50 mL), dried over
Na.sub.2SO.sub.4, and concentrated in vacuo. The residue was
subjected to silica gel chromatography eluting with EtOAc-MeOH, to
provide 66A. LCMS (m/z): 481.30[M+H].sup.+; t.sub.R=0.89 min. on
LC/MS Method A.
Synthesis of
(R)-N-(2-((2-amino-7-methylpyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
yl)acetamide (66)
[0797] To 66A (54 mg, 0.11 mmol) was added TFA (3 mL). After 60
minutes, the mixture was concentrated in vacuo and co-evaporated
with MeOH (10 mL.times.3). The resulting residue was suspended in
MeOH (10 mL), filtered, and concentrated in vacuo to provide 66 as
a TFA salt. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.48 (d,
J=1.8 Hz, 1H), 7.64 (s, 1H), 3.94 (d, J=14.0 Hz, 1H), 3.57 (d,
J=13.9 Hz, 1H), 2.50 (s, 3H), 2.17 (ddd, J=13.4, 11.4, 4.7 Hz, 1H),
1.95 (s, 3H), 1.88 (ddd, J=16.1, 8.9, 4.4 Hz, 1H), 1.53 (s, 3H),
1.39-1.29 (m, 4H), 0.97-0.86 (m, 3H). .sup.19F NMR (377 MHz,
MeOH-d.sub.4) .delta. -77.86. LCMS (m/z): 331.34 [M+H].sup.+;
t.sub.R=0.93 min. on LC/MS Method A.
Example 67
##STR00207##
[0798] Synthesis of methyl 3-amino-6-bromo-5-fluoropicolinate
(67B)
[0799] To a solution of methyl 3-amino-5-fluoropicolinate 67A (270
mg, 2 mmol, 1.0 equiv., supplied by Astatech, Inc.) in acetonitrile
(2 mL, 0.1M solution) was added NBS (311 mg, 2.2 mmol, 1.1 equiv.)
over 2 minutes at rt. After 18 h, the reaction was quenched with
water (50 mL) and the mixture was extracted with EtOAc (50 mL),
washed with water (50 mL) and brine (50 mL), then dried over
Na.sub.2SO.sub.4, filtered and then concentrated in vacuo. The
residue was subjected to silica column chromatography eluting with
0% to 100% EtOAc in hexanes to provide 67B. LCMS (m/z): 250.1
[M+H].sup.+; t.sub.R=0.71 min. on LC/MS Method A.
Synthesis of methyl 3-amino-5-fluoro-6-methylpicolinate (67C)
[0800] Methyl 3-amino-6-bromo-5-fluoropicolinate 67B (50 mg, 0.2
mmol, 1 equiv.) in a microwave vial was treated with dioxane (2 mL)
and water (2 mL), along with methylboronic acid (36.05 mg, 0.06
mmol, 3 equiv.), potassium phosphate tribasic (85.23 mg, 0.4 mmol,
2 equiv.) and palladium(0) tetrakis(triphenylphosphine) (46.4 mg,
0.04 mmol, 0.2 equiv.). The mixture was heated to 120.degree. C.
for 20 min. and the reaction mixture was partitioned between EtOAc
(20 mL) and H.sub.2O (20 mL). The organic layers were combined,
dried over MgSO.sub.4 then filtered and volatiles removed in vacuo.
The resulting residue was subjected to silica gel chromatography
eluting with 0-100% EtOAc in hexanes to provide 67C. LCMS (m/z):
184.88 [M+H].sup.+; t.sub.R=0.54 min. on LC/MS Method A.
Synthesis of 2-amino-7-fluoro-6-methylpyrido[3,2-d]pyrimidin-4-ol
(67D)
[0801] A flask containing methyl
3-amino-5-fluoro-6-methylpicolinate 67C (95 mg, 0.52 mmol) was
treated with chloroformamidine hydrochloride (118 mg, 1.03 mmol,
supplied by Oakwood Scientific, Inc.). The mixture was heated to
160.degree. C. overnight. The mixture was allowed to cool to rt,
diluted with EtOAc (100 mL), filtered, and then the collected
solids washed with water (50 mL) and diethyl ether (50 mL). The
solid was allowed to air dry to furnish 67D which was used without
further purification. LCMS (m/z): 195.03 [M+H].sup.+; t.sub.R=0.31
min. on LC/MS Method A.
Synthesis of
(S)-2-((2-amino-7-fluoro-6-methylpyrido[3,2-d]pyrimidin-4-yl)amino)pentan-
-1-ol (67)
[0802] To a flask containing
2-amino-7-fluoro-6-methylpyrido[3,2-d]pyrimidin-4-ol 67D (5 mg,
0.026 mmol) was added DMF (2 mL) along with
1,8-diazabicyclo[5.4.0]undec-7-ene solution 1M in THF (0.01 mL,
0.08 mmol), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate (22.78 mg, 0.05 mmol) and
(S)-(+)-2-amino-1-pentanol, (10.63 mg, 0.1 mmol). The reaction was
allowed to stir overnight and then subjected to HPLC (10% to 70%
MeCN in water with 0.1% TFA using a Hydro-RP column) to provide,
after removal of volatiles in vacuo, 67 as its TFA salt;
t.sub.R=0.57 min. on LC/MS Method A. .sup.1H NMR (400 MHz,
MeOH-d.sub.4) .delta. 7.52 (d, J=9.4 Hz, 1H), 4.54 (s, 1H), 3.73
(d, J=5.3 Hz, 2H), 2.61 (d, J=2.9 Hz, 3H), 1.71 (q, J=7.6 Hz, 2H),
1.49-1.37 (m, 1H), 1.29 (s, 5H), 0.97 (t, J=7.4 Hz, 3H). .sup.19F
NMR (377 MHz, MeOH-d.sub.4) .delta. -77.42; LCMS (m/z): 280.1
[M+H].sup.+
Example 68
##STR00208##
[0803] Synthesis of
(R)-2-((2,4-dimethoxybenzyl)amino)-4-((1-hydroxyhexan-2-yl)amino)pyrido[3-
,2-d]pyrimidin-7-ol (68A)
[0804] Into a microwave vial containing
(R)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol 70B (22 mg, 0.049 mmol, 1 equiv.) was added
2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (2.35 mg,
0.01 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.9 mg, 0.005
mmol, 20 mol %) along with dioxane (2.5 mL) and KOH.sub.(aq) (1 mL,
0.08M). The mixture was heated to 150.degree. C. for 30 min. in a
microwave reactor. The reaction mixture was partitioned between
EtOAc (50 ml) and H.sub.2O (50 mL). The organic layer was
separated, dried over MgSO.sub.4, filtered and concentrated in
vacuo. The crude material 68A was used without further
purification. LCMS (m/z): 428.2 [M+H].sup.+; t.sub.R=0.78 min. on
LC/MS Method A.
Synthesis of
(R)-2-amino-4-((1-hydroxyhexan-2-yl)amino)pyrido[3,2-d]pyrimidin-7-ol
(68)
[0805] A solution of
(R)-2-((2,4-dimethoxybenzyl)amino)-4-((1-hydroxyhexan-2-yl)amino)pyrido[3-
,2-d]pyrimidin-7-ol 68A (21 mg, 0.05 mmol, 1 equiv.) in DCM (2 mL)
was treated with TFA (0.5 mL). After 3 h the reaction mixture was
concentrated under reduced pressure and the residue subjected to
reverse phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a
Hydro-RP column) to furnish, after product fraction collection and
the removal of volatiles in vacuo, 68 as its TFA salt. LCMS (m/z):
278.3 [M+H].sup.+; t.sub.R=0.55 min. on LC/MS Method A. .sup.1H NMR
(400 MHz, MeOH-d.sub.4) .delta. 8.61-8.34 (m, 1H), 8.19-7.98 (m,
1H), 4.39 (ddd, J=18.0, 9.2, 5.3 Hz, 2H), 3.77 (dt, J=8.3, 6.5 Hz,
1H), 1.74-1.50 (m, 6H), 1.34-1.09 (m, 10H), 0.79 (tt, J=6.9, 1.3
Hz, 6H), 0.59 (d, J=5.6 Hz, 2H). .sup.19F NMR (377 MHz,
MeOH-d.sub.4) .delta. -77.55
Example 69
##STR00209##
[0806] Synthesis of
2-amino-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ol (69B)
[0807] Methyl 3-amino-5-(trifluoromethyl)picolinate 69A (300 mg,
0.001 mol, 1 equiv., supplied by J&W Pharmlab, LLC) was treated
with chloroformamadine hydrochloride (390 mg, 0.003 mmol, 2.5
equiv.) and dimethyl sulfone (1.28 g, 0.014 mol, 10 equiv.). The
mixture was heated to 200.degree. C. overnight. The reaction
mixture was allowed to cool to rt, filtered, and washed with water
(50 mL) and diethyl ether (50 mL). The residue was allowed to air
dry to furnish 69B which was used without further purification.
LCMS (m/z): 231 [M+H].sup.+; t.sub.R=0.48 min. on LC/MS Method
A.
Synthesis of
(S)-2-((2-amino-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-yl)amino)hexa-
n-1-ol (69)
[0808] 2-amino-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ol, 69B
(100 mg, 0.44 mmol, 1 equiv.) was treated with
1,8-diazabicyclo[5.4.0]undec-7-ene solution 1M in THF (0.19 mL, 1.3
mmol, 3 equiv.).
(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate (249.83 mg, 0.56 mmol, 1.3 equiv.) was added
followed by (S)-(+)-2-Amino-1-pentanol (112.06 mg, 1.09 mmol, 2.5
equiv.)), and DMF (5 mL). After stirring 16 h, the reaction mixture
was diluted with water (5 mL) and subjected to reverse phase HPLC
(10% to 70% MeCN in water with 0.1% TFA using a Hydro-RP column) to
furnish, after product fractions were collected and the volatiles
removed in vacuo, the title compound 69 as its TFA salt. LCMS
(m/z): 316.16 [M+H].sup.+; t.sub.R=0.59 min. on LC/MS Method A.
.sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.94-8.53 (m, 1H), 8.01
(dd, J=1.8, 0.9 Hz, 1H), 4.45 (t, J=6.5 Hz, 1H), 3.71-3.54 (m, 2H),
3.42-3.24 (m, 2H), 2.72-2.55 (m, 2H), 1.59 (td, J=8.2, 6.6 Hz, 3H),
1.37-1.20 (m, 2H), 0.85 (t, J=7.3 Hz, 4H). .sup.19F NMR (377 MHz,
MeOH-d.sub.4) .delta. -64.83, -77.69.
Example 70 & Example 71
##STR00210##
[0809] Synthesis of
(R)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(70A)
[0810] A solution of 2,4,7-trichloropyrido[3,2-d]pyrimidine 19B
(250 mg, 1.06 mmol, 1 equiv.) in dioxane (4 mL) was treated with
N,N-diisopropylethylamine (0.22 mL, 1.2 mmol, 1.5 equiv.) and
(R)-(-)-2-amino-1-hexanol (312.38 mg, 3.02 mmol, 2.5 equiv.). The
reaction was allowed to stir for 1 h and the product that formed,
70A, was carried forward directly into the following reaction
without isolation.
Synthesis of
(R)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (70B)
[0811] The solution of
(R)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
70A (315 mg, 1.06 mmol, 1 equiv.) prepared as described, was
treated with dioxane (4 mL) followed by N,N-diisopropylethylamine
(0.38 mL, 2 mmol, 2 equiv.) and 2,4-dimethoxybenzylamine (0.47 mL,
3.1 mmol, 3 equiv.). The reaction was heated at 120.degree. C.
overnight. The reaction mixture partitioned between EtOAc (50 mL)
and H.sub.2O (50 mL). The organics layer was separated, dried over
Na.sub.2SO.sub.4, then filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with 0%
to 100% EtOAc in hexanes to provide the title compound 70B. LCMS
(m/z): 446.9 [M+H].sup.+; t.sub.R=0.78 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-7-vinylpyrido[3,2-d]pyrimidin-4-yl-
)amino)hexan-1-ol (70C)
[0812] A microwave vial containing
(R)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol 70B (50 mg, 0.11 mmol, 1 equiv.) was treated
with potassium vinyltrifluoroborate (26.59 mg, 0.28 mmol, 2.5
equiv.), potassium phosphate tribasic (71.4 mg, 0.34 mmol, 3
equiv.), palladium(0) tetrakis(triphenylphosphine) (25.91 mg, 0.02
mmol, 0.2 equiv.), dioxane (2.0 mL), and water (2 mL). The mixture
was heated to 150.degree. C. for 60 min. in a microwave reactor.
The reaction mixture was partitioned between EtOAc (50 mL) and
H.sub.2O (50 mL). The organic layer was separated, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to provide the
crude material 70C which was used without further purification.
LCMS (m/z): 438.27 [M+H].sup.+; t.sub.R=0.82 min. on LC/MS Method
A.
Synthesis of
(R)-2-((2-amino-7-vinylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(70)
[0813] A solution of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-7-vinylpyrido[3,2-d]pyrimidin-4-yl-
)amino)hexan-1-ol, 70C (49 mg, 0.08 mmol, 1 equiv.) in DCM (2 mL)
was treated with TFA (0.5 mL). After 3 h the reaction mixture was
concentrated under reduced pressure and the residue subjected to
reverse phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a
Hydro-RP column) to furnish, after product fractions were collected
and removal of volatiles in vacuo, 70 as its TFA salt. LCMS (m/z):
288.17 [M+H].sup.+; t.sub.R=0.61 min. on LC/MS Method A. .sup.1H
NMR (400 MHz, MeOH-d.sub.4) .delta. 8.61 (d, J=1.8 Hz, 1H),
7.75-7.62 (m, 1H), 6.80 (dd, J=17.7, 11.1 Hz, 1H), 6.05 (d, J=17.7
Hz, 1H), 5.54 (d, J=11.1 Hz, 1H), 4.47-4.31 (m, 1H), 3.71-3.51 (m,
2H), 1.77-1.47 (m, 2H), 1.35-1.16 (m, 5H), 0.93-0.71 (m, 4H).
.sup.19F NMR (377 MHz, MeOH-d.sub.4) .delta. -77.60.
Synthesis of
(R)-2-((2-amino-7-ethylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(71)
[0814]
(R)-2-((2-amino-7-vinylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol-
, 70 (25 mg, 0.09 mmol, 1 equiv.) was treated with Pd/C (Degussa 10
wt %, 50 mg) and EtOH (5 mL) and the mixture stirred under
hydrogen. After several h the solid was filtered off and the
filtrate was concentrated under reduced pressure. The residue was
subjected to reverse phase HPLC (10% to 50% MeCN in water with 0.1%
TFA using a Gemini C18 column) to furnish, after product fractions
were collected and the removal of volatiles in vacuo, 71 as its TFA
salt. LCMS (m/z): 290.42 [M+H].sup.+; t.sub.R=0.70 min. on LC/MS
Method A. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. 8.60-8.42 (m,
1H), 7.63 (td, J=1.6, 0.9 Hz, 1H), 4.61-4.44 (m, 1H), 3.82-3.63 (m,
2H), 2.85 (q, J=7.6 Hz, 2H), 1.84-1.64 (m, 3H), 1.46-1.15 (m, 9H),
0.97-0.81 (m, 4H). .sup.19F NMR (377 MHz, MeOH-d.sub.4) .delta.
-77.47.
Example 72
##STR00211## ##STR00212##
[0815] Synthesis of (3R,5R,6S)-tert-butyl
3-(but-3-en-1-yl)-2-oxo-5,6-diphenylmorpholine-4-carboxylate
(72B)
[0816] Starting with a stirred solution of (2S,3R)-tert-butyl
6-oxo-2,3-diphenylmorpholine-4-carboxylate 72A (1500 mg, 4 mmol, 1
equiv., supplied by Sigma-Aldrich) and 4-iodobutene (3862.41 mg,
0.02 mol, 5 equiv., supplied by Sigma-Aldrich) in anhydrous THF (24
mL) and HMPA (2.5 mL), cooled to -78.degree. C., 1M sodium
bis(trimethylsilyl) amide in THF (6.37 mL, 6.37 mmol, 1.5 equiv.)
was added dropwise under argon. After 10 min. the reaction mixture
was stirred at -40.degree. C. for 4 h. The reaction was quenched
with EtOAc (50 mL) and poured into a mixture of EtOAc (50 mL) and
an aqueous solution of 1M NH.sub.4Cl (50 mL). The organic layer was
separated, washed with water (50 mL) and brine (50 mL), dried with
Na.sub.2SO.sub.4, filtered and volatiles removed in vacuo to give a
residue. The residue was subjected to silica gel chromatography
eluting with 0% to 100% EtOAc in hexanes to afford the title
compound 72B. LCMS (m/z): 307.98 [M+H-Boc]+; t.sub.R=1.28 min. on
LC/MS Method A.
Synthesis of (R)-methyl 2-aminohex-5-enoate (72C)
[0817] A 2-neck flask containing lithium (91.98 mg, 13.25 mmol, 15
equiv.) was cooled to -40.degree. C. before liquid ammonia (15 mL)
was added to the flask via condensation using a cold-finger
apparatus. Intermediate 72B (360 mg, 0.88 mmol, 1 equiv.) in THF (2
mL) was then added. The reaction was maintained at -40.degree. C.
for 1 h, and then slowly quenched with NH.sub.4Cl solution (5 mL),
after which time it was allowed to warm to rt. The reaction was
then diluted with diethyl ether (50 mL) and water (50 mL) and the
diethyl ether layer separated. To the aqueous layer was then added
1 N HCl until pH 5 followed by extraction with EtOAc (50 mL). Each
of the organic layers was washed with saturated NH.sub.4Cl (50 mL)
separately, and then combined, dried over MgSO.sub.4, filtered and
concentrated in vacuo. DCM (10 mL) was added to the residue
followed by MeOH (1 mL), (trimethylsilyl)diazomethane (2.0M
solution in hexanes) (0.29 mL, 2.20 mmol, 12 equiv.). After
stirring for 1 h the reaction was concentrated under reduced
pressure. The crude residue was treated with DCM (5 mL) and TFA (5
mL). After stirring for 2 h, the reaction was concentrated under
reduced pressure to give 72C that was used without further
purification.
Synthesis of
(R)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(72D)
[0818] A solution of 2,4,-dichloropyrido[3,2-d]pyrimidine (110 mg,
0.55 mmol, 1.1 equiv) in dioxane (4 mL) was treated with
N,N-diisopropylethylamine (0.14 mL, 0.9 mmol, 2 equiv.) and then
the crude (R)-methyl 2-aminopent-4-enoate 72C (112 mg, 0.46 mmol, 1
equiv.). The reaction was allowed to stir for 1 h to provide 72D
that was used directly in solution. LCMS (m/z): 307.80 [M+H].sup.+;
t.sub.R=1.09 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)hex-5-
-enoate (72E)
[0819] The crude solution containing
(R)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
72D (128 mg, 0.42 mmol, 1 equiv.) was treated with additional
N,N-diisopropylethylamine (0.15 mL, 0.84 mmol, 2 equiv.) and then
2,4-dimethoxybenzylamine (0.47 mL, 0.85 mmol, 2 equiv.). The
reaction was heated at 120.degree. C. overnight. The reaction
mixture was then partitioned between EtOAc (50 mL) and H.sub.2O (50
mL). The organic layer was separated, dried over Na.sub.2SO.sub.4,
filtered, and then concentrated in vacuo. The residue was subjected
to silica gel chromatography eluting with 0% to 100% EtOAc in
hexanes to provide the title compound 72E. LCMS (m/z): 438.52
[M+H].sup.+; t.sub.R=0.91 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)h-
ex-5-en-1-ol (72F)
[0820] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)hex-5-
-enoate 72E (43 mg, 0.1 mmol, 1 equiv.) was dissolved in THF (5 mL)
and 1M lithium aluminum hydride in diethyl ether (0.29 mL, 0.29
mmol, 3 equiv.) was added. The reaction mixture was stirred at rt
for 2 h. The reaction mixture was quenched with water (50 mL) and
extracted with EtOAc (50 mL). The organic layer was dried over
Na.sub.2SO.sub.4, filtered, and then concentrated in vacuo. The
crude residue 72F (40 mg) was then used without further
purification. LCMS (m/z): 410.52 [M+H].sup.+; t.sub.R=0.85 min. on
LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)hex-5-en-1-ol
(72)
[0821]
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)a-
mino)hex-5-en-1-ol 72F (40 mg, 0.09 mmol, 1 equiv.) was treated
with DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction mixture
was concentrated under reduced pressure and subjected to reverse
phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a Hydro-RP
column) to furnish, after collection of product fractions and
removal of volatiles in vacuo, 72 as its TFA salt. LCMS (m/z):
260.14 [M+H].sup.+; t.sub.R=0.58 min. on LC/MS Method A. .sup.1H
NMR (400 MHz, MeOH-d.sub.4) .delta. 8.66 (ddd, J=10.3, 4.2, 1.5 Hz,
1H), 7.94-7.65 (m, 2H), 5.86 (ddt, J=16.9, 10.3, 6.7 Hz, 1H),
5.15-4.90 (m, 2H), 4.63-4.43 (m, 1H), 2.29-2.06 (m, 2H), 2.00-1.71
(m, 2H). .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.31,
-77.69.
Example 73
##STR00213##
[0822] Synthesis of (2R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-fl-
uorohexanoate (73A)
[0823] Iron(III) oxalate hexahydrate (172 mg, 0.36 mmol, 2 equiv.)
was stirred in water (10 mL) until completely dissolved (typically
1-2 h). The clear yellow solution was cooled to 0.degree. C. and
degassed for 10 min. Selectfluor (126 mg, 0.36 mmol, 2 equiv.) and
MeCN (5 mL) were added to the reaction mixture. A solution of
(R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)hex-5-
-enoate 72E (78 mg, 0.18 mmol, 1 equiv.) in MeCN (5 mL) was added
to the reaction mixture followed by sodium borohydride (23.6 mg,
0.62 mmol, 3.5 equiv.) at 0.degree. C. After 2 min, the reaction
mixture was treated with an additional portion of NaBH.sub.4 (24
mg, 0.62 mmol, 3.5 equiv.). The resulting mixture was stirred for
30 min. and then quenched by the addition of 28-30% aqueous
NH.sub.4OH (4 mL). The mixture was extracted with 10% MeOH in
CH.sub.2Cl.sub.2 and the organic layer was dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was subjected to silica gel chromatography eluting with
0% to 100% EtOAc in hexanes, to provide 73A. LCMS (m/z): 458.63
[M+H].sup.+; t.sub.R=0.91 min. on LC/MS Method A.
Synthesis of
(2R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-
-5-fluorohexan-1-ol (73B)
[0824] (2R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-fl-
uorohexanoate 73A (43 mg, 0.1 mmol, 1 equiv.) was treated with THF
(5 mL) and 1M lithium aluminum hydride in ether (0.29 mL, 0.29
mmol, 3 equiv.). The reaction mixture was allowed to stir at rt for
2 h. The reaction mixture was quenched with water (50 mL) and
extracted with EtOAc (50 mL). The organics were combined, dried
over Na.sub.2SO.sub.4, and concentrated in vacuo. The crude
material 73B was used without further purification. LCMS (m/z):
430.19 [M+H].sup.+; t.sub.R=0.82 min. on LC/MS Method A.
Synthesis of
(2R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-5-fluorohexan-1-ol
(73)
[0825]
(2R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)-
amino)-5-fluorohexan-1-ol 73B (40 mg, 0.09 mmol, 1 equiv.) was
treated with DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction
mixture was concentrated under reduced pressure and the residue
subj ected to reverse phase HPLC (10% to 70% MeCN in water with
0.1% TFA using a Hydro-RP column) to furnish, after collection of
product fractions and removal of volatiles in vacuo, 73 as its TFA
salt. LCMS (m/z): 280.12 [M+H].sup.+; t.sub.R=0.59 min. on LC/MS
Method A. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. 8.64 (dd,
J=4.3, 1.4 Hz, 1H), 7.84 (dd, J=8.5, 1.4 Hz, 1H), 4.63-4.50 (m,
1H), 4.47 (t, J=6.0 Hz, 1H), 4.35 (t, J=6.0 Hz, 1H), 3.74 (d, J=5.3
Hz, 2H), 1.89-1.61 (m, 4H), 1.60-1.39 (m, 2H). .sup.19F NMR (377
MHz, Methanol-d4) .delta. -77.66, -220.85 (ddd, J=47.6, 25.5, 22.1
Hz).
Example 74
##STR00214##
[0826] Synthesis of (3R,5R,6S)-tert-butyl
3-(4-fluorobutyl)-2-oxo-5,6-diphenylmorpholine-4-carboxylate
(74B)
[0827] A stirred solution of (2S,3R)-tert-butyl
6-oxo-2,3-diphenylmorpholine-4-carboxylate 72A (1000 mg, 2.8 mmol,
1 equiv.) and 1-bromo-4-fluorobutane (2.57 g, 13.5 mmol, 4.5
equiv., supplied by Sigma-Aldrich) in anhydrous THF (10 mL) and
HMPA (1 mL) was cooled to -78.degree. C. and treated dropwise with
1M Lithium bis(trimethylsilyl) amide in THF (4.2 mL, 4.2 mmol, 1.5
equiv.) under argon. After 10 min. the reaction mixture was stirred
at -40.degree. C. for 4 h. The reaction was quenched with EtOAc and
poured into a mixture of EtOAc (50 mL) and an aqueous solution of
NH.sub.4Cl (50 mL, 1 M). The organic layer was separated and
concentrated in vacuo to provide a crude residue which was
subjected to silica gel chromatography eluting with 0% to 100%
EtOAc in hexanes, to afford the title compound 74B LCMS (m/z):
328.9 [M+H-Boc]+; t.sub.R=1.38 min. on LC/MS Method A.
Synthesis of (R)-methyl 2-amino-6-fluorohexanoate (74C)
[0828] A 2-neck flask containing lithium (170 mg, 24.5 mmol, 15
equiv.) was cooled at -40.degree. C. before liquid ammonia (15 mL)
was added via a cold-finger. To the deep blue mixture
(3R,5R,6S)-tert-butyl
3-(4-fluorobutyl)-2-oxo-5,6-diphenylmorpholine-4-carboxylate 74B
(700 mg, 1.6 mmol, 1 equiv.) was added. The reaction mixture was
maintained at this temperature for 1 h and then allowed to warm up
to rt. The reaction was slowly quenched with NH.sub.4Cl solution
and diluted with diethyl ether and the organic layer separated. The
aqueous layer was adjusted to pH 5 with 1N HCl and was then
extracted with EtOAc. The organic layers were washed with saturated
NH.sub.4Cl, dried over MgSO.sub.4, filtered, and concentrated under
reduced pressure. The organic residues were combined and treated
with DCM (10 mL) and MeOH (1 mL) along with
(trimethylsilyl)diazomethane (2.0M solution in hexanes, 0.50 mL,
3.2 mmol, 4 equiv.). After 1 h the reaction mixture was
concentrated under reduced pressure. The crude residue material was
treated with DCM (5 mL) and TFA (5 mL). The mixture was stirred for
2 h and then concentrated under reduced pressure to provide crude
74C that was used without further purification.
Synthesis of (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-6-fluorohexanoate
(74D)
[0829] 2,4,-dichloropyrido[3,2-d]pyrimidine (163 mg, 0.82 mmol, 1.1
equiv.) was dissolved in dioxane (6 mL), N,N-diisopropylethylamine
(0.53 mL, 2.9 mmol, 4 equiv.) and (R)-methyl
2-amino-6-fluorohexanoate 74C (205 mg, 0.74 mmol, 1 equiv.). The
reaction mixture was stirred for 1h and then the mixture of 74D
used directly. LCMS (m/z): 326.80 [M+H].sup.+; t.sub.R=1.04 min. on
LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-6-fl-
uorohexanoate (74E)
[0830] A solution of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-6-fl-
uorohexanoate 74D (243 mg, 0.74 mmol, 1 equiv.) prepared as
described, was treated with 2,4-dimethoxybenzylamine (0.22 mL, 1.49
mmol, 2 equiv.). The reaction was heated at 120.degree. C.
overnight. The reaction mixture was partitioned between EtOAc (50
mL) and H.sub.2O (50 mL). The organic layer was separated, dried
over Na.sub.2SO.sub.4, and concentrated in vacuo. The residue was
subjected to silica gel chromatography eluting with 0% to 100%
EtOAc in hexanes to provide 74E. LCMS (m/z): 445.61[M+H].sup.+;
t.sub.R=0.87 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
6-fluorohexan-1-ol (74F)
[0831] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-6-fl-
uorohexanoate 74E (236 mg, 0.52 mmol, 1 equiv) was treated with THF
(5 mL) and 1M lithium aluminum hydride in ether (1.5 mL, 1.54 mmol,
3 equiv.). The reaction was stirred at rt. After 2 h, the reaction
was quenched with water (50 mL) and extracted with EtOAc (50 mL).
The organic layer was dried over Na.sub.2SO.sub.4, and concentrated
in vacuo. The crude material 74F was used without further
purification. LCMS (m/z): 430.52 [M+H].sup.+; t.sub.R=0.79 min. on
LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-6-fluorohexan-1-ol
(74)
[0832]
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)a-
mino)-6-fluorohexan-1-ol 74F (80 mg, 0.18 mmol, 1 equiv.) was
treated with DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction
mixture was concentrated under reduced pressure and subjected to
reverse phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a
Hydro-RP column) to furnish, after collection of product fractions
and removal of volatiles in vacuo, 74 as its TFA salt. LCMS (m/z):
280.15 [M+H].sup.+; t.sub.R=0.56 min. on LC/MS Method A. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 8.64 (dd, J=4.3, 1.4 Hz, 1H),
7.84 (dd, J=8.5, 1.4 Hz, 1H), 4.63-4.50 (m, 1H), 4.47 (t, J=6.0 Hz,
1H), 4.35 (t, J=6.0 Hz, 1H), 3.74 (d, J=5.3 Hz, 2H), 1.89-1.61 (m,
4H), 1.60-1.39 (m, 2H). .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-77.66, -220.85 (ddd, J=47.6, 25.5, 22.1 Hz).
Example 75
##STR00215##
[0833] Synthesis of (3R,5R,6S)-tert-butyl
2-oxo-3-pentyl-5,6-diphenylmorpholine-4-carboxylate (75B)
[0834] A stirred solution of (2S,3R)-tert-butyl
6-oxo-2,3-diphenylmorpholine-4-carboxylate 72A (1000 mg, 2.8 mmol,
1 equiv., supplied by Sigma-Aldrich) and 1-iodopentane (1.8 mL,
14.2 mmol, 5 equiv., supplied by Sigma-Aldrich) in anhydrous THF
(15 mL) and HMPA (1.5 mL) cooled to -78.degree. C., was treated
dropwise with 1M lithium bis(trimethylsilyl) amide in THF (4.2 ml,
1.5 equiv.) under argon. After 10 min. the reaction mixture was
stirred at -40.degree. C. for 4 h. The reaction mixture was
quenched with EtOAc and poured into a mixture of EtOAc (50 mL) and
an aqueous solution of NH.sub.4Cl (50 mL, 1 M). The organic layer
was separated and concentrated in vacuo to provide a crude residue
which was subjected to silica gel chromatography eluting with 0% to
100% EtOAc in hexanes to afford 75B. LCMS (m/z): 310.08
[M+H].sup.+; t.sub.R=0.1.33 min. on LC/MS Method A.
Synthesis of (R)-methyl 2-aminoheptanoate (75C)
[0835] A 2-neck flask containing lithium (110 mg, 15.9 mmol, 15
equiv.) was cooled at -40.degree. C. before liquid ammonia (15 mL)
was added via a cold-finger. To the deep blue mixture was added
(3R,5R,6S)-tert-butyl
2-oxo-3-pentyl-5,6-diphenylmorpholine-4-carboxylate 75B (450 mg,
1.06 mmol, 1 equiv.). The reaction was maintained at this
temperature for 1h and then allowed to warm to rt. The reaction was
slowly quenched with NH.sub.4Cl (5 mL) solution and diluted with
ether (50 mL) and separated. To the aqueous layer was added 1N HCl
to pH 5 which was then extracted with EtOAc (50 mL). Each of the
organic layers was then washed separately with saturated
NH.sub.4Cl, then combined, dried over MgSO.sub.4, filtered, and
concentrated under reduced pressure. The residue was treated with
DCM (10 mL) and MeOH (1 mL) along with
(trimethylsilyl)diazomethane, 2.0M solution in hexanes (1.1 mL, 2.1
mmol, 4 equiv.). After 1 h the reaction was concentrated under
reduced pressure and the residue dissolved in DCM (5 mL) and TFA (5
mL). The mixture was stirred for 2 h and then concentrated under
reduced pressure to afford crude 75C which was used without further
purification.
Synthesis of (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)heptanoate (75D)
[0836] A solution of 2,4,-dichloropyrido[3,2-d]pyrimidine (89 mg,
0.44 mmol, 1.2 equiv.) in THF (5 mL) was treated with
N,N-diisopropylethylamine (0.26 mL, 1.76 mmol, 4 equiv.) and
(R)-methyl 2-aminoheptanoate 75C (71 mg, 0.44 mmol, 1 equiv., TFA
salt). The reaction was stirred for 1 h and then the mixture
containing 75D was used without purification. LCMS (m/z): 323.8
[M+H].sup.+; t.sub.R=1.32 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)hepta-
noate (75E)
[0837] To the solution containing (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)heptanoate 75D (120
mg, 0.37 mmol, 1 equiv.) prepared as described, was added
2,4-dimethoxybenzylamine (0.17 mL, 1.1 mmol, 3 equiv.). The
reaction mixture was heated at 120.degree. C. overnight. The
reaction mixture partitioned between EtOAc (50 mL) and H.sub.2O (50
mL). The organic layer was separated, dried, and concentrated in
vacuo. The residue was subjected to silica gel chromatography
eluting with 0% to 100% EtOAc in hexanes to provide the title
compound 75E. LCMS (m/z): 454.6 [M+H].sup.+; t.sub.R=1.02 min. on
LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)h-
eptan-1-ol (75F)
[0838] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)hepta-
noate 75E (169 mg, 0.37 mmol, 1 equiv.) was dissolved in THF (5 mL)
and treated with 1M lithium aluminum hydride in ether (1.1 mL, 1.1
mmol, 3 equiv.). The reaction mixture was stirred at rt. After 2 h,
the reaction was quenched with water and extracted with EtOAc. The
organics were separated, dried, and concentrated in vacuo. The
crude product 75F was used without further purification. LCMS
(m/z): 426.4 [M+H].sup.+; t.sub.R=0.95 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)heptan-1-ol
(75)
[0839]
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)a-
mino)heptan-1-ol 75F (20 mg, 0.05 mmol, 1 equiv.) was dissolved in
DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction mixture was
concentrated under reduced pressure and the residue subjected to
reverse phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a
Hydro-RP column) to furnish, after collection of product fractions
and removal of volatiles in vacuo, 75 as its TFA salt. LCMS (m/z):
276.4 [M+H].sup.+; t.sub.R=0.71 min. on LC/MS Method A. .sup.1H NMR
(400 MHz, Methanol-d.sub.4) .delta. 8.65 (dd, J=4.3, 1.6 Hz, 1H),
7.92-7.66 (m, 2H), 4.66-4.43 (m, 1H), 3.73 (d, J=5.3 Hz, 2H),
1.81-1.57 (m, 2H), 1.51-1.20 (m, 9H), 0.89 (t, J=7.0 Hz, 3H).
.sup.19F NMR (377 MHz, Methanol-d.sub.4) .delta. -77.55.
Example 76 and Example 77
##STR00216## ##STR00217##
[0840] Synthesis of (S)-methyl
2-((tert-butoxycarbonyl)amino)-3-iodopropanoate (76B)
[0841] (R)-methyl
2-((tert-butoxycarbonyl)amino)-3-hydroxypropanoate 76A (6 g, 27.37
mmol, supplied by Sigma-Aldrich) was treated with DMF (100 mL) and
cooled to 0.degree. C. before methyltriphenoxyphosphonium iodide
(16.1 g, 35.58 mmol, 1.3 equiv., supplied by Sigma-Aldrich) was
slowly added. The reaction mixture was stirred overnight and solid
NaHCO.sub.3 (14 g) and water (100 mL) were added to the reaction.
The reaction mixture was stirred for 15 min. and then the mixture
was extracted with hexanes in diethyl ether, (1:1) (2.times.250
mL). The combined organic extracts were washed with 0.5M NaOH
solution (3.times.75 mL) and saturated NH.sub.4Cl (75 mL), dried
over MgSO.sub.4, filtered and concentrated under reduced pressure
to afford the crude product 76B. LCMS (m/z): 331.13 [M+H].sup.+;
t.sub.R=1.16 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((tert-butoxycarbonyl)amino)-5-methylhex-5-enoate (76C)
[0842] Zinc dust (2.4 g, 36.4 mmol, 4 equiv.) was added to iodine
(93 mg, 0.37 mmol, 0.04 equiv.) in a three-neck round-bottomed
flask and heated under vacuum for 10 min. The flask was flushed
with nitrogen and evacuated three times. (S)-methyl
2-((tert-butoxycarbonyl)amino)-3-iodopranoate 76B (3000 mg, 9.11
mmol) was dissolved in dry DMF (5 mL) and added to the zinc slurry
at 0.degree. C. The reaction mixture was stirred at rt for 1 h.
Copper (I) bromide-dimethylsulfide complex (187.39 mg, 0.91 mmol,
0.1 equiv., supplied by Sigma-Aldrich) was placed in a separate
three-necked flask and gently dried under vacuum until a color
change from white to green was observed. Dry DMF (4 mL) and
3-chloro-2-methylpropene (1.34 mL, 13.67 mmol, supplied by
Sigma-Aldrich) were added, and the reaction was cooled to
-15.degree. C. Once zinc insertion in the first step was complete,
stirring was stopped, and the zinc allowed to settle. The
supernatant was removed via syringe and added dropwise to the
electrophile and Cu catalyst mixture at -15.degree. C. The cold
bath was removed, and the reaction mixture was stirred at rt for 2
days. EtOAc (100 mL) was added, and the reaction was stirred for 15
min. The reaction mixture was washed with 1M Na.sub.2S.sub.2O.sub.3
(100 mL), water (2.times.100 mL), and brine (100 mL), dried over
MgSO.sub.4, filtered, and concentrated reduced pressure. The
residue was subjected to silica gelchromatography eluting with 0%
to 100% EtOAc in hexane to provide 76C. LCMS (m/z): 157.95
[M+H-Boc]+; t.sub.R=1.16 min. on LC/MS Method A.
Synthesis of (R)-methyl 2-amino-5-methylhex-5-enoate (76D)
[0843] (R)-methyl 2-((tert-butoxycarbonyl)amino)heptanoate 76C (655
mg, 3 mmol) was treated with DCM (5 mL) and TFA (5 mL) and stirred
for 2 h. The mixture was then concentrated under reduced pressure
to provide 76D that was used without further purification.
Synthesis of (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-5-methylhex-5-enoate
(76E)
[0844] 2,4,-dichloropyrido[3,2-d]pyrimidine (466 mg, 2 mmol, 1
equiv.) was treated with THF (10 mL) followed by
N,N-diisopropylethylamine (1.66 mL, 9 mmol, 4 equiv.), and then
(R)-methyl 2-amino-5-methylhex-5-enoate 76D (593 mg, 2 mmol, 1
equiv., TFA salt). The reaction mixture was stirred for 1 h and
then the product 76E was used directly. LCMS (m/z): 321.2
[M+H].sup.+; t.sub.R=1.19 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-me-
thylhex-5-enoate (76F)
[0845] The solution of (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-5-methylhex-5-enoate
76E (748 mg, 2 mmol, 1 equiv.) prepared as described, was treated
with 2,4-dimethoxybenzylamine (0.69 mL, 5 mmol, 2 equiv.) and
N,N-diisopropylethylamine (1.66 mL, 9 mmol, 4 equiv.). The reaction
mixture was heated at 120.degree. C. overnight. The reaction
mixture was partitioned between EtOAc (50 mL) and H.sub.2O (50 mL).
The organic layer was separated, dried over MgSO.sub.4, and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with 0% to 100% EtOAc in hexane to provide
the title compound 76F (LCMS (m/z): 452.55 [M+H].sup.+;
t.sub.R=0.97 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-me-
thylhexanoate (76G)
[0846] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-me-
thylhex-5-enoate 76F (35 mg, 0.08 mmol) was treated with Pd/C (50
mg) and EtOH (5 mL) and then stirred under hydrogen. After 4 h the
solid was removed by filtration and the filtrate was concentrated
under reduced pressure. The resulting residue of 76G was used
without further purification. LCMS (m/z): 454.24 [M+H].sup.+;
t.sub.R=1.06 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
5-methylhexan-1-ol (76H)
[0847] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-me-
thylhexanoate 76G (32 mg, 0.37 mmol, 1 equiv.) was treated with THF
(5 mL) and 1M lithium aluminum hydride in ether (0.2 mL, 0.2 mmol,
3 equiv.). The reaction mixture was stirred for 2 h and then
quenched with water (50 mL) and extracted with EtOAc (50 mL). The
organic layer was separated, dried over MgSO.sub.4, and
concentrated in vacuo. The crude material 76H was used without
further purification. LCMS (m/z): 426.23 [M+H].sup.+; t.sub.R=0.96
min. on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-5-methylhexan-1-ol.
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
5-methylhexan-1-ol (76)
[0848] Compound 76H (25 mg, 0.05 mmol, 1 equiv.) was treated with
DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction mixture was
concentrated under reduced pressure and subjected to reverse phase
HPLC (10% to 70% MeCN in water with 0.1% TFA using a Hydro-RP) to
furnish, after collection of product fractions and removal of
volatiles in vacuo, 76. LCMS (m/z): 276.13 [M+H].sup.+;
t.sub.R=0.70 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
5-methylhex-5-en-1-ol (77A)
[0849] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-me-
thylhex-5-enoate 76F (40 mg, 90 mmol, 1 equiv.) was treated with
THF (5 mL) and 1M lithium aluminum hydride in ether (0.27 mL, 0.27
mmol, 3 equiv.). The reaction mixture was stirred for 2 h and then
quenched with water (50 ml) and extracted with EtOAc (50 mL). The
organics were separated, dried, and concentrated in vacuo to
provide a residue of 77A that was used without further
purification. LCMS (m/z): 424.20 [M+H].sup.+; t.sub.R=0.88 min. on
LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-5-methylhex-5-en-1-ol
(77)
[0850] 77A (40 mg, 0.095 mmol, 1 equiv.) was treated with DCM (2
mL) and TFA (0.5 mL). After 3 h the reaction mixture was
concentrated under reduced pressure and subjected to reverse phase
HPLC (10% to 70% MeCN in water with 0.1% TFA using a Hydro-RP
column) to furnish, after collection of product fractions and
removal of volatiles in vacuo, the title compound 77 as its TFA
salt. LCMS (m/z): 274.43 [M+H].sup.+; t.sub.R=0.65 min. on LC/MS
Method A. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.59-8.42 (m,
1H), 7.75-7.52 (m, 2H), 4.45-4.13 (m, 1H), 3.87-3.69 (m, 1H),
3.65-3.44 (m, 2H), 2.30 (dq, J=15.0, 7.1 Hz, 1H), 2.01-1.73 (m,
2H), 1.68-1.41 (m, 4H), 1.26-1.05 (m, 6H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.52.
Example 78
##STR00218## ##STR00219##
[0851] Synthesis of (R)-methyl
2-((tert-butoxycarbonyl)amino)-5-oxohexanoate (78A)
[0852] (R)-methyl
2-((tert-butoxycarbonyl)amino)-5-methylhex-5-enoate 76C (775 mg,
3.01 mmol) was treated with DCM (20 mL) and MeOH (5 mL) before
cooling to -78.degree. C. Ozone was bubbled through the reaction
mixture. After 10 min., the mixture was quenched with dimethyl
sulfide (0.90 mL, 12 mmol, 4 equiv.) and allowed to warm up to rt.
EtOAc (100 mL) was added, and the reaction was stirred for 15 min.
The mixture was washed with 1M Na.sub.2S.sub.2O.sub.3 (100 mL),
water (2.times.100 mL), and brine (100 mL) and dried over
MgSO.sub.4. The organic solution was filtered and concentrated
under reduced pressure, and the resulting residue was subjected to
silica gel chromatography eluting with 0% to 100% EtOAc in hexane
to provide 78A .sup.1H NMR (400 MHz, Chloroform-d) .delta. 5.11 (d,
J=8.3 Hz, 1H), 4.33-4.20 (m, 1H), 3.73 (s, 4H), 2.63-2.42 (m, 3H),
2.14 (s, 4H), 2.12-2.05 (m, 1H), 1.94-1.81 (m, 1H), 1.42 (s,
13H).
Synthesis of (R)-methyl
2-((tert-butoxycarbonyl)amino)-5,5-difluorohexanoate (78B)
[0853] (R)-methyl 2-((tert-butoxycarbonyl)amino)-5-oxohexanoate 78A
(235 mg, 0.91 mmol) was dissolved in DCM (10 mL), then treated with
DAST 95% (0.36 mL, 2.72 mmol). The reaction was stirred for 16 h.
EtOAc (50 mL) and NaHCO.sub.3 solution (5 mL) were added and the
reaction was stirred for 5 min. The reaction mixture was washed
with 1M Na.sub.2S.sub.2O.sub.3 (100 mL), water (2.times.100 mL),
and brine (100 mL) and dried over MgSO.sub.4. The solvent was
removed under reduced pressure and the residue subjected to silica
gel chromatography eluting with 0% to 100% EtOAc in hexanes to
afford 78B. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 5.04 (s,
1H), 4.32 (s, 1H), 3.76 (s, 5H), 2.16-1.99 (m, 2H), 1.98-1.75 (m,
5H), 1.69-1.52 (m, 7H), 1.44 (s, 16H), 1.34-1.20 (m, 2H), 0.92-0.80
(m, 1H). .sup.19F NMR (377 MHz, Chloroform-d) 6-92.14 (dq, J=50.1,
17.0 Hz).
Synthesis of (R)-methyl 2-amino-5,5-difluorohexanoate (78C)
[0854] (R)-methyl
2-((tert-butoxycarbonyl)amino)-5,5-difluorohexanoate 78B (36 mg,
0.13 mmol, 1 equiv.) was treated with DCM (2 mL) and TFA (0.5 mL).
After 3 h the reaction mixture was concentrated under reduced
pressure and the crude product 78C was used without further
purification.
Synthesis of (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-5,5-difluorohexanoate
(78D)
[0855] 2,4,-dichloropyrido[3,2-d]pyrimidine (33 mg, 0.16 mmol, 1.25
equiv.) was treated with THF (10 mL) followed by
N,N-diisopropylethylamine (0.18 mL, 1.0 mmol, 8 equiv.), and
(R)-methyl 2-amino-5,5-difluorohexanoate 78C (36 mg, 0.13 mmol, 1
equiv., TFA salt). The reaction mixture was stirred for 1 h to
generate 78D and then this mixture was used directly. LCMS (m/z):
345.13 [M+H].sup.+; t.sub.R=1.08 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5,5--
difluorohexanoate (78E)
[0856] (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-5,5-difluorohexanoate
78D (45 mg, 0.13 mmol, 1 equiv.) solution as described, was treated
with 2,4-dimethoxybenzylamine (0.077 mL, 0.52 mmol, 4 equiv.). The
reaction was heated at 120.degree. C. overnight. The reaction
mixture was partitioned between EtOAc (100 mL) and H.sub.2O (100
mL). The organics were separated, dried, and concentrated in vacuo.
The residue was subjected to silica gel chromatography eluting with
0% to 100% EtOAc in hexane to provide the title compound 78E. LCMS
(m/z): 476.13 [M+H].sup.+; t.sub.R=0.99 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
5,5-difluorohexan-1-ol (78F)
[0857] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5,5--
difluorohexanoate 78E (26 mg, 0.055 mmol, 1 equiv.) was treated
with THF (5 mL) and 1M lithium aluminum hydride in ether (0.2 mL,
0.2 mmol, 4 equiv.). The reaction mixture was stirred at rt for 2 h
and then the reaction was quenched with water (50 mL) and extracted
with EtOAc (50 mL). The organics were separated, dried, and
concentrated in vacuo. The crude material 78E was used without
further purification. LCMS (m/z): 448.12 [M+H].sup.+; t.sub.R=0.91
min. on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-5,5-difluorohexan-1-ol
(78)
[0858]
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)a-
mino)-5,5-difluorohexan-1-ol 78F (24 mg, 0.055 mmol, 1 equiv.) was
treated with DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction
mixture was concentrated under reduced pressure and subjected to
reverse phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a
Hydro-RP column) to furnish, after collection of product fractions
and removal of volatiles in vacuo, 78. LCMS (m/z): 298.10
[M+H].sup.+; t.sub.R=0.60 min. on LC/MS Method A. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.66 (dd, J=4.3, 1.5 Hz, 5H), 7.86-7.73
(m, 10H), 4.55 (dd, J=9.0, 4.7 Hz, 5H), 4.30 (s, 1H), 3.83 (s, 2H),
3.76 (t, J=5.1 Hz, 12H), 3.34 (s, 3H), 2.05-1.85 (m, 23H), 1.58 (t,
J=18.5 Hz, 17H), 1.41-1.26 (m, 17H), 1.14 (s, 1H), 0.96-0.88 (m,
4H), 0.87 (s, 2H). .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-77.67, -92.96 (p, J=17.4 Hz).
Example 79
##STR00220## ##STR00221##
[0859] Synthesis of (R)-methyl
2-((tert-butoxycarbonyl)amino)-4-oxohexanoate (79A)
[0860] Zinc dust (1.58 g, 24.3 mmol, 4 equiv.) was added to iodine
(61 mg, 0.24 mmol, 0.04 equiv.) in a three-neck round-bottomed
flask and heated under vacuum for 10 min. The flask was flushed
with nitrogen and evacuated three times. After cooling, benzene (10
mL) and DMA (1 mL) were added. 1,2-bromoethane (0.05 mL, 0.61 mmol)
and chlorotrimethylsilane (33.01 mg, 0.3 mmol) were then added
consecutively and this process repeated three times in the course
of 1 hour. (S)-methyl
2-((tert-butoxycarbonyl)amino)-3-iodopropanoate 76B (2400 mg, 0.6
mmol, 1 equiv.) was dissolved in benzene (10 mL) and DMA (1 mL) and
added to the zinc slurry. After about 1 h, bis(triphenylphosphine)
palladium (II) dichloride, (106.62 mg, 0.025 equiv.) and
Tetrakis(triphenylphosphine)palladium(0) (175.68 mg, 0.025 equiv.)
were added followed by propionyl chloride (0.8 mL, 0.01 mol, 1.5
equiv.). The reaction mixture was warmed to 70.degree. C. and
stirred for 1 h. EtOAc (100 mL) was added, and the reaction mixture
was filtered over a pad of Celite. The filtrate was washed with
water (2.times.100 mL), brine (100 mL), dried over MgSO.sub.4,
filtered and concentrated under reduced pressure. The residue was
subjected to silica gel chromatography eluting with 0% to 100%
EtOAc in hexane to afford 79A. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 5.48 (d, J=8.6 Hz, 1H), 4.46 (dt, J=8.7, 4.4 Hz, 1H), 3.69
(s, 3H), 3.10 (dd, J=18.0, 4.5 Hz, 1H), 2.89 (dd, J=17.9, 4.4 Hz,
1H), 2.40 (qd, J=7.3, 1.7 Hz, 2H), 1.40 (s, 10H), 1.01 (t, J=7.3
Hz, 3H).
Synthesis of (R)-methyl
2-((tert-butoxycarbonyl)amino)-4,4-difluorohexanoate (79B)
[0861] (R)-methyl 2-((tert-butoxycarbonyl)amino)-4-oxohexanoate 79A
(475 mg, 1.8 mmol, 1 equiv.) was treated with DAST (0.97 mL, 7.3
mmol, 4 equiv.). The reaction mixture was stirred for 16 h. EtOAc
(50 mL) and NaHCO.sub.3 solution (5 mL) were added and the reaction
was stirred for 5 min. The reaction mixture was washed with 1M
Na.sub.2S.sub.2O.sub.3 (100 mL), water (2.times.100 mL), brine (100
mL), dried over MgSO.sub.4, filtered, and concentrated under
reduced pressure. The residue was subjected to silica gel
chromatography eluting with 0% to 100% EtOAc in hexane to afford
79B. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 5.20 (d, J=8.3 Hz,
1H), 4.51 (d, J=7.0 Hz, 1H), 3.82 (s, 1H), 3.75 (d, J=0.5 Hz, 5H),
3.35-3.17 (m, 2H), 3.11 (q, J=7.1 Hz, 2H), 2.52-2.27 (m, 3H), 1.89
(ddt, J=24.1, 16.8, 7.5 Hz, 3H), 1.44 (d, J=0.6 Hz, 15H), 1.23-1.13
(m, 4H), 1.00 (dt, J=10.7, 7.5 Hz, 6H). .sup.19F NMR (377 MHz,
Chloroform-d) 6-93.56--109.28 (m).
Synthesis of (R)-methyl 2-amino-5,5-difluorohexanoate. (R)-methyl
2-((tert-butoxycarbonyl)amino)-4,4-difluorohexanoate (79C)
[0862] Compound 79B (98 mg, 0.35 mmol, 1 equiv.) was treated with
DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction mixture was
concentrated under reduced pressure and the crude product 79C as
its TFA salt was used without further purification.
Synthesis of (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-4,4-difluorohexanoate
(79D)
[0863] 2,4,-dichloropyrido[3,2-d]pyrimidine (80 mg, 0.39 mmol, 1
equiv.) was treated with THF (10 ml) followed by
N,N-diisopropylethylamine (0.28 mL, 1.5 mmol, 4 equiv.), and then
(R)-methyl 2-amino-5,5-difluorohexanoate 79C (110 mg, 0.39 mmol, 1
equiv., TFA salt). The reaction mixture was stirred for 1 h to form
79D and then this solution was used directly. LCMS (m/z): 345.11
[M+H].sup.+; t.sub.R=1.09 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-4,4--
difluorohexanoate (79E)
[0864] (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-5,5-difluorohexanoate
79D solution prepared as described, was treated with
2,4-dimethoxybenzylamine (0.077 mL, 0.52 mmol, 4 equiv.). The
reaction was heated at 120.degree. C. overnight. The reaction
mixture partitioned between EtOAc (50 mL) and H.sub.2O (50 mL). The
organics were separated, dried over MgSO.sub.4, and concentrated in
vacuo. The residue was subjected to silica gel chromatography
eluting with 0% to 100% EtOAc in hexane to provide 79E. LCMS (m/z):
476.32 [M+H].sup.+; t.sub.R=0.96 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
4,4-difluorohexan-1-ol (79F)
[0865] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-4,4--
difluorohexanoate 79E (35 mg, 0.074 mmol, 1 equiv.) was treated
with THF (5 mL) and 1M lithium aluminum hydride in ether (0.29 mL,
0.29 mmol, 4 equiv.). The reaction mixture was stirred for 2 h and
then the reaction was quenched with water (50 mL) and extracted
with EtOAc (50 mE). The organic layer was separated, dried over
MgSO.sub.4, and concentrated in vacuo. The crude material 79F was
used without further purification. LCMS (m/z): 448.20 [M+H].sup.+;
t.sub.R=0.86 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-4,4-difluorohexan-1-ol
(79)
[0866]
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)a-
mino)-4,4-difluorohexan-1-ol 79F (24 mg, 0.055 mmol, 1 equiv.) was
treated with DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction
mixture was concentrated under reduced pressure and subjected to
reverse phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a
Hydro-RP column) to furnish, after collection of product fractions
and removal of volatiles in vacuo, 79 as its TFA salt. LCMS (m/z):
298.11 [M+H].sup.+; t.sub.R=0.63 min. on LC/MS Method A. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 8.51 (dd, J=4.3, 1.5 Hz, 1H),
7.77-7.54 (m, 2H), 3.60 (d, J=5.7 Hz, 2H), 2.37-2.11 (m, 2H),
1.93-1.69 (m, 2H), 0.87 (t, J=7.5 Hz, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.80, -98.15, -105.45 (m).
Example 80 and Example 81
##STR00222##
[0867] Synthesis of (R)-methyl 2-amino-2-methylpent-4-enoate
(80B)
[0868]
(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpent-4-en-
oic acid 80A (1 g, 2.8 mmol, 1 equiv., provided by Okeanos Inc.)
was treated with DCM (10 mL) and MeOH (1 mL) along with
(trimethylsilyl)diazomethane (2.0M solution in hexanes, 2.3 mL, 5.6
mmol, 2.5 equiv.). After 1 h the reaction mixture was concentrated
under reduced pressure to provide a residue. The residue was
treated with THF (10 mL) followed by piperidine (0.56 mL, 0.006
mol, 2 equiv.). The mixture was stirred for 2 h and then
concentrated under reduced pressure to provide 80B that was used
without further purification.
Synthesis of (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylpent-4-enoate
(80C)
[0869] 2,4,-dichloropyrido[3,2-d]pyrimidine (540 mg, 2.71 mmol, 1
equiv.) was treated with dioxane (15 ml) followed by
N,N-diisopropylethylamine (1.9 mL, 10.8 mmol, 4 equiv.), and then
(R)-methyl 2-amino-2-methylpent-4-enoate 80B (486 mg, 2.71 mmol, 1
equiv.). The reaction mixture was stirred at 80.degree. C. for 15
minutes, then more 2,4,-dichloropyrido[3,2-d]pyrimidine (250 mg,
1.25 mmol) was added. The mixture was stirred at 80.degree. C.
overnight to form 80C which was then used directly. LCMS (m/z):
307.12 [M+H].sup.+; t.sub.R=1.14 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-2-me-
thylpent-4-enoate (80D)
[0870] (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylpent-4-enoate
80C solution prepared as described was treated with
2,4-dimethoxybenzylamine (0.80 mL, 5.0 mmol, 2 equiv.). The
reaction was heated at 120.degree. C. overnight. The reaction
mixture was partitioned between EtOAc (50 mL) and H.sub.2O (50 mL).
The organics were separated, dried over MgSO.sub.4, and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with 0% to 100% EtOAc in hexane to provide
80D. LCMS (m/z): 438.20 [M+H].sup.+; t.sub.R=1.04 min. on LC/MS
Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
2-methylpent-4-en-1-ol (80E)
[0871] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-2-me-
thylpent-4-enoate 80D (634 mg, 1.44 mmol, 1 equiv.) was treated
with THF (20 mL) and 1M lithium aluminum hydride in ether (3.6 mL,
3.62 mmol, 2.5 equiv.). The reaction mixture was stirred for 2 h
and then the reaction was quenched with water (100 mL) and
extracted with EtOAc (100 mL). The organic layer was separated,
dried over MgSO.sub.4, and concentrated in vacuo. The residue was
subjected to silica gel chromatography eluting with 0% to 100%
EtOAc in hexane to provide the 80E. LCMS (m/z): 410.17 [M+H].sup.+;
t.sub.R=0.97 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
2-methylpentan-1-ol (80F)
[0872] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-me-
thylhex-5-enoate 80E (35 mg, 0.09 mmol) was treated with Pd/C (60
mg) and EtOH (5 mL) and then stirred under hydrogen. After 24 h,
the solid was filtered off and the filtrate was concentrated under
reduced pressure. The resulting residue 80F was used without
further purification. LCMS (m/z): 454.24 [M+H].sup.+; t.sub.R=1.06
min. on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylpentan-1-ol
(80)
[0873]
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)a-
mino)-2-methylpentan-1-ol 80F (35 mg, 0.09 mmol, 1 equiv.) was
treated with DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction
mixture was concentrated under reduced pressure and subjected to
reverse phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a
Hydro-RP column) to furnish, after collection of product fractions
and removal of volatiles in vacuo, 80 as its TFA salt. LCMS (m/z):
262.13 [M+H].sup.+; t.sub.R=0.64 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylpent-4-en-1-ol
(81)
[0874] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-5-me-
thylhex-5-enoate 80E (40 mg, 0.10 mmol, 1 equiv.) was treated with
DCM (2 mL) and TFA (0.5 mL). After 4 h the reaction mixture was
concentrated under reduced pressure and subjected to reverse phase
HPLC (10% to 70% MeCN in water with 0.1% TFA using a Hydro-RP
column) to furnish, after collection of product fractions and
removal of volatiles in vacuo, 81 as its TFA salt. LCMS (m/z):
260.10 [M+H].sup.+; t.sub.R=0.63 min. on LC/MS Method A. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 8.59 (dd, J=4.4, 1.4 Hz, 1H),
7.84 (dd, J=8.5, 1.4 Hz, 1H), 7.75 (dd, J=8.5, 4.4 Hz, 1H), 5.87
(ddt, J=17.5, 10.1, 7.4 Hz, 1H), 5.33-4.94 (m, 2H), 3.94 (d, J=11.2
Hz, 1H), 3.78 (d, J=11.2 Hz, 1H), 2.97-2.76 (m, 1H), 2.70 (ddt,
J=13.9, 7.3, 1.2 Hz, 1H), 1.55 (s, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.56.
Example 82
##STR00223##
[0875] Synthesis of 2-amino-7-bromopyrido[3,2-d]pyrimidin-4-ol
(82A)
[0876] A mixture of 3-amino-5-bromopyridine-2-carboxamide (3.0 g,
13.9 mmol, 1 equiv., supplied by Combi-Blocks Inc.),
chloroformamidine hydrochloride (3192.9 mg, 27.8 mmol, 2 equiv.),
methyl sulfone (13.1 g, 139 mmol, 10 equiv.) in sulfolane (1 mL) in
a sealed tube, was heated at 165.degree. C. After 24 h, the mixture
was diluted with water and then cooled to rt. The reaction was
adjusted to pH 12 using NH.sub.4OH and stirred for 20 minutes. The
precipitates were then filtered, rinsed with water, hexanes, and
ether, and dried in a vacuum oven at 1000C overnight to afford 82A
that was used without further purification. LCMS (m/z): 242.92
[M+H].sup.+; t.sub.R=0.55 min. on LC/MS Method A.
Synthesis of 2-amino-7-bromopyrido[3,2-d]pyrimidin-4-yl
4-methylbenzenesulfonate (82B)
[0877] 2-amino-7-bromopyrido[3,2-d]pyrimidin-4-ol 82A (1000 mg, 4.2
mmol, 1 equiv.) was treated with acetonitrile (40 mL) followed by
potassium carbonate (1433.4 mg, 10.37 mmol, 2.5 equiv.) and
p-toluenesulfonyl chloride (1186.38 mg, 6.22 mmol, 1.5 equiv.). The
reaction mixture was heated to 100.degree. C. and stirred
overnight. The mixture was allowed to cool and then diluted with
EtOAc, washed with water and saturated NH.sub.4Cl. The organic
layer was dried over MgSO.sub.4, filtered, and concentrated under
reduced pressure to afford 82B that was used without further
purification. LCMS (m/z): 396.98 [M+H].sup.+; t.sub.R=1.15 min. on
LC/MS Method A.
Synthesis of
(R)-2-((2-amino-7-bromopyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(82)
[0878] 2-Amino-7-bromopyrido[3,2-d]pyrimidin-4-yl
4-methylbenzenesulfonate 82B (50 mg, 0.13 mmol, 1 equiv.) was
treated with acetonitrile (5 mL), N,N-diisopropylethylamine (0.07
mL, 0.38 mmol, 3 equiv.) and (R)-(-)-2-amino-1-hexanol (44.48 mg,
0.38 mmol, 3 equiv.). After 16 h, the reaction mixture was
concentrated under reduced pressure and subjected to reverse phase
HPLC (10% to 70% MeCN in water using a Hydro-RP column) to furnish,
after collection of product fractions and removal of volatiles in
vacuo, 82 as its TFA salt. LCMS (m/z): 342.1 [M+H].sup.+;
t.sub.R=0.90 min. on LC/MS Method A. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.69 (d, J=1.9 Hz, 1H), 8.06 (d, J=1.9 Hz,
1H), 4.52 (dq, J=8.7, 5.5 Hz, 1H), 3.86-3.54 (m, 2H), 1.95-1.63 (m,
2H), 1.57-1.29 (m, 5H), 1.11-0.76 (m, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.42.
Example 83
##STR00224##
[0879] Synthesis of (R)-methyl 2-amino-2-methylhex-5-enoate
(83B)
[0880] (R)-methyl
2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylhex-5-enoate
83A (2 g, 5.5 mmol, 1 equiv., provided by Okeanos Inc.) was treated
with DCM (20 mL) and MeOH (4 mL) along with
(trimethylsilyl)diazomethane (2.0M solution in hexanes, 4.4 mL,
11.0 mmol, 2.5 equiv.). After 30 minutes, the reaction mixture was
concentrated under reduced pressure to provide a residue. The
residue was treated with THF (33 mL) followed by piperidine (1.9
mL, 0.02 mol, 3.5 equiv.). The mixture was stirred for 3 days and
then concentrated under reduced pressure. The residue was subjected
to silica gel chromatography eluting with 0% to 20% MeOH in DCM to
provide 83B. LCMS (m/z): 157.91 [M+H].sup.+; t.sub.R=0.59 min. on
LC/MS Method A.
Synthesis of (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-5-enoate
(83C)
[0881] 2,4,-dichloropyrido[3,2-d]pyrimidine (55 mg, 0.28 mmol, 1
equiv.) was treated with dioxane (15 ml) followed by
N,N-diisopropylethylamine (0.25 mL, 1.4 mmol, 4 equiv.), and then
(R)-methyl 2-amino-2-methylhex-5-enoate 83B (47.6 mg, 0.30 mmol, 1
equiv.). The mixture was stirred at 80.degree. C. overnight to form
83C which was used directly. LCMS (m/z): 321.14 [M+H].sup.+;
t.sub.R=1.21 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-2-me-
thylhex-5-enoate (83D)
[0882] (R)-methyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-5-enoate
83C solution prepared as described, was treated with
2,4-dimethoxybenzylamine (0.10 mL, 0.69 mmol, 2.5 equiv.). The
reaction was heated at 120.degree. C. overnight. The reaction
mixture was partitioned between EtOAc (50 mL) and H.sub.2O (50 mL).
The organics were separated, dried over MgSO.sub.4, and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with 0% to 100% EtOAc in hexane to provide
83D. LCMS (m/z): 452.21 [M+H].sup.+; t.sub.R=1.22 min. on LC/MS
Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
2-methylhex-5-en-1-ol (83E)
[0883] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-2-me-
thylhex-5-enoate 83D (25 mg, 0.06 mmol, 1 equiv.) was treated with
THF (20 mL) and 1M lithium aluminum hydride in ether (0.14 mL, 0.14
mmol, 2.5 equiv.). The reaction mixture was stirred for 2 h and
then the reaction was quenched with water (100 mL) and extracted
with EtOAc (100 mL). The organic layer was separated, dried over
MgSO4, and concentrated in vacuo to provide the 83E that was used
without further purification. LCMS (m/z): 424.14 [M+H].sup.+;
t.sub.R=1.12 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-5-en-1-ol
(83)
[0884]
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)a-
mino)-2-methylhex-5-en-1-ol 83E (23 mg, 0.05 mmol, 1 equiv.) was
treated with DCM (2 mL) and TFA (0.5 mL). After 3 h the reaction
mixture was concentrated under reduced pressure and subjected to
reverse phase HPLC (10% to 70% MeCN in water with 0.1% TFA using a
Hydro-RP column) to furnish, after collection of product fractions
and removal of volatiles in vacuo, 83 (10 mg, 65%) as its TFA salt.
LCMS (m/z): 274.7 [M+H].sup.+; t.sub.R=0.73 min. on LC/MS Method A.
.sup.1H NMR (400 MHz, Methanol-d4) .delta. 9.01 (d, J=4.5 Hz, 1H),
8.33-8.09 (m, 2H), 6.23 (ddt, J=16.4, 11.0, 5.8 Hz, 1H), 5.42 (d,
J=17.1 Hz, 1H), 4.40 (d, J=11.3 Hz, 1H), 4.26-4.03 (m, 2H), 2.57
(ddd, J=29.2, 14.7, 8.4 Hz, 3H), 2.42 (dq, J=10.9, 6.9 Hz, 1H),
1.96 (s, 3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.19
(d, J=144.5 Hz).
Example 84
Synthesis of Intermediate Compound 84E
##STR00225##
[0885] Synthesis of 3-amino-5-fluoropicolinonitrile (84B)
[0886] 3-amino-2-bromo-5-fluoropyridine 84A (25 g, 131 mmol,
Astatech Chemical, Inc) was treated with ZnCN.sub.2 (16.9 g, 1.1
equiv., 144 mmol), Pd(Ph.sub.3).sub.4 (11.3 g, 0.075 equiv., 9.8
mmol) and DMF (200 mL) and then heated to 115.degree. C. After 6 h,
the reaction mixture was allowed to cool and then concentrated
under reduced pressure to a solid. The solid was washed with EtOAc
(2.times.100 mL). The organic layers were combined and washed with
water (3.times.100 mL), saturated NH.sub.4Cl solution (100 mL),
dried over MgSO.sub.4, filtered and concentrated under reduced
pressure to provide 84B that was used without further purification.
LCMS (m/z): 138.87 [M+H].sup.+; t.sub.R=0.59 min. on LC/MS Method
A.
Synthesis of 3-amino-5-fluoropicolinamide (84C)
[0887] Compound 84B (2.6 g, 19.0 mmol, 1 equiv.) was treated with
DMSO (10 mL) and cooled to 0.degree. C. before K.sub.2CO.sub.3 (524
mg, 0.2 equiv., 3.8 mmol) was added. H.sub.2O.sub.2 (2.3 mL, 1.2
equiv., 22.8 mmol, 30% water) was then slowly added. The cooling
bath was removed and the reaction was stirred for 1 h. The reaction
mixture was diluted with water (100 mL) and extracted with EtOAc
(3.times.100). The combined organic layers were washed with water
(3.times.500) and saturated NH.sub.4Cl solution (500 mL), dried
over MgSO.sub.4, filtered and concentrated under reduced pressure.
The crude material 84C was used without further purification. LCMS
(m/z): 155.87 [M+H].sup.+; t.sub.R=0.62 min. on LC/MS Method A.
[0888] The following procedure was adapted from De Jonghe, WO
2006/1359931.
Synthesis of 7-fluoropyrido[3,2-d]pyrimidine-2,4-diol (84D)
[0889] Carboxamide 84C (1 g, 1 equiv., 6.4 mmol) was treated with
triphosgene (1.9 g, 1.0 equiv., 6.4 mmol) and dioxane (20 mL). The
reaction mixture was heated to 110.degree. C. for 30 min. The
reaction mixture was allowed to cool and concentrated under reduced
pressure. The crude solid residue was washed with DCM and diethyl
ether and allowed to air dry to provide 84D. LCMS (m/z): 181.95
[M+H].sup.+; t.sub.R=0.62 min. on LC/MS Method A.
Synthesis of 2,4-dichloro-7-fluoropyrido[3,2-d]pyrimidine (84E)
[0890] Dione 84D (13.7 g, 75.6 mmol, 1 equiv.) was treated with
phosphorus pentachloride (63.0 g, 302.6 mmol, 4 equiv.) and
phosphorus (V) oxychloride (141 mL, 20 equiv.) and heated to
110.degree. C. under a under reflux condenser for 8 h. The reaction
mixture was concentrated under reduced pressure and azeotroped with
toluene. The resultant solid was treated with EtOAc (500 mL) and
ice-water (500 mL). The organic layer was separated and washed with
saturated NaHCO.sub.3 solution (500 mL), water (500 mL), and
saturated NH.sub.4Cl (500 mL). The organic solution was dried over
MgSO.sub.4, filtered and concentrated under reduced pressure to
furnish the crude product 84E. LCMS (m/z): 213.9
[M+H+2(OMe)-2Cl].sup.+; t.sub.R=0.82 min. on LC/MS Method A.
.sup.1H NMR (400 MHz, Chloroform-d) .delta. 9.01 (d, J=2.6 Hz, 1H),
7.94 (dd, J=7.9, 2.7 Hz, 1H). .sup.19F NMR (377 MHz, Chloroform-d)
6-111.79 (d, J=7.9 Hz).
Synthesis of Compound 84
##STR00226##
[0891] Synthesis of (R)-methyl
2-((2-chloro-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-5-eno-
ate (84F)
[0892] 2,4-dichloro-7-fluoropyrido[3,2-d]pyrimidine 84E (75 mg,
0.34 mmol, 1 equiv.) was treated with dioxane (15 ml) followed by
N,N-diisopropylethylamine (0.31 mL, 1.7 mmol, 5 equiv.), and then
(R)-methyl 2-amino-2-methylhex-5-enoate 83B (59.5 mg, 0.38 mmol, 1
equiv.). The mixture was stirred at 80.degree. C. overnight to form
84F in solution which was then used directly. LCMS (m/z): 339.1
[M+H].sup.+; t.sub.R=1.23 min. on LC/MS Method A.
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin-4-yl)am-
ino)-2-methylhex-5-enoate (84G)
[0893] (R)-methyl
2-((2-chloro-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-5-eno-
ate 84F solution prepared as described, was treated with
2,4-dimethoxybenzylamine (0.10 mL, 0.69 mmol, 2.5 equiv.). The
reaction was heated at 120.degree. C. overnight. The reaction
mixture partitioned between EtOAc (50 mL) and H.sub.2O (50 mL). The
organics were separated, dried over MgSO.sub.4, and concentrated in
vacuo. The residue was subjected to silica gel chromatography
eluting with 0% to 100% EtOAc in hexane to provide 84G. LCMS (m/z):
470.25 [M+H].sup.+; t.sub.R=1.12 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin-4-y-
l)amino)-2-methylhex-5-en-1-ol (84H)
[0894] (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin-4-yl)am-
ino)-2-methylhex-5-enoate 83G (85 mg, 0.18 mmol, 1 equiv.) was
treated with THF (5 mL) and 1M lithium aluminum hydride in ether
(0.54 mL, 0.54 mmol, 3 equiv.). The reaction mixture was stirred
for 2 h and then the reaction was quenched with water (100 mL) and
extracted with EtOAc (100 mL). The organic layer was separated,
dried over MgSO.sub.4, and concentrated in vacuo to provide 84H
that was used without further purification. LCMS (m/z): 442.16
[M+H].sup.+; t.sub.R=1.07 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-5--
en-1-ol (84)
[0895]
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimid-
in-4-yl)amino)-2-methylhex-5-en-1-ol 84H (35 mg, 0.08 mmol, 1
equiv.) was treated with DCM (2 mL) and TFA (0.5 mL). After 3 h the
reaction mixture was concentrated under reduced pressure and
subjected to reverse phase HPLC (10% to 70% MeCN in water with 0.1%
TFA using a Hydro-RP column) to furnish, after collection of
product fractions and removal of volatiles in vacuo, as its TFA
salt. LCMS (m/z): 292.13 [M+H].sup.+; t.sub.R=0.62 min. on LC/MS
Method A. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.55 (d, J=2.4
Hz, 1H), 8.25 (s, 1H), 7.63 (dd, J=8.7, 2.5 Hz, 1H), 5.83 (ddt,
J=16.6, 10.2, 6.2 Hz, 1H), 5.02 (dq, J=17.1, 1.5 Hz, 1H), 4.92
(ddt, J=10.2, 2.1, 1.1 Hz, 8H), 4.08-3.88 (m, 1H), 3.69 (d, J=11.3
Hz, 1H), 2.34-1.90 (m, 4H), 1.56 (s, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.54, -118.17 (dd, J=8.8, 4.3 Hz).
Example 85
##STR00227##
[0896] Synthesis of ethyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-ethylhexanoate
(85B)
[0897] 2,4,-dichloropyrido[3,2-d]pyrimidine (1068 mg, 5.34 mmol, 1
equiv.) was treated with dioxane (10 ml) followed by
N,N-diisopropylethylamine (5.7 mL, 32.0 mmol, 6 equiv.), and then
2-amino-2-ethyl-hexanoic acid ethyl ester 85A (1000 mg, 5.34 mmol,
1 equiv., supplied by J&W Pharmlab, LLC). The mixture was
stirred at 80.degree. C. overnight. The reaction mixture
partitioned between EtOAc (50 mL) and H.sub.2O (50 mL). The
organics were separated, dried over MgSO.sub.4, and concentrated in
vacuo to afford 85B that was then used directly. LCMS (m/z): 351.23
[M+H].sup.+; t.sub.R=1.43 min. on LC/MS Method A.
Synthesis of ethyl
2-((2-((2,4-diethylbenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-2-ethy-
lhexanoate (85C)
[0898] Ethyl
2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-ethylhexanoate 85B
prepared as described, was treated with dioxane (10 mL),
N,N-diisopropylethylamine (1.7 mL, 9.5 mmol, 3 equiv.), and
2,4-dimethoxybenzylamine (0.94 mL, 6.3 mmol, 2 equiv.). The
reaction was heated at 120.degree. C. overnight. The reaction
mixture partitioned between EtOAc (50 mL) and H.sub.2O (50 mL). The
organics were separated, dried over MgSO.sub.4, and concentrated in
vacuo. The residue was subjected to silica gel chromatography
eluting with 0% to 100% EtOAc in hexane to provide 85C. LCMS (m/z):
482.27 [M+H].sup.+; t.sub.R=1.02 min. on LC/MS Method A.
Synthesis of
2-((2-((2,4-diethylbenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-2-ethy-
lhexan-1-ol (85D)
[0899] Ethyl
2-((2-((2,4-diethylbenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-2-ethy-
lhexanoate 85C (111 mg, 0.23 mmol, 1 equiv.) was treated with THF
(10 mL) and 1M lithium aluminum hydride in ether (0.92 mL, 0.92
mmol, 4 equiv.). The reaction mixture was stirred for 2 h and then
the reaction was quenched with water (100 mL) and extracted with
EtOAc (100 mL). The organic layer was separated, dried over
MgSO.sub.4, and concentrated in vacuo. The residue was subjected to
silica gel chromatography eluting with 0% to 100% EtOAc in hexane
to provide 85D. LCMS (m/z): 440.24 [M+H].sup.+; t.sub.R=0.94 min.
on LC/MS Method A.
Synthesis of
2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-ethylhexan-1-ol
(85)
[0900]
2-((2-((2,4-Diethylbenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
2-ethylhexan-1-ol 85D (16 mg, 0.04 mmol, 1 equiv.) was treated with
DCM (2 mL) and TFA (0.5 mL). After 6 h the reaction mixture was
concentrated under reduced pressure and subjected to reverse phase
HPLC (10% to 70% MeCN in water with 0.1% TFA using a Hydro-RP
column) to furnish, after collection of product fractions and
removal of volatiles in vacuo, 85 as its TFA salt. LCMS (m/z):
290.15 [M+H].sup.+; t.sub.R=0.73 min. on LC/MS Method A. .sup.1H
NMR (400 MHz, Methanol-d.sub.4) .delta. 8.62 (dd, J=4.4, 1.4 Hz,
1H), 7.93-7.61 (m, 2H), 3.98 (s, 3H), 3.91 (s, 2H), 2.10-1.82 (m,
4H), 1.46-1.20 (m, 4H), 1.10-0.71 (m, 5H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.69 (d, J=231.2 Hz).
Example 86
##STR00228##
[0901] Synthesis of (R)-2-(Dibenzylamino)hexan-1-ol (86b)
[0902] (R)-norleucinol (86a, 2046.4 mg, 17.46 mmol) was treated
with acetonitrile (40 mL) and K.sub.2CO.sub.3 (4842.4 mg, 35.04
mmol) followed by benzyl bromide (6.222 mL, 52.39 mmol) at
0.degree. C. The resulting mixture was stirred at rt. After 18 h,
the precipitate was filtered and the solids were washed with EtOAc
(30 mL). Filtrates were concentrated under reduced pressure and the
resultant residue was subjected to silica gel chromatography
eluting with 0-70% EtOAc in hexanes to provide 86b LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.20H.sub.28NO: 298.22;
found: 298.16; t.sub.R=0.82 min on LC/MS Method A.
Synthesis of (R)-2-(dibenzylamino)hexanal (86c)
[0903] Oxalyl chloride (0.18 mL, 2.10 mmol) in DCM (3 mL) was
cooled in an acetone-dry ice bath and then treated with DMSO (0.3
mL, 4.22 mmol) in DCM (1 mL) dropwise over 2 minutes. After 10 min,
a solution of compound 86b (503.5 mg, 1.69 mmol) in DCM (2 mL) was
added and resulting mixture was allowed to stir for 30 min. before
addition of triethylamine (1.2 mL, 8.61 mmol). After 1 h at
-70.about.-55.degree. C., the reaction mixture was allowed to warm
to rt, diluted with EtOAc (30 mL), and washed with water (30
mL.times.2). The aqueous fractions were extracted with EtOAc
(.times.1), and the combined organic fractions were then dried
(MgSO.sub.4), concentrated under reduced pressure, and the residue
vacuum dried to obtain compound 86c, which was used without further
purification. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.20H.sub.26NO: 296.20; found: 296.16; t.sub.R=1.12 min on
LC/MS Method A.
Synthesis of (2S,3R)-3-(Dibenzylamino)heptan-2-ol (86d) and
(2R,3R)-3-(Dibenzylamino)heptan-2-ol (86e)
[0904] Compound 86c (134.87 mg, 0.457 mmol) in diethyl ether (4 mL)
was stirred at -15.degree. C. and a 1.6 M solution of methyl
lithium in diethyl ether (4.2 mL, 6.72 mmol) was added. After 0.5
h, the reaction mixture was quenched with saturated aqueous
ammonium chloride (10 mL) and water (10 mL), and the product was
extracted with EtOAc (20 mL.times.2). The organic extracts were
washed with water (20 mL.times.1), combined, dried (MgSO.sub.4),
and then concentrated under reduced pressure. The crude residue was
subjected to silica gel chromatography eluting with 5-30% EtOAc in
hexanes to obtain 86d (first eluting compound) and compound 86e
second eluting compound.
(2S,3R)-3-(Dibenzylamino)heptan-2-ol (86d)
[0905] .sup.1H NMR (400 MHz, Chloroform-d) .delta. 7.37-7.17 (m,
10H), 4.33 (s, 1H), 3.86 (d, J=13.3 Hz, 1.9H), 3.73 (d, J=13.7 Hz,
0.1H), 3.67-3.55 (m, 1H), 3.45 (d, J=13.3 Hz, 2H), 2.64 (d, J=5.8
Hz, 0.05H), 2.33 (dt, J=9.3, 5.5 Hz, 0.95H), 1.72 (ddd, J=14.8,
12.0, 6.5 Hz, 1H), 1.50-1.20 (m, 6H), 1.18 (d, J=6.7 Hz, 0.15H),
1.09 (d, J=6.0 Hz, 2.85H), 0.96 (t, J=7.1 Hz, 3H). LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.21H.sub.30NO: 312.23;
found: 312.16; t.sub.R=0.98 min on LC/MS Method A.
(2R,3R)-3-(Dibenzylamino)heptan-2-ol (86e)
[0906] .sup.1H NMR (400 MHz, Chloroform-d) .delta. 7.44-7.13 (m,
10H), 3.88 (dt, J=8.6, 5.8 Hz, 1H), 3.73 (d, J=13.6 Hz, 2H), 3.63
(d, J=13.6 Hz, 2H), 2.65 (td, J=6.5, 4.3 Hz, 1H), 2.31 (s, 1H),
1.73 (td, J=11.0, 9.8, 5.8 Hz, 1H), 1.50-1.22 (m, 6H), 1.18 (d,
J=6.6 Hz, 3H), 0.92 (t, J=7.0 Hz, 3H). LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.21H.sub.30NO: 312.23; found:
312.16; t.sub.R=0.93 min on LC/MS Method A.
Synthesis of (2S,3R)-3-aminoheptan-2-ol (86f)
[0907] Diastereomer 86d (108.9 mg, 0.349 mmol) and 20% palladium
hydroxide on carbon (25.3 mg) in EtOH (4 mL) was stirred under
H.sub.2 atmosphere for 16 h. The resulting mixture was filtered and
the filtrate was concentrated under reduced pressure to provide
compound 86f contaminated with some EtOH, which was used without
further purification. .sup.1H NMR (400 MHz, Methanol-d4) .delta.
3.51 (p, J=6.3 Hz, 1H), 2.49 (ddd, J=8.2, 6.0, 4.0 Hz, 1H),
1.57-1.20 (m, 6H), 1.15 (d, J=6.4 Hz, 3H), 0.97-0.87 (m, 3H).
Synthesis of
(2S,3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)ami-
no)heptan-2-ol (86g)
[0908] Compound 86f prepared as described and
2,4-dichloropyrido[3,2-d]pyrimidine (73.2 mg, 0.350 mmol, Astatech,
Inc.) in THF (3 mL) were treated with N,N-diisopropylethylamine
(0.19 mL, 1.091 mmol) and the resulting mixture stirred for 1.5 h.
Additional THF (3 mL), N,N-diisopropylethylamine (0.19 mL, 1.091
mmol), and 2,4-dimethoxybenzylamine (0.27 mL, 1.797 mmol) were
added. The reaction mixture was stirred at 100.degree. C. for 15.5
h and then cooled to rt. The reaction mixture was diluted with DCM
(30 mL), washed with water (30 mL.times.2). The aqueous fractions
were then extracted with DCM (20 mL.times.1), and the combined
organic fractions, dried (MgSO.sub.4), and concentrated in vacuo.
The residue was subjected to silica gel chromatography eluting with
0-20% methanol in DCM to provide crude 86g. The crude 86g was
further subjected to preparative HPLC (Gemini 10u C18 110A, AXIA;
10% aq. acetonitrile-80% aq. acetonitrile with 0.1% TFA, over 20
min. gradient). The collected fractions were neutralized with
NaHCO.sub.3 before concentration. The residue was dissolved in
EtOAc, washed with water, dried (MgSO.sub.4), and concentrated
under reduced pressure to provide compound 86g. LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.23H.sub.32N.sub.5O.sub.3:
426.25; found: 426.14; t.sub.R=1.23 min on LC/MS Method A.
Synthesis of
(2S,3R)-3-(2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)heptan-2-ol
(86)
[0909] Compound 86g (76.0 mg, 0.179 mmol) was dissolved in TFA (2
mL) and stirred at rt for 1 h. The reaction mixture was
concentrated and co-evaporated with methanol (10 mL.times.1). The
resulting residue was dissolved in methanol (2 mL) and concentrated
ammonium hydroxide (0.2 mL) was added to the solution. After 10
min. at rt, the mixture was concentrated to dryness, and the
residue was dissolved in methanol (3 mL) and water (3 mL). The
insoluble material was removed by filtration, and the filtrate was
subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient) to provide, after collection of product fractions and
removal of volatiles in vacuo, compound 86 as its TFA salt. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 8.64 (dd, J=4.4, 1.4 Hz, 1H),
7.84 (dd, J=8.5, 1.5 Hz, 1H), 7.77 (dd, J=8.5, 4.4 Hz, 1H), 4.37
(td, J=7.2, 3.4 Hz, 1H), 3.99 (qd, J=6.4, 3.4 Hz, 1H), 1.76 (q,
J=7.4 Hz, 2H), 1.48-1.26 (m, 4H), 1.18 (d, J=6.4 Hz, 3H), 0.97-0.82
(m, 3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.14H22N.sub.5O: 276.18; found: 276.15; t.sub.R=0.67 min on
LC/MS Method A.
Example 87
##STR00229##
[0910] Synthesis of
(2S,3R)-3-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)heptan-2-ol
(87)
[0911] A solution of 2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-ol
(43B, 20.0 mg, 0.068 mmol), compound 86f (27.2 mg, 0.207 mmol), and
(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate (BOP, 58.9 mg, 0.133 mmol) in DMF (3 mL) was
stirred at rt and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 0.05 mL,
0.333 mmol) was added. After 24 h stirring at rt, the reaction
mixture was diluted with water (2 mL) and 1 N HCl (1 mL), and the
resulting solution filtered. The filtrate was subjected to
preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The concentrated fractions containing product were
concentrated, co-evaporated with methanol (10 mL.times.3), and then
dried in vacuo to obtain compound 87 as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d4) .delta. 8.56 (d, J=2.4 Hz, 1H), 7.64 (dd,
J=8.8, 2.4 Hz, 1H), 4.36 (td, J=7.2, 3.6 Hz, 1H), 4.03-3.91 (m,
1H), 1.82-1.69 (m, 2H), 1.37 (tddd, J=12.8, 10.3, 7.7, 5.0 Hz, 4H),
1.18 (d, J=6.4 Hz, 3H), 0.94-0.85 (m, 3H). .sup.19F NMR (376 MHz,
Methanol-d4) .delta. -77.82, -117.98 (d, J=8.8 Hz). LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.14H.sub.21FN.sub.5O:
294.17; found: 294.13; t.sub.R=0.71 min on LC/MS Method A.
Example 88
##STR00230## ##STR00231##
[0912] Synthesis of
(3R)-3-(dibenzylamino)-1-fluoro-1-(phenylsulfonyl)heptan-2-ol
(88a)
[0913] A solution of fluoromethyl phenyl sulphone (935.6 mg, 5.371
mmol) in THF (3 mL) was stirred in an acetone-dry ice bath and 2.5
M n-butyllithium in hexane (2.15 mL) was added. After 30 min, the
crude compound 86c (393.9 mg, 1.333 mmol) in THF (2 mL) was added
and the resulting solution stirred with cooling by an acetone-dry
ice bath. After 30 minutes, the reaction mixture was quenched with
saturated NH.sub.4Cl (15 mL), diluted with EtOAc (30 mL), and
warmed up to rt before the two fractions were separated. The
aqueous fraction was extracted with EtOAc (20 mL.times.1), and the
organic fractions were then washed with water (30 mL.times.1),
before being combined, dried (MgSO.sub.4), and concentrated under
reduced pressure. The residue was subjected to silica gel
chromatography eluting with 0-40% EtOAc in hexanes to provide
compound 88a, as a mixture of 4 diastereomers. LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.27H.sub.33FNO.sub.3S:
470.22; found: 470.24; t.sub.R=1.40-1.45 min.
Synthesis of (2R,3R)-3-(dibenzylamino)-1-fluoroheptan-2-ol and
(2S,3R)-3-(dibenzylamino)-1-fluoroheptan-2-ol (88b and 88c)
[0914] A suspension of compound 88a (635.4 mg, 1.333 mmol) and
Na.sub.2HPO.sub.4 (1325.9 mg, 9.340 mmol) in methanol (10 mL) was
stirred in -30.about.-40.degree. C. bath as sodium-mercury amalgam
(1853.9 mmol, 8.060 mmol) was added. The reaction mixture was
slowly warmed to .about.5.degree. C. over 2 h and then stirred 1 h
at .about.5.degree. C. The mixture was then filtered through a
Celite pad and the filtrate was concentrated in vacuo. The residue
was dissolved in EtOAc and water (20 mL each), and the two
fractions separated. The aqueous fraction was extracted with EtOAc
(20 mL.times.1). The organic fractions were washed with water (30
mL.times.1), then combined, dried (MgSO.sub.4), and concentrated
under reduced pressure. The residue was subjected to repeated
silica gel chromatography eluting with 5-20% EtOAc in hexanes to
provide compound 88b, as the first eluting fraction, and compound
88c as the second eluting fraction.
[0915] Compound 88b: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
7.63-6.91 (m, 10H), 4.53-4.27 (m, 2H), 4.16 (s, 1H), 3.90 (d,
J=13.2 Hz, 2H), 3.66 (dt, J=22.5, 5.7 Hz, 1H), 3.49 (d, J=13.3 Hz,
2H), 2.69 (dt, J=9.2, 5.3 Hz, 1H), 1.90-1.70 (m, 1H), 1.39 (tdd,
J=12.6, 8.2, 5.5 Hz, 5H), 0.97 (t, J=7.0 Hz, 3H). .sup.19F NMR (376
MHz, Chloroform-d) 8-230.59 (td, J=47.8, 23.5 Hz). LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.21H.sub.29FNO: 330.22;
found: 330.17; t.sub.R=0.96 min on LC/MS Method A.
[0916] Compound 88c: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
7.54-6.94 (m, 10H), 4.54 (ddd, J=47.2, 9.4, 3.4 Hz, 1H), 4.25 (ddd,
J=48.2, 9.4, 7.3 Hz, 1H), 4.01 (d, J=18.6 Hz, 1H), 3.66 (d, J=2.5
Hz, 4H), 2.68 (q, J=6.1 Hz, 1H), 2.35 (s, 1H), 1.88-1.70 (m, 1H),
1.53-1.21 (m, 5H), 1.00-0.80 (m, 3H). .sup.19F NMR (376 MHz,
Chloroform-d) 6-228.21 (td, J=47.7, 18.4 Hz). LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.21H.sub.29FNO: 330.22; found:
330.13; t.sub.R=1.07 min on LC/MS Method A.
Synthesis of (3R)-3-amino-1-fluoroheptan-2-ol (88d)
[0917] A mixture of compound 88b (38.25 mg, 0.116 mmol) and 20%
palladium hydroxide on carbon (15.61 mg) in EtOH (2 mL) was stirred
under H.sub.2 atmosphere. After 20.5 h, the reaction mixture was
filtered and the solids washed with EtOH (10 mL). After the
filtrate and washing was concentrated, the residue was
co-evaporated with toluene (5 mL.times.2) to obtain compound 88d.
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.7H.sub.17FNO: 150.13; found: 149.97; t.sub.R=0.40 min on
LC/MS Method A.
Synthesis of
(3R)-3-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-1-fluoroheptan-2-ol
(88e)
[0918] To a solution of compound 88d (14.9 mg, 0.100 mmol) and
2,4-dichloropyrido[3,2-d]pyrimidine (11.6 mg, 0.158 mmol) in THF (2
mL) was added N,N-diisopropylethylamine (0.1 mL, 0.574 mmol). The
mixture was stirred at rt for 1.5 h and at 50.degree. C. for 30
min. The reaction mixture was then concentrated in vacuo, and the
residue subjected to silica gel chromatography eluting with 20-70%
EtOAc in hexanes to obtain compound 88e. LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.14H.sub.19ClFN.sub.4O: 313.12;
found: 313.14; t.sub.R=1.06 min on LC/MS Method A.
Synthesis of
(3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-
-1-fluoroheptan-2-ol (88f)
[0919] To solution of compound 88e (22.0 mg, 0.070 mmol) in dioxane
(2 mL), N,N-diisopropylethylamine (0.06 mL, 0.344 mmol), and
2,4-dimethoxybenzylamine (0.04 mL, 0.266 mmol) were added. The
resulting solution was refluxed at 110.degree. C. for 19 h. After
the reaction mixture was concentrated, the residue was subjected to
silica gel chromatography eluting with hexanes-EtOAc to provide
crude product 88f. The crude product was then subjected to
preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-80% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The combined product fractions were neutralized by the
addition of saturated aqueous NaHCO.sub.3 (1 mL), concentrated to
remove acetonitrile, and then extracted with EtOAc (20 mL.times.2).
The organic extracts were washed with water (.times.1), combined,
dried (MgSO.sub.4), and concentrated under reduced pressure to
obtain compound 88f LCMS-ESI.sup.+ (m/z):
[M+H-C.sub.2H4]+calculated for C.sub.23H.sub.31FN.sub.5O.sub.3:
444.24; found: 444.18; t.sub.R=0.95 min on LC/MS Method A.
Synthesis of
(3R)-3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-1-fluoroheptan-2-ol
(88)
[0920] Compound 88f (8.7 mg, 30.44 umol) was dissolved in TFA (1
mL) and stirred at rt for 1 h. The reaction mixture was
concentrated in vacuo and co-evaporated with methanol (10 mL). The
residue was dissolved in methanol (1 mL) and concentrated ammonium
hydroxide (0.1 mL) was added. The resulting mixture was stirred at
rt for 10 min, concentrated under reduced pressure. The residue was
triturated in 1 N HCl (0.5 mL) and methanol (2 mL), filtered, and
diluted with water (3 mL) before subjecting to preparative HPLC
(Gemini 10u C18 110A, AXIA; 10% aq. acetonitrile-70% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient). The product
fractions were combined, concentrated in vacuo, co-evaporated with
methanol (10 mL.times.3) and dried in vacuo to obtain compound 88
as its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.64
(dd, J=4.4, 1.4 Hz, 1H), 7.84 (dd, J=8.5, 1.4 Hz, 1H), 7.77 (dd,
J=8.5, 4.4 Hz, 1H), 4.59 (ddd, J=8.0, 6.5, 3.0 Hz, 1H), 4.51-4.38
(m, 1H), 4.38-4.26 (m, 1H), 4.04 (dddd, J=16.2, 6.1, 4.9, 3.1 Hz,
1H), 1.89-1.73 (m, 2H), 1.39 (dtd, J=10.4, 6.9, 6.3, 3.4 Hz, 4H),
0.96-0.84 (m, 3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta.
-77.56, -231.26 (td, J=47.3, 16.2 Hz). LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.14H.sub.21FN.sub.5O: 294.17;
found: 294.15; t.sub.R=0.69 min on LC/MS Method A.
Example 89
##STR00232##
[0921] Synthesis of
(2S,3R)-3-(dibenzylamino)-1,1,1-trifluoroheptan-2-ol (89a) and
(2R,3R)-3-(dibenzylamino)-1,1,1-trifluoroheptan-2-ol (89b)
[0922] A solution of compound 86c (492.7 mg, 1.668 mmol) and
tetrabutylammonium fluoride (TBAF, 21.8 mg, 0.083 mmol) in THF (4
mL) was stirred at 0.degree. C. and
trimethyl(trifluoromethyl)silane (0.76 mL, 5.17 mmol) was added.
After the resulting mixture was stirred at 0.degree. C. for 30 min,
additional TBAF (87.2 mg, 0.334 mmol) was added and the reaction
mixture was stirred for 1h at rt. The reaction mixture was quenched
with saturated aqueous NH.sub.4Cl (10 mL). The resulting solution
was diluted with EtOAc (20 mL) and two layers were separated. The
aqueous fraction was extracted with EtOAc (20 mL.times.3) and the
organic fractions were washed with brine (20 mL.times.1), combined,
dried (MgSO.sub.4), and concentrated in vacuo. The residue was then
subjected to silica gel chromatography eluting with 0-20% EtOAc in
hexanes to obtain compound 89a, as the first eluting product and
compound 89b as the second eluting product.
[0923] Compound 89a: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
7.36-7.26 (m, 10H), 5.30 (s, 1H), 3.90 (d, J=13.1 Hz, 2H),
3.74-3.64 (m, 1H), 3.60 (d, J=13.1 Hz, 2H), 2.97 (d, J=9.3 Hz, 1H),
1.94-1.80 (m, 1H), 1.60-1.44 (m, 3H), 1.38 (h, J=7.4 Hz, 2H), 0.98
(t, J=7.2 Hz, 3H). .sup.19F NMR (376 MHz, Chloroform-d) .delta.
-76.57 (d, J=6.3 Hz). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated
for C.sub.21H.sub.27F.sub.3NO: 366.20; found: 366.15; TR=1.46
min.
[0924] Compound 89b: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
7.32 (d, J=4.8 Hz, 10H), 4.22 (s, 1H), 3.82 (d, J=13.6 Hz, 2H),
3.50 (d, J=13.6 Hz, 2H), 3.00 (d, J=9.4 Hz, 1H), 2.66 (s, 1H), 1.79
(q, J=9.1 Hz, 1H), 1.49 (s, 2H), 1.35-1.11 (m, 4H), 0.87 (t, J=7.2
Hz, 3H). .sup.19F NMR (376 MHz, Chloroform-d) 8-76.53 (d, J=8.3
Hz). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.21H.sub.27F.sub.3NO: 366.20; found: 366.15; t.sub.R=1.49 min
on LC/MS Method A.
Synthesis of (2R,3R)-3-amino-1,1,1-trifluoroheptan-2-ol (89c)
[0925] To a stirred solution of compound 89a (121.35 mg, 0.332
mmol) in EtOH (4 mL) was added 20% palladium hydroxide on carbon
(52 mg, 0.074 mmol). The resulting mixture was stirred under
H.sub.2 atmosphere for 20 h. The reaction mixture was then filtered
and washed with ethanol (10 mL). The filtrate was then concentrated
in vacuo to obtain compound 89c. LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.7H.sub.15F.sub.3NO: 186.11; found: 185.96;
t.sub.R=0.55 min on LC/MS Method A.
Synthesis of
(2R,3R)-3-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-1,1,1-trifluorohep-
tan-2-ol (89d)
[0926] To a solution of compound 89c (53.4 mg, 0.288 mmol) and
2,4-dichloropyrido[3,2-d]pyrimidine (57.68 mg, 0.288 mmol) in THF
(3 mL) was added N,N-diisopropylethylamine (0.151 mL, 0.865 mmol)
and the mixture heated to 80.degree. C. After 2 h, the reaction
mixture was allowed to cool to rt and then concentrated in vacuo
and the residue subjected to silica gel chromatography eluting with
0-100% EtOAc in hexanes to afford compound 89d.
Synthesis of
(2R,3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)ami-
no)-1,1,1-trifluoroheptan-2-ol (89e)
[0927] To a solution of compound 89d (106.7 mg, 0.346 mmol) in
dioxane (3 mL) was added N,N-diisopropylethylamine (0.160 mL, 0.918
mmol) and 2,4-dimethoxybenzylamine (0.230 mL, 1.530 mmol). The
resulting solution was refluxed at 110.degree. C. and stirred for
20 h. The reaction mixture was then cooled to rt and diluted with
EtOAc (20 mL), washed with water (20 mL.times.3) and brine (20
mL.times.1), dried (MgSO.sub.4), filtered and then concentrated in
vacuo. The residue was subjected to silica gel chromatography
eluting with 0-100% EtOAc in hexanes to afford compound 89e.
LCMS-ESI.sup.+ (m/z): [M+H-C.sub.2H.sub.4].sup.+ calculated for
C.sub.23H.sub.29F.sub.3N.sub.5O.sub.3: 480.22; found: 480.17;
t.sub.R=1.03 min on LC/MS Method A.
Synthesis of
(2R,3R)-3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-1,1,1-trifluorohept-
an-2-ol (89)
[0928] Compound 89e (12 mg, 25.0 umol) was dissolved in TFA (1 mL)
and stirred at rt for 1 h. The reaction mixture was concentrated in
vacuo and co-evaporated with methanol (10 mL). The resulting
residue was dissolved in aqueous methanol (1 mL), filtered through
a Celite-membrane filter to remove insoluble material, and the
filtrate subjected to preparative HPLC (Gemini 10u C18 110A, AXIA;
10% aq. acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20
min. gradient). The collected product fractions were concentrated
in vacuo, and the residue was co-evaporated with methanol (10
mL.times.3), and dried in vacuum overnight to obtain compound 89 as
its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.65 (dd,
J=4.4, 1.4 Hz, 1H), 7.85 (dd, J=8.5, 1.4 Hz, 1H), 7.79 (dd, J=8.5,
4.4 Hz, 1H), 4.82 (ddd, J=8.3, 6.5, 2.1 Hz, 1H), 4.22 (qd, J=7.3,
1.9 Hz, 1H), 1.92-1.74 (m, 2H), 1.50-1.31 (m, 4H), 0.96-0.87 (m,
3H). .sup.19F NMR (376 MHz, Methanol-d.sub.4) .delta. -77.56,
-79.32 (d, J=7.3 Hz). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated
for C.sub.14H.sub.19F.sub.3N.sub.5O: 330.15; found: 330.15;
t.sub.R=0.77 min on LC/MS Method A.
Example 90
##STR00233##
[0929] Synthesis of
(2R,3R)-3-(dibenzylamino)-1,1-difluoro-1-(phenylsulfonyl)heptan-2-ol
and
(2S,3R)-3-(dibenzylamino)-1,1-difluoro-1-(phenylsulfonyl)heptan-2-ol
(90a and 90b)
[0930] A solution of compound 86c (235.6 mg, 0.798 mmol) and
difluoromethyl phenyl sulfone (153.3 mg, 0.80 mmol) in THF (5 mL)
was stirred at -78.degree. C. and then 1.0 M LHMDS in THF (1.60 mL,
1.60 mmol) was added slowly. The reaction mixture was stirred for 2
h at -78.degree. C., and warmed to rt. before quenching with
saturated aqueous NH.sub.4Cl solution (15 mL). The resulting
solution was diluted with EtOAc (25 mL) and the two layers
separated. The separated aqueous fraction was back extracted with
EtOAc (15 mL.times.2). The separate organic fractions were washed
with water (25 mL.times.2), brine (25 mL), then combined, dried
over MgSO.sub.4, filtered and concentrated in vacuo. The residue
was subjected to silica gel chromatography eluting with 0-30% EtOAc
in hexanes to afford of compound 90a as the first eluting isomer,
and compound 90b as the second eluting isomer.
[0931] Compound 90a. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated
for C.sub.27H.sub.32F.sub.2NO.sub.3S: 488.21; found: 488.20;
t.sub.R=1.50 min on LC/MS Method A.
[0932] Compound 90b. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated
for C.sub.27H.sub.32F.sub.2NO.sub.3S: 488.21; found: 488.23;
t.sub.R=1.52 min on LC/MS Method A.
Synthesis of (3R)-3-(dibenzylamino)-1,1-difluoroheptan-2-ol
(90c)
[0933] To a solution of compound 90a (132.9 mg, 0.273 mmol) in
methanol (2 mL) at -40.degree. C. was added Na.sub.2HPO.sub.4
(236.3 mg, 1.664 mmol) and 5% sodium mercury-amalgam beads (646.1
mg, 1.41 mmol). The resulting mixture was stirred for 2 h in a cold
bath, and then filtered through a Celite pad. The filtrate was
concentrated in vacuo and the residue was treated with EtOAc (20
mL) and water (20 mL). The two layers were separated and the
aqueous fraction was extracted with EtOAc (20 mL.times.2). The
organic fractions were washed with water (20 mL.times.1), then
combined, dried (MgSO.sub.4), filtered and concentrated under
reduced pressure. The residue was subjected to silica gel
chromatography eluting with 0-30% EtOAc in hexanes to provide
compound 90c. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.21H.sub.28F.sub.2NO: 348.21; found: 348.16; t.sub.R=1.26 min
on LC/MS Method A.
Synthesis of (3R)-3-amino-1,1-difluoroheptan-2-ol (90d)
[0934] To a solution of compound 90c (27.2 mg, 0.078 mmol) in EtOH
(1 mL) was added 20% palladium hydroxide on carbon (15.9 mg, 0.023
mmol). The resulting mixture was stirred under H.sub.2 atmosphere
for 20 h. The reaction mixture was then filtered and washed with
EtOH (5 mL). The filtrate was concentrated in vacuo to obtain
compound 90d. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.7H.sub.116F.sub.2NO: 168.12; found: 167.94; t.sub.R=0.49 min
on LC/MS Method A.
Synthesis of
(3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-
-1,1-difluoroheptan-2-ol (90e)
[0935] To a solution of compound 90d (12.4 mg, 0.074 mmol) and
2,4-dichloropyrido[3,2-d]pyrimidine (11.8 mg, 0.059 mmol) in THF (1
mL) was added N,N-diisopropylethylamine (0.039 mL, 0.222 mmol). The
mixture was stirred for 2 h at rt, then additional THF (1 mL),
N,N-diisopropylethylamine (0.039 mL, 0.222 mmol), and
2,4-dimethoxybenzylamine (0.056 mL, 0.371 mmol) were added, and the
resulting mixture heated to 100.degree. C. for 20 h. The reaction
mixture was cooled to rt, diluted with EtOAc (.about.20 mL), washed
with water (20 mL.times.3) and brine (20 mL.times.1), dried
(MgSO.sub.4), filtered and concentrated in vacuo. The residue was
subjected to silica gel chromatography eluting with 0-100% EtOAc in
hexanes to isolate impure 90e. The impure material was then
subjected to preparative HPLC purification (column, Gemini 10u C18
110A, AXIA; 10% aq. acetonitrile-80% aq. acetonitrile with 0.1%
TFA, over 20 min. gradient) to afford compound 90e LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for
C.sub.23H.sub.30F.sub.2N.sub.5O.sub.3: 462.23; found: 462.17;
t.sub.R=1.00 min on LC/MS Method A.
Synthesis of
(3R)-3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-1,1-difluoroheptan-2-o-
l (90)
[0936] Compound 90e (16 mg, 34.67 umol) was dissolved in TFA (1 mL)
and stirred at rt. After 1 h, the mixture was concentrated in
vacuo, and the residue was triturated in methanol (1 mL.times.3),
filtered, and diluted with water (.about.6 mL). The mixture was
subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). Collected product fractions were concentrated in vacuo,
co-evaporated with methanol (10 mL.times.3) and dried in vacuo to
obtain compound 90 as its TFA salt. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.64 (dd, J=4.3, 1.4 Hz, 1H), 7.84 (dd, J=8.5,
1.5 Hz, 1H), 7.78 (dd, J=8.5, 4.3 Hz, 1H), 5.73 (td, J=55.6, 4.9
Hz, 1H), 4.70 (t, J=7.4 Hz, 1H), 3.98-3.82 (m, 1H), 1.90-1.72 (m,
2H), 1.54-1.31 (m, 4H), 1.00-0.82 (m, 3H). .sup.19F NMR (376 MHz,
Methanol-d4) .delta. -77.78, -129.57 (ddd, J=289.8, 55.1, 8.6 Hz),
-132.42 (ddd, J=290.1, 56.0, 12.5 Hz). LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.14H.sub.20F.sub.2N.sub.5O: 312.16;
found: 312.15; t.sub.R=0.74 min on LC/MS Method A.
Example 91
##STR00234## ##STR00235##
[0937] Synthesis of (3R)-3-amino-1-fluoroheptan-2-ol (91a)
[0938] A mixture of compound 88b (300.1 mg, 0.911 mmol) and 20%
palladium hydroxide on carbon (30.9 mg) in EtOH (5 mL) was stirred
under H.sub.2. The reaction mixture was stirred for 20 h, filtered,
and the solids were washed with EtOH (10 mL). The filtrate was
concentrated in vacuo and the residue was co-evaporated with
toluene (10 mL.times.2) to obtain compound 91a. LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.7H.sub.17FNO: 150.13;
found: 149.95; t.sub.R=0.47 min on LC/MS Method A.
Synthesis of
(3R)-3-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-1-fluoroheptan-2-ol
(91b)
[0939] A solution of 91a (133.7 mg, 0.896 mmol) and
2,4-dichloropyrido[3,2-d]pyrimidine (201.6 mg, 1.008 mmol) in THF
(6 mL) was treated with N,N-diisopropylethylamine (0.48 mL, 2.756
mmol). The mixture was stirred at rt for 2.75 h. The reaction
mixture was concentrated in vacuo, and the residue was subjected to
silica gel chromatography eluting with 20-70% EtOAc in hexanes to
obtain, after removal of solvent in vacuo, compound 91b.
LCMS-ESI.sup.+ (m/z): [M+H-C.sub.2H.sub.4].sup.+ calculated for
C.sub.14H.sub.19ClFN.sub.4O: 313.12; found: 313.14; t.sub.R=1.04
min on LC/MS Method A.
Synthesis of
(3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-
-1-fluoroheptan-2-ol (91c)
[0940] To a solution of compound 91b (233.6 mg, 0.747 mmol) in
dioxane (7 mL) was added N,N-diisopropylethylamine (0.64 mL, 3.674
mmol), and 2,4-dimethoxybenzylamine (0.45 mL, 2.995 mmol). The
resulting solution was refluxed at 110.degree. C. bath for 24 h.
The reaction mixture was concentrated in vacuo, and the residue was
dissolved in DCM (30 mL), and washed with water (30 mL.times.1).
The aqueous fraction was extracted with DCM (30 mL.times.1), and
the organic fractions were combined, dried (MgSO.sub.4), filtered
and concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with 20-100% EtOAc in hexanes. The collected
fractions were concentrated under reduced pressure and the residue
was subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 10%
aq. acetonitrile-80% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The collected product fractions were combined,
neutralized by saturated aqueous NaHCO.sub.3 solution (1 mL),
partially concentrated in vacuo to remove acetonitrile and then
extracted with EtOAc (20 mL.times.2). The organic extracts were
washed with water (20 mL), combined, dried over MgSO.sub.4,
filtered and concentrated in vacuo to obtain compound 91c.
LCMS-ESI.sup.+ (m/z): [M+H-C.sub.2H.sub.4].sup.+ calculated for
C.sub.23H.sub.31FN.sub.5O.sub.3: 444.24; found: 444.19;
t.sub.R=0.97 min on LC/MS Method A.
Synthesis of
2-((3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)ami-
no)-1-fluoroheptan-2-yl)isoindoline-1,3-dione (91d)
[0941] To a solution of compound 91c (654 mg, 1.475 mmol),
phthalimide (347.1 mg, 2.359 mmol), and triphenylphosphine (874.8
mg, 3.359 mmol) in THF (24 mL) at 0.degree. C. was added
diisopropyl azodicarboxylate (0.697 mL, 3.539 mmol). The reaction
mixture was warmed to rt and stirred for 2 h. After the reaction
mixture was concentrated under reduced pressure, the residue was
subjected to silica gel chromatography eluting with 0-100% EtOAc in
hexanes to obtain, after removal of volatiles in vacuo, compound
91d. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.31H.sub.34FN.sub.6O.sub.4: 573.26; found: 573.20;
t.sub.R=1.27 min on LC/MS Method A.
Synthesis of
N.sup.4-((3R)-2-amino-1-fluoroheptan-3-yl)-N.sup.2-(2,4-dimethoxybenzyl)p-
yrido[3,2-d]pyrimidine-2,4-diamine (91e)
[0942] To a solution of compound 91d (489.3 mg, 0.854 mmol) in EtOH
(5 mL) was added hydrazine hydrate (0.07 mL, 1.28 mmol) at rt. The
reaction mixture was refluxed for 3.5 h, the precipitates were
removed by filtration and then the solid washed with EtOH (15 mL).
The filtrates were concentrated in vacuo and the residue was
dissolved in DCM (30 mL), washed with water (30 mL.times.2), dried
over MgSO.sub.4, filtered and concentrated in vacuo to obtain
compound 91e. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.23H.sub.32FN.sub.6O.sub.2: 443.26; found: 443.20;
t.sub.R=0.79 min on LC/MS Method A.
Synthesis of
N-((3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)ami-
no)-1-fluoroheptan-2-yl)acetamide (91f)
[0943] To a solution of 91e (395.3 mg, 0.893 mmol) and
N,N-diisopropylethylamine (0.311 mL, 1.787 mmol) in THF (8 mL) was
added acetic anhydride (0.127 mL, 1.340 mmol), and the reaction was
stirred for 30 min. at rt. The mixture was then diluted with EtOAc
(30 mL), washed with saturated aqueous NaHCO.sub.3 solution (30
mL), brine (30 mL), dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. The residue was subjected to
silica gel chromatography eluting with 0-100% EtOAc in hexanes,
followed by elution with 0-20% methanol in EtOAc. The collected
product fractions were concentrated in vacuo and then subjected to
preparative HPLC purification (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient) to obtain, after removal of volatiles in vacuo, compound
91f. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.25H.sub.34FN.sub.6O.sub.3: 485.27; found: 485.23;
t.sub.R=1.28 min on LC/MS Method A.
Synthesis of
N-((3R)-3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-1-fluoroheptan-2-yl-
)acetamide (91)
[0944] Compound 91f (50 mg, 0.103 mmol) was dissolved in TFA (3 mL)
and stirred at rt for 11 h. The mixture was concentrated under
reduced pressure, and the residue was triturated with methanol (1
mL.times.3). After the insoluble material was removed by filtration
and the filtrate was diluted with water (3 mL), the resulting
solution was subjected to preparative HPLC (Gemini 10u C18 110A,
AXIA; 10% aq. acetonitrile-70% aq. acetonitrile with 0.1% TFA, over
20 min. gradient). Product-containing fractions were combined,
concentrated under reduced pressure to dryness, co-evaporated with
methanol (.times.3), and finally dried under high vacuum to provide
91 as its TFA salt. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta.
8.67 (ddd, J=4.3, 1.4, 0.6 Hz, 1H), 7.96-7.69 (m, 2H), 4.82-4.67
(m, 1H), 4.60 (d, J=5.1 Hz, 1H), 4.48 (d, J=5.0 Hz, 1H), 4.41 (dq,
J=21.7, 5.1 Hz, 1H), 1.96 (d, J=4.2 Hz, 3H), 1.78 (td, J=8.6, 4.6
Hz, 1H), 1.48-1.24 (m, 4H), 0.90 (tt, J=5.5, 2.3 Hz, 3H).
LCMS-ESI.sup.+(m/z): [M+H].sup.+ calculated for
C.sub.16H.sub.27FN.sub.6O: 335.19; found: 335.19; t.sub.R=0.82 min
on LC/MS Method A.
Example 92
##STR00236## ##STR00237##
[0945] Synthesis of (S)-methyl
2-((tert-butoxycarbonyl)amino)-2-methylhexanoate (92b)
[0946] To a suspension of (S)-2-amino-2-methylhexanoic acid 92a
(2018.9 mg, 11.11 mmol, Asiba Pharmatech Inc.) in methanol (30 mL)
was added thionyl chloride (1.62 mL) dropwise, and the resulting
solution was refluxed for 41 h. The solution was concentrated under
reduced pressure and the residue was co-evaporated with methanol
(30 mL.times.2). The residue was treated with NaHCO.sub.3 (4.6964
g, 55.90 mmol) in water (30 mL) and methanol (5 mL) and was stirred
at rt. Di-tert-butyl dicarbonate (2932 mg, 13.43 mmol) was added
and the mixture stirred for 4 h. Additional NaHCO.sub.3 (1014.6 mg,
12.08 mmol) and di-tert-butyl dicarbonate (1234.0 mg, 5.654 mmol)
were then added and the resulting suspension was stirred at rt
overnight. The reaction mixture was then diluted with water (100
mL) and extracted with EtOAc (100 mL.times.2). The organic extracts
were washed with water (100 mL), then combined, dried over
MgSO.sub.4 filtered and concentrated in vacuo. The residue was
subjected to silica gel chromatography eluting with 0-20% EtOAc in
hexanes to obtain compound 92b. LCMS-ESI.sup.+ (m/z):
[M+H-C.sub.4H.sub.8].sup.+ calculated for C.sub.9H.sub.18NO.sub.4:
204.12; found: 203.68; t.sub.R=1.24 min on LC/MS Method A.
Synthesis of (S)-tert-butyl (1-hydroxy-2-methylhexan-2-yl)carbamate
(92c)
[0947] To a stirred solution of compound 92b (2515.4 mg, 9.699
mmol) in THF (20 mL) and methanol (2.8 mL) at 0.degree. C., was
added 2.0 M LiBH.sub.4 in THF (9.7 mL, 19.4 mmol). The solution was
stirred at rt for 5 h, was and then diluted with water (100 mL) at
0.degree. C., and extracted with EtOAc (100 mL.times.2). The
combined extracts were washed with water (100 mL), dried over
MgSO.sub.4, filtered and concentrated in vacuo. The residue was
subjected to silica gel chromatography eluting with 0-40% EtOAc in
hexanes to provide compound 92c LCMS-ESI.sup.+ (m/z):
[M+H-C.sub.4H.sub.8]calculated for C.sub.12H.sub.26NO.sub.3:
232.19; found: 231.60; t.sub.R=1.07 min on LC/MS Method A.
Synthesis of (S)-tert-butyl (2-methyl-1-oxohexan-2-yl)carbamate
(92d)
[0948] To a solution of compound 92c (543.3 mg, 2.349 mmol) in DCM
(20 mL) was added Dess-Martin Periodinane (1495.1 mg, 3.525 mmol)
and the resulting mixture stirred for 3 h. The reaction mixture was
diluted with DCM (30 mL) and filtered through a pad of Celite. The
filtrate was washed with saturated aqueous Na.sub.2S.sub.2O.sub.3
(50 mL), water (50 mL), and brine (50 mL). The aqueous fraction was
re-extracted with DCM (30 mL.times.2), and the combined organic
fractions were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with 0-70% EtOAc in hexanes to obtain
compound 92d. LCMS-ESI.sup.+ (m/z): [M+H-C.sub.4Hs].sup.+
calculated for C.sub.8H.sub.16NO.sub.3: 174.11; found: 174.76,
t.sub.R=1.28 min on LC/MS Method A.
Synthesis of tert-butyl
((3S)-2-hydroxy-3-methylheptan-3-yl)carbamate (92e)
[0949] To a solution of compound 92d (511.8 mg, 2.232 mmol) in
diethyl ether (5 mL) cooled in an ice-salt bath (-15.degree. C.),
was added 1.6 M solution of MeLi in diethyl ether (5.58 mL, 8.927
mmol) dropwise over 5 min. After 30 min, the reaction mixture was
quenched with saturated aqueous NH.sub.4Cl solution (15 mL). The
resulting mixture was diluted with water and the product was
extracted with EtOAc (25 mL.times.2). The combined extracts were
dried over MgSO.sub.4, filtered and concentrated in vacuo. The
residue was then subjected to silica gel chromatography eluting
with 0-70% EtOAc in hexanes to provide compound 92e as a mixture of
two diastereomers. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.13H.sub.28NO.sub.3: 246.21; found: 245.63; t.sub.R=1.28 min
on LC/MS Method A.
Synthesis of
(3S)-3-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylheptan-2-ol
(92f)
[0950] Compound 92e (347 mg, 1.414 mmol) was dissolved in 4M HCl in
dioxane (3.1 mL) and stirred at rt for 4 h. The reaction mixture
was then concentrated in vacuo. The residue in THF (10.5 mL) was
treated with 2,4-dichloropyrido[3,2-d]pyrimidine (259.1 mg, 1.295
mmol) and N,N-diisopropylethylamine (1.18 mL, 6.77 mmol), and
placed in 80.degree. C. bath for 1 h. The reaction mixture was
cooled to rt, concentrated under reduced pressure, and the residue
subjected to silica gel chromatography eluting with 0-70% EtOAc in
hexanes to obtain compound 92f. LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.15H.sub.21C.sub.1N.sub.4O: 309.15; found:
309.12; t.sub.R=1.32 min on LC/MS Method A.
Synthesis of
(2R,3S)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)ami-
no)-3-methylheptan-2-ol and
(2S,3S)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)ami-
no)-3-methylheptan-2-ol (92g and 92h)
[0951] To a solution of compound 92f (331.8 mg, 1.074 mmol) in
dioxane (11 mL) was added N,N-diisopropylethylamine (0.561 mL,
3.223 mmol) and 2,4-dimethoxybenzylamine (0.807 mL, 5.372 mmol).
The resulting mixture was refluxed at 110.degree. C. bath for 17 h.
The mixture was then concentrated in vacuo and the resulting
residue dissolved in EtOAc (50 mL) and washed with water (50
mL.times.2) and brine (50 mL). The organic fraction was dried over
Na.sub.2SO.sub.4, filtered and then concentrated in vacuo. The
resulting residue was subjected to silica gel chromatography
eluting with 0-100% EtOAc in hexanes. The collected product was
then concentrated in vacuo and resubjected to column chromatography
on silica gel eluting with 0-20% MeOH in DCM to obtain a mixture of
compound 92g and 92h. The mixture was then concentrated in vacuo
and the residue subjected to preparative chiral SFC (SFC IC-5
um-4.6.times.100 mm, 40% EtOH-ammonia) to obtain after removal of
volatiles in vacuo compound 92g eluting first, and compound 92h
eluting second.
[0952] Compound 92g: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
8.29 (dd, J=4.5, 1.5 Hz, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.44 (dd,
J=8.5, 4.3 Hz, 1H), 7.29 (d, J=8.2 Hz, 1H), 6.46 (d, J=2.4 Hz, 1H),
6.42 (dd, J=8.2, 2.4 Hz, 1H), 4.56 (d, J=5.8 Hz, 2H), 3.84 (s, 3H),
3.79 (s, 3H), 2.13 (t, J=12.7 Hz, 1H), 1.88 (t, J=11.5 Hz, 1H),
1.45 (ddd, J=12.9, 9.7, 5.5 Hz, 1H), 1.38 (s, 3H), 1.35-1.22 (m,
2H), 1.21 (d, J=6.3 Hz, 4H), 0.87 (t, J=7.2 Hz, 3H). LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.24H.sub.34N.sub.5O.sub.3:
440.27; found: 440.18; t.sub.R=1.29 min on LC/MS Method A.
[0953] Compound 92h: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
8.29 (dd, J=4.3, 1.5 Hz, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.43 (dd,
J=8.5, 4.3 Hz, 1H), 7.29 (d, J=8.2 Hz, 1H), 7.20 (s, 1H), 6.46 (d,
J=2.4 Hz, 1H), 6.42 (dd, J=8.2, 2.4 Hz, 1H), 4.56 (d, J=5.7 Hz,
2H), 3.84 (s, 3H), 3.79 (s, 3H), 1.97 (d, J=10.6 Hz, 1H), 1.59 (dt,
J=13.9, 7.2 Hz, 1H), 1.48 (s, 3H), 1.36 (qd, J=7.2, 6.7, 4.0 Hz,
4H), 1.26 (d, J=1.4 Hz, 1H), 1.18 (d, J=6.4 Hz, 3H), 0.97-0.90 (m,
3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.24H.sub.34N.sub.5O.sub.3: 440.27; found: 440.18; t.sub.R=1.28
min on LC/MS Method A.
Synthesis of
(3S)-3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylheptan-2-ol
(92)
[0954] Compound 92g (74.1 mg, 0.169 mmol) was dissolved in TFA (3
mL) and stirred at rt for 0.75 h. The reaction mixture was
carefully concentrated under reduced pressure to dryness. The
residue was triturated with 50% aq. methanol and filtered through a
Celite-membrane filter. The filtrate was then subjected to
preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The product fractions were combined, concentrated in
vacuo, then co-evaporated with methanol (10 mL.times.3), and dried
under vacuum to provide compound 92 as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d.sub.4) .delta. 8.61 (dd, J=4.4, 1.4 Hz, 1H),
7.84 (dd, J=8.5, 1.4 Hz, 1H), 7.76 (dd, J=8.5, 4.4 Hz, 1H), 4.36
(q, J=6.5 Hz, 1H), 2.30 (dt, J=16.4, 6.8 Hz, 1H), 1.91-1.78 (m,
1H), 1.56 (s, 3H), 1.46-1.29 (m, 4H), 1.23 (d, J=6.5 Hz, 3H),
0.97-0.85 (m, 3H). .sup.19F NMR (376 MHz, Methanol-d.sub.4) .delta.
-77.60. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.15H.sub.24N.sub.5O: 290.20; found: 290.14; t.sub.R=0.82 min
on LC/MS Method A.
Example 93
##STR00238## ##STR00239##
[0955] Synthesis of (4R)-ethyl
4-phenyl-2-(trifluoromethyl)oxazolidine-2-carboxylate (93c)
[0956] A solution of (R)--N-Boc-phenylglycinol 93a (522.4 mg, 2.249
mmol, Combi-Blocks, Inc.), ethyl trifluoropyruvate 93b (0.328 mL,
2.474 mmol, Oakwood Products), and pyridinium p-toluenesulfonate
(113.1 mg, 0.450 mmol) in toluene (20 mL) was refluxed with a
Dean-Stark apparatus for 20 h. The reaction mixture was then cooled
to 0.degree. C. using an ice-water bath and filtered through a pad
of Celite. After the filtrate was concentrated in vacuo, the
residue was subjected to silica gel chromatography eluting with
0-30% EtOAc in hexanes to obtain compound 93c. LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.13H.sub.15F.sub.3NO.sub.3:
290.10; found: 289.84; t.sub.R=1.21 min on LC/MS Method A.
Synthesis of
((4R)-4-phenyl-2-(trifluoromethyl)oxazolidin-2-yl)methanol
(93d)
[0957] To a solution of compound 93c (384.9 mg, 1.331 mmol) in MeOH
(6 mL) at 0.degree. C. was added sodium borohydride (50.3 mg, 1.331
mmol). The reaction mixture was warmed to rt and stirred for 30
min. before quenching with aqueous saturated NH.sub.4Cl (15 mL).
After methanol was removed under reduced pressure, the resulting
aqueous solution was extracted with EtOAc (25 mL.times.3). The
organic extracts were washed with water (25 mL.times.2) and brine
(25 mL), combined, dried over MgSO.sub.4, filtered and then
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with 0-40% EtOAc in hexanes to obtain
compound 93d LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.11H.sub.13F.sub.3NO.sub.2: 248.09; found: 247.90;
t.sub.R=0.96 min on LC/MS Method A.
Synthesis of
(R)-2-(((R)-2-hydroxy-1-phenylethyl)amino)-2-(trifluoromethyl)hexan-1-ol
(93e)
[0958] To a solution of compound 93d (264.7 mg, 1.071 mmol) in THF
(13 mL) at -78.degree. C. was added n-butyllithium (2.5 M in
hexane, 1.713 mL, 4.283 mmol) dropwise. The resulting solution was
stirred in a cold bath for 2 h before quenching with aqueous
saturated NH.sub.4Cl (30 mL). The mixture was extracted with EtOAc
(30 mL.times.3) and the extracts were washed with water (30
mL.times.2) and brine (30 mL.times.1). The organic fractions were
combined, dried over MgSO.sub.4, filtered and concentrated in
vacuo. The residue was subjected to silica gel chromatography
eluting with 0-70% EtOAc in hexanes to obtain compound 93e
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.15H.sub.23F.sub.3NO.sub.2: 306.17; found: 305.90,
t.sub.R=1.13 min on LC/MS Method A.
Synthesis of (R)-2-amino-2-(trifluoromethyl)hexan-1-ol
hydrochloride (93f)
[0959] To a solution of compound 93e (146.5 mg, 0.480 mmol) in EtOH
(1 mL) and concentrated HCl (0.3 mL) was added palladium hydroxide
on carbon (67.4 mg) and the resulting mixture was stirred under
H.sub.2 atmosphere for 24 h. The reaction mixture was filtered
through a pad of Celite and then the solids rinsed with EtOH (25
mL). The eluants were concentrated under reduced pressure, diluted
with water (20 mL) and then extracted with EtOAc (20 mL.times.2).
The organic extracts were combined and concentrated under reduced
pressure to obtain of compound 93f as its HCl salt. LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.7H15F.sub.3NO: 186.11;
found: 185.95; t.sub.R=0.51 min on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
2-(trifluoromethyl)hexan-1-ol (93h)
[0960] To a solution of compound 93f (123.84 mg, 0.480 mmol) and
2,4-dichloropyrido[3,2-d]pyrimidine (96.0 mg, 0.480 mmol) in THF (4
mL) was added N,N-diisopropylethylamine (0.251 mL, 1.439 mmol). The
reaction mixture was stirred and heated to 80.degree. C. for 18 h.
The reaction mixture was allowed to cool and concentrated in vacuo.
The resulting residue was subjected to silica gel chromatography
eluting with 0-100% EtOAc in hexanes to afford compound 93g (109.9
mg, 66%). To a solution of compound 93g (109.9 mg, 0.315 mmol) in
dioxane (3.5 mL) was added N,N-diisopropylethylamine (0.165 mL,
0.945 mmol) and 2,4-dimethoxybenzylamine (0.237 mL, 1.576 mmol).
The mixture was refluxed at 110.degree. C. for 20 h, allowed to
cool to rt, diluted with EtOAc (30 mL), washed with water (30
mL.times.3) and brine (30 mL), dried over MgSO.sub.4, filtered and
concentrated in vacuo. The resulting residue was subjected to
silica gel chromatography eluting with 0-100% EtOAc in hexanes. The
collected fractions were concentrated in vacuo to a residue that
was subjected to preparative HPLC purification (Gemini 10u C18
110A, AXIA; 10% aq. acetonitrile-80% aq. acetonitrile with 0.1%
TFA, over 20 min. gradient) to afford compound 93h LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for
C.sub.23H.sub.29F.sub.3N.sub.5O.sub.3: 480.22; found: 480.17;
t.sub.R=0.96 min on LC/MS Method A.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-(trifluoromethyl)hexa-
n-1-ol (93)
[0961] Compound 93h (7.8 mg, 16.27 umol) was dissolved in TFA (1
mL) and stirred at rt for 1 h. The reaction mixture was then
concentrated in vacuo and the residue was co-evaporated with
methanol (5 mL.times.3). The residue was triturated with 50% aq.
methanol and filtered through a Celite-membrane filter. The
filtrate was subjected to preparative HPLC (Gemini 10u C18 110A,
AXIA; 10% aq. acetonitrile-70% aq. acetonitrile with 0.1% TFA, over
20 min. gradient). The product fractions were combined,
concentrated under reduced pressure, co-evaporated with methanol
(10 mL.times.3), and dried under vacuum to provide compound 93 as
its TFA salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.67 (dd,
J=4.4, 1.4 Hz, 1H), 7.89 (dd, J=8.5, 1.4 Hz, 1H), 7.82 (dd, J=8.5,
4.4 Hz, 1H), 4.11 (d, J=12.2 Hz, 1H), 4.06-3.97 (m, 1H), 2.81 (ddd,
J=13.8, 11.0, 4.4 Hz, 1H), 1.99-1.85 (m, 1H), 1.38 (m, 4H), 0.92
(t, J=7.0 Hz, 3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta.
-75.96 (s, 3F), -77.39 (s, 3F). LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.14H.sub.19F.sub.3N.sub.5O: 330.15; found:
330.16; t.sub.R=0.76 min on LC/MS Method A.
Example 94
##STR00240## ##STR00241##
[0962] Synthesis of
(R)-3-methyl-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one (94c) and
3-methyl-5-phenyl-3,6-dihydro-2H-1,4-oxazin-2-one (94d)
[0963] To a mixture of (R)-(-)-2-phenylglycinol 94a,
(Sigma-Aldrich, 98%, 99% ee, 3.6296 g, 172.25 mmol) and molecular
sieves (86.03 g) in 2,2,2-trifluoroethanol (500 mL) was added ethyl
pyruvate 94b (19.2 mL, 172.29 mmol) and the resulting mixture
heated to reflux temperature. After 24 h, the mixture was cooled to
rt, filtered through a pad of Celite, and washed with EtOAc (50
mL). The orange filtrate and the EtOAc washes were separated into
two flasks and each was concentrated under reduced pressure. Each
of the resulting residues was subjected to silica gel
chromatography eluting with 0-40% EtOAc in hexanes. Product
fractions from the two chromatography's were combined, concentrated
under reduced pressure, and dried in vacuo to provide compound 94c
as well as the later eluting compound 94d.
[0964] Compound 94c: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
7.45-7.38 (m, 2H), 7.38-7.32 (m, 3H), 4.85 (ddd, J=10.9, 4.6, 2.4
Hz, 1H), 4.57 (dd, J=11.6, 4.5 Hz, 1H), 4.26 (dd, J=11.6, 10.9 Hz,
1H), 2.41 (d, J=2.4 Hz, 3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.11H.sub.12NO.sub.2: 190.09; found: 189.92;
t.sub.R=0.88 min on LC/MS Method A.
[0965] Compound 94d: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
7.81-7.71 (m, 2H), 7.55-7.41 (m, 3H), 5.47 (dd, J=16.0, 1.2 Hz,
1H), 5.25 (dd, J=16.0, 2.8 Hz, 1H), 4.31 (qdd, J=7.1, 3.0, 1.1 Hz,
1H), 1.72 (d, J=7.3 Hz, 3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.11H.sub.12NO.sub.2: 190.09; found: 189.94;
t.sub.R=0.83 min on LC/MS Method A.
Synthesis of (3R,5R)-3-butyl-3-methyl-5-phenylmorpholin-2-one
(94e)
[0966] A solution of compound 94c (14.84 g, 78.43 mmol) in THF (500
mL) was stirred at -78.degree. C. bath under argon and boron
trifluoride diethyl etherate (20.5 mL, 161.11 mmol) was added
slowly over 30 min. The reaction mixture was allowed to stir at
-78.degree. C. for 1.5 h. 2M butylmagnesium chloride solution 2.0 M
in THF (83.0 mL) was added slowly over .about.30 min. and the
reaction mixture was allowed to stir at -78.degree. C. for 2h
before addition of saturated ammonium chloride (300 mL) followed by
warming to rt. The mixture was diluted with water (200 mL) and
extracted with EtOAc (300 mL.times.3). The organic extracts were
washed with water (500 mL.times.3), brine (300 mL), combined, dried
(Na.sub.2SO.sub.4), and concentrated under reduced pressure. After
the residue was dissolved in DCM (150 mL, heating), the insoluble
material was removed by filtration. The filtrate was concentrated
under reduced pressure to a small volume, and was subjected to
silica gel chromatography eluting with 0-20% EtOAc in hexanes to
provide compound 94e. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated
for C.sub.15H.sub.22NO.sub.2: 248.17; found: 248.02; t.sub.R=1.07
min on LC/MS Method A.
Synthesis of
(R)-2-(((R)-2-hydroxy-1-phenylethyl)amino)-2-methylhexan-1-ol
(94f)
[0967] To a stirred solution of compound 94e (14.01 g, 56.64 mmol)
in THF (100 mL) at 0.degree. C. was added 2.0 M LiBH.sub.4 in THF
(57 mL, 114 mmol). The solution was stirred at rt for 2 h, cooled
with an ice bath and quenched with water (500 mL). The product was
extracted with EtOAc (300 mL.times.3) and the extracts were washed
with water (500 mL) and brine (100 mL). The combined extracts were
dried (Na.sub.2SO.sub.4) and concentrated under reduced pressure to
obtain 94f LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.15H.sub.26NO.sub.2: 252.20; found: 252.05; t.sub.R=0.68 min
on LC/MS Method A.
Synthesis of (R)-2-amino-2-methylhexan-1-ol hydrochloride (94g)
[0968] To a mixture of compound 94f (14.24 g, 56.65 mmol) and 20%
Pd(OH).sub.2 on carbon (2.847 g) in EtOH (210 mL) was added 4 N HCl
in dioxane (21.5 mL, 86.0 mmol) The resulting mixture was purged
with H.sub.2 gas (3 times) and then stirred under H.sub.2
atmosphere at 70.degree. C. for 8 h. The reaction mixture was
allowed to cool and additional 20% Pd(OH).sub.2 on carbon (0.71 g)
was added. The resulting mixture was purged with H.sub.2 gas (3
times) and then stirred under H.sub.2 atmosphere at 70.degree. C.
for 2 h. The reaction mixture was cooled and filtered through a
Celite pad and the removed solids washed with EtOH (50 mL). The
filtrate and EtOH washings were combined and concentrated under
reduced pressure. The residue was co-evaporated with DCM (100
mL.times.3) and dried under vacuum to give compound 94g. The
residue was triturated with DCM (50 mL) and toluene (50 mL) and
then concentrated under reduced pressure. The residue was
co-evaporated with toluene (50 mL.times.1) and dried under vacuum
at 40.degree. C. for 1 h, and rt overnight to obtain compound 94g
as its HCl salt. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.7H8NO: 132.14; found: 131.90; t.sub.R=0.42 min on LC/MS
Method A.
Synthesis of (R)-tert-butyl (1-hydroxy-2-methylhexan-2-yl)carbamate
(94h)
[0969] To a solution of 94g (3.1403 g, 16.01 mmol) in methanol (7
mL) and water (45 mL) was added sodium bicarbonate (4.05 g, 48.21
mmol) and di-tert-butyl dicarbonate (Boc.sub.2O, 4.25 g, 19.47
mmol). The resulting mixture was stirred at rt for 3 h and then
additional sodium bicarbonate (0.68 g, 8.095 mmol) and
di-tert-butyl dicarbonate (1.752 g, 8.028 mmol) were added. The
mixture was stirred for 48 h and then additional sodium bicarbonate
(0.808 g, 9.618 mmol) and di-tert-butyl dicarbonate (1.92 g, 8.797
mmol) were added. The reaction mixture was stirred for 4 h, diluted
with water (100 mL), and extracted with EtOAc (100 mL.times.2). The
extracts were washed with water (100 mL), dried over MgSO.sub.4,
filtered and then concentrated under reduced pressure. The residue
was subjected to silica gel chromatography eluting with 0-40% EtOAc
in hexanes to obtain compound 94h LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.12H.sub.26NO.sub.3: 232.19; found: 231.65;
t.sub.R=1.08 min on LC/MS Method A.
Synthesis of (R)-tert-butyl (2-methyl-1-oxohexan-2-yl)carbamate
(94i)
[0970] To a solution of compound 94h (446.7 mg, 1.931 mmol) in DCM
(15 mL) was added Dess-Martin Periodinane (1230.6 mg, 2.901 mmol)
and the resulting mixture was stirred for 3 h. The reaction mixture
was filtered through a pad of Celite, and the filtrate was then
washed with saturated aqueous Na.sub.2S.sub.2O.sub.3 (30 mL)
followed by water (30 mL.times.2). The aqueous fractions were back
extracted with DCM (30 mL), and all the organic fractions were then
combined, dried over MgSO.sub.4, filtered and concentrated in
vacuo. The resulting residue was subjected to silica gel
chromatography eluting with 0-30% EtOAc in hexanes to obtain
compound 94i. LCMS-ESI.sup.+ (m/z): [M+H-C.sub.4Hs].sup.+
calculated for C.sub.5H.sub.16NO.sub.3: 174.11; found: 173.77;
t.sub.R=1.17 min on LC/MS Method A.
Synthesis of tert-butyl
((3R)-2-hydroxy-3-methylheptan-3-yl)carbamate (94j)
[0971] To a solution of compound 94i (322.4 mg, 1.406 mmol) in
diethyl ether (5 mL) in an ice-NaCl bath was added 1.6 M MeLi in
diethyl ether (3.6 mL, 5.76 mmol) dropwise over 2 min. After 30
min, the reaction mixture was quenched with saturated aqueous
ammonium chloride solution (20 mL). The two phases were separated
and the aqueous fraction was extracted with DCM (30 mL). The
organic fractions were washed with water (30 mL), combined, dried
over MgSO.sub.4, filtered and then concentrated in vacuo. The
residue was then subjected to silica gel chromatography eluting
with 0-40% EtOAc in hexanes to obtain compound 94j. LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.13H.sub.28NO.sub.3: 246.21;
found: 245.70; t.sub.R=1.14 min. and t.sub.R=1.16 min on LC/MS
Method A.
Synthesis of
(3R)-3-((2-chloro-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylhept-
an-2-ol (94k)
[0972] Compound 94j (119.8 mg, 0.488 mmol) was dissolved in 4M HCl
in dioxane (3 mL) and stirred at rt for 1 h. The reaction mixture
was concentrated in vacuo and the residue was then treated with THF
(10.5 mL) followed by 2,4-dichloro-7-fluoropyrido[3,2-d]pyrimidine
84E (110.9 mg, 0.508 mmol) and N,N-diisopropylethylamine (0.36 mL,
2.067 mmol). The mixture was heated in a 80.degree. C. bath for 3
h. The reaction mixture was allowed to cool to rt, concentrated in
vacuo and the residue subjected to silica gel chromatography
eluting with 0-100% EtOAc in hexanes to obtain compound 94k as a
mixture of two diastereomers (.about.2:3 ratio). .sup.1H NMR (400
MHz, Chloroform-d) .delta. 8.55 (dd, J=2.6, 1.2 Hz, 1H), 7.66 (dd,
J=8.8, 2.6 Hz, 1H), 7.35 (d, J=10.9 Hz, 1H), 5.29 (br, 1H), 3.97
(q, J=6.1 Hz, 0.4H), 3.91 (q, J=6.4 Hz, 0.6H), 2.09 (ddd, J=13.8,
12.3, 4.4 Hz, 0.6H), 2.03-1.88 (m, 1H), 1.67 (dt, J=14.2, 7.0 Hz,
0.4H), 1.51 (s, 1.2H), 1.43 (s, 1.8H), 1.49-1.136 (m, 4H), 1.22 (d,
J=6.5 Hz, 1.8H), 1.20 (d, J=6.5 Hz, 1.2H), 0.99-0.91 (m, 1.2H),
0.88 (t, J=7.3 Hz, 1.8H). .sup.19F NMR (376 MHz, Chloroform-d)
6-117.38 (t, J=8.9 Hz). LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.15H.sub.21ClFN.sub.4O: 327.14; found: 327.11;
t.sub.R=1.23 min on LC/MS Method A.
Synthesis of
(2R,3R)-3-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin-
-4-yl)amino)-3-methylheptan-2-ol and
(2S,3R)-3-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin-
-4-yl)amino)-3-methylheptan-2-ol (941 and 94m)
[0973] To a solution of compound 94k (128.5 mg, 0.416 mmol) in
dioxane (5 mL) was added N,N-diisopropylethylamine (0.22 mL, 1.263
mmol) and 2,4-dimethoxybenzylamine (0.16 mL, 1.065 mmol) and the
resulting mixture was refluxed in a 110.degree. C. bath for 20 h.
The reaction mixture was allowed to cool to rt, diluted with EtOAc
(30 mL) and then washed with water (30 mL.times.2). The aqueous
fractions were then back extracted with EtOAc (30 mL). The organic
fractions were combined, dried over MgSO.sub.4, and concentrated
under reduced pressure. The residue was then subjected to silica
gel chromatography eluting with 0-100% EtOAc in hexanes to obtain a
mixture of compounds 941 and 94m. The compound mixture was further
subjected to preparative chiral SFC (SFC IC-5 um-4.6.times.100 mm,
30% EtOH-ammonia, flow rate=3 mL/min) to obtain, compound 941,
eluting first, and compound 94m, eluting second.
[0974] Compound 941: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
8.14 (d, J=2.5 Hz, 1H), 7.32 (s, 1H), 7.28 (d, J=8.3 Hz, 1H), 6.46
(d, J=2.4 Hz, 1H), 6.42 (dd, J=8.3, 2.4 Hz, 1H), 4.55 (d, J=5.7 Hz,
2H), 3.84 (s, 3H), 3.79 (s, 3H), 4.0-3.7 (m, 1H), 1.97 (s, 1H),
1.59 (s, 2H), 1.47 (s, 3H), 1.36 (d, J=5.2 Hz, 4H), 1.17 (d, J=6.4
Hz, 3H), 1.00-0.89 (m, 3H). .sup.19F NMR (376 MHz, Chloroform-d)
.delta. -121.41. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.24H.sub.33FN.sub.5O.sub.3: 458.26; found: 458.17;
t.sub.R=1.19 min on LC/MS Method A.
[0975] Compound 94m: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
8.14 (d, J=2.6 Hz, 1H), 7.33 (s, 1H), 7.28 (d, J=8.3 Hz, 1H), 6.46
(d, J=2.3 Hz, 1H), 6.42 (dd, J=8.3, 2.4 Hz, 1H), 4.55 (d, J=5.8 Hz,
2H), 3.84 (d, J=1.1 Hz, 3H), 3.79 (s, 3H), 3.9-3.6 (m, 1H), 2.09
(d, J=14.1 Hz, 1H), 1.87 (s, 1H), 1.57 (s, 1H), 1.43 (m, 1H), 1.37
(s, 3H), 1.30 (m, 2H), 1.20 (d, J=6.4 Hz, 3H), 0.87 (t, J=7.2 Hz,
3H). .sup.19F NMR (376 MHz, Chloroform-d) .delta. -121.40.
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.24H.sub.33FN.sub.5O.sub.3: 458.26; found: 458.16;
t.sub.R=1.22 min on LC/MS Method A.
Synthesis of
(3R)-3-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylhepta-
n-2-ol (94)
[0976] Compound 94m (9.0 mg, 20.5 umol) was dissolved in TFA (1 mL)
and stirred at rt for 1 h. The reaction mixture was carefully
concentrated under reduced pressure to dryness, and the residue was
then triturated with 50% aq. methanol, and filtered through a
Celite-membrane filter. The filtrate was subjected to preparative
HPLC (Gemini 10u C18 110A, AXIA; 10% aq. acetonitrile-70% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient). The product
fractions were combined, concentrated under reduced pressure,
co-evaporated with methanol (10 mL.times.3), and dried under vacuum
to obtain compound 94 as its TFA salt. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.54 (d, J=2.4 Hz, 1H), 8.31 (s, 1H), 7.62
(dd, J=8.8, 2.5 Hz, 1H), 4.39-4.29 (m, 1H), 2.29 (dt, J=15.7, 6.7
Hz, 1H), 1.84 (dt, J=16.0, 6.9 Hz, 1H), 1.55 (s, 3H), 1.44-1.30 (m,
4H), 1.23 (d, J=6.5 Hz, 3H), 0.96-0.84 (m, 3H). .sup.19F NMR (376
MHz, Methanol-d4) .delta. -77.53 (s, 3F), -118.19 (dd, J=8.8, 4.0
Hz, 1F). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.15H.sub.23FN.sub.5O: 308.19; found: 308.12; t.sub.R=1.46 min
on LC/MS Method A.
Example 95
##STR00242##
[0977] Synthesis of
(2R,3R)-3-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylhe-
ptan-2-ol (95)
[0978] Compound 941 (10.3 mg, 23.4 umol) was dissolved in TFA (1
mL) and stirred at rt for 1 h. After the reaction mixture was
carefully concentrated to dryness in vacuo, the residue was
triturated with 50% aq. methanol and filtered through
Celite-membrane filter. The filtrate was subjected to preparative
HPLC (Gemini 10u C18 110A, AXIA; 10% aq. acetonitrile-70% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient). The product
fractions were combined, concentrated under reduced pressure,
co-evaporated with methanol (10 mL.times.3), and dried under vacuum
overnight to obtain compound 95 as its TFA salt. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.53 (d, J=2.4 Hz, 1H), 8.41 (s, 1H),
7.62 (dd, J=8.7, 2.5 Hz, 1H), 4.24 (q, J=6.4 Hz, 1H), 2.14 (ddd,
J=15.0, 11.3, 4.2 Hz, 1H), 2.04 (dq, J=14.3, 5.2 Hz, 1H), 1.48 (s,
3H), 1.39-1.24 (m, 4H), 1.22 (d, J=6.4 Hz, 3H), 0.89 (t, J=7.0 Hz,
3H). .sup.19F NMR (376 MHz, Methanol-d.sub.4) .delta. -77.52 (s,
3F), -118.31 (dd, J=8.7, 4.1 Hz, 1F). LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.15H.sub.23FN.sub.5O: 308.19;
found: 308.12; t.sub.R=1.47 min on LC/MS Method A.
Example 96
##STR00243##
[0979] Synthesis of
(3R)-3-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylheptan-2-ol
(96a)
[0980] Compound 94j (195.7 mg, 0.798 mmol) was dissolved in 4M HCl
in dioxane (3 mL) and stirred at rt for 1 h. The reaction mixture
was then concentrated in vacuo. The residue was treated with
2-methyltetrahydrofuran (5 mL), 2,4-dichloropyrido[3,2-d]pyrimidine
(160 mg, 0.525 mmol) and N,N-diisopropylethylamine (0.57 mL, 3.272
mmol) and heated with an 80.degree. C. bath for 3 h. The reaction
mixture was cooled to rt, concentrated under reduced pressure and
the residue was subjected to silica gel chromatography eluting with
0-100% EtOAc in hexanes to obtain compound 96a as a mixture of two
diastereomers (.about.2:3 ratio). LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.15H.sub.22ClN.sub.4O: 309.15; found: 309.08;
TR=1.41 min on LC/MS Method A.
Synthesis of
(2S,3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)ami-
no)-3-methylheptan-2-ol and
(2R,3R)-3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)ami-
no)-3-methylheptan-2-ol (96b and 96c)
[0981] To a solution of compound 96a (132.6 mg, 0.429 mmol) in
dioxane (5 mL) was added N,N-diisopropylethylamine (0.23 mL, 1.320
mmol) and 2,4-dimethoxybenzylamine (0.16 mL, 1.065 mmol), and the
resulting mixture refluxed at 110.degree. C. for 20 h. The reaction
mixture was diluted with EtOAc (30 mL) and washed with water (30
mL.times.2). The aqueous fractions were back extracted with EtOAc
(50 mL). The organic fractions were combined, dried over
MgSO.sub.4, filtered and then concentrated under reduced pressure.
The residue was subjected to silica gel chromatography eluting with
0-100% EtOAc in hexanes to obtain a mixture of compounds 96b and
96c. The mixture was further subjected to chiral SFC (SFC IC-5
um-4.6.times.100 mm, 40% EtOH-ammonia, flow rate=3 mL/min) to
obtain compound 96b, eluting first, and compound 96c, eluting
second.
[0982] Compound 96b: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
8.28 (dd, J=4.2, 1.5 Hz, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.43 (dd,
J=8.5, 4.3 Hz, 1H), 7.29 (d, J=8.2 Hz, 1H), 7.19 (s, 1H), 6.46 (d,
J=2.4 Hz, 1H), 6.42 (dd, J=8.2, 2.4 Hz, 1H), 5.3 (br, 1H), 4.56 (d,
J=5.7 Hz, 2H), 3.86 (m, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 1.98 (m,
1H), 1.66-1.53 (m, 1H), 1.48 (s, 3H), 1.44-1.30 (m, 4H), 1.17 (d,
J=6.4 Hz, 3H), 0.98-0.89 (m, 3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.24H.sub.34N.sub.5O.sub.3: 440.27; found:
440.25; TR=0.99 min on LC/MS Method A.
[0983] Compound 96c: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
8.29 (dd, J=4.2, 1.5 Hz, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.43 (dd,
J=8.5, 4.2 Hz, 1H), 7.30 (d, J=8.2 Hz, 1H), 7.16 (s, 1H), 6.46 (d,
J=2.3 Hz, 1H), 6.42 (dd, J=8.2, 2.4 Hz, 1H), 5.25 (s, 1H), 4.56 (d,
J=5.7 Hz, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 3.86-3.75 (m, 1H), 2.13
(t, J=13.0 Hz, 1H), 1.93-1.79 (m, 1H), 1.52-1.40 (m, 1H), 1.38 (s,
3H), 1.35-1.15 (m, 3H), 1.20 (d, J=6.4 Hz, 3H), 0.87 (t, J=7.2 Hz,
3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.24H.sub.34N.sub.5O.sub.3: 440.27; found: 440.25; t.sub.R=1.00
min on LC/MS Method A.
Synthesis of
(3R)-3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylheptan-2-ol
(96)
[0984] Compound 96b (8.7 mg, 19.79 umol) was dissolved in TFA (1
mL) and stirred at rt for 1 h. The reaction mixture was
concentrated under reduced pressure to dryness and then
co-evaporated with methanol (10 mL). The resulting residue was
dissolved in methanol (1 mL) and concentrated ammonium hydroxide
(0.1 mL). The reaction mixture was stirred for 10 min. and then
concentrated under reduced pressure to dryness and co-evaporated
with methanol (10 mL). The residue was triturated with 50% aq. MeOH
(10 mL) and filtered through a Celite-membrane filter. The filtrate
was subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 10%
aq. acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The product fractions were combined, concentrated in
vacuo, co-evaporated with methanol (10 mL.times.3), and dried under
high-vacuum to provide compound 96 as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d4) .delta. 8.61 (dd, J=4.4, 1.5 Hz, 1H), 7.82
(dd, J=8.5, 1.5 Hz, 1H), 7.76 (dd, J=8.5, 4.4 Hz, 1H), 4.36 (q,
J=6.5 Hz, 1H), 2.30 (dt, J=16.3, 6.8 Hz, 1H), 1.91-1.78 (m, 1H),
1.56 (s, 3H), 1.43-1.30 (m, 4H), 1.23 (d, J=6.5 Hz, 3H), 0.98-0.85
(m, 3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.15H.sub.24N.sub.5O: 290.20; found: 290.11; t.sub.R=0.74 min
on LC/MS Method A.
Example 97
##STR00244##
[0985] Synthesis of
(3R)-3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-3-methylheptan-2-ol
(97)
[0986] Compound 96c (9.0 mg, 20.5 umol) was dissolved in TFA (1 mL)
and stirred at rt for 1 h. The reaction mixture was carefully
concentrated under reduced pressure to dryness and co-evaporated
with methanol (10 mL). The residue was dissolved in methanol (1 mL)
and concentrated ammonium hydroxide (0.1 mL). The reaction mixture
was stirred for 10 min. and then concentrated under reduced
pressure to dryness and then co-evaporated with methanol (10 mL).
The resulting residue was triturated with 50% aq. methanol and
filtered through a Celite-membrane filter. The filtrate was then
subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The product fractions were combined, concentrated under
reduced pressure, co-evaporated with methanol (10 mL.times.3), and
dried under high-vacuum to provide compound 97 as its TFA salt.
.sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.61 (dd, J=4.3, 1.3 Hz,
1H), 7.82 (dd, J=8.5, 1.4 Hz, 1H), 7.76 (dd, J=8.5, 4.3 Hz, 1H),
4.26 (q, J=6.4 Hz, 1H), 2.11 (dddd, J=24.9, 19.8, 12.8, 7.0 Hz,
2H), 1.49 (s, 3H), 1.40-1.24 (m, 4H), 1.22 (d, J=6.4 Hz, 3H), 0.89
(t, J=6.9 Hz, 3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.15H.sub.24N.sub.5O: 290.20; found: 290.10; t.sub.R=0.74 min
on LC/MS Method A.
Example 98
##STR00245##
[0987] Synthesis of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol (98)
[0988] Intermediate 43B (101 mg, 0.56 mmol) and
(R)-a-Me-norleucinol 59A (109 mg, 0.83 mmol) were added to NMP (5.5
mL) followed by BOP reagent (0.36 g, 0.83 mmol) and DBU (0.25 mL,
1.67 mmol). The reaction mixture was stirred at rt for 16 h, and
then diluted with EtOH (2 mL) and water (2 mL). The resulting
mixture was subjected directly to HPLC purification (Gemini 10u C18
110A, AXIA; 10% aq. acetonitrile-80% aq. acetonitrile with 0.1%
TFA, over 20 min. gradient) to provide, after collection of product
fractions and removal of solvent in vacuo, compound 98 as a TFA
salt. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.55 (d, J=2.4 Hz,
1H), 8.22 (s, 1H), 7.64 (dd, J=8.7, 2.5 Hz, 1H), 3.97 (d, J=11.2
Hz, 1H), 3.71 (d, J=11.2 Hz, 1H), 2.09 (m, 1H), 1.92 (m, 1H), 1.54
(s, 3H), 1.40-1.31 (m, 4H), 1.00-0.85 (m, 3H). .sup.19F NMR (376
MHz, Methanol-d4) .delta. -77.68, -118.20 (d, J=8.8 Hz).
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.14H.sub.20FN.sub.5O: 293.34; found: 294.1; t.sub.R=0.68
min.
Example 99
##STR00246##
[0989] Synthesis of (3R,5R,6S)-tert-butyl
2-oxo-5,6-diphenyl-3-(4,4,4-trifluorobutyl)morpholine-4-carboxylate
(99a)
[0990] Imidazole (1.75 g, 0.03 mol), and triphenylphosphine, 99+%
(6.08 g, 0.02 mol) were stirred in DCM (100 mL) under argon and
cooled to 0.degree. C. for 10 minutes. Iodine (5.94 g, 0.02 mol)
was added over 5 minutes and the reaction was stirred at 0.degree.
C. for 20 minutes. A solution of 4,4,4-trifluoro-1-butanol, 97%
(2.48 mL, 0.02 mol) was slowly added. The reaction was stirred and
allowed to warm to rt. After 16 h, pentane (200 mL) was added and
the resulting solids filtered off. Solvent was partially removed
under reduced pressure, and then additional cold pentane (50 mL)
was added. The solids were filtered off and the eluent concentrated
under reduced pressure to afford 1,1,1-trifluoro-4-iodobutane.
[0991] (2S,3R)-tert-butyl
6-oxo-2,3-diphenylmorpholine-4-carboxylate, 72A (1 g, 2.83 mmol)
and 1,1,1-trifluoro-4-iodobutane (2.02 g, 8.49 mmol) were dissolved
in THF (24 mL) and HMPA (2.5 mL), and the mixture was then cooled
to -78.degree. C. under argon. 1M lithium hexamethyldisilazide
(1.0M THF in THF, 4.24 mL) was added and the reaction transferred
to a -40.degree. C. bath. The cold bath was recharged with dry ice
and the reaction left to warm to ambient temperature with stirring
overnight. The reaction was quenched with EtOAc (25 mL) and poured
into a mixture of EtOAc (100 mL) and saturated aqueous solution of
NH.sub.4Cl (50 mL). The organic layer was separated and washed with
water (100 mL), brine (100 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure. The residue was
subjected to silica gel chromatography eluting with hexanes-EtOAc
to provide (3R,5R,6S)-tert-butyl
2-oxo-5,6-diphenyl-3-(4,4,4-trifluorobutyl)morpholine-4-carboxylate
99a.
Synthesis of
(R)-2-((tert-butoxycarbonyl)amino)-6,6,6-trifluorohexanoic acid
(99b)
[0992] Lithium (granular), (157.24 mg, 22.65 mmol) was cooled in a
-40.degree. C. bath. Ammonia gas was slowly condensed via a cold
finger into the reaction for 15-20 minutes. After an additional 20
minutes(3R,5R,6S)-tert-butyl
2-oxo-5,6-diphenyl-3-(4,4,4-trifluorobutyl)morpholine-4-carboxylate,
99a (700 mg, 1.51 mmol) in THF (10 mL) and EtOH (0.5 mL) was added.
The reaction was allowed to warm to rt, and the liquid ammonia
allowed to evaporate with stirring overnight. The resulting residue
was treated with THF (50 mL) and water (50 mL) and stirred until
all the solids dissolved. A saturated aq. ammonium chloride (50 mL)
solution was added followed by 1N NaOH to adjust the pH to basic.
The reaction mixture was washed with diethyl ether (100 mL), and
the aqueous layer was then pH adjusted with 1N HCl to .about.pH 4.
The aq. layer was then extracted with EtOAc (3.times.50 mL). The
combined organics were then washed with ammonium chloride (50 mL),
water (50 mL), brine (50 mL), dried over sodium sulfate, filtered
and concentrated under reduced pressure to provide 99b.
Synthesis of (R)-methyl 2-amino-6,6,6-trifluorohexanoate (99c)
[0993] Compound 99b (230 mg, 0.81 mmol) was dissolved in DCM (10
mL) and MeOH (1 mL). A solution of 2M (Trimethylsilyl)
Diazomethane, 2M solution in hexanes (0.6 mL, 1.2 mmol) was added
dropwise. The reaction was allowed to stir for 20 minutes and then
2 drops of acetic acid were added. The reaction mixture was
concentrated under reduced pressure and. the resulting residue
treated with DCM (5 mL) and TFA (5 mL). The mixture was stirred for
90 minutes and then concentrated under reduced pressure. The
residue was co-evaporated with DCM (20 mL.times.2) to provide 99c
as its TFA salt.
##STR00247##
Synthesis of (R)-methyl
2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)-6,6,-
6-trifluorohexanoate (99d)
[0994] 99d was synthesized in a similar fashion to compound 63B,
instead replacing 63A with (R)-methyl
2-amino-6,6,6-trifluorohexanoate TFA salt 99c (100 mg, 0.75 mmol),
to obtain 99d. MS (m/z) 494.2 [M+H].sup.+; t.sub.R=0.95 min.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
6,6,6-trifluorohexan-1-ol (99e)
[0995] Compound 99d (100 mg, 0.2 mmol) was treated with THF (15 mL)
and cooled to 0.degree. C. under argon. To this solution was added
1M LiAlH.sub.4 in THF (0.61 mL, 0.61 mmol) and the reaction mixture
stirred at 0.degree. C. Upon completion, the reaction was diluted
in EtOAc/H.sub.2O and extracted with EtOAc (50 mL.times.3). The
combined organics were then washed with aq. ammonium chloride (50
mL), water (50 mL), brine (50 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure. The crude residue
was subjected to silica gel chromatography eluting with
hexanes-EtOAc to afford 99e. LCMS (m/z) 466.1 [M+H].sup.+.
t.sub.R=1.14 min
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-6,6,6-trifluorohexan-1--
ol (99)
[0996] Compound 99e (75 mg, 0.16 mmol) was dissolved in TFA (5 mL)
and allowed to stir for 1 h. The TFA was removed under reduced
pressure and MeOH (10 mL) was added. The mixture was stirred for 1
h and then filtered. The eluent was removed in vacuo and the
residue was treated with MeOH (10 mL). The mixture was stirred for
16 h and then concentrated under reduced pressure. The residue was
co-evaporated with MeOH (10 mL, x 3) and the resulting residue
dried under high vacuum to afford compound 99 as its TFA salt.
.sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.65 (dd, J=4.4, 1.4 Hz,
1H), 7.84 (dd, J=8.5, 1.4 Hz, 1H), 7.77 (dd, J=8.5, 4.4 Hz, 1H),
4.56 (ddt, J=10.9, 5.5, 3.1 Hz, 1H), 3.75 (d, J=5.3 Hz, 2H),
2.40-2.07 (m, 2H), 1.94-1.76 (m, 2H), 1.66 (dddd, J=19.0, 16.1,
8.7, 5.9 Hz, 2H). .sup.19F NMR (376 MHz, Methanol-d.sub.4) .delta.
-68.49 (t, J=11.0 Hz), -77.91. LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.13H.sub.16F.sub.3N.sub.5O: 315.29; found:
316.2; t.sub.R=0.82 min.
Example 100
##STR00248##
[0997] Synthesis of (E)-tert-butyl hept-2-enoate (100a)
[0998] To a solution of valeraldehyde (2.82 mL, 26.57 mmol) in THF
(50 mL) was added
(tert-butoxycarbonylmethylene)triphenylphosphorane (10 g, 26.57
mmol) and the reaction mixture stirred for 16 h at rt. The solvents
were then removed under reduced pressure, and the residue slurried
in diethyl ether and filtered. The filtrate was concentrated in
vacuo and the residue subjected to silica gel chromatography
eluting with hexanes-EtOAc to give 100a. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 6.85 (dt, J=15.5, 7.0 Hz, 1H), 5.73 (dt,
J=15.6, 1.6 Hz, 1H), 2.26-2.11 (m, 2H), 1.52-1.25 (m, 13H), 0.93
(t, J=7.2 Hz, 3H).
Synthesis of (R)-tert-butyl
3-(benzyl((S)-1-phenylethyl)amino)heptanoate (100b)
[0999] 2.5M Butyllithium (2.5M in Hexanes, 14.33 mL) was added to a
stirred solution of (R)-(+)-N-benzyl-alpha-methylbenzylamine (7.99
mL, 38.2 mmol) in THF (100 mL) at -78.degree. C. The reaction
mixture was stirred for 30 minutes, and then 100a (4.4 g, 23.88
mmol) in THF (50 mL) was added slowly to the reaction mixture. The
reaction mixture was then stirred at -78.degree. C. for 2 h,
quenched with sat. aq. NH.sub.4Cl solution (100 mL) and allowed to
warm to rt. EtOAc (200 mL) and water (100 mL) were added, and the
organic layer separated. The aqueous layer was extracted with EtOAc
(3.times.50 mL) and the combined organics were washed with brine
(100 mL), dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The resulting residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc to provide 100b. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 7.41 (d, J=7.2 Hz, 2H),
7.36-7.10 (m, 8H), 3.87-3.73 (m, 2H), 3.50 (d, J=15.0 Hz, 1H), 3.24
(tt, J=9.4, 4.2 Hz, 1H), 2.04 (dd, J=14.4, 3.6 Hz, 1H), 1.89 (dd,
J=14.4, 9.4 Hz, 1H), 1.57-1.43 (m, 3H), 1.38 (s, 8H), 1.33-1.12 (m,
7H), 0.87 (t, J=7.3 Hz, 3H).
Synthesis of (R)-3-(benzyl((S)-1-phenylethyl)amino)heptanoic acid
(100c)
[1000] (R)-tert-butyl 3-(benzyl((S)-1-phenylethyl)amino)heptanoate
100b (6.4 g, 16.18 mmol) was dissolved in DCM (40 mL) and treated
with TFA (20 mL). The reaction mixture was allowed to stir at
40.degree. C. for 24 h and then concentrated under reduced pressure
to provide 100c. LCMS (m/z) 340.0 [M+H].sup.+. t.sub.R=0.94 min
Synthesis of (R)-3-(benzyl((S)-1-phenylethyl)amino)heptan-1-ol
(100d)
[1001] (R)-3-(benzyl((S)-1-phenylethyl)amino)heptanoic acid 100c
(5.5 g, 16.2 mmol) was dissolved in THF (100 mL) under argon, and
1M borane-tetrahydrofuran in THF (64.81 mL, 64.81 mmol) was slowly
added. The reaction was allowed to stir for several h at rt. MeOH
was slowly added to quench the reaction and the mixture was allowed
to stir for an additional 20 minutes. A .about.2N HCl (aq) (14 mL)
solution was added and the mixture concentrated under reduced
pressure to afford a white solid. The solid material was suspended
in DCM (100 mL) and filtered. The filter cake was rinsed with DCM
(25 mL). The mother liquor was concentrated under reduced pressure
to afford a light yellow oil which was subjected to silica gel
chromatography eluting with DCM-MeOH to afford 100d. MS (m/z) 326.1
[M+H].sup.+; t.sub.R=0.82 min
Synthesis of (R)-3-aminoheptan-1-ol (100e)
[1002] (R)-3-(benzyl((S)-1-phenylethyl)amino)heptan-1-ol 100d (0.78
g, 2.4 mmol) was treated with EtOH (25 mL) and 20% Pd(OH).sub.2/C
(300 mg, 0.43 mmol). The reaction vessel was purged 3x with H.sub.2
gas and then allowed to stir for 2 days under H.sub.2. The reaction
mixture was filtered and solvents were removed under reduced
pressure to afford 100e. .sup.1H NMR (400 MHz, Methanol-d4) .delta.
3.90-3.68 (m, 2H), 3.39-3.27 (m, 1H), 1.98-1.72 (m, 2H), 1.72-1.57
(m, 3H), 1.39 (h, J=4.5, 4.0 Hz, 4H), 1.03-0.86 (m, 3H).
##STR00249##
Synthesis of
(R)-3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)heptan-1-ol
(100)
[1003] 2,4-dichloropyrido[3,2-d]pyrimidine (100 mg, 0.5 mmol) was
reacted with 100e (65.6 mg, 0.5 mmol) followed by
2,4-dimethoxybenzylamine (150.21 .mu.l, 1 mmol) as described for
the synthesis of 59B from 59A, to prepare 100f. Compound 100f was
then subjected to TFA (3 mL) for 1h as described in the preparation
of compound 59 from 59B to afford, 100 as its TFA salt. MS (m/z)
276.1 [M+H].sup.+; t.sub.R=0.64 min; .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.63 (dd, J=4.4, 1.5 Hz, 1H), 7.82 (dd, J=8.5,
1.5 Hz, 1H), 7.76 (dd, J=8.5, 4.4 Hz, 1H), 4.64 (tt, J=7.9, 5.6 Hz,
1H), 3.72-3.59 (m, 2H), 1.99-1.83 (m, 2H), 1.81-1.66 (m, 2H),
1.46-1.29 (m, 4H), 0.97-0.82 (m, 3H). .sup.19F NMR (376 MHz,
Methanol-d4) .delta. -77.56.
Example 101
##STR00250##
[1004] Synthesis of
(R)-N-(2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
yl)acetamide (101)
[1005] Compound 101 was prepared following the procedure described
in Example 84, using 2,4-dichloro-7-fluoropyrido[3,2-d]pyrimidine
84E (30 mg, 0.14 mmol) and reacting sequentially with
(R)-N-(2-amino-2-methylhexyl)acetamide hydrochloride 61E (28.72 mg,
0.14 mmol) followed by 2,4-dimethoxybenzylamine (82.69 .mu.l, 0.55
mmol). The resulting product was then subjected to TFA treatment as
described in the preparation of 84 from 84G, to provide 101 as its
TFA salt. MS (m/z) 335.2 [M+H].sup.+; t.sub.R=0.64 min; .sup.1H NMR
(400 MHz, Methanol-d4) .delta. 8.54 (t, J=2.9 Hz, 2H), 7.62 (dd,
J=8.8, 2.5 Hz, 1H), 3.99-3.86 (m, 1H), 3.51 (d, J=14.0 Hz, 1H),
2.26-2.05 (m, 1H), 1.95 (s, 4H), 1.54 (s, 3H), 1.45-1.27 (m, 4H),
0.99-0.80 (m, 3H); .sup.19F NMR (376 MHz, Methanol-d4) .delta.
-78.04, -118.27 (d, J=8.8 Hz).
Example 102
##STR00251##
[1006] Synthesis of
(3R)-3-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-1-fluorohepta-
n-2-ol (102)
[1007] A solution of compound 43B (131.5 mg, 0.730 mmol), compound
88d (212.2 mg, 1.415 mmol), and BOP (392.7 mg, 0.888 mmol) in DMF
(7 mL) was stirred at rt as DBU (0.33 mL, 2.209 mmol) was added.
The reaction mixture was stirred at rt for 17.5 h, diluted with
water (7 mL), and then the mixture was filtered. The filtrate was
subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient) and the product fractions were combined, concentrated
under reduced pressure to obtain the crude product. The crude
product was re-subjected to preparative HPLC (Gemini 10u C18 110A,
AXIA; 10% aq. acetonitrile-70% aq. acetonitrile with 0.1% TFA, over
20 min. gradient), and the combined product fractions concentrated
under reduced pressure, co-evaporated with methanol (10
mL.times.4), and dried to obtain compound 102 as its TFA salt.
.sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.67 (d, J=9.6 Hz, 0H),
8.55 (d, J=2.4 Hz, 1H), 7.65 (dd, J=8.8, 2.5 Hz, 1H), 4.63-4.54 (m,
1H), 4.51-4.39 (m, 1H), 4.39-4.26 (m, 1H), 4.03 (dddd, J=16.5, 6.0,
4.9, 3.2 Hz, 1H), 1.87-1.73 (m, 2H), 1.49-1.28 (m, 4H), 0.98-0.83
(m, 3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta. -77.71,
-117.85 (d, J=8.3 Hz), -231.37 (td, J=47.3, 16.5 Hz).
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.14H.sub.2OF.sub.2N.sub.5O: 312.16; found: 312.16;
t.sub.R=0.70 min.
Example 103
##STR00252##
[1008] Synthesis of (R)-benzyl (1-hydroxyhexan-2-yl)carbamate
(103a)
[1009] A solution of (R)-2-aminohexan-1-ol (1.853 g, 15.81 mmol)
and sodium bicarbonate (1961.6 mg, 31.63 mmol) in water (80 mL) was
stirred at rt and benzyl chloroformate (2.7 mL, 95% purity, 18.98
mmol) was added. After stirring for 1 h at rt, the mixture was
extracted with EtOAc (100 mL x 1, 80 mL x 2). The combined extracts
were washed with brine, dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with 0-100% EtOAc in hexanes to obtain 103a.
.sup.1H NMR (400 MHz, Methanol-d4) .delta. 7.44-7.18 (m, 5H), 6.75
(d, J=8.7 Hz, 0H), 5.07 (d, J=2.2 Hz, 2H), 3.57 (dt, J=11.1, 5.4
Hz, 1H), 3.48 (d, J=5.6 Hz, 2H), 1.58 (dq, J=14.0, 8.4, 6.4 Hz,
1H), 1.35 (dq, J=14.3, 7.4, 6.4 Hz, 5H), 0.91 (t, J=5.6 Hz, 3H).
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.14H.sub.22NO.sub.3: 252.16; found: 251.80; t.sub.R=0.90
min.
Synthesis of benzyl (1-oxohexan-2-yl)carbamate (103b)
[1010] To a stirred solution of oxalyl chloride (0.125 mL, 1.432
mmol) in DCM (10 mL) cooled with an -78.degree. C. bath was added
DMSO (0.203 mL, 2.865 mmol) in DCM (2 mL) over 8 min. After 15 min,
a solution of compound 103a (300 mg, 1.194 mmol) in DCM (4 mL) was
added to the reaction mixture. The mixture was stirred at
-78.degree. C. for 30 min. and then triethylamine (0.832 mL, 5.968
mmol) was added with vigorous stirring. The resulting mixture was
allowed to warm to rt, diluted with DCM (20 mL), washed with water
(30 mL.times.3), brine (20 mL), dried (MgSO.sub.4), filtered and
concentrated under reduced pressure. The residue was subjected to
silica gel chromatography eluting with 0-50% EtOAc in hexanes to
obtain 103b. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 9.41 (d,
J=80.7 Hz, 0H), 7.51-7.06 (m, 5H), 5.08 (d, J=2.1 Hz, 2H), 4.43 (d,
J=3.9 Hz, 1H), 3.57 (dd, J=9.8, 5.1 Hz, 1H), 1.65 (dd, J=11.3, 6.7
Hz, 1H), 1.46-1.20 (m, 5H), 0.90 (t, J=6.3 Hz, 3H). LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.14H.sub.20NO.sub.3: 250.14;
found: 249.83; t.sub.R=0.93 min.
Synthesis of benzyl (2-hydroxyheptan-3-yl)carbamate (103c)
[1011] To a solution of compound 103b (277.0 mg, 1.111 mmol)
dissolved in diethyl ether (10 mL) and cooled to -78.degree. C. was
added dropwise 1.57 M methyllithium in diethyl ether (1.557 mL,
2.444 mmol). After 10 min, saturated ammonium chloride (10 mL) was
added to the reaction mixture and the resulting mixture was allowed
to warm to rt for 45 min. The mixture was extracted with EtOAc (50
mL.times.3), the combined organic extracts were washed with brine,
dried over MgSO.sub.4, filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
0-70% EtOAc in hexanes to obtain compound 103c as a mixture of 4
diastereomers. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 7.44-7.19
(m, 5H), 5.08 (d, J=3.0 Hz, 2H), 3.83-3.57 (m, 1H), 3.54-3.40 (m,
1H), 1.76-1.41 (m, 2H), 1.43-1.24 (m, 6H), 1.12 (dd, J=9.4, 6.4 Hz,
3H), 0.90 (dd, J=7.9, 4.9 Hz, 3H). LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.15H.sub.24NO.sub.3: 266.18; found:
265.81; t.sub.R=0.93 min.
Synthesis of 3-aminoheptan-2-ol (103d)
[1012] Compound 103c (59.6 mg, 0.225 mmol) and 20% Pd(OH).sub.2 on
carbon (15.2 mg) were dissolved in EtOH (2 mL) and stirred under
H.sub.2 atmosphere. After 2 h, the reaction mixture was filtered
through Celite pad and the removed solid was washed with EtOH (10
mL). The filtrate and washing were concentrated under reduced
pressure and the crude compound, 103d, was used without further
purification. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.7H.sub.18NO: 132.14; found: 131.91; t.sub.R=0.37 min.
Synthesis
3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)am-
ino)heptan-2-ol (103e)
[1013] To a solution of compound 103d (29.5 mg, 0.225 mmol) and
2,4-dichloropyrido[3,2-d]pyrimidine (37.4 mg, 0.187 mmol) in
dioxane (2 mL) was added N,N-diisopropylethylamine (0.05 mL, 0.281
mmol). After 20 min, additional N,N-diisopropylethylamine (0.080
mL, 0.449 mmol) and 2,4-dimethoxybenzylamine (0.10 mL, 0.674 mmol)
were added and the resulting mixture was heated at 115.degree. C.
bath for 7 h. The reaction mixture was allowed to cool to rt,
diluted with water (50 mL), extracted with DCM (25 mL.times.2). The
combined organic extracts were washed with water (25 mL.times.2),
dried over MgSO.sub.4, filtered and then concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
0-100% EtOAc in hexanes to obtain compound 103e. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.31 (dt, J=4.3, 1.0 Hz, 0.85H), 8.05 (s,
0.15H), 7.63 (s, 1H), 7.48 (dd, J=8.5, 4.2 Hz, 1H), 7.18 (dd,
J=8.3, 1.9 Hz, 1H), 6.52 (d, J=2.3 Hz, 1H), 6.48-6.38 (m, 1H),
4.64-4.47 (m, 2H), 4.35-4.21 (m, 1H), 4.00-3.87 (m, 1H), 3.83 (two
s, 3H), 3.76 (two s, 3H), 3.35 (s, 1H), 1.90-1.52 (m, 2H), 1.33 (m,
4H), 1.16 (m, 3H), 0.97-0.78 (m, 3H). LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.23H.sub.34N.sub.5O.sub.3: 426.25;
found: 426.17; t.sub.R=1.00 min.
Synthesis of
3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)heptan-2-ol (103)
[1014] Compound 103e (17.4 mg, 40.9 umol) was dissolved in TFA (1
mL) and stirred at rt for 1 h. The reaction mixture was
concentrated under reduced pressure and co-evaporated with MeOH (10
mL). The resulting residue was dissolved in MeOH (1 mL) and
concentrated ammonium hydroxide (0.1 mL). The mixture was stirred
for 10 min. at rt and then concentrated under reduced pressure to
dryness. The residue was dissolved in DMF-water (1:1, 5 mL) and
filtered through a Celite/membrane filter. The filtrate was
subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The product fractions were combined, concentrated under
reduced pressure, co-evaporated with methanol (10 mL.times.3), and
dried under high vacuum to obtain compound 103 as its TFA salt.
.sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.64 (dt, J=4.4, 1.2 Hz,
1H), 7.84 (dt, J=8.5, 1.4 Hz, 1H), 7.77 (ddd, J=8.5, 4.4, 1.5 Hz,
1H), 4.47-4.31 (m, 1H), 3.99 (tq, J=6.5, 3.5 Hz, 0.5H), 3.94 (dd,
J=6.6, 5.5 Hz, 0.5H), 1.95-1.82 (m, 0.5H), 1.82-1.72 (m, 1H),
1.72-1.63 (m, 0.5H), 1.48-1.25 (m, 4H), 1.22 (d, J=6.4 Hz, 1.5H),
1.19 (d, J=6.4 Hz, 1.5H), 0.89 (two d, J=6.9, Hz each, 3H).
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.14H.sub.22N.sub.5O: 276.18; found: 276.15; t.sub.R=0.68
min.
Example 104
##STR00253##
[1015] Synthesis of (S)-benzyl (1-hydroxyhexan-2-yl)carbamate
(104a)
[1016] To a mixture of (S)-2-aminohexan-1-ol (504.4 mg, 4.30 mmol)
and sodium bicarbonate (533.9 mg, 8.61 mmol) in water (20 mL) was
added benzyl chloroformate (0.74 mL, 95% purity, 5.17 mmol). The
resulting mixture was vigorously stirred at rt overnight. The solid
was dissolved with EtOAc (75 mL) and the mixture extracted with
EtOAc (75 mL.times.2). The organic extracts were combined, dried
over Na.sub.2SO.sub.4, filtered and concentrated in vacuo to obtain
white solids. The solids were subjected to silica gel
chromatography eluting with 0-100% EtOAc in hexanes to obtain
compound 104a. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta.
7.42-7.22 (m, 5H), 5.07 (d, J=2.1 Hz, 2H), 3.59 (d, J=8.0 Hz, 1H),
3.48 (d, J=5.6 Hz, 2H), 1.59 (d, J=10.8 Hz, 1H), 1.34 (td, J=15.4,
11.8, 7.3 Hz, 6H), 0.91 (t, J=6.0 Hz, 3H). LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.14H.sub.22NO.sub.3: 252.16; found:
251.78; t.sub.R=0.88 min.
Synthesis of benzyl (1-oxohexan-2-yl)carbamate (104b)
[1017] To a stirred solution of oxalyl chloride (0.052 mL, 0.602
mmol) in DCM (1.5 mL) at -78.degree. C. was added DMSO (0.086 mL,
1.205 mmol) in DCM (2 mL) over 8 min. After 15 min, a solution of
compound 104a (108.1 mg, 0.430 mmol) in DCM (1.5 mL) was added to
the reaction mixture. The mixture was stirred at -78.degree. C. for
30 min. and then triethylamine (0.174 mL, 1.248 mmol) was added
with vigorous stirring. The resulting mixture was allowed to warm
to rt over 45 min. The mixture was diluted with DCM (30 mL), washed
with water (30 mL.times.3), brine (25 mL), dried over MgSO.sub.4,
filtered and concentrated under reduced pressure to obtain the
mixture 104b. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.14H.sub.20NO.sub.3: 250.14; found: 249.79; t.sub.R=0.91
min.
Synthesis of benzyl (2-hydroxyheptan-3-yl)carbamate (104c)
[1018] To a solution of compound 104b (107.3 mg, 0.430 mmol),
dissolved in diethyl ether (4 mL) and cooled to -78.degree. C. was
added 1.57 M methyllithium in diethyl ether (0.685 mL, 1.076 mmol)
dropwise. After 10 min, saturated aq. ammonium chloride (7 mL) was
added to the reaction mixture and the resulting mixture was allowed
to warm to rt for 45 min. The mixture was extracted with EtOAc (25
mL.times.2), and the combined organic extracts washed with brine,
dried over MgSO.sub.4, filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
0-70% EtOAc in hexanes to obtain compound 104c as a mixture of 4
diastereomers. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta.
7.42-7.20 (m, 5H), 6.63 (dd, J=102.5, 9.6 Hz, 1H), 5.08 (d, J=3.3
Hz, 2H), 3.80-3.54 (m, 1H), 3.52-3.41 (m, 1H), 1.75-1.42 (m, 2H),
1.42-1.27 (m, 5H), 1.12 (dd, J=9.3, 6.4 Hz, 3H), 0.90 (d, J=3.5 Hz,
3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.15H.sub.24NO.sub.3: 266.18; found: 265.81; t.sub.R=1.06
min.
Synthesis of 3-aminoheptan-2-ol (104d)
[1019] Compound 104c (71.68 mg, 0.270 mmol) and 20% Pd(OH).sub.2 on
carbon (19 mg) were dissolved in EtOH (2 mL) and stirred under
H.sub.2 atmosphere. After 2 h, the reaction mixture was filtered
through Celite pad and the removed solid washed with EtOH (5 mL).
The filtrate and washings were concentrated under reduced pressure
to provide 104d that was used without further purification.
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for C.sub.7H8NO:
132.14; found: 131.91; t.sub.R=0.51 min.
Synthesis of
3-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)hepta-
n-2-ol (104e)
[1020] To a solution of compound 104d (35.45 mg, 0.270 mmol) and
2,4-dichloropyrido[3,2-d]pyrimidine (5.02 mg, 0.225 mmol) in
dioxane (3 mL) was added N,N-diisopropylethylamine (0.06 mL, 0.338
mmol). After 20 min. additional N,N-diisopropylethylamine (0.096
mL, 0.540 mmol) and 2,4-dimethoxybenzylamine (0.120 mL, 0.811 mmol)
were added and the resulting mixture was heated at 115.degree. C.
bath for 6 h. The reaction mixture was cooled to rt, diluted with
water (30 mL), and extracted with DCM (20 mL.times.2). The organic
extracts were combined, washed with water (30 mL.times.2), brine
(25 mL), dried over MgSO.sub.4, filtered and concentrated under
reduced pressure. The residue was subjected to silica gel
chromatography eluting with 0-100% EtOAc in hexanes to obtain
compound 104e. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.31
(ddd, J=4.2, 1.5, 0.8 Hz, 1H), 7.63 (d, J=8.4 Hz, 1H), 7.48 (dd,
J=8.5, 4.2 Hz, 1H), 7.25-7.08 (m, 1H), 6.60-6.37 (m, 2H), 4.84 (s,
3H), 4.54 (d, J=5.3 Hz, 2H), 4.35-4.22 (m, 1H), 3.83 (d, J=10.3 Hz,
3H), 3.79-3.73 (m, 3H), 1.88-1.52 (m, 2H), 1.46-1.28 (m, 4H),
1.23-1.12 (m, 3H), 0.86 (td, J=7.0, 2.2 Hz, 3H). LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.23H.sub.34N.sub.5O.sub.3:
426.25; found: 426.19; t.sub.R=0.97 min.
Synthesis of
3-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)heptan-2-ol (104)
[1021] Compound 104e (27.3 mg, 64.2 umol) was dissolved in TFA (1
mL) and stirred at rt for 1 h. The reaction mixture was
concentrated under reduced pressure and co-evaporated with MeOH (10
mL). The resulting residue was dissolved in MeOH (1 mL) and
concentrated ammonium hydroxide (0.1 mL). The reaction mixture was
stirred at rt, and then concentrated under reduced pressure to
dryness. The residue was treated with DMF-water (1:1, 5 mL). The
insoluble material was removed via filtration through a
Celite/membrane filter, and the filtrate was subjected to
preparative HPLC (Gemini 10u C18 110A, AXIA; 10% aq.
acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The fractions were combined, concentrated under reduced
pressure, co-evaporated with methanol (10 mL.times.3), and dried in
vacuum overnight to obtain 104 as its TFA salt. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.64 (dt, J=4.4, 1.2 Hz, 1H), 7.84 (dt,
J=8.5, 1.4 Hz, 1H), 7.77 (ddd, J=8.5, 4.4, 1.5 Hz, 1H), 4.46-4.40
(m, 0.5H), 4.37 (m, 1H), 4.00 (m, 0.5H), 3.97-3.88 (m, 0.5H), 1.88
(m, 0.5H), 1.82-1.72 (m, 1H), 1.72-1.62 (m, 0.5H), 1.48-1.25 (m,
4H), 1.22 (d, J=6.4 Hz, 1.5H), 1.19 (d, J=6.4 Hz, 1.5H), 0.89 (two
t, J=6.8 Hz each, 3H). LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated
for C.sub.14H.sub.22N.sub.5O: 276.18; found: 276.15; t.sub.R=0.68
min.
Example 105
##STR00254##
[1022] Synthesis of 2,4,7-trichloropyrido[3,2-d]pyrimidine
(105a)
[1023] A mixture of pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione 19A
(supplied by Astatech, Inc., 2.00 g, 12.26 mmol), phosphorus
pentachloride (15.32 g, 73.56 mmol) and phosphorus oxychloride
(22.86 mL, 245.20 mmol) in a sealed, thick-walled reaction tube,
was stirred at 160.degree. C. for 5 h. The mixture was concentrated
in vacuo and the residue was dissolved in DCM (100 mL). The organic
solution was washed with water (100 mL), brine (100 mL), dried over
MgSO.sub.4, filtered and then concentrated in vacuo. The residue
was subjected to silica gel chromatography eluting with 0-50% EtOAc
in hexanes to obtain compound 105a. .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 9.02 (d, J=2.2 Hz, 21H), 8.29 (d, J=2.2 Hz,
21H). LCMS-ESI.sup.+ (m/z): t.sub.R=0.86 min.
Synthesis of
(R)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (105b)
[1024] To a solution of compound 105a (336 mg, 1.066 mmol) and
(R)-2-aminohexan-1-ol 86a (137.5 mg, 1.173 mmol) in dioxane (4 mL)
was added N,N-diisopropylethylamine (0.23 mL, 1.292 mmol). The
mixture was stirred for 40 min. and then additional
N,N-diisopropylethylamine (0.38 mL, 2.132 mmol) and
2,4-dimethoxybenzylamine (0.473 mL, 3.198 mmol) were added. The
resulting mixture was heated at 115.degree. C. for 2 h. The
reaction mixture was cooled to rt, diluted with water (30 mL) and
extracted with DCM (30 mL). The organic extracts were washed with
water (30 mL), brine (30 mL), dried over MgSO.sub.4, filtered and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with 0-100% EtOAc in hexanes to obtain
compound 105b. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.22H.sub.29ClN.sub.5O.sub.3: 446.20; found: 446.23,
t.sub.R=0.80 min.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-7-methoxypyrido[3,2-d]pyrimidin-4--
yl)amino)hexan-1-ol (105c)
[1025] To a solution of compound 105b (50 mg, 0.113 mmol) in
dioxane (2 mL) was added sodium methoxide (25 wt. %, 0.064 mL,
0.280 mmol) in a microwave vial. The resulting mixture was heated
at 120.degree. C. for 45 min. in a microwave reactor. The reaction
mixture was concentrated in vacuo and the residue was dissolved in
methanol (2 mL) and sodium methoxide (25 wt. %, 0.2 mL, 0.874
mmol). The resulting mixture was heated at 150.degree. C. for 1 h
in a microwave reactor. The reaction mixture was diluted with water
(25 mL) and extracted with EtOAc (25 mL.times.2). The combined
extracts were washed with saturated aqueous ammonium chloride (25
mL), dried over MgSO.sub.4, filtered and concentrated under reduced
pressure to obtain crude compound 105c. LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.23H.sub.32N.sub.5O.sub.4: 442.25;
found: 442.23; t.sub.R=0.82 min.
Synthesis of
(R)-2-((2-amino-7-methoxypyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(105)
[1026] The compound 105c was dissolved in TFA (1 mL) and stirred at
rt for 1 h. The reaction mixture was concentrated under reduced
pressure and co-evaporated with MeOH (10 mL). The resulting residue
was subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 5%
aq. acetonitrile-50% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The product fractions were concentrated in vacuo,
co-evaporated with methanol (10 mL.times.3), and dried under vacuum
to obtain compound 105 as its TFA salt. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 8.32 (d, J=2.5 Hz, 1H), 7.22 (d, J=2.6
Hz, 1H), 4.58-4.39 (m, 1H), 4.00 (s, 4H), 3.77-3.60 (m, 3H), 1.72
(dtd, J=14.7, 8.5, 8.0, 5.4 Hz, 2H), 1.51-1.22 (m, 5H), 1.00-0.80
(m, 4H). .sup.19F NMR (376 MHz, Methanol-d.sub.4) .delta. -77.51.
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.14H.sub.22N.sub.5O.sub.2: 292.18; found: 292.19; t.sub.R=0.45
min.
Example 106
##STR00255##
[1027] Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-7-ethoxypyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (106a)
[1028] To a solution of compound 105c (40 mg, 0.090 mmol) in EtOH
(3 mL) was added sodium ethoxide (21 wt. %, 0.335 mL, 0.897 mmol)
in a microwave vial. The resulting mixture was heated at
120.degree. C. for 45 min. in a microwave reactor. The reaction
mixture was concentrated in vacuo and the residue was then
dissolved in water (25 mL) and EtOAc (25 mL). The organic layer was
separated and washed with saturated aqueous ammonium chloride,
dried over MgSO.sub.4, filtered and then concentrated in vacuo to
obtain crude compound 106a. LCMS-ESI.sup.+ (m/z): [M+H].sub.+
calculated for C.sub.24H.sub.34N.sub.5O.sub.4: 456.26; found:
456.23; t.sub.R=0.76 min.
Synthesis of
(R)-2-((2-amino-7-ethoxypyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(106)
[1029] The compound 106a was dissolved in TFA (1 mL) and stirred at
rt for 1 h. The reaction mixture was concentrated in vacuo and
co-evaporated with MeOH (10 mL). The resulting residue was
dissolved in MeOH (1 mL) and concentrated ammonium hydroxide (0.1
mL). The mixture was stirred at 50.degree. C. for 10 min. and then
concentrated under reduced pressure. The resulting residue was
subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 5% aq.
acetonitrile-50% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The product fractions were concentrated in vacuo,
co-evaporated with methanol (10 mL.times.3), and then dried under
high vacuum to obtain compound 106 as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d.sub.4) .delta. 7.94 (d, J=2.6 Hz, 1H), 6.83
(d, J=2.6 Hz, 1H), 4.02 (q, J=7.0 Hz, 3H), 3.55 (d, J=4.9 Hz, 3H),
1.33 (t, J=7.0 Hz, 4H), 1.30-1.15 (m, 4H), 0.91-0.63 (m, 3H).
.sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.50. LCMS-ESI.sup.+
(m/z): [M+H].sup.+ calculated for C.sub.15H.sub.24N.sub.5O.sub.2:
306.19; found: 306.20; t.sub.R=0.51 min.
Example 107
##STR00256##
[1030] Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-7-methylpyrido[3,2-d]pyrimidin-4-y-
l)amino)hexan-1-ol (107a)
[1031] A mixture of compound 105c (35 mg, 0.078 mmol),
methylboronic acid (18.8 mg, 0.314 mmol), potassium phosphate
tribasic (50.0 mg, 0.235 mmol), and palladium
tetrakis(triphenylphosphine (18.14 mg, 0.016 mmol) in water (2 mL)
and dioxane (2 mL) was stirred at 150.degree. C. for 45 min. in a
microwave reactor. The reaction mixture was diluted with water (25
mL) and extracted with EtOAc (25 mL). The organic layer was washed
with water (25 mL), brine (25 mL), dried over MgSO.sub.4, filtered
and then concentrated under reduced pressure to obtain crude
compound 107a. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.23H.sub.32N.sub.5O.sub.3: 292.18; found: 426.22; t.sub.R=0.70
min.
Synthesis of
(R)-2-((2-amino-7-methylpyrido[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol
(107)
[1032] The compound 107a was dissolved in TFA (1 mL) and stirred at
rt for 1 h. The reaction mixture was concentrated in vacuo and the
residue co-evaporated with MeOH (10 mL). The resulting residue was
dissolved in MeOH (1 mL) and concentrated ammonium hydroxide (0.1
mL). The mixture was stirred for 10 min. at 50.degree. C. and then
concentrated under reduced pressure. The resulting residue was
subjected to preparative HPLC (Gemini 10u C18 110A, AXIA; 5% aq.
acetonitrile-50% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient). The product fractions were concentrated in vacuo,
co-evaporated with methanol (10 mL.times.3), and dried under
high-vacuum to obtain compound 107 as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d4) .delta. 8.53-8.46 (m, 1H), 7.62 (tt, J=1.9,
1.0 Hz, 1H), 4.51 (dtd, J=9.0, 5.5, 3.1 Hz, 1H), 3.72 (d, J=5.3 Hz,
2H), 2.51 (d, J=2.2 Hz, 3H), 1.83-1.62 (m, 2H), 1.49-1.29 (m, 4H),
0.98-0.86 (m, 3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta.
-77.52. LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.14H.sub.22N.sub.5O: 276.18; found: 276.16; t.sub.R=0.50
min.
Example 108
##STR00257##
[1033] Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)p-
ent-4-en-1-ol (108b)
[1034] To a solution of 2,4-dichloropyrido[3,2-d]pyrimidine (50 mg,
0.250 mmol) and (R)-2-aminopent-4-en-1-ol hydrochloride 108a (26.6
mg, 0.280 mmol, Chiralix B.V., Netherland) in dioxane (2 mL) was
added N,N-diisopropylethylamine (0.09 mL, 0.500 mmol). The mixture
was stirred overnight and then additional N,N-diisopropylethylamine
(0.09 mL, 0.500 mmol) and 2,4-dimethoxybenzylamine (0.403 mL, 2.727
mmol) were added. The resulting mixture was heated at 120.degree.
C. overnight. The reaction mixture was allowed to cool to rt,
diluted with water (25 mL) and extracted with EtOAc (25
mL.times.3). The organic extracts were washed with water (25 mL),
brine (25 mL), dried over MgSO), filtered and then concentrated in
vacuo to obtain the crude compound 108b. LCMS-ESI.sup.+ (m/z):
[M+H].sup.+ calculated for C.sub.21H.sub.26N.sub.5O.sub.3: 396.20;
found: 396.14, t.sub.R=0.69 min.
Synthesis of
(R)-2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)pent-4-en-1-ol
(108)
[1035] The compound 108b (99 mg) was dissolved in TFA (3 mL) and
stirred at rt for 3 h. The reaction mixture was concentrated under
reduced pressure and co-evaporated with MeOH (10 mL). The resulting
residue was subjected to preparative HPLC (Gemini 10u C18 110A,
AXIA; 5% aq. acetonitrile-50% aq. acetonitrile with 0.1% TFA, over
20 min. gradient). The product fractions were concentrated in
vacuo, co-evaporated with methanol (10 mL.times.3), and dried under
high vacuum to obtain compound 108 as its TFA salt. .sup.1H NMR
(400 MHz, Methanol-d4) .delta. 8.64 (dd, J=4.3, 1.5 Hz, 1H),
7.89-7.65 (m, 2H), 6.02-5.70 (m, 1H), 5.24-5.10 (m, 1H), 5.11-4.99
(m, 1H), 4.63-4.45 (m, 1H), 3.76 (d, J=5.3 Hz, 2H), 2.68-2.35 (m,
2H). .sup.19F NMR (376 MHz, Methanol-d4) .delta. -77.49.
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.12H.sub.16N.sub.5O: 246.14; found: 246.09, t.sub.R=0.45
min.
Example 110
##STR00258##
[1036] Synthesis of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylheptan-
-1-ol (110)
[1037] To 77A (40 mg, 0.09 mmol) was added TFA (3 mL) and the
mixture stirred for 2 h. The reaction mixture was concentrated
under reduced pressure and the residue subjected to preparative
HPLC (Synergi 4u Polar-RP 80A, Axia; 10% aq. acetonitrile-70% aq.
acetonitrile with 0.1% TFA, over 20 min. gradient) to afford 110 as
its TFA salt. LCMS (m/z): 292.12 [M+H].sup.+; t.sub.R=0.50 min. on
LC/MS Method A. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.63
(dd, J=4.4, 1.4 Hz, 1H), 7.87 (dd, J=8.5, 1.4 Hz, 1H), 7.76 (dd,
J=8.5, 4.4 Hz, 1H), 4.61-4.34 (m, 1H), 3.76 (d, J=5.3 Hz, 2H),
1.96-1.70 (m, 2H), 1.64-1.51 (m, 2H), 1.19 (s, 6H). .sup.19F NMR
(377 MHz, Methanol-d.sub.4) .delta. -77.52.
Example 111
##STR00259## ##STR00260##
[1038] Synthesis of
(3R,5R)-3-methyl-3-pentyl-5-phenylmorpholin-2-one (111A)
[1039] To a solution of 94c (2 g, 10.57 mmol) in THF (50 ml) at
-78.degree. C. was added 2M boron trifluoride diethyl etherate in
THF (2.76 ml, 22.39 mmol, 2.1 equiv.) over 10 minutes. After 90
minutes, 2M pentylmagnesium chloride solution in THF (11.19 ml,
22.38 mmol, 2.1 equiv.) was added slowly. The reaction was stirred
for 2 h and then quenched with sat. NH.sub.4Cl (200 mL). The
mixture was allowed to warm to rt and then diluted with water (200
mL). The mixture was extracted with EtOAc (3.times.300 mL) and the
combined extracts washed with water (3.times.500 mL), brine (300
mL), dried over NaSO.sub.4, and concentrated under reduced
pressure. The residue was subjected to silica gel chromatography
eluting with hexanes-EtOAc to afford 111A. LCMS (m/z): 262.06
[M+H].sup.+; t.sub.R=1.14 min. on LC/MS Method A.
Synthesis of
(R)-2-(((R)-2-hydroxy-1-phenylethyl)amino)-2-methylheptan-1-ol
(111B)
[1040] To a solution of 111A (1.65 g, 6.31 mmol) in THF (100 ml) at
0.degree. C. was added 2M lithium borohydride in THF (6.35 ml, 12.7
mmol, 2 equiv.). The reaction was warmed to rt and stirred
overnight. The mixture was then quenched with water (100 mL) and
extracted with EtOAc (3.times.300 mL). The combined organics were
washed with water (500 mL), brine (100 mL), dried over
Na.sub.2SO.sub.4, and concentrated under reduced pressure to afford
111B that was used without further purification. LCMS (m/z): 266.05
[M+H].sup.+; t.sub.R=0.64 min. on LC/MS Method A.
Synthesis of (R)-2-amino-2-methylheptan-1-ol (111C)
[1041] To a solution of 111B (1.66 g, 6.25 mmol) in EtOH (20 mL)
was added Pd(OH).sub.2/C (20% wt %, 0.92 g) and 4M HCl in dioxane
(2.37 ml, 9.50 mmol, 1.5 equiv.). The mixture was stirred under and
atmosphere of H.sub.2 at 70.degree. C. overnight. The reaction was
then filtered through Celite and concentrated to afford 111C that
was used without further purification. LCMS (m/z): 145.95
[M+H].sup.+; t.sub.R=0.57 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
2-methylheptan-1-ol (111D)
[1042] To 2,4-dichloropyrido[3,2-d]pyrimidine (118.89 mg, 0.59
mmol) in dioxane (12 mL) was added 111C (135 mg, 0.74 mmol, 1.25
equiv.), and N,N-diisopropylethylamine (0.78 ml, 4.46 mmol, 7.5
equiv.). The reaction mixture was stirred at 80.degree. C.
overnight. 2,4-dimethoxybenzylamine (0.27 ml, 1.85 mmol, 3.1
equiv.) was added and the mixture was heated to 100.degree. C. for
6 h. The reaction mixture was allowed to cool, diluted with EtOAc
(50 mL), washed with water (50 mL), saturated NH.sub.4Cl (50 mL),
dried over MgSO.sub.4, filtered, and concentrated under reduced
pressure. The residue was subjected to silica gel chromatography
eluting with hexanes-EtOAc to afford 111D. LCMS (m/z): 440.30
[M+H].sup.+; t.sub.R=0.93 min. on LC/MS Method A.
Synthesis of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylheptan-
-1-ol (111)
[1043] To 111D (155 mg, 0.35 mmol) was added TFA (3 mL). After 1 h,
the reaction was concentrated under reduced pressure and the
residue subjected to preparative HPLC (Synergi 4u Polar-RP 80A,
Axia; 10% aq. acetonitrile-70% aq. acetonitrile with 0.1% TFA, over
20 min. gradient) to afford 111 as its TFA salt. LCMS (m/z): 290.15
[M+H].sup.+; t.sub.R=0.72 min. on LC/MS Method A. .sup.1H NMR (400
MHz, Methanol-d4) .delta. 8.63 (dd, J=4.3, 1.5 Hz, 1H), 7.86-7.80
(m, 1H), 7.77 (dd, J=8.5, 4.3 Hz, 1H), 3.98 (d, J=11.2 Hz, 1H),
3.72 (d, J=11.2 Hz, 1H), 2.16-2.04 (m, 1H), 1.92 (tt, J=11.1, 4.9
Hz, 1H), 1.55 (s, 3H), 1.42-1.28 (m, 7H), 0.93-0.85 (m, 3H).
.sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.58.
Example 112
##STR00261##
[1044] Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-d]pyrimidin-4-y-
l)amino)-2-methylheptan-1-ol (112A)
[1045] To a solution of 84E (119.98 mg, 0.55 mmol) in dioxane (10
mL) was added 111C (125 mg, 0.69 mmol, 1.25 equiv.) and
N,N-diisopropylethylamine (0.72 ml, 4.13 mmol, 6 equiv.). The
mixture was stirred at 80.degree. C. overnight.
2,4-dimethoxybenzylamine (0.2 ml, 1.38 mol, 2.5 equiv.) was added
and the reaction heated to 100.degree. C. for 6 h. The reaction
mixture was allowed to cool, diluted with EtOAc (50 mL), washed
with water (50 mL), sat. NH.sub.4Cl (50 mL), dried over MgSO.sub.4,
filtered, and concentrated under reduced pressure. The residue was
subjected to silica gel chromatography eluting with hexanes-EtOAc
to afford 112A. LCMS (m/z): 458.26 [M+H].sup.+; t.sub.R=1.00 min.
on LC/MS Method A.
Synthesis of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylheptan-
-1-ol (112)
[1046] To 112A (105 mg, 0.23 mmol) was added TFA (3 mL). After 1 h,
the reaction mixture was concentrated under reduced pressure and
subjected to preparative HPLC (Synergi 4u Polar-RP 80A, Axia; 10%
aq. acetonitrile-70% aq. acetonitrile with 0.1% TFA, over 20 min.
gradient) to afford 112 as its TFA salt. LCMS (m/z): 308.14
[M+H].sup.+; t.sub.R=0.75 min. on LC/MS Method A. .sup.1H NMR (400
MHz, Methanol-d.sub.4) .delta. 8.54 (d, J=2.5 Hz, 1H), 8.22 (s,
1H), 7.62 (ddd, J=8.7, 2.4, 0.8 Hz, 1H), 3.96 (d, J=11.2 Hz, 1H),
3.70 (d, J=11.2 Hz, 1H), 2.13-2.02 (m, 1H), 1.91 (s, 1H), 1.53 (s,
3H), 1.41-1.28 (m, 7H), 0.93-0.84 (m, 3H). .sup.19F NMR (377 MHz,
Methanol-d4) .delta. -77.56, -118.19 (dd, J=8.7, 4.2 Hz).
Example 113
##STR00262##
[1047] Synthesis of
N-(7-fluoro-4-hydroxypyrido[3,2-d]pyrimidin-2-yl)acetamide
(113a)
[1048] Acetic anhydride was cooled to 0.degree. C. under nitrogen
and 2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-ol 43B (200 mg, 1.11
mmol; Supplied by Medicilon, Shanghai) was added. The reaction
mixture was then heated to 110.degree. C. for 4 h. The mixture was
cooled and concentrated under reduced pressure. The residue was
triturated with DCM (20 mL), and the solids removed by filtration
and air dried to provide of compound 113a as a solid.
LCMS-ESI.sup.+ (m/z): [M+H].sup.+ calculated for
C.sub.9H.sub.7FN.sub.4O.sub.2: 223.06; found: 222.96; t=0.58
min.
Synthesis of
N.sup.4-(tert-butyl)-7-methoxypyrido[3,2-d]pyrimidine-2,4-diamine
(113)
[1049] 113a was suspended in POCl.sub.3 (5 mL) and heated to
110.degree. C. for 1 h. The reaction was then cooled and POCl.sub.3
removed under reduced pressure. The residue was co-evaporated with
toluene (15 mL) and then treated within THF (5 mL). tert-Butylamine
(70 .mu.L, 0.66 mmol) was added and the mixture stirred at rt for
15 minutes. 25% Sodium methoxide in methanol (100 .mu.L, 0.45 mmol)
was added and the reaction mixture heated in a sealed vessel at
80.degree. C. The reaction mixture was allowed to cool to rt and
was directly subjected to preparative HPLC (Synergi 4u Polar-RP
80A, Axia; 10% aq. acetonitrile-70% aq. acetonitrile with 0.1% TFA,
over 20 min. gradient). The product fractions were concentrated in
vacuo to afford 113 as its TFA salt. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 8.30 (d, J=2.5 Hz, 1H), 8.04 (s, 1H), 7.18 (d,
J=2.6 Hz, 1H), 3.99 (s, 3H), 1.61 (s, 9H). .sup.19F NMR (376 MHz,
Methanol-d4) .delta. -77.51. LCMS-ESI.sup.+ (m/z): [M+H].sup.+
calculated for C.sub.12H.sub.17N.sub.5O: 248.14; found: 248.09;
t.sub.R=0.81 min.
Example 114
##STR00263##
[1050] Synthesis of
(R)-2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol
(114A)
[1051] To a solution of 94G (75 mg, 0.30 mmol) and 19B (51 mg, 0.30
mmol) in THF (5 mL) was added N,N-diisopropylethylamine (0.16 mL,
0.90 mmol). After stirring at 80.degree. C. for 23 h, the reaction
was cooled to ambient temperature, diluted with EtOAc (50 mL),
washed with water (50 mL) and brine (50 mL), dried over
Na.sub.2SO.sub.4, then filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
hexanes-EtOAc (0-75%) to provide 114A. LCMS (m/z): 329.11
[M+H].sup.+; t.sub.R=1.27 min. on LC/MS Method A.
Synthesis of
(R)-2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-y-
l)amino)-2-methylhexan-1-ol (114B)
[1052] To a solution of 114A in THF (5 mL) was added
N,N-diisopropylethylamine (0.16 mL, 0.90 mmol) followed by
2,4-dimethoxybenzylamine (0.25 mL, 1.5 mmol). After stirring at
100.degree. C. for 18 h, the reaction was cooled to ambient
temperature, diluted with EtOAc (100 mL), washed with water (100
mL) and brine (100 mL), dried over Na.sub.2SO.sub.4, then filtered
and concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc (15-100%) to provide
114B. LCMS (m/z): 460.29 [M+H].sup.+; t.sub.R=0.94 min. on LC/MS
Method A.
Synthesis of
(R)-2-((2-amino-7-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol (114)
[1053] To 114B (11 mg, 0.02 mmol) was added TFA (3 mL). After 4 h,
the reaction mixture was concentrated in vacuo and coevaporated
with MeOH (3.times.20 mL). The residue was suspended in MeOH (20
mL) and filtered. After stirring overnight, the solution was
concentrated in vacuo to afford 114 as a TFA salt. LCMS (m/z):
310.12 [M+H].sup.+; t.sub.R=0.98 min. on LC/MS Method A. .sup.1H
NMR (400 MHz, Methanol-d.sub.4) .delta. 8.59 (d, J=2.1 Hz, 1H),
8.25 (s, 1H), 7.91 (d, J=2.1 Hz, 1H), 3.97 (d, J=11.3 Hz, 1H), 3.71
(d, J=11.2 Hz, 1H), 2.10 (ddd, J=13.9, 10.9, 5.0 Hz, 1H), 1.96-1.82
(m, 1H), 1.54 (s, 3H), 1.35 (qt, J=6.8, 2.8 Hz, 4H), 0.95-0.88 (m,
3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta. -77.61.
Example 115
##STR00264##
[1054] Synthesis of
(R)-2-((2-chloro-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-
-1-ol (115A)
[1055] To a solution of 94G (55 mg, 0.30 mmol) and 84E (65 mg, 0.30
mmol) in THF (5 mL) was added N,N-diisopropylethylamine (0.16 mL,
0.90 mmol). After stirring at 80.degree. C. for 18 h, the reaction
was cooled to ambient temperature, diluted with EtOAc (50 mL),
washed with water (50 mL) and brine (50 mL), dried over
Na.sub.2SO.sub.4, then filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
hexanes-EtOAc to provide 115A. LCMS (m/z): 313.08 [M+H].sup.+;
t.sub.R=1.19 min. on LC/MS Method A.
Synthesis of
(R)-2-((2,7-bis((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)am-
ino)-2-methylhexan-1-ol (115B)
[1056] To a solution of 115A in THF (5 mL) was added
N,N-diisopropylethylamine (0.16 mL, 0.90 mmol) followed by
2,4-dimethoxybenzylamine (0.25 mL, 1.5 mmol). After stirring at
140.degree. C. for 18 h, the reaction was cooled to ambient
temperature, diluted with EtOAc (100 mL), washed with water (100
mL) and brine (100 mL), dried over Na.sub.2SO.sub.4, then filtered
and concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc (0-100%) to provide 115B.
LCMS (m/z): 444.23 [M+H].sup.+; t.sub.R=0.90 min. on LC/MS Method
A.
Synthesis of
(R)-2-((2,7-diaminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol
(115)
[1057] To 115B (14 mg, 0.02 mmol) was added TFA (3 mL). After 4 h,
the reaction mixture was concentrated in vacuo and coevaporated
with MeOH (3.times.20 mL). The residue was suspended in MeOH (20
mL) and filtered. After stirring overnight, the solution was
concentrated in vacuo to afford 115 as a bis-TFA salt. LCMS (m/z):
291.19 [M+H].sup.+; t.sub.R=0.93 min. on LC/MS Method A. .sup.1H
NMR (400 MHz, Methanol-d4) .delta. 8.02 (d, J=2.4 Hz, 1H), 6.69 (d,
J=2.4 Hz, 1H), 3.94 (d, J=11.2 Hz, 1H), 3.69 (d, J=11.2 Hz, 1H),
2.06 (ddd, J=13.4, 11.0, 5.0 Hz, 1H), 1.91-1.79 (m, 1H), 1.49 (s,
3H), 1.35 (td, J=7.4, 4.2 Hz, 4H), 0.92 (t, J=7.0 Hz, 3H). .sup.19F
NMR (377 MHz, Methanol-d.sub.4) .delta. -77.58.
Example 116
##STR00265## ##STR00266##
[1058] Synthesis of tert-butyl
(R)-(l-hydroxy-2-methylheptan-2-yl)carbamate (116A)
[1059] To 111C (315 mg, 2.17 mmol) in THF (30 mL) was added 1M
aqueous NaOH (2.2 mL) followed by DIPEA (1.7 mL, 9.76 mmol) and
Boc.sub.2O (2.17 g, 9.94 mmol). After 18 hours, the mixture was
diluted with water (50 mL) and extracted with EtOAc (2.times.50
mL). The combined organics were washed with brine (100 mL), dried
over Na.sub.2SO.sub.4, and concentrated in vacuo. The material was
purified by flash chromatography equipped with an ELSD using
hexane-EtOAc (0-50%) to afford 116A. LCMS (m/z): 245.77
[M+H].sup.+; t.sub.R=1.15 min. on LC/MS Method A.
Synthesis of tert-butyl (R)-(2-methyl-1-oxoheptan-2-yl)carbamate
(116B)
[1060] To a solution of 116A (378 mg, 1.54 mmol) in DCM (15 mL) was
added Dess-Martin periodinane (981 g, 2.31 mmol). After 90 min, the
reaction was quenched with sat. Na.sub.2S.sub.2O.sub.3(aq) (20 mL).
The layers were separated and the aqueous was extracted with DCM
(25 mL). The combined organics were washed with water (50 mL) and
brine (50 mE), dried over Na.sub.2SO.sub.4, and concentrated in
vacuo. The material was purified by flash chromatography equipped
with an ELSD using hexane-EtOAc (0-50%) to afford 116B. LCMS (m/z):
143.95 [M+H].sup.+; t.sub.R=1.23 min. on LC/MS Method A.
Synthesis of tert-butyl
(R)-(1-(benzylamino)-2-methylheptan-2-yl)carbamate (116C)
[1061] To a solution of 116B (351 mg, 1.44 mmol) in MeOH (6 mL) was
added benzylamine (0.16 mL, 1.44 mmol). After 18 h, sodium
borohydride (91 mg, 2.17 mmol) was added to the reaction. After 90
min, the mixture was concentrated in vacuo. The residue was diluted
with EtOAc (25 mL), washed with 1 M NaOH.sub.(aq) (20 mL), dried
over Na.sub.2SO.sub.4, and concentrated in vacuo to provide crude
116C that was used without further purification. LCMS (m/z): 335.02
[M+H].sup.+; t.sub.R=0.95 min. on LC/MS Method A.
Synthesis of tert-butyl
(R)-(1-(N-benzylacetamido)-2-methylheptan-2-yl)carbamate (116D)
[1062] To a solution of 116C (519 mg, 1.55 mmol) in THF (15 mL) was
added N,N-diisopropylethylamine (0.54 mL, 3.10 mmol) followed by
acetyl chloride (0.17 mL, 2.33 mmol). After 60 min, the reaction
was diluted with EtOAc (50 mL), washed with water (30 mL), sat.
NaHCO.sub.3(aq) (30 mL), and brine (30 mL), dried over
Na.sub.2SO.sub.4, and concentrated in vacuo. The material was
purified by flash chromatography equipped with an ELSD using
hexane-EtOAc (0-100%) to afford 116D. LCMS (m/z): 376.82
[M+H].sup.+; t.sub.R=1.36 min. on LC/MS Method A.
Synthesis of (R)-N-(2-amino-2-methylheptyl)acetamide (116E)
[1063] To a solution of 116D (584 mg, 1.55 mmol) in EtOH (15 mL)
was added HCl solution (0.78 mL, 3.10 mmol, 4 M in 2,4-dioxane).
The solution was then purged with Ar and Pd(OH).sub.2 (441 mg) were
added. The mixture was purged with H.sub.2 and heated to 75.degree.
C. After 18 h, the mixture was cooled to ambient temperature,
purged with Ar, filtered, and concentrated in vacuo to provide
crude 116E (288 mg) as an HCl salt. LCMS (m/z): 186.96 [M+H].sup.+;
t.sub.R=0.52 min. on LC/MS Method A.
Synthesis of
(R)-N-(2-((2-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylheptyl)acet-
amide (116F)
[1064] To a solution of 116E (50 mg, 0.22 mmol) and
2,4-dichloropyrido[3,2-d]pyrimidine (45 mg, 0.22 mmol) in THF (3
mL) was added N,N-diisopropylethylamine (0.12 mL, 0.67 mmol). After
stirring at 80.degree. C. for 18 h, the reaction was cooled to
ambient temperature, diluted with EtOAc (25 mL), washed with water
(25 mL) and brine (25 mL), dried over Na.sub.2SO.sub.4, and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc (0-100%) to provide 116F.
LCMS (m/z): 350.06 [M+H].sup.+; t.sub.R=1.09 min. on LC/MS Method
A
Synthesis of
(R)-N-(2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amin-
o)-2-methylheptyl)acetamide (116G)
[1065] To a solution of 116F (58 mg, 0.17 mmol) in 2-MeTHF (3 mL)
was added potassium carbonate (46 mg, 0.33 mmol) followed by
2,4-dimethoxybenzylamine (0.05 mL, 0.33 mmol). After stirring at
85.degree. C. for 18 h, the reaction was cooled to ambient
temperature, diluted with EtOAc (25 mL), washed with water (20 mL)
and brine (20 mL), dried over Na.sub.2SO.sub.4, then filtered and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc (20-100%) to provide
116G. LCMS (m/z): 481.27 [M+H].sup.+; t.sub.R=0.94 min. on LC/MS
Method A.
Synthesis of
(R)-N-(2-((2-aminopyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylheptyl)aceta-
mide (116)
[1066] To 116G (53 mg, 0.11 mmol) was added TFA (3 mL). After 2 h,
the reaction mixture was concentrated in vacuo and coevaporated
with MeOH (3.times.20 mL). The residue was suspended in MeOH and
filtered. The solution was concentrated in vacuo to afford 116 as a
TFA salt. LCMS (m/z): 331.25 [M+H].sup.+; t.sub.R=0.72 min. on
LC/MS Method A. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta.
8.63 (dd, J=4.4, 1.4 Hz, 1H), 7.85 (dd, J=8.5, 1.4 Hz, 1H), 7.76
(ddd, J=8.5, 4.4, 1.2 Hz, 1H), 3.95 (d, J=14.0 Hz, 1H), 3.56 (d,
J=13.9 Hz, 1H), 2.22-2.12 (m, 1H), 1.95 (s, 3H), 1.94-1.85 (m, 1H),
1.54 (s, 3H), 1.41-1.30 (m, 6H), 0.88 (t, J=6.3 Hz, 3H). .sup.19F
NMR (377 MHz, Methanol-d.sub.4) .delta. -77.86.
Example 117
##STR00267##
[1067] Synthesis of
(R)-N-(2-((2,7-dichloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylheptyl)-
acetamide (117A)
[1068] To a solution of 116E (50 mg, 0.22 mmol) and 19B (53 mg,
0.22 mmol) in THF (3 mL) was added N,N-diisopropylethylamine (0.12
mL, 0.67 mmol). After stirring at 80.degree. C. for 18 h, the
reaction was cooled to ambient temperature, diluted with EtOAc (25
mL), washed with water (25 mL) and brine (25 mL), dried over
Na.sub.2SO.sub.4, then filtered and concentrated in vacuo. The
residue was subjected to silica gel chromatography eluting with
hexanes-EtOAc (0-100%) to provide 117A. LCMS (m/z): 384.01
[M+H].sup.+; t.sub.R=1.77 min. on LC/MS Method A.
Synthesis of
(R)-N-(2-((7-chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin--
4-yl)amino)-2-methylheptyl)acetamide (117B)
[1069] To a solution of 117A (33 mg, 0.09 mmol) in 2-MeTHF (3 mL)
was added potassium carbonate (24 mg, 0.17 mmol) followed by
2,4-dimethoxybenzylamine (0.05 mL, 0.17 mmol). After stirring at
85.degree. C. for 18 h, the reaction was cooled to ambient
temperature, diluted with EtOAc (50 mL), washed with water (20 mL)
and brine (20 mL), dried over Na.sub.2SO.sub.4, then filtered and
concentrated in vacuo. The residue was subjected to silica gel
chromatography eluting with hexanes-EtOAc (0-100%) then EtOAc-MeOH
(0-25%) to provide 117B. LCMS (m/z): 515.26 [M+H].sup.+;
t.sub.R=1.06 min. on LC/MS Method A.
Synthesis of
(R)-N-(2-((2-amino-7-chloropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhep-
tyl)acetamide (117)
[1070] To 117B (38 mg, 0.07 mmol) was added TFA (3 mL). After 2 h,
the reaction mixture was concentrated in vacuo and coevaporated
with MeOH (3.times.20 mL). The residue was suspended in MeOH and
filtered. The solution was concentrated in vacuo to afford 117 as a
TFA salt. LCMS (m/z): 632.22 [M+H].sup.+; t.sub.R=0.89 min. on
LC/MS Method A. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.59
(dd, J=3.5, 2.1 Hz, 1H), 7.92 (d, J=1.9 Hz, 1H), 3.93 (d, J=14.0
Hz, 1H), 3.51 (d, J=14.0 Hz, 1H), 2.21-2.10 (m, 1H), 1.96 (s, 3H),
1.95-1.87 (m, 1H), 1.54 (s, 3H), 1.35 (dd, J=17.6, 5.4 Hz, 6H),
0.88 (t, J=6.4 Hz, 3H). .sup.19F NMR (377 MHz, Methanol-d4) .delta.
-77.80.
Example 118
##STR00268##
[1071] Synthesis of
(R)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)--
2-methylhexanal (118A)
[1072] To a solution of 59B (548 mg, 1.29 mmol) in DCM (24 mL) was
added Dess-Martin periodinane (829 mg, 1.93 mmol). After 60 min,
the reaction was quenched with sat. Na.sub.2S.sub.2O.sub.3(aq) (20
mL), the layers were separated, and the aqueous was extract with
DCM (25 mL). The combined organics were washed with water (50 mL),
sat. NaHCO.sub.3(aq) (50 mL), and brine (50 mL), dried over
Na.sub.2SO.sub.4, and concentrated in vacuo. The material was
purified by flash chromatography using hexane-EtOAc (25-100%)
followed by EtOAc-MeOH (0-20%) to afford 118A. LCMS (m/z): 424.18
[M+H].sup.+; t.sub.R=1.04 min. on LC/MS Method A.
Synthesis of
N2-(2,4-dimethoxybenzyl)-N.sup.4-((R)-2-methyl-1-(((S)-1,1,1-trifluoropro-
pan-2-yl)amino)hexan-2-yl)pyrido[3,2-d]pyrimidine-2,4-diamine
(118B)
[1073] To a solution of 118A (70 mg, 0.17 mmol) in MeOH (1 mL) was
added (S)-1,1,1-trifluoro-2-propylamine (39 mg, 0.33 mmol, supplied
by Oakwood Chemical). After 5 h, the reaction was concentrated in
vacuo. The residue was diluted with THF (2 mL) and lithium aluminum
hydride solution (0.82 mL, 0.82 mmol, 1 M in THF) was added. After
30 min, the reaction was quenched with water (20 mL) and extracted
with EtOAc (2.times.20 mL). The combined organics were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to afford crude 118B.
LCMS (m/z): 521.24 [M+H].sup.+; t.sub.R=1.26 min. on LC/MS Method
A.
Synthesis of
N.sup.4-((R)-2-methyl-1-(((S)-1,1,1-trifluoropropan-2-yl)amino)hexan-2-yl-
)pyrido[3,2-d]pyrimidine-2,4-diamine (118)
[1074] To 118B (66 mg, 0.13 mmol) was added TFA (3 mL). After 4 h,
the reaction mixture was concentrated in vacuo. The residue was
suspended in 50% EtOH.sub.(aq) (6 mL) and filtered. The solution
was purified by preparative HPLC (Synergi 4u Polar-RP 80A, Axia;
20% aq. acetonitrile-60% aq. acetonitrile with 0.1% TFA, over 20
min. gradient) to afford 122 as a bis-TFA salt. LCMS (m/z): 371.10
[M+H].sup.+; t.sub.R=1.14 min. on LC/MS Method A. .sup.1H NMR (400
MHz, Methanol-d.sub.4) .delta. 8.62 (dd, J=4.4, 1.4 Hz, 1H), 7.87
(dd, J=8.5, 1.4 Hz, 1H), 7.78 (dd, J=8.5, 4.4 Hz, 1H), 3.75 (hept,
J=7.1 Hz, 1H), 3.64 (d, J=12.8 Hz, 1H), 3.28 (d, J=12.8 Hz, 1H),
2.17 (ddd, J=13.6, 11.4, 4.6 Hz, 1H), 1.95 (ddd, J=16.1, 12.3, 4.1
Hz, 1H), 1.61 (s, 3H), 1.42 (d, J=6.9 Hz, 3H), 1.40-1.26 (m, 4H),
0.92 (t, J=6.9 Hz, 3H). .sup.19F NMR (376 MHz, Methanol-d4) .delta.
-76.47 (d, J=7.1 Hz), -77.87.
[1075] Unless otherwise stated, LC/MS retention times (tR) reported
above were measured using LC/MS Method A.
[1076] Method for LC/MS HPLC (Method A):
[1077] HPLC LC/MS chromatograms were generated using a Thermo
Scientific LCQ LC/MS system eluting with a Kinetex 2.6u C18 100 A,
5.times.30 mm HPLC column, using a 1.85 minute gradient elution
from 2% aq. acetonitrile-98% aq. acetonitrile with 0.1% formic acid
modifier.
[1078] Method for LC/MS HPLC (Method B):
[1079] HPLC LC/MS chromatograms were generated using a Thermo
Scientific LCQ LC/MS system eluting with a Kinetex 2.6u C18 100 A,
5.times.30 mm HPLC column, using a 2.85 minute gradient elution
from 2% aq. acetonitrile-98% aq. acetonitrile with 0.1% formic acid
modifier.
Biological Example 1--PBMC IFN.alpha., IL12-p40 and TNF.alpha.
Assays
[1080] Certain compounds disclosed herein we tested according to
the procedure described below. Additionally, certain reference
compounds were prepared and tested along with the compounds of the
present disclosure. For example, the Compound X was prepared in a
manner similar to that disclosed in PCT Application Publication No.
WO2012/156498 (where the compound is identified as Compound 72).
Compound Y was prepared in a manner similar to that disclosed in
PCT Application Publication No. WO2015/014815 (where the compound
is identified as Compound 6).
##STR00269##
[1081] Compounds were dissolved and stored in DMSO (Sigma-Aldrich,
St. Louis, Mo.) at 10 mM concentration.
Cells and Reagents
[1082] Cryopreserved human PBMCs isolated from healthy donors were
purchased from StemCell Technologies (Vancouver, Canada). Cell
culture medium used was RPMI with L-Glutamine (Mediatech, Manassas,
Va.) supplemented with 10% fetal bovine serum (Hyclone, GE
Healthcare, Logan, Utah) and Penicillin-Streptomycin (Mediatech).
Human TNF.alpha., IL12p40, and IFN.alpha.2a 384-well Assay capture
plates, standards, buffers and processing reagents were obtained
from MesoScale Discovery Technologies (MSD; Rockville, Md.).
[1083] Cryopreserved human PBMCs (1.times.10e8 cells/ml) were
thawed at 37.degree. C. and resuspended in 25 mL warm cell culture
medium. The cells were pelleted at 200.times.g (Beckman Avanti J-E)
for 5 min and resuspended in 20 mL of fresh culture media. Cells
were counted using a Cellometer (Nexcelcom Bioscience), adjusted to
2.times.10e6 cells, and incubated for 2 hours in an incubator set
at 37.degree. C., 5% CO.sub.2 to recover from cryopreservation.
Compounds were serially diluted in DMSO at half-log steps to
generate a 10-point dose range. Using a Bravo pipette equipped with
a 384 well head (Agilent), 0.4 .mu.L of compound was transferred to
each well of a 384 well black, clear bottom plate (Greiner Bio-One,
Germany) containing 30 .mu.L of cell culture medium. Recovered
PBMCs were then dispensed into the assay plate at 50 .mu.L per well
(100k cells/well) using the MicroFlow multichannel dispenser
(Biotek). Final DMSO concentration was 0.5%. DMSO was used as the
negative control. The plates were incubated for 24 hours at
37.degree. C. PBMCs in the assay plate were pelleted by
centrifugation (Beckman Avanti J-E) at 200.times.g for 5 min.
[1084] Using a Biomek FX 384 well pipetting station (Beckman),
conditioned culture medium (CCM) from the assay plate was
transferred to MSD capture plates customized for each cytokine. For
IFN.alpha. and IL12-p40 detection, 25 .mu.L and 20 .mu.L of CCM
were added directly to each capture plate, respectively. For
TNF.alpha. detection, CCM was diluted 1:9 in fresh culture medium,
and 20 .mu.L of diluted CCM was used. Serially diluted calibration
standards for each cytokine were used to generate standard curves
and establish assay linearity. The plates were sealed and incubated
overnight at 4.degree. C. in a plate shaker (Titer Plate) set at
200 rpm. On the following day, antibodies specific for each
cytokine were diluted 1:50 in MSD Diluent 100 antibody dilution
buffer. Diluted antibodies were added to corresponding capture
plates at 10 .mu.L/well, and incubated at RT for 1-2 hrs in the
shaker. The plates were washed with PBST buffer (3.times., 60
.mu.l/well) using a Biotek Multiflow plate washer. MSD Read Buffer
diluted to 2.times. in deionized water and 35 .mu.L/well was added
via Biomek FX instrument. The plates were read immediately in a
MSD6000 reader. Data were normalized to positive and negative
controls in each assay plate. AC.sub.50 values represent compound
concentrations at half-maximal effect based on normalized percent
activation and calculated by non-linear regression using Pipeline
Pilot software (Accelrys, San Diego, Calif.).
[1085] Results of the cytokine profiling assay are reported in
Table 1, Table 2, and Table 3 below.
TABLE-US-00001 TABLE 1 TNF.alpha. AC.sub.50 IL12p40 AC.sub.50
IFN.alpha. AC.sub.50 Compound (.mu.M) (.mu.M) (.mu.M) 1B 3.9 2 2.7
2B 5.4 2.8 4.3 3B 29.4 15.5 14.5 4B 9.1 5.4 5.9 5B >50 >50 41
6B >50 >50 >50 7 >50 >50 34 8 20.2 19.4 >50 9 1.9
1.1 7.2 10 29.2 23.8 >50 11 10.1 6 6.9 12 >50 >50 >50
13 >50 >50 >50 14 1.1 0.94 1.6 15 1.6 1.2 >200 16
>50 >50 >50 17 >50 >50 >50 18F 16.1 15.2 30.6 19E
3.3 2.5 21.6 20 3.2 2.8 5.4 21 3.1 2.3 4.8 22 >50 >50 35.9
23C 24.7 25.7 >50 24D 3.4 3.1 18.4 25E 20 19.7 12.3 26E 2.3 1.7
13.5 27C 0.52 0.42 2 28 28.6 28.2 45 29 18.3 15.5 3.9 30B 10.6 8.6
>50 31 4.7 4.7 32.9 32 >50 >50 >50 33 0.92 0.85 5.9 34
12.2 10.9 >50 35 39.4 22.6 >50 36 21.5 10.8 >50 37 >50
>50 >50 38C >50 >50 >50 39C >50 41.5 >50 40C
0.94 0.87 2.4 41 11 9.1 13 42B 1.1 0.9 3.6 43C 1.1 1 10.9 44 3 2.4
>50 45 1.6 1.3 8.3 46C 28.6 28.5 >50 47B 2.70 2.0 >50 48
0.85 0.71 0.57
TABLE-US-00002 TABLE 2 TNF.alpha. AC.sub.50 IL12p40 AC.sub.50
IFN.alpha. AC.sub.50 Compound (.mu.M) (.mu.M) (.mu.M) X 1.2 0.97
7.1 Y 11.2 13.0 >50
TABLE-US-00003 TABLE 3 TNF.alpha. AC.sub.50 IL12p40 AC.sub.50
IFN.alpha. AC.sub.50 Compound (.mu.M) (.mu.M) (.mu.M) 49 22.4 18.1
41.6 50 26.9 23.1 >50 51 0.37 0.33 >200 52 3.2 3.6 >50 53
0.26 0.28 3.9 54 34.0 42.5 >50 55 23.9 21.5 28.8 56 3.6 3.4 1.9
57 11.0 9.7 >50 58 3.9 3.8 4.1 59 0.18 0.17 15.0 60 2.6 2.3 7.9
61 0.02 0.02 42.1 62 1.0 0.91 >50 63 0.41 0.43 22.4 64 3.1 3.2
37.9 65 0.11 0.09 >50 66 0.04 0.03 1.6 67 6.3 3.9 23.0 68 11.1
14.2 >50 69 31.0 30.8 34.8 70 3.3 2.7 >50 71 2.6 2.7 >50
72 7.2 7.0 >50 73 1.3 1.3 >50 74 9.1 9.6 >50 75 4.0 3.3
20.3 76 36.9 31.8 36.9 77 43.6 43.6 43.6 78 16.0 14.2 >50 79 9.1
11.5 >50 80 2.7 2.4 >50 81 7.6 7.8 >50 82 16.6 14.3 >50
83 1.7 1.8 43.1 84 3.0 3.9 >50 85 0.86 0.80 4.0 86 2.9 2.4 37.4
87 5.0 4.5 >50 88 0.4 0.37 35.6 89 2.2 1.7 >50 90 0.86 0.62
7.8 91 2.0 1.9 >50 92 4.3 4.7 >50 93 0.44 0.40 >50 94 1.0
0.7 2.2 95 0.15 0.15 >50 96 1.1 1.0 2.8 97 0.14 0.13 26.0 98
0.24 0.23 134 99 3.4 3.6 >50 100 3.8 3.5 4.6 101 0.10 0.11
>50 102 0.81 0.76 >50 103 3.3 2.6 10.3 104 2.1 1.9 4.2 105
3.5 3.4 >50 106 13.8 10.2 >50 107 2.8 1.8 >50 108 38.7
22.0 >50 110 32.6 32.6 32.6 111 0.61 0.47 19.8 112 0.36 0.33
>50 113 12.5 13.6 >50 114 0.34 0.20 34.1 115 0.024 0.027 9.0
116 0.036 0.11 >50 117 0.37 0.33 >50 118 9.3 9.1 >50
[1086] In certain embodiments, certain compounds disclosed herein
have an AC.sub.50 for TNF.alpha. that is less than about 100 .mu.M,
less than about 50 .mu.M, less than about 40 .mu.M, less than about
30 .mu.M, less than about 25 .mu.M, less than about 20 .mu.M, less
than about 15 .mu.M, less than about 10 .mu.M, less than about 5
.mu.M, less than about 4 .mu.M, less than about 3 .mu.M, less than
about 2 .mu.M, or less than about 1 .mu.M. In certain embodiments,
certain compounds disclosed herein have an AC.sub.50 for TNF.alpha.
that is greater than about 25 .mu.M or greater than about 50 .mu.M.
In certain embodiments, certain compounds disclosed herein have an
AC.sub.50 for TNF.alpha. that is less than about 0.75 .mu.M, less
than about 0.5 .mu.M, or less than about 0.25 .mu.M. As is
understood by those of skill in the art, the induction of
TNF.alpha. is associated with agonism of TLR8.
[1087] In certain embodiments, certain compounds disclosed herein
have an AC.sub.50 for IL12p40 that is less than about 100 .mu.M,
less than about 50 .mu.M, less than about 40 .mu.M, less than about
30 .mu.M, less than about 25 .mu.M, less than about 20 .mu.M, less
than about 15 .mu.M, less than about 10 .mu.M, less than about 5
.mu.M, less than about 4 .mu.M, less than about 3 .mu.M, less than
about 2 .mu.M, less than about 1 .mu.M, or less than about 0.5
.mu.M. In certain embodiments, certain compounds disclosed herein
have an AC.sub.50 for IL12p40 that is greater than about 25 .mu.M
or greater than about 50 .mu.M. As is understood by those of skill
in the art, the induction of IL12p40 is associated with agonism of
TLR8.
[1088] In certain embodiments, certain compounds disclosed herein
have an AC.sub.50 for IFN.alpha. that is less than about 200 .mu.M,
less than about 100 .mu.M, less than about 50 .mu.M, less than
about 40 .mu.M, less than about 30 .mu.M, less than about 25 .mu.M,
less than about 20 .mu.M, less than about 15 .mu.M, less than about
10 .mu.M, less than about 5 .mu.M, less than about 4 .mu.M, less
than about 3 .mu.M, less than about 2 .mu.M, or less than about 1
.mu.M. In certain embodiments, certain compounds disclosed herein
have an AC.sub.50 for IFN.alpha. that is greater than about 25
.mu.M, greater than about 50 .mu.M, greater than about 100 .mu.M,
greater than about 150 .mu.M, or greater than about 200 .mu.M. As
is understood by those of skill in the art, the induction of
IFN.alpha. is associated with agonism of TLR7.
[1089] In certain embodiments, the compounds of the present
disclosure are selective TLR8 agonists. Compounds that are
selective TLR8 agonists produce a cytokine effect associated with
TLR8 induction (e.g. TNF.alpha. and IL12p40) at a lower
concentraction than that associated with TLR7 induction (e.g.
IFN.alpha.). In certrain embodiments, when analyzed in the cytokine
profiling assay, the compounds induce IFN.alpha. at a concentration
at least about 2 times higher than the concentration at which
TNF.alpha. and/or IL12p40 are induced; in certain embodiments the
compounds induce IFN.alpha. at a concentration at least about 4
times higher than the concentration at which TNF.alpha. and/or
IL12p40 are induced; in certain embodiments the compounds induce
IFN.alpha. at a concentration at least about 6 times higher than
the concentration at which TNF.alpha. and/or IL12p40are induced; in
certain embodiments the compounds induce IFN.alpha. at a
concentration at least about 8 times higher than the concentration
at which TNF.alpha. and/or IL12p40 are induced; in certain
embodiments the compounds induce IFN.alpha. at a concentration at
least about 10 times higher than the concentration at which
TNF.alpha. and/or IL12p40 are induced; in certain embodiments the
compounds induce IFN.alpha. at a concentration at least about 20
times higher than the concentration at which TNF.alpha. and/or
IL12p40 are induced; in certain embodiments the compounds induce
IFN.alpha. at a concentration at least about 30 times higher than
the concentration at which TNF.alpha. and/or IL12p40 are induced;
in certain embodiments the compounds induce IFN.alpha. at a
concentration at least about 40 times higher than the concentration
at which TNF.alpha. and/or IL12p40 are induced; in certain
embodiments the compounds induce IFN.alpha. at a concentration at
least about 50 times higher than the concentration at which
TNF.alpha. and/or IL12p40 are induced; in certain embodiments the
compounds induce IFN.alpha. at a concentration at least about 75
times higher than the concentration at which TNF.alpha. and/or
IL12p40 are induced; in certain embodiments the compounds induce
IFN.alpha. at a concentration at least about 100 times higher than
the concentration at which TNF.alpha. and/or IL12p40 are induced;
in certain embodiments the compounds induce IFN.alpha. at a
concentration at least about 125 times higher than the
concentration at which TNF.alpha. and/or IL12p40 are induced; in
certain embodiments the compounds induce IFN.alpha. at a
concentration at least about 150 times higher than the
concentration at which TNF.alpha. and/or IL12p40 are induced; in
certain embodiments the compounds induce IFN.alpha. at a
concentration at least about 175 times higher than the
concentration at which TNF.alpha. and/or IL12p40 are induced; and
in certain embodiments the compounds induce IFN.alpha. at a
concentration at least about 200 times higher than the
concentration at which TNF.alpha. and/or IL12p40 are induced.
[1090] As is understood by those of skill in the art, each compound
of the present disclosure may have AC.sub.50 values for each
cytokine tested (e.g. TNF.alpha., IL12p40, and IFN.alpha.) that
include various combinations of the ranges disclosed above. As
such, the present disclosure provides for such combinations.
Further, the ability of any particular compound or group of
compounds to selectively modulate a particular receptor can be
extrapolated from the AC.sub.50 data disclosed herein. One of skill
in the art will necessarily appreciate the various selectivities of
any particular compound or group of compounds.
Biological Example 2--Efficacy Study in WHV-Infected Woodchucks
[1091] The in vivo antiviral efficacy of a compound disclosed
herein was evaluated in the woodchuck model of CHB. Woodchucks
chronically infected with woodchuck hepatitis virus (WHV) (n=23)
were stratified into a placebo group (n=1), a 1 mg/kg dose group
(n=6), and a 3 mg/kg dose group (n=6) based on gender and baseline
antiviral parameters. Animals with high gamma glutamyltransferase
(GGT) levels (that correlate with an increased risk of
hepatocellular carcinoma (HCC)) and/or with liver tumors observed
at the pre-study biopsy screening were included in the placebo
group. This stratification was performed so that adverse events
(including death) associated with HCC would not confound safety
assessment of the dosing groups receiving a compound disclosed
herein. The plan for this ongoing study was as follows: animals
were dosed PO once a week for 8 weeks with compound or vehicle,
followed by a follow-up period of 24 weeks. The animals were
monitored for safety and in-life parameters (blood
chemistry/hematology/temperature), pharmacokinetics (serum PK),
pharmacodynamics (whole blood MARCO mRNA and WHV-specific T cell
responses) and antiviral efficacy (serum WHV DNA, woodchuck
hepatitis surface antigen (WHsAg) and anti-sAg antibodies, and
liver WHV cccDNA, DNA and mRNA).
[1092] Interim analysis of this ongoing study revealed that animals
dosed with vehicle or 1 mg/kg for 8 weeks did not have any changes
in serum WHV DNA or WHsAg levels. In contrast, there was a strong
decline in both viral endpoints in 4/6 animals in the 3 mg/kg dose
group. Serum WHV DNA and WHsAg levels for three of these animals
did not revert at week 12, four weeks after cessation of treatment.
Of note, three animals had detectable levels of anti-WHsAg starting
at week 4 that were still increasing, stabilizing, or decreasing by
week 12. These interim data show that a compound of the present
disclosure has antiviral and anti-HBsAg activity as well as the
ability to induce anti-HBsAg antibody in vivo in the woodchuck
model of CHB.
Biological Example 3--Off Target Toxicity
[1093] To assess potential off-target toxicity of certain compounds
disclosed herein, the in vitro cytotoxicity of those compounds was
profiled using a panel of 5cell lines with various tissue origins.
Compound cytotoxicity was examined in hepatoma-derived Huh-7 and
HepG2 cells, prostate carcinoma-derived PC-3 cells, lymphoma
derived MT-4 cells and a normal diploid lung cell line MRC-5. HepG2
and PC-3 cells used were adapted to grow in glucose-free
galactose-containing medium. These cells have a relatively higher
sensitivity to inhibitors of mitochondrial oxidative
phosphorylation compared to the same cells maintained in standard
glucose-containing culture medium (Marroquin et al., Toxicol. Sci.
2007; 97 (2):539-47). Cell viability was determined by measuring
intracellular ATP levels following five days of continuous
incubation with test compounds.
[1094] Cell Cultures
[1095] The human hepatoma Huh-7 cell line was obtained from
ReBLikon GmbH (Mainz, Germany) {20879}. The MT-4 cell line (HTLV-1
transformed, human T lymphoblastoid cells) was obtained from the
NIH AIDS Reagent program (Bathesda, Md.). The human hepatoblastoma
cell line HepG2, human prostate carcinoma cell line PC-3, and
normal fetal lung derived MRC-5 cells were obtained from the
American Type Culture Collection (ATCC, Manassas, Va.).
[1096] Huh-7 cells were maintained in Dulbecco's Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS,
Hyclone, Logan, Utah), 1% non-essential amino acids (Gibco,
Carlsbad, Calif.). PC-3 and HepG2 cells were adapted to grow in
0.2% galactose-containing, glucose-free Dulbecco's Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS,
Hyclone, Logan, Utah), 1% non-essential amino acids (Gibco,
Carlsbad, Calif.), 1% Pyruvate (Cellgro), 1% Glutamax (Invitrogen,
Carlsbad, Calif.). Galactose-adapted cells were maintained in the
same culture medium. MRC-5 cells were maintained in Eagle's Minimum
Essential Medium (EMEM) supplemented with 10% fetal bovine serum
(FBS, Hyclone, Logan, Utah). MT-4 cells were maintained in
RPMI-1640 supplemented with 10% fetal bovine serum (FBS, Hyclone,
Logan, Utah). All cell culture media were also supplemented with
100 Units/mL penicillin, 100 .mu.g/mL streptomycin (Gibco).
[1097] Cytotoxicity Assays
[1098] Using a Biotek uFlow Workstation (Biotek, Winooski, Vt.),
1500 HepG2, 1500 PC-3, 500 Huh7 or 1500 MRC-5 cells in 90 .mu.L of
culture media were dispensed into each well of black polystyrene
tissue culture-treated 384-well plates. Plated cells were incubated
for 24 hours in an incubator at 37.degree. C., 5% CO.sub.2 and 90%
humidity. Compound serial dilutions were performed in 100% DMSO in
384-well polypropylene (high recovery) plates on a Biomek FX
Workstation (Beckman Coulter, Fullerton, Calif.). After 3-fold
serial dilutions, 0.4 .mu.L of compounds were transferred into
384-well plates containing cells using a Velocity 11 system
equipped with a Bravo 384-well pipettor. The DMSO concentration in
the final assay plates was 0.44% (v/v). Cells were incubated with
compound(s) for five days at 37.degree. C. Puromycin (44 M final
concentration) and DMSO (0.44%, v/v) were used as a positive and
negative controls, respectively
[1099] At the end of the incubation period the cytotoxicity assay
was performed as follows: Media from 384-well cell culture plates
were aspirated with a Biotek EL405 plate-washer (Biotek) and cells
were washed with 100 .mu.L PBS once. Twenty microliters of Cell
Titer Glo (Promega, Madison, Wis.) was added to each well of the
plates with a Biotek uFlow liquid dispenser. Plates were incubated
for 15 minutes at room temperature before luminescence was measured
with a Perkin Elmer Envision Plate Reader (Perkin Elmer, Waltham,
Mass.).
[1100] For the MT-4 cytotoxicity assay, 0.4 .mu.L of serially
diluted compounds were added to 40 .mu.l of cell maintenance media
in 384-well black, solid bottom plate using a Biomek FX workstation
(Beckman Coulter). Two thousand cells in 35 .mu.L were added to
each well using a Biotek uFlow Workstation (Biotek). Each assay
plate contained 10 .mu.M Puromycin (final concentration) and 0.5%
DMSO in RPMI-1640 as positive and negative controls, respectively.
Assay plates were incubated for five days at 37.degree. C. in an
incubator set at 5% CO2 and 90% humidity. After five days, 22 .mu.L
of Cell Titer Glo reagent (Promega) was added to the assay plates
with a Biotek uFlow Workstation. Plates were subsequently placed on
a Perkin Elmer Envision Plate Reader for five minutes before the
luminescence signal was read.
[1101] Data Analysis
[1102] CC.sub.50 values were defined as the compound concentration
that caused a 50% decrease in luminescence signal, and were
calculated by non-linear regression using Pipeline Pilot software
by applying a four parameter fit equation (Accelrys, San Diego,
Calif.). Results are summarized in the table below. Individual CC50
values are listed as .mu.M concentrations.
TABLE-US-00004 CC50 CC50 CC50 CC50 GALHEPG2 GALPC3 HUH7 MRC5 CC50
Compound CTG 5D CTG 5D CTG 5D CTG 5D (MT4) 15 1.23 0.69. 10.70 7.60
8.62 44 1.07 0.52 9.64 3.72 1.97 59 8.88 5.20 35.39 40.31 31.40 98
6.70 4.53 21.90 24.42 16.17 51 44.44 37.23 44.44 44.44 57.14 102
27.42 19.08 44.44 44.44 57.14 61 44.44 44.44 44.44 44.44 212.39 62
44.44 29.74 44.44 44.44 19.23 93 7.73 3.63 44.44 38.80 18.55 64
3.56 1.55 10.36 6.97 0.79 101 44.44 44.44 44.44 44.44 50.0 65 44.44
44.44 44.44 44.44 50.0 95 28.06 16.76 31.34 44.44 44.11 97 33.01
27.51 44.44 44.44 50.0 X 7.85 6.79 16.91 20.95 53.77 Y 0.19 0.18.
2.31 0.95 1.42
As will be appreciated by one of skill in the art, a high ratio of
CC.sub.50 from the cytotoxicity assays to AC.sub.50 (e.g. of
TNF.alpha. and/or IL12p40) indicates potential good safety margins
in vivo.
[1103] All references, including publications, patents, and patent
documents are incorporated by reference herein, as though
individually incorporated by reference. The present disclosure
provides reference to various embodiments and techniques. However,
it should be understood that many variations and modifications may
be made while remaining within the spirit and scope of the present
disclosure.
* * * * *